[
  {
    "id": 10,
    "user_query": "You MUST give a detailed answer to the following question: Name synonym of Acrokeratosis paraneoplastica.",
    "llama-7b_response": "Acrokeratosis paraneoplastica is a rare skin condition that is characterized by the development of thick, rough, and scaly patches of skin on the fingers, toes, and soles of the feet. These patches are caused by the body's immune system reacting to a cancerous tumor in the body.\n\nThere are several synonyms for acrokeratosis paraneoplastica, including:\n\n1. Acrokeratotic paraneoplastic pemphigus\n2. Acrokeratotic paraneoplastic pemphigoid\n3. Acrokeratotic paraneoplastic dermatitis\n4. Acrokeratotic paraneoplastic eczema\n5. Acrokeratotic paraneoplastic psoriasis\n6. Acrokeratotic paraneoplastic lichen planus\n7. Acrokeratotic paraneoplastic scleroderma\n8. Acrokeratotic paraneoplastic discoid lupus erythematosus\n9. Acrokeratotic paraneoplastic lupus erythematosus\n10. Acrokeratotic paraneoplastic dermatomyositis.",
    "llama-7b_fact_raw": "1. Acrokeratosis paraneoplastica is characterized by thick, rough, and scaly patches of skin.\n2. The condition is associated with the body's immune system reacting to a cancerous tumor.\n3. Acrokeratotic paraneoplastic pemphigus is a synonym for acrokeratosis paraneoplastica.\n4. Acrokeratotic paraneoplastic dermatitis is a synonym for acrokeratosis paraneoplastica.\n5. Acrokeratotic paraneoplastic scleroderma is a synonym for acrokeratosis paraneoplastica.",
    "llama-7b_fact": [
      "Acrokeratosis paraneoplastica is characterized by thick, rough, and scaly patches of skin.",
      "The condition is associated with the body's immune system reacting to a cancerous tumor.",
      "Acrokeratotic paraneoplastic pemphigus is a synonym for acrokeratosis paraneoplastica.",
      "Acrokeratotic paraneoplastic dermatitis is a synonym for acrokeratosis paraneoplastica.",
      "Acrokeratotic paraneoplastic scleroderma is a synonym for acrokeratosis paraneoplastica."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Acrokeratotic paraneoplastic pemphigus is not a synonym for acrokeratosis paraneoplastica; it is a distinct condition known as paraneoplastic pemphigus, which is a rare autoimmune blistering disorder associated with neoplasia.\n4. UNKNOWN: Without more context, it's unclear whether \"Acrokeratotic paraneoplastic dermatitis\" is a recognized medical term or synonym. The term does not appear to be widely used or recognized in medical literature.\n5. FALSE [correction]: Acrokeratotic paraneoplastic scleroderma is not a synonym for acrokeratosis paraneoplastica. Scleroderma is a group of autoimmune diseases that may cause changes in the skin, blood vessels, muscles, and internal organs, and is not the same as acrokeratosis paraneoplastica.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 47,
    "user_query": "You MUST give a detailed answer to the following question: Is Weaver syndrome similar to Sotos?",
    "llama-7b_response": "Weaver syndrome and Sotos syndrome are both genetic disorders that affect growth and development, but they are distinct conditions with different genetic causes and clinical features.\n\nWeaver syndrome, also known as Simpson-Golabi-Behmel syndrome (SGBS), is caused by mutations in the GH1 gene on chromosome 17q21. This gene encodes for the growth hormone receptor, which plays a crucial role in regulating growth and development. Individuals with Weaver syndrome have characteristic physical features such as macrocephaly (large head), hypotonia (low muscle tone), and distinctive facial features such as a broad forehead, low-set and malformed ears, and a single crease in the palm of the hand. Intellectual disability and delayed puberty are also common in this condition.\n\nSotos syndrome, on the other hand, is caused by mutations in the NSD1 gene on chromosome 5q31. This gene encodes for a transcription factor that plays a crucial role in regulating gene expression during embryonic development. Individuals with Sotos syndrome have characteristic physical features such as a large head, wide-set eyes, and a distinctive facial structure with a broad forehead, full cheeks, and a flat nasal bridge. Intellectual disability and rapid growth during childhood are also common in this condition.\n\nWhile both Weaver syndrome and Sotos syndrome are genetic disorders that affect growth and development, they differ in their genetic causes and clinical features. Weaver syndrome is caused by mutations in the GH1 gene, while Sotos syndrome is caused by mutations in the NSD1 gene. Additionally, individuals with Weaver syndrome have characteristic physical features such as macrocephaly, hypotonia, and distinctive facial features, while individuals with Sotos syndrome have characteristic physical features such as a large head, wide-set eyes, and a distinctive facial structure. It is important for healthcare professionals to accurately diagnose these conditions in order to provide appropriate management and support to affected individuals and their families.",
    "llama-7b_fact_raw": "1. Weaver syndrome is caused by mutations in the GH1 gene on chromosome 17q21.\n2. Sotos syndrome is caused by mutations in the NSD1 gene on chromosome 5q31.\n3. Individuals with Weaver syndrome often have macrocephaly, hypotonia, and distinctive facial features.\n4. Individuals with Sotos syndrome typically have a large head, wide-set eyes, and a distinctive facial structure.\n5. Both Weaver syndrome and Sotos syndrome are genetic disorders that affect growth and development.",
    "llama-7b_fact": [
      "Weaver syndrome is caused by mutations in the GH1 gene on chromosome 17q21.",
      "Sotos syndrome is caused by mutations in the NSD1 gene on chromosome 5q31.",
      "Individuals with Weaver syndrome often have macrocephaly, hypotonia, and distinctive facial features.",
      "Individuals with Sotos syndrome typically have a large head, wide-set eyes, and a distinctive facial structure.",
      "Both Weaver syndrome and Sotos syndrome are genetic disorders that affect growth and development."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Weaver syndrome is caused by mutations in the EZH2 gene on chromosome 7q36.3.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "You MUST give a detailed answer to the following question: List the releases of JASPAR database",
    "llama-7b_response": "The JASPAR database is a widely used database of protein-coding transcription factor binding profiles. Here are the releases of the JASPAR database, along with their corresponding years:\n\n1. JASPAR 2004 Release: This was the first release of the JASPAR database, which was published in 2004. It contained binding profiles for 18 transcription factors.\n2. JASPAR 2007 Release: This release of the JASPAR database was published in 2007 and contained binding profiles for 35 transcription factors.\n3. JASPAR 2010 Release: This release of the JASPAR database was published in 2010 and contained binding profiles for 45 transcription factors.\n4. JASPAR 2012 Release: This release of the JASPAR database was published in 2012 and contained binding profiles for 55 transcription factors.\n5. JASPAR 2014 Release: This release of the JASPAR database was published in 2014 and contained binding profiles for 65 transcription factors.\n6. JASPAR 2016 Release: This release of the JASPAR database was published in 2016 and contained binding profiles for 75 transcription factors.\n7. JASPAR 2018 Release: This release of the JASPAR database was published in 2018 and contained binding profiles for 85 transcription factors.\n8. JASPAR 2020 Release: This release of the JASPAR database was published in 2020 and contained binding profiles for 95 transcription factors.",
    "llama-7b_fact_raw": "1. The first release of the JASPAR database was in 2004 with binding profiles for 18 transcription factors.\n2. The JASPAR 2007 Release contained binding profiles for 35 transcription factors.\n3. The JASPAR 2010 Release contained binding profiles for 45 transcription factors.\n4. The JASPAR 2012 Release contained binding profiles for 55 transcription factors.\n5. The JASPAR 2014 Release contained binding profiles for 65 transcription factors.",
    "llama-7b_fact": [
      "The first release of the JASPAR database was in 2004 with binding profiles for 18 transcription factors.",
      "The JASPAR 2007 Release contained binding profiles for 35 transcription factors.",
      "The JASPAR 2010 Release contained binding profiles for 45 transcription factors.",
      "The JASPAR 2012 Release contained binding profiles for 55 transcription factors.",
      "The JASPAR 2014 Release contained binding profiles for 65 transcription factors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The JASPAR 2007 Release contained binding profiles for 123 transcription factors.\n3. FALSE [correction]: The JASPAR 2010 Release contained binding profiles for 123 transcription factors, not 45.\n4. FALSE [correction]: The JASPAR 2012 Release contained binding profiles for 135 transcription factors.\n5. FALSE [correction]: The JASPAR 2014 Release contained binding profiles for 179 transcription factors.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 99,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of the viral KP4 protein?",
    "llama-7b_response": "The KP4 protein is a viral protein that is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV), which is a member of the herpesvirus family. The KP4 protein is also known as ORF73, and it is one of the largest and most complex viral proteins produced by KSHV.\n\nThe function of the KP4 protein is not fully understood, but it is believed to play a crucial role in the life cycle of the virus. The KP4 protein is synthesized as a precursor protein that is cleaved into two smaller proteins, K1 and K2, which are then transported to the cell membrane.\n\nOne of the functions of the KP4 protein is to help the virus evade the host immune system. Studies have shown that the KP4 protein can interact with immune cells, such as macrophages and dendritic cells, and prevent them from recognizing and attacking the virus. This helps the virus to establish a persistent infection in the host.\n\nIn addition to its role in immune evasion, the KP4 protein may also play a role in the replication of the virus. Studies have shown that the KP4 protein is localized to the nucleus of infected cells and may be involved in the transcription of viral genes.\n\nOverall, the function of the KP4 protein is complex and not fully understood, but it is clear that it plays an important role in the life cycle of the Kaposi's sarcoma-associated herpesvirus. Further research is needed to fully understand the role of the KP4 protein in the virus's replication and pathogenesis.",
    "llama-7b_fact_raw": "1. The KP4 protein is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV).\n2. KP4 protein is also known as ORF73.\n3. The KP4 protein is synthesized as a precursor protein that is cleaved into two smaller proteins, K1 and K2.\n4. The KP4 protein can interact with immune cells such as macrophages and dendritic cells to help the virus evade the host immune system.\n5. The KP4 protein is localized to the nucleus of infected cells and may be involved in the transcription of viral genes.",
    "llama-7b_fact": [
      "The KP4 protein is encoded by the Kaposi's sarcoma-associated herpesvirus (KSHV).",
      "KP4 protein is also known as ORF73.",
      "The KP4 protein is synthesized as a precursor protein that is cleaved into two smaller proteins, K1 and K2.",
      "The KP4 protein can interact with immune cells such as macrophages and dendritic cells to help the virus evade the host immune system.",
      "The KP4 protein is localized to the nucleus of infected cells and may be involved in the transcription of viral genes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The KP4 protein is not encoded by Kaposi's sarcoma-associated herpesvirus (KSHV). KP4 is a viral protein from Ustilago maydis, a type of fungus. KSHV encodes a protein called LANA (Latency-Associated Nuclear Antigen) which is also known as ORF73.\n2. FALSE [correction]: KP4 protein is not known as ORF73. ORF73 is a gene of KSHV that encodes LANA.\n3. UNKNOWN: Without specific information on the KP4 protein from Ustilago maydis, it is unclear whether it is synthesized as a precursor that is cleaved into two smaller proteins, K1 and K2. This statement may be confusing KP4 with another protein or system.\n4. UNKNOWN: The interaction of KP4 protein with immune cells such as macrophages and dendritic cells is not well-documented in the context provided. More information is needed to confirm or refute this statement.\n5. UNKNOWN: The localization of the KP4 protein to the nucleus of infected cells and its involvement in the transcription of viral genes is not specified in the context provided. This statement requires more information to determine its accuracy.",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "You MUST give a detailed answer to the following question: Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-7b_response": "Yes, 3,5-diiodo-L-thyronine (DITPA) is a thyroid hormone analog that has been utilized in both experimental and clinical studies. DITPA is structurally similar to triiodothyronine (T3), one of the two primary hormones produced by the thyroid gland. However, DITPA has an iodine atom replaced by an iodine analog, which results in increased potency and stability compared to T3.\n\nDITPA has been studied for its potential to treat a variety of thyroid-related conditions, including hypothyroidism, hyperthyroidism, and thyroid cancer. In animal studies, DITPA has been shown to improve thyroid hormone levels, increase metabolism, and reduce weight gain. Additionally, DITPA has been used in clinical trials to treat patients with hypothyroidism and hyperthyroidism, with some evidence suggesting that it may be more effective than traditional thyroid hormone replacement therapy.\n\nHowever, more research is needed to fully understand the safety and efficacy of DITPA in humans, and its use is currently limited to experimental and clinical studies.",
    "llama-7b_fact_raw": "1. 3,5-diiodo-L-thyronine (DITPA) is a thyroid hormone analog used in experimental and clinical studies.\n2. DITPA is structurally similar to triiodothyronine (T3), a primary hormone produced by the thyroid gland.\n3. DITPA has been studied for its potential to treat thyroid-related conditions such as hypothyroidism, hyperthyroidism, and thyroid cancer.\n4. In animal studies, DITPA has shown to improve thyroid hormone levels, increase metabolism, and reduce weight gain.\n5. DITPA has been used in clinical trials to treat patients with hypothyroidism and hyperthyroidism.",
    "llama-7b_fact": [
      "3,5-diiodo-L-thyronine (DITPA) is a thyroid hormone analog used in experimental and clinical studies.",
      "DITPA is structurally similar to triiodothyronine (T3), a primary hormone produced by the thyroid gland.",
      "DITPA has been studied for its potential to treat thyroid-related conditions such as hypothyroidism, hyperthyroidism, and thyroid cancer.",
      "In animal studies, DITPA has shown to improve thyroid hormone levels, increase metabolism, and reduce weight gain.",
      "DITPA has been used in clinical trials to treat patients with hypothyroidism and hyperthyroidism."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: DITPA has been used in clinical trials to treat patients with heart conditions such as heart failure, not specifically for treating hypothyroidism and hyperthyroidism.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 144,
    "user_query": "You MUST give a detailed answer to the following question: What is the COUGER tool?",
    "llama-7b_response": "The COUGER tool is a software tool developed by the National Institute of Standards and Technology (NIST) that is used to generate cryptographic key pairs and other cryptographic operations. COUGER stands for \"Cryptographic Operations Using Generated Keys.\"\n\nThe COUGER tool is designed to be a flexible and extensible tool that can be used to perform a wide range of cryptographic operations, including key generation, encryption, decryption, signature generation, and signature verification. It can be used to generate key pairs using a variety of cryptographic algorithms, including RSA, ElGamal, Diffie-Hellman, and more.\n\nOne of the key features of the COUGER tool is its ability to generate large key sizes, making it suitable for use in high-security applications. It can also generate key pairs with different levels of security, allowing users to choose the level of security that is appropriate for their needs.\n\nIn addition to key generation, the COUGER tool can also be used to perform other cryptographic operations, such as encryption and decryption of data, generation of digital signatures, and verification of digital signatures. It can also be used to generate random numbers, which are often used in cryptographic operations.\n\nOverall, the COUGER tool is a powerful and flexible tool that can be used to perform a wide range of cryptographic operations, making it a valuable tool for anyone working with cryptography.",
    "llama-7b_fact_raw": "1. The COUGER tool is a software tool developed by the National Institute of Standards and Technology (NIST).\n2. COUGER stands for \"Cryptographic Operations Using Generated Keys.\"\n3. The COUGER tool can generate key pairs using cryptographic algorithms such as RSA, ElGamal, and Diffie-Hellman.\n4. The COUGER tool is capable of generating large key sizes for high-security applications.\n5. The COUGER tool's functionalities include key generation, encryption, decryption, signature generation, signature verification, and random number generation.",
    "llama-7b_fact": [
      "The COUGER tool is a software tool developed by the National Institute of Standards and Technology (NIST).",
      "COUGER stands for \"Cryptographic Operations Using Generated Keys.\"",
      "The COUGER tool can generate key pairs using cryptographic algorithms such as RSA, ElGamal, and Diffie-Hellman.",
      "The COUGER tool is capable of generating large key sizes for high-security applications.",
      "The COUGER tool's functionalities include key generation, encryption, decryption, signature generation, signature verification, and random number generation."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the COUGER tool, it is not possible to verify the accuracy of these statements. The acronym COUGER is not widely recognized in the context of cryptographic tools developed by NIST or otherwise, and there is no publicly available information that confirms these details as of my knowledge cutoff date.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "You MUST give a detailed answer to the following question: Are there drugs for Tick-borne Encephalitis?",
    "llama-7b_response": "Tick-borne encephalitis (TBE) is a viral infection that is transmitted to humans through the bite of an infected tick. There are several different viruses that can cause TBE, including the European tick-borne encephalitis virus (TBEV), the Far Eastern tick-borne encephalitis virus (FEV), and the Siberian tick-borne encephalitis virus (Siberian TBEV).\n\nTreatment for TBE typically involves supportive care to manage symptoms such as fever, headache, and muscle weakness. There is no specific antiviral treatment for TBE, and antibiotics are not effective against viral infections.\n\nIn some cases, hospitalization may be necessary to manage complications such as seizures, coma, or respiratory failure.\n\nThere are no specific drugs that have been proven to be effective in preventing or treating TBE. However, there are vaccines available that can provide protection against TBEV and FEV. These vaccines are generally recommended for people who are at high risk of exposure to TBE, such as travelers to endemic areas, outdoor workers, and people who live in rural or forested areas.",
    "llama-7b_fact_raw": "1. Tick-borne encephalitis (TBE) is transmitted to humans through the bite of an infected tick.\n2. The European tick-borne encephalitis virus (TBEV), the Far Eastern tick-borne encephalitis virus (FEV), and the Siberian tick-borne encephalitis virus (Siberian TBEV) are different viruses that can cause TBE.\n3. There is no specific antiviral treatment for TBE.\n4. Antibiotics are not effective against viral infections such as TBE.\n5. Vaccines are available that can provide protection against TBEV and FEV.",
    "llama-7b_fact": [
      "Tick-borne encephalitis (TBE) is transmitted to humans through the bite of an infected tick.",
      "The European tick-borne encephalitis virus (TBEV), the Far Eastern tick-borne encephalitis virus (FEV), and the Siberian tick-borne encephalitis virus (Siberian TBEV) are different viruses that can cause TBE.",
      "There is no specific antiviral treatment for TBE.",
      "Antibiotics are not effective against viral infections such as TBE.",
      "Vaccines are available that can provide protection against TBEV and FEV."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The European tick-borne encephalitis virus (TBEV), the Far Eastern tick-borne encephalitis virus (FEV), and the Siberian tick-borne encephalitis virus (Siberian TBEV) are different subtypes or strains of the same virus that can cause TBE, not different viruses.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 151,
    "user_query": "You MUST give a detailed answer to the following question: Which genome browser database for DNA shape annotations is available?",
    "llama-7b_response": "There are several genome browser databases for DNA shape annotations that are available. Some of the most popular ones include:\n\n1. UCSC Genome Browser: This is a free, online genome browser that provides access to a wide range of genomic data, including DNA shape annotations. The browser allows users to visualize and analyze genomic data using a variety of tools and resources.\n2. Ensembl Genome Browser: This is another free, online genome browser that provides access to a wide range of genomic data, including DNA shape annotations. The browser allows users to visualize and analyze genomic data using a variety of tools and resources.\n3. Integrative Genomics Viewer (IGV): This is a free, open-source genome browser that provides access to a wide range of genomic data, including DNA shape annotations. The browser allows users to visualize and analyze genomic data using a variety of tools and resources.\n4. Genome Analysis Toolkit (GATK): This is a free, open-source software suite that provides tools for analyzing and interpreting genomic data, including DNA shape annotations. The suite includes tools for aligning genomic data, calling variants, and analyzing population genetics data.\n\nOverall, these genome browser databases provide a wealth of information and resources for studying DNA shape annotations and other aspects of genomic data.",
    "llama-7b_fact_raw": "1. The UCSC Genome Browser is a free, online genome browser that includes DNA shape annotations.\n2. The Ensembl Genome Browser is a free, online genome browser that provides access to DNA shape annotations.\n3. The Integrative Genomics Viewer (IGV) is a free, open-source genome browser that offers DNA shape annotations.\n4. The Genome Analysis Toolkit (GATK) is a free, open-source software suite that includes tools for analyzing DNA shape annotations.",
    "llama-7b_fact": [
      "The UCSC Genome Browser is a free, online genome browser that includes DNA shape annotations.",
      "The Ensembl Genome Browser is a free, online genome browser that provides access to DNA shape annotations.",
      "The Integrative Genomics Viewer (IGV) is a free, open-source genome browser that offers DNA shape annotations.",
      "The Genome Analysis Toolkit (GATK) is a free, open-source software suite that includes tools for analyzing DNA shape annotations."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: The Genome Analysis Toolkit (GATK) is a free, open-source software suite for analyzing genomic data, but it does not specifically include tools for analyzing DNA shape annotations.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 174,
    "user_query": "You MUST give a detailed answer to the following question: Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-7b_response": "The EZH2 gene encodes for an enzyme called enhancer of zeste homolog 2, which is involved in the regulation of gene expression. Mutations in the EZH2 gene have been associated with several syndromes, including:\n\n1. Wolf-Hirschhorn syndrome: This is a genetic disorder that is caused by a deletion on chromosome 4, which includes the EZH2 gene. The syndrome is characterized by intellectual disability, developmental delays, and abnormal facial features.\n2. DICER1 syndrome: This is a rare genetic disorder that is caused by mutations in the DICER1 gene, which is located on chromosome 7. DICER1 syndrome is characterized by a wide range of symptoms, including hearing loss, developmental delays, and abnormal facial features.\n3. Beckwith-Wiedemann syndrome: This is a genetic disorder that is caused by mutations in the IGF2 gene, which is located on chromosome 11. Beckwith-Wiedemann syndrome is characterized by macroglossia (enlarged tongue), macrocephaly (large head), and an increased risk of developing tumors, including Wilms' tumor and hepatoblastoma.\n4. PTEN hamartoma tumor syndrome: This is a genetic disorder that is caused by mutations in the PTEN gene, which is located on chromosome 10. PTEN hamartoma tumor syndrome is characterized by the development of benign tumors in various parts of the body, including the brain, kidneys, and skin. The syndrome is also associated with intellectual disability, developmental delays, and abnormal facial features.\n\nIn summary, mutations in the EZH2 gene have been associated with several syndromes, including Wolf-Hirschhorn syndrome, DICER1 syndrome, Beckwith-Wiedemann syndrome, and PTEN hamartoma tumor syndrome. These syndromes are characterized by a wide range of symptoms and are caused by mutations in different genes.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 193,
    "user_query": "You MUST give a detailed answer to the following question: List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-7b_response": "There are several human proteins that are known to undergo a dimer-to-tetramer transition. These proteins are characterized by having multiple copies of the same protein molecule come together to form a larger, more complex structure. Some examples of proteins that undergo this transition include:\n\n1. Hemoglobin: Hemoglobin is a protein found in red blood cells that carries oxygen throughout the body. It is a tetramer made up of two alpha and two beta subunits.\n2. Myoglobin: Myoglobin is a protein found in muscle cells that helps to store and transport oxygen. It is a dimer made up of two alpha subunits.\n3. Cytochrome C: Cytochrome C is a protein found in the mitochondria of cells that plays a role in cellular respiration. It is a tetramer made up of two alpha and two beta subunits.\n4. Ferritin: Ferritin is a protein found in cells that helps to store iron. It is a tetramer made up of four identical subunits.\n5. Ceruloplasmin: Ceruloplasmin is a protein found in the blood that helps to transport iron throughout the body. It is a tetramer made up of two alpha and two beta subunits.\n\nThese are just a few examples of human proteins that undergo a dimer-to-tetramer transition. The dimer-to-tetramer transition is a common structural feature of many proteins and plays an important role in their function.",
    "llama-7b_fact_raw": "1. Hemoglobin is a protein found in red blood cells that carries oxygen throughout the body and is a tetramer composed of two alpha and two beta subunits.\n2. Myoglobin is a protein found in muscle cells that stores and transports oxygen and is a dimer composed of two alpha subunits.\n3. Cytochrome C is a protein found in the mitochondria that plays a role in cellular respiration and is a tetramer composed of two alpha and two beta subunits.\n4. Ferritin is a protein that helps to store iron in cells and is a tetramer made up of four identical subunits.\n5. Ceruloplasmin is a protein that helps to transport iron in the blood and is a tetramer composed of two alpha and two beta subunits.",
    "llama-7b_fact": [
      "Hemoglobin is a protein found in red blood cells that carries oxygen throughout the body and is a tetramer composed of two alpha and two beta subunits.",
      "Myoglobin is a protein found in muscle cells that stores and transports oxygen and is a dimer composed of two alpha subunits.",
      "Cytochrome C is a protein found in the mitochondria that plays a role in cellular respiration and is a tetramer composed of two alpha and two beta subunits.",
      "Ferritin is a protein that helps to store iron in cells and is a tetramer made up of four identical subunits.",
      "Ceruloplasmin is a protein that helps to transport iron in the blood and is a tetramer composed of two alpha and two beta subunits."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Myoglobin is a protein found in muscle cells that stores and transports oxygen and is a monomer, not a dimer.\n3. FALSE [correction]: Cytochrome C is a protein found in the mitochondria that plays a role in cellular respiration and is a monomer, not a tetramer.\n4. TRUE\n5. FALSE [correction]: Ceruloplasmin is a protein that helps to transport copper in the blood and is a single polypeptide chain; it is not a tetramer composed of two alpha and two beta subunits.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 210,
    "user_query": "You MUST give a detailed answer to the following question: Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-7b_response": "Phospholamban (PLN) is a protein that plays a crucial role in the regulation of cardiovascular function. It has been found to interact with a number of other proteins, including the anti-apoptotic protein Bcl-xL.\n\nBcl-xL is a member of the Bcl-2 family of proteins, which are involved in the regulation of programmed cell death (apoptosis). Bcl-xL is an anti-apoptotic protein, which means that it helps to prevent cells from undergoing programmed cell death. It does this by binding to and inhibiting the activity of pro-apoptotic proteins, such as Bax and Bak.\n\nStudies have shown that PLN and Bcl-xL interact with each other and that this interaction is important for the regulation of cardiovascular function. For example, it has been shown that the interaction between PLN and Bcl-xL is important for the maintenance of cardiac contractility and for the prevention of cardiac remodeling following myocardial infarction.\n\nIn summary, the anti-apoptotic protein Bcl-xL has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein that helps to prevent cells from undergoing programmed cell death. The interaction between PLN and Bcl-xL is important for the regulation of cardiovascular function.",
    "llama-7b_fact_raw": "1. Phospholamban (PLN) interacts with the anti-apoptotic protein Bcl-xL.\n2. Bcl-xL is a member of the Bcl-2 family of proteins.\n3. Bcl-xL helps to prevent cells from undergoing programmed cell death by inhibiting the activity of pro-apoptotic proteins like Bax and Bak.\n4. The interaction between PLN and Bcl-xL is important for the maintenance of cardiac contractility.\n5. The interaction between PLN and Bcl-xL plays a role in preventing cardiac remodeling following myocardial infarction.",
    "llama-7b_fact": [
      "Phospholamban (PLN) interacts with the anti-apoptotic protein Bcl-xL.",
      "Bcl-xL is a member of the Bcl-2 family of proteins.",
      "Bcl-xL helps to prevent cells from undergoing programmed cell death by inhibiting the activity of pro-apoptotic proteins like Bax and Bak.",
      "The interaction between PLN and Bcl-xL is important for the maintenance of cardiac contractility.",
      "The interaction between PLN and Bcl-xL plays a role in preventing cardiac remodeling following myocardial infarction."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding the specific interactions between Phospholamban (PLN) and Bcl-xL, and their roles in cardiac contractility and remodeling following myocardial infarction, are highly specialized and would require specific scientific literature to confirm their accuracy. Without access to the relevant research or context, it is not possible to determine the truthfulness of these statements.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 218,
    "user_query": "You MUST give a detailed answer to the following question: Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-7b_response": "Yes, vitamin D has been shown to reduce the incidence of falls in older people in clinical trials. Several studies have found that vitamin D supplementation can reduce the risk of falls in older adults, particularly those who are deficient in vitamin D.\n\nFor example, a meta-analysis of 25 randomized controlled trials found that vitamin D supplementation significantly reduced the risk of falls in older adults by 19%. Another study found that vitamin D supplementation reduced the risk of falls by 22% in older adults who were deficient in vitamin D.\n\nThese findings suggest that maintaining adequate levels of vitamin D through diet or supplementation may be an important strategy for preventing falls in older adults. However, it is worth noting that more research is needed to fully understand the relationship between vitamin D and falls in older adults, and the optimal dosage and form of vitamin D supplementation for fall prevention.",
    "llama-7b_fact_raw": "1. Vitamin D supplementation has been shown to reduce the incidence of falls in older people in clinical trials.\n2. A meta-analysis of 25 randomized controlled trials indicated that vitamin D supplementation reduced the risk of falls in older adults by 19%.\n3. Another study demonstrated a 22% reduction in the risk of falls among older adults who were deficient in vitamin D after they received vitamin D supplementation.\n4. Adequate levels of vitamin D may be important for preventing falls in older adults.\n5. Further research is necessary to fully understand the relationship between vitamin D and falls in older adults, including the optimal dosage and form of vitamin D supplementation for fall prevention.",
    "llama-7b_fact": [
      "Vitamin D supplementation has been shown to reduce the incidence of falls in older people in clinical trials.",
      "A meta-analysis of 25 randomized controlled trials indicated that vitamin D supplementation reduced the risk of falls in older adults by 19%.",
      "Another study demonstrated a 22% reduction in the risk of falls among older adults who were deficient in vitamin D after they received vitamin D supplementation.",
      "Adequate levels of vitamin D may be important for preventing falls in older adults.",
      "Further research is necessary to fully understand the relationship between vitamin D and falls in older adults, including the optimal dosage and form of vitamin D supplementation for fall prevention."
    ],
    "llama-7b_judge_raw": "1. TRUE: Vitamin D supplementation has been shown in various clinical trials to reduce the incidence of falls in older people.\n2. UNKNOWN: Without access to the specific meta-analysis, the exact percentage reduction in the risk of falls cannot be verified.\n3. UNKNOWN: The exact percentage reduction in the risk of falls from a specific study cannot be verified without access to that study.\n4. TRUE: Adequate levels of vitamin D are generally considered important for bone health and muscle function, which can help in preventing falls in older adults.\n5. TRUE: There is ongoing research to better understand the relationship between vitamin D and falls, including the optimal dosage and form of supplementation.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "You MUST give a detailed answer to the following question: Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-7b_response": "There is some evidence to suggest that Jarid2 and miR-155 may be associated in the regulation of Th17 cells.\n\nmiR-155 is a microRNA that has been implicated in the regulation of Th17 cell differentiation and function. It has been shown to negatively regulate the expression of genes involved in Th17 cell differentiation, including the transcription factor RORgt, which is a key regulator of Th17 cell differentiation. miR-155 has also been shown to negatively regulate the expression of genes involved in the production of IL-17, a key cytokine produced by Th17 cells.\n\nJarid2, on the other hand, is a non-coding RNA that has been shown to play a role in the regulation of gene expression at the level of transcription. It has been shown to negatively regulate the expression of genes involved in Th17 cell differentiation and function, including the transcription factor RORgt. Jarid2 has also been shown to negatively regulate the expression of genes involved in the production of IL-17 in Th17 cells.\n\nWhile there is some evidence to suggest that Jarid2 and miR-155 may be associated in the regulation of Th17 cells, the exact mechanism by which they interact is not fully understood. It is possible that Jarid2 and miR-155 may work together to negatively regulate the expression of genes involved in Th17 cell differentiation and function. Alternatively, they may act independently of each other to regulate gene expression in Th17 cells. Further research is needed to fully understand the relationship between Jarid2 and miR-155 in the regulation of Th17 cells.",
    "llama-7b_fact_raw": "1. miR-155 is a microRNA that negatively regulates the expression of genes involved in Th17 cell differentiation.\n2. miR-155 has been shown to negatively regulate the expression of the transcription factor RORgt, which is crucial for Th17 cell differentiation.\n3. miR-155 negatively affects the expression of genes involved in the production of IL-17, a cytokine produced by Th17 cells.\n4. Jarid2 is a non-coding RNA that negatively regulates the expression of genes involved in Th17 cell differentiation and function, including RORgt.\n5. Jarid2 has been shown to negatively regulate the expression of genes involved in the production of IL-17 in Th17 cells.",
    "llama-7b_fact": [
      "miR-155 is a microRNA that negatively regulates the expression of genes involved in Th17 cell differentiation.",
      "miR-155 has been shown to negatively regulate the expression of the transcription factor RORgt, which is crucial for Th17 cell differentiation.",
      "miR-155 negatively affects the expression of genes involved in the production of IL-17, a cytokine produced by Th17 cells.",
      "Jarid2 is a non-coding RNA that negatively regulates the expression of genes involved in Th17 cell differentiation and function, including RORgt.",
      "Jarid2 has been shown to negatively regulate the expression of genes involved in the production of IL-17 in Th17 cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Jarid2 is not a non-coding RNA; it is a protein that can regulate gene expression, potentially including genes involved in Th17 cell differentiation and function, but it is not an RNA molecule.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "You MUST give a detailed answer to the following question: How many genes does the human hoxD cluster contain?",
    "llama-7b_response": "The human HOXD cluster contains 11 genes.",
    "llama-7b_fact_raw": "1. The human HOXD cluster contains 11 genes.",
    "llama-7b_fact": [
      "The human HOXD cluster contains 11 genes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The human HOXD cluster contains 9 genes.",
    "llama-7b_judge": [
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "You MUST give a detailed answer to the following question: List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-7b_response": "Casein Kinase 1 (CK1) is an enzyme that catalyzes the transfer of the phosphate group from ATP to a target protein, resulting in phosphorylation. There are several different consensus motifs for CK1 phosphorylation sites, which are based on the amino acid sequence of the target protein and the specific residues that are most likely to be phosphorylated by CK1. Here are a few examples of CK1 phosphorylation consensus motifs:\n\n1. S/T-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-x-",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 305,
    "user_query": "You MUST give a detailed answer to the following question: Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-7b_response": "The ASPH (aspartate beta-hydroxylase) gene encodes for the enzyme aspartate beta-hydroxylase, which is involved in the metabolism of aspartate and other amino acids. The gene is located on the long (q) arm of chromosome 12 at position 12q24.3.\n\nThere are several different transcript variants of the ASPH gene, which can result from alternative splicing of the gene's pre-mRNA. These transcript variants can encode different isoforms of the aspartate beta-hydroxylase enzyme, which may have different functions or substrate specificities.\n\nSome of the different isoforms of aspartate beta-hydroxylase encoded by the ASPH gene include:\n\n1. Aspartate beta-hydroxylase 1 (ASPH1): This isoform is primarily expressed in the liver and kidneys, and is involved in the metabolism of aspartate and other amino acids.\n2. Aspartate beta-hydroxylase 2 (ASPH2): This isoform is primarily expressed in the brain and testes, and is involved in the metabolism of aspartate and other amino acids.\n3. Aspartate beta-hydroxylase 3 (ASPH3): This isoform is primarily expressed in the brain and testes, and is involved in the metabolism of aspartate and other amino acids.\n4. Aspartate beta-hydroxylase 4 (ASPH4): This isoform is primarily expressed in the brain and testes, and is involved in the metabolism of aspartate and other amino acids.\n5. Aspartate beta-hydroxylase 5 (ASPH5): This isoform is primarily expressed in the brain and testes, and is involved in the metabolism of aspartate and other amino acids.\n6. Aspartate beta-hydroxylase 6 (ASPH6): This isoform is primarily expressed in the brain and testes, and is involved in the metabolism of aspartate and other amino acids.\n7. Aspartate beta-h",
    "llama-7b_fact_raw": "1. The ASPH gene encodes for the enzyme aspartate beta-hydroxylase.\n2. The ASPH gene is located on the long (q) arm of chromosome 12 at position 12q24.3.\n3. Transcript variants of the ASPH gene can result from alternative splicing of the gene's pre-mRNA.\n4. Different isoforms of the aspartate beta-hydroxylase enzyme encoded by the ASPH gene may have different functions or substrate specificities.\n5. Isoform ASPH1 is primarily expressed in the liver and kidneys.",
    "llama-7b_fact": [
      "The ASPH gene encodes for the enzyme aspartate beta-hydroxylase.",
      "The ASPH gene is located on the long (q) arm of chromosome 12 at position 12q24.3.",
      "Transcript variants of the ASPH gene can result from alternative splicing of the gene's pre-mRNA.",
      "Different isoforms of the aspartate beta-hydroxylase enzyme encoded by the ASPH gene may have different functions or substrate specificities.",
      "Isoform ASPH1 is primarily expressed in the liver and kidneys."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements are consistent with general knowledge about genes and protein encoding. The ASPH gene does encode for the enzyme aspartate beta-hydroxylase, it is located on chromosome 12 at the specified position, alternative splicing can lead to transcript variants, and different isoforms can have different functions or substrate specificities. However, without specific information about the expression patterns of the isoforms of the aspartate beta-hydroxylase enzyme, the fifth statement cannot be confirmed or corrected, hence it is marked as UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "You MUST give a detailed answer to the following question: When was empagliflozin FDA approved?",
    "llama-7b_response": "Empagliflozin, also known by the brand name Jardiance, was approved by the U.S. Food and Drug Administration (FDA) on August 27, 2014, for the treatment of adults with type 2 diabetes. Empagliflozin is a medication that is used in combination with diet and exercise to improve glycemic control in patients with type 2 diabetes. It works by helping the body to excrete excess glucose through the urine. Empagliflozin is not recommended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.",
    "llama-7b_fact_raw": "1. Empagliflozin was approved by the U.S. Food and Drug Administration (FDA) on August 27, 2014.\n2. Empagliflozin is used for the treatment of adults with type 2 diabetes.\n3. The brand name for empagliflozin is Jardiance.\n4. Empagliflozin is intended to be used in combination with diet and exercise to improve glycemic control.\n5. Empagliflozin is not recommended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.",
    "llama-7b_fact": [
      "Empagliflozin was approved by the U.S. Food and Drug Administration (FDA) on August 27, 2014.",
      "Empagliflozin is used for the treatment of adults with type 2 diabetes.",
      "The brand name for empagliflozin is Jardiance.",
      "Empagliflozin is intended to be used in combination with diet and exercise to improve glycemic control.",
      "Empagliflozin is not recommended for use in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "You MUST give a detailed answer to the following question: What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-7b_response": "Lon1 is a protein that plays an important role in the regulation of protein homeostasis in various organisms, including plants. In the plant Arabidopsis, loss of the Lon1 protein has been shown to result in various changes in the plant's growth and development.\n\nOne of the most notable effects of Lon1 loss in Arabidopsis is an increase in the accumulation of misfolded and damaged proteins in the endoplasmic reticulum (ER) of the plant cells. This accumulation of misfolded proteins can lead to the formation of protein aggregates, which can disrupt the normal functioning of the ER and cause cellular stress. As a result, the plant cells may undergo programmed cell death, leading to the death of the plant tissue.\n\nAnother effect of Lon1 loss in Arabidopsis is an alteration in the expression of various genes involved in the plant's response to stress. For example, Lon1 loss has been shown to increase the expression of genes involved in the plant's defense response, such as those encoding for reactive oxygen species (ROS) scavenging enzymes and antioxidant proteins. This increase in defense gene expression may help the plant to cope with the increased cellular stress caused by the accumulation of misfolded proteins.\n\nAdditionally, Lon1 loss in Arabidopsis has been shown to affect the plant's growth and development. For example, Lon1 loss has been shown to result in reduced plant height, reduced leaf size, and delayed flowering. These effects may be due to the altered expression of genes involved in plant growth and development, as well as the increased cellular stress caused by the accumulation of misfolded proteins.\n\nOverall, the loss of the protein Lon1 in the plant Arabidopsis results in changes in the plant's growth and development, as well as an increase in the accumulation of misfolded proteins in the ER and an alteration in the expression of genes involved in the plant's response to stress.",
    "llama-7b_fact_raw": "1. Loss of the Lon1 protein in Arabidopsis leads to an increase in the accumulation of misfolded and damaged proteins in the endoplasmic reticulum.\n2. The accumulation of misfolded proteins in Arabidopsis cells due to Lon1 loss can result in the formation of protein aggregates and cellular stress.\n3. Lon1 loss in Arabidopsis may cause programmed cell death and lead to the death of plant tissue.\n4. The expression of genes involved in Arabidopsis's defense response, such as those for ROS scavenging enzymes and antioxidant proteins, is increased due to Lon1 loss.\n5. Arabidopsis plants with Lon1 loss exhibit reduced plant height, reduced leaf size, and delayed flowering.",
    "llama-7b_fact": [
      "Loss of the Lon1 protein in Arabidopsis leads to an increase in the accumulation of misfolded and damaged proteins in the endoplasmic reticulum.",
      "The accumulation of misfolded proteins in Arabidopsis cells due to Lon1 loss can result in the formation of protein aggregates and cellular stress.",
      "Lon1 loss in Arabidopsis may cause programmed cell death and lead to the death of plant tissue.",
      "The expression of genes involved in Arabidopsis's defense response, such as those for ROS scavenging enzymes and antioxidant proteins, is increased due to Lon1 loss.",
      "Arabidopsis plants with Lon1 loss exhibit reduced plant height, reduced leaf size, and delayed flowering."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the general understanding of the role of Lon1 protease in Arabidopsis thaliana. Lon1 is involved in the degradation of misfolded and damaged proteins within the mitochondria, and its loss can lead to the accumulation of such proteins, potentially causing cellular stress, programmed cell death, and various phenotypic changes. However, without specific experimental data or a reference to a particular study, it is not possible to confirm the absolute accuracy of these statements. They are generally in line with the known functions of Lon1 in plant cells.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "You MUST give a detailed answer to the following question: Does a linker histone exist in the yeast genome?",
    "llama-7b_response": "Yes, a linker histone exists in the yeast genome. Linker histones are a type of histone protein that helps to package DNA into nucleosomes, which are the basic units of chromatin. In yeast, there are three types of linker histones: H1a, H1b, and H1c. These histones are involved in the regulation of gene expression and play a role in the formation of higher-order chromatin structures.",
    "llama-7b_fact_raw": "1. A linker histone exists in the yeast genome.\n2. Linker histones are a type of histone protein that packages DNA into nucleosomes.\n3. Nucleosomes are the basic units of chromatin.\n4. In yeast, the types of linker histones are H1a, H1b, and H1c.\n5. Linker histones in yeast are involved in the regulation of gene expression and the formation of higher-order chromatin structures.",
    "llama-7b_fact": [
      "A linker histone exists in the yeast genome.",
      "Linker histones are a type of histone protein that packages DNA into nucleosomes.",
      "Nucleosomes are the basic units of chromatin.",
      "In yeast, the types of linker histones are H1a, H1b, and H1c.",
      "Linker histones in yeast are involved in the regulation of gene expression and the formation of higher-order chromatin structures."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Yeast, specifically Saccharomyces cerevisiae, does not have a canonical linker histone H1. Other yeast species may have H1 or H1-like proteins, but they are not as well-characterized as those in multicellular eukaryotes.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Since Saccharomyces cerevisiae does not have a canonical H1 linker histone, it does not have types such as H1a, H1b, and H1c. These subtypes are characteristic of multicellular eukaryotes that have multiple H1 variants.\n5. TRUE (with the caveat that this statement is true for organisms that have linker histones; however, as stated in response 1, Saccharomyces cerevisiae does not have a canonical H1 linker histone, but other yeast species may have H1 or H1-like proteins that could be involved in such regulatory processes.)",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "You MUST give a detailed answer to the following question: Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-7b_response": "There is limited evidence to support the claim that tomato juice can lower cholesterol levels. While tomatoes are a rich source of lycopene, a phytochemical that has been shown to have potential cholesterol-lowering properties, the amount of lycopene found in tomato juice is not sufficient to have a significant impact on cholesterol levels.\n\nA study published in the Journal of the American College of Nutrition in 2009 found that consuming tomato juice daily for four weeks did not significantly reduce cholesterol levels in healthy adults. The study suggested that other factors, such as the type and amount of fat in the diet, may play a more significant role in regulating cholesterol levels than the lycopene content of tomato products.\n\nAnother study published in the Journal of Nutrition in 2012 found that supplementing with lycopene did not significantly reduce cholesterol levels in overweight or obese adults.\n\nWhile tomato juice may have other health benefits, such as its high vitamin C and potassium content, there is currently insufficient evidence to support the claim that it can lower cholesterol levels. It is always best to consult with a healthcare professional before making dietary changes to manage cholesterol levels.",
    "llama-7b_fact_raw": "1. Tomatoes are a rich source of lycopene, a phytochemical that has been shown to have potential cholesterol-lowering properties.\n2. A study published in the Journal of the American College of Nutrition in 2009 found that consuming tomato juice daily for four weeks did not significantly reduce cholesterol levels in healthy adults.\n3. The 2009 study suggested that factors like the type and amount of fat in the diet may have a more significant impact on cholesterol levels than the lycopene content of tomato products.\n4. A study published in the Journal of Nutrition in 2012 found that supplementing with lycopene did not significantly reduce cholesterol levels in overweight or obese adults.\n5. Tomato juice is high in vitamin C and potassium.",
    "llama-7b_fact": [
      "Tomatoes are a rich source of lycopene, a phytochemical that has been shown to have potential cholesterol-lowering properties.",
      "A study published in the Journal of the American College of Nutrition in 2009 found that consuming tomato juice daily for four weeks did not significantly reduce cholesterol levels in healthy adults.",
      "The 2009 study suggested that factors like the type and amount of fat in the diet may have a more significant impact on cholesterol levels than the lycopene content of tomato products.",
      "A study published in the Journal of Nutrition in 2012 found that supplementing with lycopene did not significantly reduce cholesterol levels in overweight or obese adults.",
      "Tomato juice is high in vitamin C and potassium."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "You MUST give a detailed answer to the following question: How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-7b_response": "Hsp70 and Hsp110 are two types of heat shock proteins (HSPs) that play important roles in protecting cells from stress and maintaining cellular homeostasis. One of the functions of Hsp70 and Hsp110 is to regulate the stability of messenger RNA (mRNA).\n\nmRNA stability refers to the length of time that an mRNA molecule remains intact and functional within a cell. In general, mRNAs have a relatively short half-life, which means that they are degraded quickly by enzymes such as ribonuclease (RNase).\n\nHsp70 and Hsp110 can affect mRNA stability in several ways:\n\n1. Chaperone activity: Hsp70 and Hsp110 can bind to and stabilize mRNAs by acting as chaperones. They help to protect mRNAs from degradation by RNase and other enzymes, allowing them to remain intact and functional for longer periods of time.\n2. mRNA translation: Hsp70 and Hsp110 can also affect mRNA stability by regulating the translation of mRNAs. For example, they can bind to and inhibit the activity of eukaryotic initiation factor 4E (eIF4E), which is an important regulator of mRNA translation. By inhibiting eIF4E, Hsp70 and Hsp110 can reduce the rate of mRNA translation and prolong the half-life of mRNAs.\n3. mRNA decay: Hsp70 and Hsp110 can also participate in the process of mRNA decay, which is the breakdown of mRNAs by enzymes such as RNase. By binding to and inhibiting the activity of these enzymes, Hsp70 and Hsp110 can slow down the rate of mRNA decay and extend the half-life of mRNAs.\n\nIn summary, Hsp70 and Hsp110 can affect mRNA stability by acting as chaperones, regulating mRNA translation, and participating in the process of mRNA decay. These functions help to protect mRNAs from degradation",
    "llama-7b_fact_raw": "1. Hsp70 and Hsp110 are types of heat shock proteins that help in protecting cells from stress and maintaining cellular homeostasis.\n2. Hsp70 and Hsp110 can regulate the stability of messenger RNA (mRNA).\n3. Hsp70 and Hsp110 can bind to and stabilize mRNAs by acting as chaperones, protecting them from degradation by enzymes like ribonuclease (RNase).\n4. Hsp70 and Hsp110 can regulate mRNA translation by binding to and inhibiting the activity of eukaryotic initiation factor 4E (eIF4E).\n5. Hsp70 and Hsp110 can participate in the process of mRNA decay by binding to and inhibiting the activity of enzymes responsible for mRNA breakdown.",
    "llama-7b_fact": [
      "Hsp70 and Hsp110 are types of heat shock proteins that help in protecting cells from stress and maintaining cellular homeostasis.",
      "Hsp70 and Hsp110 can regulate the stability of messenger RNA (mRNA).",
      "Hsp70 and Hsp110 can bind to and stabilize mRNAs by acting as chaperones, protecting them from degradation by enzymes like ribonuclease (RNase).",
      "Hsp70 and Hsp110 can regulate mRNA translation by binding to and inhibiting the activity of eukaryotic initiation factor 4E (eIF4E).",
      "Hsp70 and Hsp110 can participate in the process of mRNA decay by binding to and inhibiting the activity of enzymes responsible for mRNA breakdown."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation:\n1. Hsp70 and Hsp110 are indeed types of heat shock proteins that play a crucial role in protecting cells from stress and maintaining cellular homeostasis by assisting in the proper folding of proteins and preventing the aggregation of misfolded proteins.\n\n2-5. The specific roles of Hsp70 and Hsp110 in regulating the stability of mRNA, binding to mRNAs, regulating mRNA translation, and participating in mRNA decay are more specialized functions that are not universally recognized or may only be supported by certain studies. Without specific references to scientific literature that confirm these roles, it is difficult to determine the truthfulness of these statements. Heat shock proteins are primarily known for their role in protein folding and stress response, but their involvement in mRNA regulation is a more nuanced topic that requires specific evidence.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "You MUST give a detailed answer to the following question: Which deiodinases are present in skeletal  muscle?",
    "llama-7b_response": "Deiodinases are enzymes that convert one type of thyroid hormone into another. There are three main types of deiodinases: type 1 (D1), type 2 (D2), and type 3 (D3).\n\nSkeletal muscle contains all three types of deiodinases. D1 is the most abundant type of deiodinase in skeletal muscle and is responsible for converting T4 to the active form of thyroid hormone, T3. D2 is also present in skeletal muscle and is responsible for converting T4 to the less active form of thyroid hormone, T2. D3 is the least abundant type of deiodinase in skeletal muscle and is responsible for converting T3 to the inactive form of thyroid hormone, rT3.\n\nIt is worth noting that the activity of these deiodinases can be regulated by a variety of factors, including thyroid hormone levels, nutrition, and exercise. For example, exercise can increase the activity of D1 and D2 in skeletal muscle, leading to an increase in T3 levels and improved muscle function.",
    "llama-7b_fact_raw": "1. There are three main types of deiodinases: type 1 (D1), type 2 (D2), and type 3 (D3).\n2. Skeletal muscle contains all three types of deiodinases.\n3. Type 1 deiodinase (D1) in skeletal muscle is responsible for converting T4 to the active form of thyroid hormone, T3.\n4. Type 2 deiodinase (D2) in skeletal muscle is responsible for converting T4 to the less active form of thyroid hormone, T2.\n5. Type 3 deiodinase (D3) in skeletal muscle is responsible for converting T3 to the inactive form of thyroid hormone, rT3.",
    "llama-7b_fact": [
      "There are three main types of deiodinases: type 1 (D1), type 2 (D2), and type 3 (D3).",
      "Skeletal muscle contains all three types of deiodinases.",
      "Type 1 deiodinase (D1) in skeletal muscle is responsible for converting T4 to the active form of thyroid hormone, T3.",
      "Type 2 deiodinase (D2) in skeletal muscle is responsible for converting T4 to the less active form of thyroid hormone, T2.",
      "Type 3 deiodinase (D3) in skeletal muscle is responsible for converting T3 to the inactive form of thyroid hormone, rT3."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Type 2 deiodinase (D2) in skeletal muscle is responsible for converting T4 to the active form of thyroid hormone, T3.\n4. FALSE [correction]: Type 2 deiodinase (D2) is responsible for converting T4 to T3, not T2. There is no deiodinase that converts T4 directly to T2.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 534,
    "user_query": "You MUST give a detailed answer to the following question: List inflammatory caspase proteins?",
    "llama-7b_response": "",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 579,
    "user_query": "You MUST give a detailed answer to the following question: Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-7b_response": "Yes, there is a link between the Aurora B kinase and the Polycomb protein Ring1B.\n\nAurora B is a serine/threonine kinase that plays a crucial role in the regulation of mitosis, the process of cell division. It is involved in the formation of mitotic spindles and the separation of chromosomes during cell division. Ring1B is a member of the Polycomb family of proteins, which are involved in the regulation of gene expression.\n\nStudies have shown that Aurora B and Ring1B interact with each other and that this interaction is important for the regulation of mitosis. Specifically, Aurora B phosphorylates Ring1B at multiple sites, which leads to the degradation of Ring1B and the repression of target genes. Conversely, the degradation of Ring1B leads to the activation of target genes, including those involved in the regulation of mitosis.\n\nFurthermore, studies have shown that the interaction between Aurora B and Ring1B is important for the regulation of cell proliferation and the development of cancer. For example, overexpression of Aurora B and Ring1B has been observed in various types of cancer, and these proteins have been implicated in the development of resistance to chemotherapy in cancer cells.\n\nIn summary, there is a clear link between Aurora B and Ring1B, and this link is important for the regulation of mitosis and the control of gene expression. Dysregulation of this interaction has been implicated in the development of cancer and other diseases.",
    "llama-7b_fact_raw": "1. Aurora B is a serine/threonine kinase that plays a crucial role in the regulation of mitosis.\n2. Ring1B is a member of the Polycomb family of proteins, which are involved in the regulation of gene expression.\n3. Aurora B phosphorylates Ring1B at multiple sites, leading to the degradation of Ring1B.\n4. The interaction between Aurora B and Ring1B is important for the regulation of cell proliferation and the development of cancer.\n5. Overexpression of Aurora B and Ring1B has been observed in various types of cancer.",
    "llama-7b_fact": [
      "Aurora B is a serine/threonine kinase that plays a crucial role in the regulation of mitosis.",
      "Ring1B is a member of the Polycomb family of proteins, which are involved in the regulation of gene expression.",
      "Aurora B phosphorylates Ring1B at multiple sites, leading to the degradation of Ring1B.",
      "The interaction between Aurora B and Ring1B is important for the regulation of cell proliferation and the development of cancer.",
      "Overexpression of Aurora B and Ring1B has been observed in various types of cancer."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Aurora B phosphorylates Ring1B at multiple sites, but this does not necessarily lead to the degradation of Ring1B. The phosphorylation can regulate Ring1B's function in various ways, but degradation is not the direct or sole outcome.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "You MUST give a detailed answer to the following question: What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-7b_response": "The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates include:\n\n1. GT-AG motif at the donor splice site: This is the canonical splice site motif and is recognized by the spliceosome.\n2. AT-AC motif at the acceptor splice site: This motif is also recognized by the spliceosome and plays a role in regulating alternative splicing.\n3. GU-AG motif at the donor splice site: This motif is found in some species, including humans, and is recognized by the spliceosome.\n4. UG-AG motif at the acceptor splice site: This motif is found in some species, including humans, and is recognized by the spliceosome.\n5. CU-AG motif at the acceptor splice site: This motif is found in some species, including humans, and is recognized by the spliceosome.\n6. GU-UA motif at the donor splice site: This motif is found in some species, including humans, and is recognized by the spliceosome.\n7. UG-UA motif at the acceptor splice site: This motif is found in some species, including humans, and is recognized by the spliceosome.\n8. CU-UA motif at the acceptor splice site: This motif is found in some species, including humans, and is recognized by the spliceosome.\n\nThese non-canonical motifs can affect splicing efficiency and may play a role in regulating alternative splicing events.",
    "llama-7b_fact_raw": "1. The GT-AG motif is a canonical splice site motif recognized by the spliceosome at the donor splice site in vertebrates.\n2. The AT-AC motif is recognized by the spliceosome at the acceptor splice site in vertebrates.\n3. The GU-AG motif is recognized by the spliceosome at the donor splice site in some species, including humans.\n4. The UG-AG motif is recognized by the spliceosome at the acceptor splice site in some species, including humans.\n5. Non-canonical splice site motifs can affect splicing efficiency and may regulate alternative splicing events in vertebrates.",
    "llama-7b_fact": [
      "The GT-AG motif is a canonical splice site motif recognized by the spliceosome at the donor splice site in vertebrates.",
      "The AT-AC motif is recognized by the spliceosome at the acceptor splice site in vertebrates.",
      "The GU-AG motif is recognized by the spliceosome at the donor splice site in some species, including humans.",
      "The UG-AG motif is recognized by the spliceosome at the acceptor splice site in some species, including humans.",
      "Non-canonical splice site motifs can affect splicing efficiency and may regulate alternative splicing events in vertebrates."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The AT-AC motif is recognized by the spliceosome at the minor-class intron splice sites, not the acceptor splice site in vertebrates.\n3. TRUE\n4. FALSE [correction]: The canonical motif recognized by the spliceosome at the acceptor splice site in vertebrates is AG-G, not UG-AG.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 629,
    "user_query": "You MUST give a detailed answer to the following question: Which event results in the acetylation of S6K1?",
    "llama-7b_response": "The acetylation of S6K1 (S6 kinase 1) is a post-translational modification that is regulated by a variety of signaling pathways. One event that can result in the acetylation of S6K1 is the activation of the mammalian target of rapamycin (mTOR) pathway.\n\nThe mTOR pathway is a key regulator of cell growth and metabolism, and it is activated in response to a variety of stimuli, including growth factors, nutrients, and energy. When the mTOR pathway is activated, it leads to the phosphorylation and activation of S6K1, which in turn stimulates the translation of a number of key cellular proteins, including ribosomal proteins.\n\nThe acetylation of S6K1 is thought to play a role in the regulation of its activity and stability. Acetylation of S6K1 can inhibit its activity by preventing its association with ribosomes, and it can also promote its degradation by the proteasome.\n\nTherefore, the activation of the mTOR pathway, which leads to the phosphorylation and activation of S6K1, is one event that can result in the acetylation of S6K1.",
    "llama-7b_fact_raw": "1. The acetylation of S6K1 is a post-translational modification.\n2. The mammalian target of rapamycin (mTOR) pathway activation can result in the acetylation of S6K1.\n3. The mTOR pathway is activated in response to stimuli such as growth factors, nutrients, and energy.\n4. Activation of the mTOR pathway leads to the phosphorylation and activation of S6K1.\n5. Acetylation of S6K1 can inhibit its activity and promote its degradation by the proteasome.",
    "llama-7b_fact": [
      "The acetylation of S6K1 is a post-translational modification.",
      "The mammalian target of rapamycin (mTOR) pathway activation can result in the acetylation of S6K1.",
      "The mTOR pathway is activated in response to stimuli such as growth factors, nutrients, and energy.",
      "Activation of the mTOR pathway leads to the phosphorylation and activation of S6K1.",
      "Acetylation of S6K1 can inhibit its activity and promote its degradation by the proteasome."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 632,
    "user_query": "You MUST give a detailed answer to the following question: What is the cause of episodic ataxia type 6?",
    "llama-7b_response": "Episodic ataxia type 6 is a rare genetic disorder that is caused by mutations in the CACNA1A gene. This gene provides instructions for making a protein called the alpha-1A subunit of the voltage-gated calcium channel, which is responsible for regulating the flow of calcium ions into nerve cells.\n\nThe CACNA1A gene is located on the long (q) arm of chromosome 12. Mutations in this gene can lead to changes in the function of the alpha-1A subunit of the voltage-gated calcium channel, which can disrupt the normal communication between nerve cells in the brain and the rest of the body.\n\nEpisodic ataxia type 6 is characterized by recurrent episodes of ataxia, which is a lack of coordination in the muscles, especially in the arms and legs. These episodes can be triggered by a variety of stimuli, such as stress, exercise, or exposure to heat or cold. Other symptoms of episodic ataxia type 6 may include dizziness, vertigo, nausea, and vomiting.\n\nThe severity of the symptoms can vary greatly from person to person, and some individuals may only experience a few episodes in their lifetime, while others may have frequent and severe episodes. There is currently no cure for episodic ataxia type 6, but medications can be used to manage the symptoms and prevent episodes from occurring.",
    "llama-7b_fact_raw": "1. Episodic ataxia type 6 is caused by mutations in the CACNA1A gene.\n2. The CACNA1A gene is responsible for making the alpha-1A subunit of the voltage-gated calcium channel.\n3. The CACNA1A gene is located on the long (q) arm of chromosome 12.\n4. Episodic ataxia type 6 is characterized by recurrent episodes of ataxia.\n5. Symptoms of episodic ataxia type 6 can include dizziness, vertigo, nausea, and vomiting.",
    "llama-7b_fact": [
      "Episodic ataxia type 6 is caused by mutations in the CACNA1A gene.",
      "The CACNA1A gene is responsible for making the alpha-1A subunit of the voltage-gated calcium channel.",
      "The CACNA1A gene is located on the long (q) arm of chromosome 12.",
      "Episodic ataxia type 6 is characterized by recurrent episodes of ataxia.",
      "Symptoms of episodic ataxia type 6 can include dizziness, vertigo, nausea, and vomiting."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The CACNA1A gene is located on the short (p) arm of chromosome 19 at position 13.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "You MUST give a detailed answer to the following question: Are chromomethylases present in animal genomes?",
    "llama-7b_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that add methyl groups to DNA, and they play a role in regulating gene expression. They are found in many organisms, including animals. In animals, chromomethylases are typically found in the nucleus of cells and are involved in a variety of processes, including DNA replication, transcription, and repair. Some examples of animals that have been shown to have chromomethylases include humans, mice, and fruit flies.",
    "llama-7b_fact_raw": "1. Chromomethylases are enzymes that add methyl groups to DNA.\n2. Chromomethylases play a role in regulating gene expression.\n3. Chromomethylases are found in the nucleus of cells in animals.\n4. Chromomethylases are involved in DNA replication, transcription, and repair in animals.\n5. Humans, mice, and fruit flies are examples of animals that have been shown to have chromomethylases.",
    "llama-7b_fact": [
      "Chromomethylases are enzymes that add methyl groups to DNA.",
      "Chromomethylases play a role in regulating gene expression.",
      "Chromomethylases are found in the nucleus of cells in animals.",
      "Chromomethylases are involved in DNA replication, transcription, and repair in animals.",
      "Humans, mice, and fruit flies are examples of animals that have been shown to have chromomethylases."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Chromomethylases are primarily involved in the modification of DNA through methylation, which can affect gene expression, but they are not directly involved in DNA replication, transcription, and repair. These processes are facilitated by other enzymes and proteins.\n5. FALSE [correction]: Chromomethylases are a type of DNA methyltransferase found in plants, not in animals. Animals have DNA methyltransferases, but they are not typically referred to as chromomethylases.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 650,
    "user_query": "You MUST give a detailed answer to the following question: List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-7b_response": "There are several packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis. Some of the most commonly used packages are:\n\n1. Chipster: This package provides tools for the analysis of ChIP-chip and ChIP-seq data. It includes functions for mapping reads to the reference genome, detecting peaks, and visualizing the distribution of peaks across the genome.\n2. Bedtools: This package provides tools for working with bed files, which are used to store genomic data. It includes functions for sorting, filtering, and aligning bed files, as well as functions for visualizing the distribution of peaks across the genome.\n3. GenomicRanges: This package provides tools for working with genomic ranges, which are used to store genomic data. It includes functions for sorting, filtering, and aligning genomic ranges, as well as functions for visualizing the distribution of peaks across the genome.\n4. TopHat: This package provides tools for aligning RNA-seq data to a reference genome. It includes functions for detecting transcription start sites, splice junctions, and transcription factor binding sites.\n5. Cistrome: This package provides tools for the analysis of ChIP-seq data from chromatin immunoprecipitation experiments. It includes functions for mapping reads to the reference genome, detecting peaks, and visualizing the distribution of peaks across the genome.\n6. HOMER: This package provides tools for the analysis of ChIP-chip and ChIP-seq data. It includes functions for mapping reads to the reference genome, detecting peaks, and visualizing the distribution of peaks across the genome. It also includes functions for modeling the binding sites of transcription factors and for predicting the binding sites of unknown transcription factors.\n7. RegulatoryGenomics: This package provides tools for the analysis of ChIP-chip and ChIP-seq data. It includes functions for mapping reads to the reference genome, detecting peaks, and visualizing the distribution of peaks across the genome. It also includes functions for modeling the binding sites of transcription factors and for predicting the binding sites of unknown transcription factors.\n\nThese are just a few of the many packages available in R/Bioconductor for",
    "llama-7b_fact_raw": "1. Chipster is a package in R/Bioconductor for ChIP-chip and ChIP-seq data analysis.\n2. Bedtools is a package in R/Bioconductor that provides tools for working with bed files.\n3. GenomicRanges is a package in R/Bioconductor that provides tools for working with genomic ranges.\n4. TopHat is a package in R/Bioconductor for aligning RNA-seq data to a reference genome.\n5. Cistrome is a package in R/Bioconductor for ChIP-seq data analysis from chromatin immunoprecipitation experiments.",
    "llama-7b_fact": [
      "Chipster is a package in R/Bioconductor for ChIP-chip and ChIP-seq data analysis.",
      "Bedtools is a package in R/Bioconductor that provides tools for working with bed files.",
      "GenomicRanges is a package in R/Bioconductor that provides tools for working with genomic ranges.",
      "TopHat is a package in R/Bioconductor for aligning RNA-seq data to a reference genome.",
      "Cistrome is a package in R/Bioconductor for ChIP-seq data analysis from chromatin immunoprecipitation experiments."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Chipster is not a package in R/Bioconductor. It is a user-friendly bioinformatics software for analyzing high-throughput data such as ChIP-chip and ChIP-seq, but it is not part of the R/Bioconductor project.\n2. FALSE [correction]: Bedtools is not a package in R/Bioconductor. It is a suite of command-line tools for working with genomic intervals in various formats such as BED, but it is not part of the R/Bioconductor project.\n3. TRUE\n4. FALSE [correction]: TopHat is not a package in R/Bioconductor. It is a fast splice junction mapper for RNA-seq reads but is not part of the R/Bioconductor project. It is typically used in conjunction with the Bowtie aligner.\n5. FALSE [correction]: Cistrome is not a package in R/Bioconductor. It refers to the Cistrome Data Browser, which is a web-based tool for ChIP-seq and chromatin accessibility data analysis. It is not an R/Bioconductor package.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "You MUST give a detailed answer to the following question: List clinical trials for prevention of sarcopenia",
    "llama-7b_response": "Sure, here are some clinical trials for the prevention of sarcopenia:\n\n1. Sarcopenia Prevention with Resistance Training and Nutritional Supplementation (SPRINT): This is a randomized, double-blind, placebo-controlled trial that aims to determine the effectiveness of resistance training and nutritional supplementation in preventing sarcopenia in older adults.\n2. Sarcopenia: Prevention and Treatment (SPARC): This is a multicenter, randomized, double-blind, placebo-controlled trial that aims to evaluate the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.\n3. Sarcopenia: Prevention and Treatment with Resistance Training and Nutritional Supplementation (SPARTAN): This is a randomized, double-blind, placebo-controlled trial that aims to determine the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.\n4. Sarcopenia Prevention and Treatment Trial (SPATT): This is a randomized, double-blind, placebo-controlled trial that aims to evaluate the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.\n5. Sarcopenia Prevention and Treatment with Resistance Training and Nutritional Supplementation (SPARTS): This is a randomized, double-blind, placebo-controlled trial that aims to determine the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.\n\nThese are just a few examples of clinical trials that are currently being conducted or have been conducted in the past to study the prevention of sarcopenia.",
    "llama-7b_fact_raw": "1. The SPRINT trial is a randomized, double-blind, placebo-controlled trial focused on preventing sarcopenia in older adults through resistance training and nutritional supplementation.\n2. The SPARC trial is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.\n3. The SPARTAN trial is a randomized, double-blind, placebo-controlled trial aimed at determining the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.\n4. The SPATT trial is a randomized, double-blind, placebo-controlled trial that assesses the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.\n5. The SPARTS trial is a randomized, double-blind, placebo-controlled trial designed to determine the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.",
    "llama-7b_fact": [
      "The SPRINT trial is a randomized, double-blind, placebo-controlled trial focused on preventing sarcopenia in older adults through resistance training and nutritional supplementation.",
      "The SPARC trial is a multicenter, randomized, double-blind, placebo-controlled trial evaluating the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.",
      "The SPARTAN trial is a randomized, double-blind, placebo-controlled trial aimed at determining the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.",
      "The SPATT trial is a randomized, double-blind, placebo-controlled trial that assesses the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults.",
      "The SPARTS trial is a randomized, double-blind, placebo-controlled trial designed to determine the effectiveness of resistance training and nutritional supplementation in preventing and treating sarcopenia in older adults."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the trials mentioned (SPRINT, SPARC, SPARTAN, SPATT, SPARTS), it is not possible to determine the accuracy of the statements provided. These could be real trials with accurate descriptions, or they could be fictional or described incorrectly. Additional context or sources would be required to verify the truthfulness of each statement.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "You MUST give a detailed answer to the following question: Which is the database of molecular recognition features in membrane proteins?",
    "llama-7b_response": "There are several databases that contain information on molecular recognition features in membrane proteins, including:\n\n1. The Protein Data Bank (PDB): The PDB is a public database of three-dimensional structural data for proteins, nucleic acids, and complex assemblies. It contains a large number of structures of membrane proteins, including those with molecular recognition features.\n2. The Database of Membrane Proteins (DMP): The DMP is a comprehensive database of three-dimensional structures of membrane proteins. It contains structures of a wide range of membrane proteins, including those with molecular recognition features.\n3. The Membrane Protein Data Bank (MPDB): The MPDB is a subset of the PDB that contains only structures of membrane proteins. It contains a large number of structures of membrane proteins with molecular recognition features.\n4. The Membrane Protein Structure and Function Resource (MPSF): The MPSF is a database that provides information on the structure, function, and evolution of membrane proteins. It contains a large number of structures of membrane proteins with molecular recognition features.\n\nOverall, these databases provide a wealth of information on the structure and function of membrane proteins, including those with molecular recognition features.",
    "llama-7b_fact_raw": "1. The Protein Data Bank (PDB) is a public database that includes three-dimensional structural data for proteins, nucleic acids, and complex assemblies.\n2. The Database of Membrane Proteins (DMP) is a comprehensive database that contains three-dimensional structures of membrane proteins.\n3. The Membrane Protein Data Bank (MPDB) is a subset of the PDB that exclusively contains structures of membrane proteins.\n4. The Membrane Protein Structure and Function Resource (MPSF) provides information on the structure, function, and evolution of membrane proteins.",
    "llama-7b_fact": [
      "The Protein Data Bank (PDB) is a public database that includes three-dimensional structural data for proteins, nucleic acids, and complex assemblies.",
      "The Database of Membrane Proteins (DMP) is a comprehensive database that contains three-dimensional structures of membrane proteins.",
      "The Membrane Protein Data Bank (MPDB) is a subset of the PDB that exclusively contains structures of membrane proteins.",
      "The Membrane Protein Structure and Function Resource (MPSF) provides information on the structure, function, and evolution of membrane proteins."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. FALSE [correction]: There is no specific subset of the PDB called the Membrane Protein Data Bank (MPDB) that exclusively contains structures of membrane proteins. The PDB itself includes membrane protein structures among various other biological macromolecules.\n4. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "You MUST give a detailed answer to the following question: Is rivaroxaban metabolized in kidneys?",
    "llama-7b_response": "Yes, rivaroxaban is metabolized in the kidneys. Rivaroxaban is a direct factor Xa inhibitor that is primarily metabolized by the liver through glucuronidation and sulfation. However, the kidneys also play a role in the metabolism of rivaroxaban by eliminating unchanged drug and its metabolites in the urine.\n\nThe metabolism of rivaroxaban is primarily mediated by the cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C9. These enzymes are primarily located in the liver, but they can also be expressed in other organs, including the kidneys. Therefore, the kidneys can contribute to the metabolism of rivaroxaban by expressing these enzymes and metabolizing the drug.\n\nIn addition, the kidneys play a role in the elimination of rivaroxaban and its metabolites. Unchanged rivaroxaban and its metabolites are excreted in the urine, and the kidneys are responsible for filtering and eliminating the drug and its metabolites from the body.\n\nTherefore, while the liver is the primary site of metabolism for rivaroxaban, the kidneys also play a role in its metabolism and elimination from the body.",
    "llama-7b_fact_raw": "1. Rivaroxaban is metabolized by the liver through glucuronidation and sulfation.\n2. The kidneys eliminate unchanged rivaroxaban and its metabolites in the urine.\n3. The cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C9 are involved in the metabolism of rivaroxaban.\n4. CYP3A4 and CYP2C9 enzymes are primarily located in the liver but can also be expressed in the kidneys.\n5. The kidneys are responsible for filtering and eliminating rivaroxaban and its metabolites from the body.",
    "llama-7b_fact": [
      "Rivaroxaban is metabolized by the liver through glucuronidation and sulfation.",
      "The kidneys eliminate unchanged rivaroxaban and its metabolites in the urine.",
      "The cytochrome P450 (CYP) enzymes CYP3A4 and CYP2C9 are involved in the metabolism of rivaroxaban.",
      "CYP3A4 and CYP2C9 enzymes are primarily located in the liver but can also be expressed in the kidneys.",
      "The kidneys are responsible for filtering and eliminating rivaroxaban and its metabolites from the body."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Rivaroxaban is primarily metabolized by the liver through the cytochrome P450 enzymes, mainly CYP3A4 and CYP2J2, and also through hydrolysis.\n2. TRUE\n3. FALSE [correction]: The cytochrome P450 (CYP) enzymes involved in the metabolism of rivaroxaban are CYP3A4 and CYP2J2, not CYP2C9.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "You MUST give a detailed answer to the following question: Which genes are regulated by TRalpha2  in the heart?",
    "llama-7b_response": "TRalpha2, also known as thyroid hormone receptor alpha 2, is a nuclear receptor that plays a crucial role in regulating the expression of genes involved in various physiological processes, including metabolism, development, and growth. In the heart, TRalpha2 has been shown to play a role in the regulation of cardiac function and development.\n\nStudies have identified several genes that are regulated by TRalpha2 in the heart. For example, TRalpha2 has been shown to regulate the expression of genes involved in the development and maturation of cardiac muscle cells, including genes that encode proteins involved in the formation of cardiac muscle fibers, the regulation of heart rate, and the maintenance of cardiac contractility.\n\nAdditionally, TRalpha2 has been shown to regulate the expression of genes involved in the response to stress and injury in the heart. For example, TRalpha2 has been shown to regulate the expression of genes involved in the production of antioxidant enzymes, such as superoxide dismutase and catalase, which help to protect the heart against oxidative stress and injury.\n\nOverall, TRalpha2 plays an important role in regulating the expression of genes involved in the development, maturation, and maintenance of cardiac function, as well as the response to stress and injury in the heart.",
    "llama-7b_fact_raw": "1. TRalpha2, also known as thyroid hormone receptor alpha 2, is a nuclear receptor involved in regulating gene expression related to metabolism, development, and growth.\n2. TRalpha2 plays a role in the regulation of cardiac function and development in the heart.\n3. TRalpha2 regulates the expression of genes involved in the development and maturation of cardiac muscle cells.\n4. TRalpha2 influences the regulation of heart rate and maintenance of cardiac contractility through gene expression.\n5. TRalpha2 regulates the expression of genes that produce antioxidant enzymes like superoxide dismutase and catalase in the heart.",
    "llama-7b_fact": [
      "TRalpha2, also known as thyroid hormone receptor alpha 2, is a nuclear receptor involved in regulating gene expression related to metabolism, development, and growth.",
      "TRalpha2 plays a role in the regulation of cardiac function and development in the heart.",
      "TRalpha2 regulates the expression of genes involved in the development and maturation of cardiac muscle cells.",
      "TRalpha2 influences the regulation of heart rate and maintenance of cardiac contractility through gene expression.",
      "TRalpha2 regulates the expression of genes that produce antioxidant enzymes like superoxide dismutase and catalase in the heart."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first four statements are consistent with the known functions of thyroid hormone receptors, including TRalpha2, which are involved in regulating gene expression related to metabolism, development, growth, and cardiac function. However, the fifth statement is specific and would require more detailed scientific evidence to confirm whether TRalpha2 directly regulates the expression of genes that produce antioxidant enzymes like superoxide dismutase and catalase in the heart. Without specific evidence or context, the truth of this statement cannot be determined.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "You MUST give a detailed answer to the following question: List available biomedical question answering systems.",
    "llama-7b_response": "There are several biomedical question answering systems available, including:\n\n1. Clinical Question Answering (CRAQ) system: This system is designed to answer clinical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n2. Biocreative 2 system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n3. Biomedical Question Answering (Bio-QA) system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n4. Biomedical Text Analysis and Knowledge Extraction (BTAKE) system: This system is designed to extract biomedical knowledge from unstructured text. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n5. Biomedical Text Mining (BTM) system: This system is designed to extract biomedical knowledge from unstructured text. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n6. Biomedical Question Answering (Bio-QA) system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n7. Biomedical Question Answering (Bio-QA) system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n8. Biomedical Question Answering (Bio-QA) system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n9. Biomedical Question Answering (Bio-QA) system: This system is designed to answer biomedical questions posed in natural language. It uses a combination of natural language processing and machine learning techniques to extract relevant information from unstructured text.\n10.",
    "llama-7b_fact_raw": "1. The Clinical Question Answering (CRAQ) system is designed to answer clinical questions using natural language processing and machine learning.\n2. The Biocreative 2 system is a biomedical question answering system that employs natural language processing and machine learning.\n3. The Biomedical Question Answering (Bio-QA) system is intended to answer biomedical questions through natural language processing and machine learning techniques.\n4. The Biomedical Text Analysis and Knowledge Extraction (BTAKE) system is aimed at extracting biomedical knowledge using natural language processing and machine learning.\n5. The Biomedical Text Mining (BTM) system focuses on extracting biomedical knowledge from unstructured text with the help of natural language processing and machine learning.",
    "llama-7b_fact": [
      "The Clinical Question Answering (CRAQ) system is designed to answer clinical questions using natural language processing and machine learning.",
      "The Biocreative 2 system is a biomedical question answering system that employs natural language processing and machine learning.",
      "The Biomedical Question Answering (Bio-QA) system is intended to answer biomedical questions through natural language processing and machine learning techniques.",
      "The Biomedical Text Analysis and Knowledge Extraction (BTAKE) system is aimed at extracting biomedical knowledge using natural language processing and machine learning.",
      "The Biomedical Text Mining (BTM) system focuses on extracting biomedical knowledge from unstructured text with the help of natural language processing and machine learning."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are about specific systems (CRAQ, Biocreative 2, Bio-QA, BTAKE, and BTM) that involve natural language processing and machine learning in the biomedical field. Without additional context or information about these specific systems, it is not possible to verify the accuracy of the statements. Therefore, the truthfulness of these statements remains unknown.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "You MUST give a detailed answer to the following question: Which trancription factor activates the betalain pathway?",
    "llama-7b_response": "The betalain pathway is activated by the transcription factor MYB.\n\nMYB is a transcription factor that belongs to the MYB family of proteins. It is a DNA-binding protein that plays a crucial role in the regulation of gene expression by binding to specific DNA sequences known as MYB boxes.\n\nIn the case of the betalain pathway, MYB binds to specific MYB boxes located in the promoter region of genes involved in the biosynthesis of betalain pigments. Once bound to these MYB boxes, MYB activates the transcription of these genes, leading to the production of enzymes involved in the biosynthesis of betalain pigments.\n\nThe activation of the betalain pathway by MYB is a complex process that involves multiple steps. First, MYB binds to specific DNA sequences known as MYB boxes, which are located in the promoter region of genes involved in betalain biosynthesis. Once bound to these MYB boxes, MYB recruits other transcription factors and co-factors, which help to activate the transcription of these genes.\n\nIn addition to activating the transcription of genes involved in betalain biosynthesis, MYB also plays a role in the regulation of gene expression at the post-transcriptional level. It has been shown to interact with microRNAs, which are small non-coding RNAs that play a role in the regulation of gene expression at the post-transcriptional level.\n\nIn summary, the transcription factor MYB plays a crucial role in the activation of the betalain pathway by binding to specific DNA sequences known as MYB boxes located in the promoter region of genes involved in betalain biosynthesis. It activates the transcription of these genes and also plays a role in the regulation of gene expression at the post-transcriptional level.",
    "llama-7b_fact_raw": "1. The transcription factor MYB activates the betalain pathway.\n2. MYB belongs to the MYB family of proteins.\n3. MYB is a DNA-binding protein that regulates gene expression by binding to specific DNA sequences known as MYB boxes.\n4. MYB boxes are located in the promoter region of genes involved in the biosynthesis of betalain pigments.\n5. MYB recruits other transcription factors and co-factors to activate the transcription of genes involved in betalain biosynthesis.",
    "llama-7b_fact": [
      "The transcription factor MYB activates the betalain pathway.",
      "MYB belongs to the MYB family of proteins.",
      "MYB is a DNA-binding protein that regulates gene expression by binding to specific DNA sequences known as MYB boxes.",
      "MYB boxes are located in the promoter region of genes involved in the biosynthesis of betalain pigments.",
      "MYB recruits other transcription factors and co-factors to activate the transcription of genes involved in betalain biosynthesis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the general knowledge about MYB transcription factors, which are known to regulate gene expression by binding to specific DNA sequences (MYB boxes) and can recruit other transcription factors and co-factors to activate transcription. However, without specific scientific references, the exact details such as the role of MYB in the betalain pathway cannot be confirmed, but the statements are plausible based on the general functions of MYB transcription factors.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "You MUST give a detailed answer to the following question: Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-7b_response": "There are several technologies that are commonly used for the enrichment of phosphorylated peptides in global quantitative phosphoproteomic analyses. Here are some of the preferred technologies:\n\n1. TiO2 beads: TiO2 beads are one of the most widely used technologies for the enrichment of phosphorylated peptides. They are coated with TiO2 nanoparticles that have a high affinity for phosphorylated serine/threonine residues. The beads are mixed with the sample and then washed to remove unbound peptides. The phosphorylated peptides are then eluted and subjected to mass spectrometry analysis.\n2. IMAC (immobilized metal affinity chromatography): IMAC is another popular technology for the enrichment of phosphorylated peptides. In this method, metal ions such as nickel or gold are immobilized on a column and the sample is passed through the column. Phosphorylated peptides bind to the metal ions, while non-phosphorylated peptides do not. The bound peptides are then eluted and subjected to mass spectrometry analysis.\n3. StrepTactin beads: StrepTactin beads are another type of beads that are used for the enrichment of phosphorylated peptides. They are coated with a protein called StrepTactin that has a high affinity for phosphorylated tyrosine residues. The beads are mixed with the sample and then washed to remove unbound peptides. The phosphorylated peptides are then eluted and subjected to mass spectrometry analysis.\n4. Phosphopeptide enrichment by liquid chromatography (LC): Liquid chromatography (LC) can also be used for the enrichment of phosphorylated peptides. In this method, the sample is passed through a column that is coated with a ligand that selectively binds to phosphorylated peptides. The bound peptides are then eluted and subjected to mass spectrometry analysis.\n\nOverall, the choice of technology for the enrichment of phosphoryl",
    "llama-7b_fact_raw": "1. TiO2 beads are used for the enrichment of phosphorylated peptides and have a high affinity for phosphorylated serine/threonine residues.\n2. IMAC involves immobilizing metal ions on a column to bind phosphorylated peptides for enrichment.\n3. StrepTactin beads are used for the enrichment of phosphorylated peptides and have a high affinity for phosphorylated tyrosine residues.\n4. Liquid chromatography can be used for the enrichment of phosphorylated peptides by passing the sample through a column coated with a ligand that selectively binds to them.\n5. The enriched phosphorylated peptides are typically subjected to mass spectrometry analysis.",
    "llama-7b_fact": [
      "TiO2 beads are used for the enrichment of phosphorylated peptides and have a high affinity for phosphorylated serine/threonine residues.",
      "IMAC involves immobilizing metal ions on a column to bind phosphorylated peptides for enrichment.",
      "StrepTactin beads are used for the enrichment of phosphorylated peptides and have a high affinity for phosphorylated tyrosine residues.",
      "Liquid chromatography can be used for the enrichment of phosphorylated peptides by passing the sample through a column coated with a ligand that selectively binds to them.",
      "The enriched phosphorylated peptides are typically subjected to mass spectrometry analysis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: StrepTactin beads are used for the affinity purification of Strep-tagged proteins, not for the enrichment of phosphorylated peptides.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "You MUST give a detailed answer to the following question: Which disorder is rated by Palmini classification?",
    "llama-7b_response": "The Palmini classification is a system used to rate the severity of eating disorders, such as anorexia nervosa, bulimia nervosa, and binge eating disorder. The classification is based on the patient's body mass index (BMI), which is calculated by dividing a person's weight in kilograms by their height in meters squared.\n\nThe Palmini classification is as follows:\n\n* Class 1: BMI < 17.5\n* Class 2: BMI 17.5-18.4\n* Class 3: BMI 18.5-20.9\n* Class 4: BMI 21-23.9\n* Class 5: BMI 24-27.4\n* Class 6: BMI 27.5-30.9\n* Class 7: BMI 31-34.9\n* Class 8: BMI 35-39.9\n* Class 9: BMI 40-49.9\n* Class 10: BMI 50-59.9\n* Class 11: BMI 60-69.9\n* Class 12: BMI 70-81.9\n* Class 13: BMI 82-91.9\n* Class 14: BMI 92-100\n* Class 15: BMI 101-110\n* Class 16: BMI 111-120\n* Class 17: BMI 121-130\n* Class 18: BMI 131-140\n* Class 19: BMI 141-150\n* Class 20: BMI 151-160\n* Class 21: BMI 161-170\n* Class 22: BMI 171-180\n* Class 23: BMI 181-190\n* Class 24: BMI 191-200\n* Class 25: BMI 201-2",
    "llama-7b_fact_raw": "1. The Palmini classification is used to rate the severity of eating disorders.\n2. The Palmini classification includes anorexia nervosa, bulimia nervosa, and binge eating disorder.\n3. The classification system is based on the patient's body mass index (BMI).\n4. BMI is calculated by dividing a person's weight in kilograms by their height in meters squared.\n5. The Palmini classification has 25 classes, ranging from a BMI of less than 17.5 to a BMI of 201-2.",
    "llama-7b_fact": [
      "The Palmini classification is used to rate the severity of eating disorders.",
      "The Palmini classification includes anorexia nervosa, bulimia nervosa, and binge eating disorder.",
      "The classification system is based on the patient's body mass index (BMI).",
      "BMI is calculated by dividing a person's weight in kilograms by their height in meters squared.",
      "The Palmini classification has 25 classes, ranging from a BMI of less than 17.5 to a BMI of 201-2."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Palmini classification is not used to rate the severity of eating disorders; it is used for classifying the severity of epilepsy.\n2. FALSE [correction]: Since the Palmini classification is not for eating disorders, it does not include anorexia nervosa, bulimia nervosa, and binge eating disorder.\n3. FALSE [correction]: The Palmini classification is not based on BMI; it is based on different factors related to epilepsy.\n4. TRUE\n5. FALSE [correction]: The Palmini classification does not have 25 classes based on BMI; this statement seems to confuse a classification system for eating disorders with the Palmini classification for epilepsy.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 905,
    "user_query": "You MUST give a detailed answer to the following question: Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-7b_response": "No, viruses are not typically involved in the etiology of human subacute thyroiditis. Subacute thyroiditis is an inflammatory condition of the thyroid gland that is typically caused by a viral infection of the upper respiratory tract, such as a cold or the flu. However, the association between viral infections and subacute thyroiditis is not well established, and other factors, such as autoimmune disorders, may also play a role in the development of this condition.",
    "llama-7b_fact_raw": "1. Viruses are not typically involved in the etiology of human subacute thyroiditis.\n2. Subacute thyroiditis is an inflammatory condition of the thyroid gland.\n3. Subacute thyroiditis is typically caused by a viral infection of the upper respiratory tract.\n4. Colds or the flu are examples of viral infections that can lead to subacute thyroiditis.\n5. Autoimmune disorders may also play a role in the development of subacute thyroiditis.",
    "llama-7b_fact": [
      "Viruses are not typically involved in the etiology of human subacute thyroiditis.",
      "Subacute thyroiditis is an inflammatory condition of the thyroid gland.",
      "Subacute thyroiditis is typically caused by a viral infection of the upper respiratory tract.",
      "Colds or the flu are examples of viral infections that can lead to subacute thyroiditis.",
      "Autoimmune disorders may also play a role in the development of subacute thyroiditis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "You MUST give a detailed answer to the following question: Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-7b_response": "STAT3 (signal transducer and activator of transcription 3) is a transcription factor that plays a crucial role in various cellular processes, including cell growth, differentiation, and immune response. STAT3 has been implicated in the regulation of autophagy, a cellular process involved in the degradation and recycling of cellular components. However, the role of STAT3 in EIF2AK2-dependent suppression of autophagy is not well understood.\n\nEIF2AK2 (eukaryotic initiation factor 2 alpha kinase 2), also known as PKR (double-stranded RNA-dependent protein kinase), is a protein kinase that plays a key role in the regulation of cellular stress responses, including the suppression of autophagy. EIF2AK2 has been shown to interact with STAT3 and regulate its transcriptional activity. However, the precise mechanism by which EIF2AK2 regulates STAT3 in the suppression of autophagy is not fully understood.\n\nSome studies have suggested that STAT3 may play a role in the regulation of autophagy. For example, STAT3 has been shown to regulate the expression of autophagy-related genes, such as BECN1 (Beclin 1) and ATG5 (autophagy-related 5), which are key components of the autophagy machinery. Additionally, STAT3 has been shown to interact with and regulate the activity of other autophagy-related proteins, such as ULK1 (unc-51-like kinase 1) and ATG9 (autophagy-related 9). However, the role of STAT3 in EIF2AK2-dependent suppression of autophagy is not well understood.\n\nIn summary, while there is some evidence to suggest that STAT3 may be involved in the regulation of autophagy, the precise role of STAT3 in EIF2AK2-dependent suppression of autophagy is not well understood. Further research is needed to elucidate the precise mechanisms by which STAT3 and EIF2AK2 interact to regulate autophagy.",
    "llama-7b_fact_raw": "1. STAT3 is a transcription factor involved in cell growth, differentiation, and immune response.\n2. STAT3 has been implicated in the regulation of autophagy.\n3. EIF2AK2, also known as PKR, is a protein kinase that plays a role in the regulation of cellular stress responses, including the suppression of autophagy.\n4. EIF2AK2 has been shown to interact with STAT3 and regulate its transcriptional activity.\n5. STAT3 has been shown to regulate the expression of autophagy-related genes such as BECN1 and ATG5.",
    "llama-7b_fact": [
      "STAT3 is a transcription factor involved in cell growth, differentiation, and immune response.",
      "STAT3 has been implicated in the regulation of autophagy.",
      "EIF2AK2, also known as PKR, is a protein kinase that plays a role in the regulation of cellular stress responses, including the suppression of autophagy.",
      "EIF2AK2 has been shown to interact with STAT3 and regulate its transcriptional activity.",
      "STAT3 has been shown to regulate the expression of autophagy-related genes such as BECN1 and ATG5."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: EIF2AK2, also known as PKR, is a protein kinase that plays a role in the regulation of cellular stress responses, including the activation of autophagy, not the suppression of autophagy.\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "You MUST give a detailed answer to the following question: Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-7b_response": "The Theatre software tool is a genomic analysis tool that is used to visualize and analyze large-scale genomic data sets. It is designed to help researchers and clinicians better understand the structure and organization of the human genome, as well as identify genetic variations that may be associated with disease.\n\nTheatre allows users to view and analyze genomic data on a large scale, making it easier to identify patterns and relationships that may not be visible using other tools. It can be used to visualize and analyze a wide range of genomic data, including whole-genome and exome sequencing data, as well as data from other types of genomic studies.\n\nOne of the key features of Theatre is its ability to handle large data sets. It can be used to analyze data from thousands of individuals, allowing researchers to identify patterns and relationships that may not be visible using other tools. This makes it a valuable tool for identifying genetic variants that may be associated with disease, as well as for studying the genetic basis of complex traits and diseases.\n\nIn addition to its ability to handle large data sets, Theatre also has a number of other features that make it a powerful tool for genomic analysis. It includes a range of visualization tools that allow users to explore and analyze genomic data in a variety of ways. It also includes a number of analysis tools that can be used to identify genetic variants that may be associated with disease, as well as to study the genetic basis of complex traits and diseases.\n\nOverall, the Theatre software tool is a valuable tool for genomic analysis. It is designed to help researchers and clinicians better understand the structure and organization of the human genome, as well as identify genetic variations that may be associated with disease. Its ability to handle large data sets and its range of visualization and analysis tools make it a powerful tool for genomic analysis.",
    "llama-7b_fact_raw": "1. The Theatre software tool is used for visualizing and analyzing large-scale genomic data sets.\n2. Theatre is designed to assist in understanding the human genome structure and organization.\n3. The software can identify genetic variations that may be associated with diseases.\n4. Theatre can analyze data from thousands of individuals, including whole-genome and exome sequencing data.\n5. The tool includes visualization and analysis features to explore genomic data and identify genetic variants related to disease and complex traits.",
    "llama-7b_fact": [
      "The Theatre software tool is used for visualizing and analyzing large-scale genomic data sets.",
      "Theatre is designed to assist in understanding the human genome structure and organization.",
      "The software can identify genetic variations that may be associated with diseases.",
      "Theatre can analyze data from thousands of individuals, including whole-genome and exome sequencing data.",
      "The tool includes visualization and analysis features to explore genomic data and identify genetic variants related to disease and complex traits."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about a software tool named \"Theatre\" related to genomics, it is not possible to determine the accuracy of these statements. The statements could be true if there is a genomic data analysis tool by that name with those capabilities, but without additional context or confirmation, the truthfulness of these statements remains unknown.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "You MUST give a detailed answer to the following question: Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-7b_response": "The Smith-Waterman algorithm is a dynamic programming algorithm used for the alignment of two sequences. The execution time (complexity) of the Smith-Waterman algorithm depends on several factors, including the length of the sequences being aligned, the similarity between the sequences, and the gap penalty and gap extension parameters used in the algorithm.\n\nIn general, the execution time of the Smith-Waterman algorithm increases exponentially with the length of the sequences being aligned. For example, the time complexity of the algorithm for aligning two sequences of length n is O(n^2). This means that as the length of the sequences increases, the algorithm becomes slower and slower.\n\nThe Smith-Waterman algorithm also has a time complexity that depends on the similarity between the sequences being aligned. Sequences that are more similar will take less time to align than sequences that are less similar.\n\nThe gap penalty and gap extension parameters used in the Smith-Waterman algorithm also affect the execution time of the algorithm. Gap penalties are used to penalize the algorithm for inserting or deleting gaps in the alignment, while gap extensions are used to extend the length of gaps in the alignment. The choice of gap penalty and gap extension parameters can significantly affect the execution time of the algorithm.\n\nIn summary, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the length of the sequences, the similarity between the sequences, and the gap penalty and gap extension parameters used in the algorithm. The time complexity of the algorithm is generally O(n^2) and can be affected by the similarity between the sequences and the choice of gap penalty and gap extension parameters.",
    "llama-7b_fact_raw": "1. The Smith-Waterman algorithm is a dynamic programming algorithm used for the alignment of two sequences.\n2. The time complexity of the Smith-Waterman algorithm for aligning two sequences of length n is O(n^2).\n3. The execution time of the Smith-Waterman algorithm increases exponentially with the length of the sequences being aligned.\n4. The similarity between the sequences being aligned affects the execution time of the Smith-Waterman algorithm.\n5. The choice of gap penalty and gap extension parameters can significantly affect the execution time of the Smith-Waterman algorithm.",
    "llama-7b_fact": [
      "The Smith-Waterman algorithm is a dynamic programming algorithm used for the alignment of two sequences.",
      "The time complexity of the Smith-Waterman algorithm for aligning two sequences of length n is O(n^2).",
      "The execution time of the Smith-Waterman algorithm increases exponentially with the length of the sequences being aligned.",
      "The similarity between the sequences being aligned affects the execution time of the Smith-Waterman algorithm.",
      "The choice of gap penalty and gap extension parameters can significantly affect the execution time of the Smith-Waterman algorithm."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The execution time of the Smith-Waterman algorithm increases quadratically, not exponentially, with the length of the sequences being aligned, as it has a time complexity of O(n^2).\n4. UNKNOWN: The similarity between sequences does not directly affect the execution time since the algorithm still needs to perform the same number of comparisons. However, the similarity can affect the traceback process to some extent, but this is not typically considered a significant factor in execution time.\n5. UNKNOWN: The choice of gap penalty and gap extension parameters affects the scoring of the alignment, which can lead to different alignments being chosen, but it does not significantly affect the execution time of the algorithm itself, which is primarily determined by the lengths of the sequences.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1004,
    "user_query": "You MUST give a detailed answer to the following question: Which SLC family is FLVCR1 a member of?",
    "llama-7b_response": "FLVCR1, also known as folliculin, is a protein that belongs to the SLC26 family of solute carrier transporters. The SLC26 family is one of the subfamilies of the larger SLC (Solute Carrier) family of transporters, which are involved in the transport of a wide variety of molecules across cell membranes.\n\nThe SLC26 family is specifically involved in the transport of small molecules, such as ions, amino acids, and sugars, and is found in a wide range of organisms, including bacteria, plants, and animals. The family includes several subfamilies, each of which is characterized by a specific structure and function.\n\nFLVCR1 is a member of the SLC26A1 subfamily, which is specifically involved in the transport of small molecules such as amino acids, sugars, and other organic compounds. The SLC26A1 subfamily is found in a wide range of organisms, including bacteria, plants, and animals, and is involved in a variety of cellular processes, including metabolism, signaling, and transport.\n\nIn summary, FLVCR1 is a member of the SLC26 family, which is a subfamily of the larger SLC family of transporters. The SLC26 family is specifically involved in the transport of small molecules, and FLVCR1 is a member of the SLC26A1 subfamily, which is involved in the transport of amino acids, sugars, and other organic compounds.",
    "llama-7b_fact_raw": "1. FLVCR1 is a protein that belongs to the SLC26 family of solute carrier transporters.\n2. The SLC26 family is involved in the transport of small molecules such as ions, amino acids, and sugars.\n3. The SLC26 family is found in a wide range of organisms, including bacteria, plants, and animals.\n4. FLVCR1 is a member of the SLC26A1 subfamily.\n5. The SLC26A1 subfamily is involved in the transport of amino acids, sugars, and other organic compounds.",
    "llama-7b_fact": [
      "FLVCR1 is a protein that belongs to the SLC26 family of solute carrier transporters.",
      "The SLC26 family is involved in the transport of small molecules such as ions, amino acids, and sugars.",
      "The SLC26 family is found in a wide range of organisms, including bacteria, plants, and animals.",
      "FLVCR1 is a member of the SLC26A1 subfamily.",
      "The SLC26A1 subfamily is involved in the transport of amino acids, sugars, and other organic compounds."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: FLVCR1 is a protein that belongs to the Major Facilitator Superfamily (MFS), not the SLC26 family of solute carrier transporters.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: FLVCR1 is not a member of the SLC26A1 subfamily; it is part of the Major Facilitator Superfamily (MFS).\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1047,
    "user_query": "You MUST give a detailed answer to the following question: List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-7b_response": "GATA-1 (GATA binding protein 1) is a transcription factor that plays a crucial role in regulating the expression of genes involved in various cellular processes, including hematopoiesis, cardiovascular development, and immune function. GATA-1 interacts with a variety of proteins to regulate its target genes, and the biotinylation tagging approach has been used to identify some of these interacting partners.\n\nOne study used the biotinylation tagging approach to identify proteins that interact with GATA-1 in hematopoietic stem cells (HSCs). The study found that GATA-1 interacts with several proteins involved in HSC self-renewal and differentiation, including the transcription factors RUNX1, PU.1, and Gfi-1b, as well as the protein kinase AKT1.\n\nAnother study used the biotinylation tagging approach to identify proteins that interact with GATA-1 in cardiac progenitor cells. The study found that GATA-1 interacts with several proteins involved in cardiac development and maturation, including the transcription factors NKX2.5 and GATA4, as well as the protein kinase AKT1.\n\nOverall, the biotinylation tagging approach has identified several proteins that interact with GATA-1, including transcription factors, kinases, and other proteins involved in various cellular processes. These interactions provide insight into the mechanisms by which GATA-1 regulates gene expression and contributes to cellular function.",
    "llama-7b_fact_raw": "1. GATA-1 interacts with the transcription factor RUNX1 in hematopoietic stem cells.\n2. GATA-1 interacts with the transcription factor PU.1 in hematopoietic stem cells.\n3. GATA-1 interacts with the transcription factor Gfi-1b in hematopoietic stem cells.\n4. GATA-1 interacts with the protein kinase AKT1 in hematopoietic stem cells.\n5. GATA-1 interacts with the transcription factors NKX2.5 and GATA4 in cardiac progenitor cells.",
    "llama-7b_fact": [
      "GATA-1 interacts with the transcription factor RUNX1 in hematopoietic stem cells.",
      "GATA-1 interacts with the transcription factor PU.1 in hematopoietic stem cells.",
      "GATA-1 interacts with the transcription factor Gfi-1b in hematopoietic stem cells.",
      "GATA-1 interacts with the protein kinase AKT1 in hematopoietic stem cells.",
      "GATA-1 interacts with the transcription factors NKX2.5 and GATA4 in cardiac progenitor cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE: GATA-1 has been reported to antagonistically interact with PU.1 in hematopoietic cells, influencing the differentiation of common progenitors into either erythroid/megakaryocytic lineages or myeloid lineages.\n3. TRUE: GATA-1 is known to interact with Gfi-1b, which is involved in the regulation of hematopoietic stem cell differentiation.\n4. UNKNOWN: While GATA-1 is a transcription factor involved in hematopoiesis, and AKT1 is a kinase that can be involved in cell signaling in hematopoietic cells, direct interaction in hematopoietic stem cells is not well-established and would require specific literature to confirm.\n5. TRUE: GATA-1, NKX2.5, and GATA4 are known to be involved in cardiac development, and there is evidence suggesting that these transcription factors can interact in cardiac progenitor cells to regulate heart development.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "You MUST give a detailed answer to the following question: What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-7b_response": "TAF10 is a transcriptional co-activator that interacts with GATA1, a transcription factor that plays a crucial role in the regulation of gene expression in various tissues and cell types. The interaction between TAF10 and GATA1 can lead to the activation of target genes involved in various biological processes, including cell growth, differentiation, and development.\n\nThe outcome of TAF10 interacting with GATA1 depends on the specific context and the target genes being regulated. However, in general, the interaction between TAF10 and GATA1 leads to the recruitment of TAF10 to the promoter region of target genes, where it helps to stabilize the interaction between GATA1 and other transcriptional co-activators, such as CBP and p300. This, in turn, enhances the recruitment of RNA polymerase II and other transcriptional machinery to the promoter, leading to increased transcription of target genes.\n\nThe specific genes that are activated by the interaction between TAF10 and GATA1 depend on the tissue and cell type in question. For example, in hematopoietic cells, the interaction between TAF10 and GATA1 has been shown to play a crucial role in the regulation of genes involved in the differentiation and maturation of immune cells. In particular, the interaction between TAF10 and GATA1 has been shown to activate genes involved in the differentiation of T cells, B cells, and dendritic cells.\n\nIn summary, the outcome of TAF10 interacting with GATA1 is the activation of target genes involved in various biological processes, including cell growth, differentiation, and development. The specific genes that are activated by this interaction depend on the tissue and cell type in question.",
    "llama-7b_fact_raw": "1. TAF10 is a transcriptional co-activator that interacts with the GATA1 transcription factor.\n2. The interaction between TAF10 and GATA1 can lead to the activation of target genes involved in cell growth, differentiation, and development.\n3. TAF10 helps to stabilize the interaction between GATA1 and other transcriptional co-activators, such as CBP and p300.\n4. The interaction enhances the recruitment of RNA polymerase II to the promoter, leading to increased transcription of target genes.\n5. In hematopoietic cells, the interaction between TAF10 and GATA1 is crucial for the regulation of genes involved in the differentiation and maturation of immune cells.",
    "llama-7b_fact": [
      "TAF10 is a transcriptional co-activator that interacts with the GATA1 transcription factor.",
      "The interaction between TAF10 and GATA1 can lead to the activation of target genes involved in cell growth, differentiation, and development.",
      "TAF10 helps to stabilize the interaction between GATA1 and other transcriptional co-activators, such as CBP and p300.",
      "The interaction enhances the recruitment of RNA polymerase II to the promoter, leading to increased transcription of target genes.",
      "In hematopoietic cells, the interaction between TAF10 and GATA1 is crucial for the regulation of genes involved in the differentiation and maturation of immune cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the known roles of transcriptional co-activators and their interactions with transcription factors like GATA1, which is indeed involved in the regulation of genes during the differentiation and maturation of hematopoietic cells, including immune cells. However, without specific scientific references, the exact details of these interactions and their implications cannot be verified, but the statements are plausible based on general knowledge of gene regulation and transcription factor function.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1082,
    "user_query": "You MUST give a detailed answer to the following question: Are there any Decision support systems for chronic pain management ?",
    "llama-7b_response": "",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1149,
    "user_query": "You MUST give a detailed answer to the following question: Which is the subcellular localization of the protein angiogenin?",
    "llama-7b_response": "Angiogenin is a protein that plays a role in the process of angiogenesis, which is the formation of new blood vessels. It is a glycoprotein that is synthesized and secreted by a variety of cells, including endothelial cells, fibroblasts, and smooth muscle cells.\n\nAngiogenin is primarily localized to the cytoplasm of cells, although it can also be found in the nucleus of some cells. It is thought to play a role in the regulation of gene expression, and has been shown to bind to specific DNA sequences known as angiogenin response elements (AngREs). These AngREs are found in the promoter regions of genes that are involved in the process of angiogenesis, and the binding of angiogenin to these elements is thought to play a role in the regulation of gene expression.\n\nIn addition to its role in angiogenesis, angiogenin has also been implicated in the regulation of cell proliferation, differentiation, and survival. It has been shown to promote the growth and survival of endothelial cells, and to play a role in the development of tumors.\n\nOverall, the subcellular localization of angiogenin is primarily in the cytoplasm, although it can also be found in the nucleus of some cells. It plays a role in the regulation of gene expression, and has been implicated in the regulation of cell proliferation, differentiation, and survival.",
    "llama-7b_fact_raw": "1. Angiogenin is a protein involved in angiogenesis, the formation of new blood vessels.\n2. Angiogenin is a glycoprotein synthesized and secreted by various cell types, including endothelial cells, fibroblasts, and smooth muscle cells.\n3. The primary subcellular localization of angiogenin is in the cytoplasm of cells.\n4. Angiogenin can also be found in the nucleus of some cells.\n5. Angiogenin binds to specific DNA sequences known as angiogenin response elements (AngREs) in the promoter regions of genes involved in angiogenesis.",
    "llama-7b_fact": [
      "Angiogenin is a protein involved in angiogenesis, the formation of new blood vessels.",
      "Angiogenin is a glycoprotein synthesized and secreted by various cell types, including endothelial cells, fibroblasts, and smooth muscle cells.",
      "The primary subcellular localization of angiogenin is in the cytoplasm of cells.",
      "Angiogenin can also be found in the nucleus of some cells.",
      "Angiogenin binds to specific DNA sequences known as angiogenin response elements (AngREs) in the promoter regions of genes involved in angiogenesis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Angiogenin is not typically classified as a glycoprotein. It is a protein synthesized by various cell types, including endothelial cells and some cancer cells, but it is not characterized by glycosylation.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Angiogenin does not bind to specific DNA sequences known as angiogenin response elements (AngREs) in the promoter regions of genes. Angiogenin is known to accumulate in the nucleus and can stimulate rRNA transcription, but it does not directly bind to DNA to regulate gene expression in the manner described.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1161,
    "user_query": "You MUST give a detailed answer to the following question: How does ranolazine affect kinase signaling activation in the heart?",
    "llama-7b_response": "Ranolazine is a medication that is used to treat chronic angina, a type of chest pain that occurs when the heart muscle does not receive enough oxygen-rich blood. It works by blocking the voltage-gated sodium channels in the heart, which helps to reduce the electrical activity in the heart and reduce the frequency of angina attacks.\n\nOne of the ways that ranolazine affects kinase signaling activation in the heart is by inhibiting the activity of protein kinases. Protein kinases are enzymes that play a key role in many cellular processes, including signal transduction pathways that are involved in the regulation of the heart's electrical activity. By inhibiting the activity of protein kinases, ranolazine can help to reduce the electrical activity in the heart and reduce the frequency of angina attacks.\n\nIn addition to inhibiting protein kinases, ranolazine also affects kinase signaling activation in the heart by inhibiting the activity of other enzymes that are involved in the regulation of the heart's electrical activity. For example, ranolazine has been shown to inhibit the activity of the enzyme L-type calcium channels, which are involved in the regulation of the heart's electrical activity. By inhibiting the activity of L-type calcium channels, ranolazine can help to reduce the electrical activity in the heart and reduce the frequency of angina attacks.\n\nOverall, ranolazine affects kinase signaling activation in the heart by inhibiting the activity of protein kinases and other enzymes that are involved in the regulation of the heart's electrical activity. This helps to reduce the electrical activity in the heart and reduce the frequency of angina attacks.",
    "llama-7b_fact_raw": "1. Ranolazine is used to treat chronic angina.\n2. Ranolazine works by blocking voltage-gated sodium channels in the heart.\n3. Ranolazine inhibits the activity of protein kinases in the heart.\n4. Protein kinases play a key role in signal transduction pathways that regulate the heart's electrical activity.\n5. Ranolazine has been shown to inhibit the activity of L-type calcium channels in the heart.",
    "llama-7b_fact": [
      "Ranolazine is used to treat chronic angina.",
      "Ranolazine works by blocking voltage-gated sodium channels in the heart.",
      "Ranolazine inhibits the activity of protein kinases in the heart.",
      "Protein kinases play a key role in signal transduction pathways that regulate the heart's electrical activity.",
      "Ranolazine has been shown to inhibit the activity of L-type calcium channels in the heart."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Ranolazine does not inhibit the activity of protein kinases; it primarily affects sodium channels and has some effect on potassium channels.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "You MUST give a detailed answer to the following question: Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-7b_response": "The regulation of the VSR endonuclease in bacteria is not necessarily independent of the growth phase. While the expression of VSR endonuclease has been shown to be influenced by growth phase in some studies, other studies have found that the regulation of VSR endonuclease is complex and can be influenced by a variety of factors, including growth phase, environmental cues, and the presence of antibiotics.\n\nFor example, one study found that the expression of VSR endonuclease in Escherichia coli was influenced by growth phase, with the highest levels of expression occurring in the stationary phase of growth. However, other studies have found that the regulation of VSR endonuclease is more complex, with the expression of the enzyme being influenced by a variety of factors, including the presence of antibiotics, nutrient availability, and environmental cues.\n\nOverall, while the regulation of VSR endonuclease in bacteria may be influenced by growth phase in some cases, the regulation of the enzyme is likely to be complex and influenced by a variety of factors. Further research is needed to fully understand the regulation of VSR endonuclease in bacteria and how it is influenced by growth phase and other factors.",
    "llama-7b_fact_raw": "1. The regulation of VSR endonuclease in bacteria can be influenced by the growth phase.\n2. Expression of VSR endonuclease in Escherichia coli has been shown to be higher in the stationary phase of growth.\n3. The regulation of VSR endonuclease can also be affected by environmental cues and the presence of antibiotics.\n4. The regulation of VSR endonuclease is complex and not solely dependent on the growth phase.\n5. Further research is necessary to fully understand the regulation of VSR endonuclease in bacteria.",
    "llama-7b_fact": [
      "The regulation of VSR endonuclease in bacteria can be influenced by the growth phase.",
      "Expression of VSR endonuclease in Escherichia coli has been shown to be higher in the stationary phase of growth.",
      "The regulation of VSR endonuclease can also be affected by environmental cues and the presence of antibiotics.",
      "The regulation of VSR endonuclease is complex and not solely dependent on the growth phase.",
      "Further research is necessary to fully understand the regulation of VSR endonuclease in bacteria."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with general knowledge about bacterial enzyme regulation, which can indeed be influenced by growth phase, environmental cues, and the presence of antibiotics. The complexity of regulation and the need for further research are typical of many biological processes, making these statements plausible. However, without specific references to scientific studies or literature, it is not possible to fact-check the exact details about VSR endonuclease. Therefore, these responses are based on general principles of bacterial gene regulation.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "You MUST give a detailed answer to the following question: What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-7b_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins. Here are some of the most popular ones:\n\n1. TMHMM: TMHMM (Transmembrane Helices of Microbial Homologues) is a web-based tool that uses hidden Markov models to predict transmembrane helices in proteins. It can also predict beta-barrels, which are composed of multiple transmembrane helices. TMHMM has a high accuracy in predicting transmembrane helices and beta-barrels, and it is widely used in bioinformatics research.\n2. SMART: SMART (Simple Modular Architecture Research Tool) is a web-based tool that predicts the occurrence of domains and functional sites in proteins. It can also predict beta-barrels and transmembrane helices. SMART has a high accuracy in predicting beta-barrels and transmembrane helices, and it is widely used in bioinformatics research.\n3. PSIPRED: PSIPRED (Protein Secondary Structure Prediction by Hidden Markov Models) is a web-based tool that uses hidden Markov models to predict protein secondary structure. It can also predict beta-barrels, which are composed of multiple transmembrane helices. PSIPRED has a high accuracy in predicting beta-barrels and transmembrane helices, and it is widely used in bioinformatics research.\n4. IUPred: IUPred (Improved Prediction of Protein Secondary Structure) is a web-based tool that uses machine learning algorithms to predict protein secondary structure. It can also predict beta-barrels, which are composed of multiple transmembrane helices. IUPred has a high accuracy in predicting beta-barrels and transmembrane helices, and it is widely used in bioinformatics research.\n\nOverall, these computational tools are useful for predicting beta-barrel transmembrane proteins, and they can be used in combination to improve the accuracy of the predictions.",
    "llama-7b_fact_raw": "1. TMHMM is a computational tool that uses hidden Markov models to predict transmembrane helices and beta-barrels in proteins.\n2. SMART is a web-based tool that predicts the occurrence of domains, functional sites, beta-barrels, and transmembrane helices in proteins.\n3. PSIPRED is a tool that uses hidden Markov models to predict protein secondary structure, including beta-barrels and transmembrane helices.\n4. IUPred uses machine learning algorithms to predict protein secondary structure, including beta-barrels and transmembrane helices.\n5. These computational tools, TMHMM, SMART, PSIPRED, and IUPred, are noted for their high accuracy in predicting beta-barrels and transmembrane helices and are widely used in bioinformatics research.",
    "llama-7b_fact": [
      "TMHMM is a computational tool that uses hidden Markov models to predict transmembrane helices and beta-barrels in proteins.",
      "SMART is a web-based tool that predicts the occurrence of domains, functional sites, beta-barrels, and transmembrane helices in proteins.",
      "PSIPRED is a tool that uses hidden Markov models to predict protein secondary structure, including beta-barrels and transmembrane helices.",
      "IUPred uses machine learning algorithms to predict protein secondary structure, including beta-barrels and transmembrane helices.",
      "These computational tools, TMHMM, SMART, PSIPRED, and IUPred, are noted for their high accuracy in predicting beta-barrels and transmembrane helices and are widely used in bioinformatics research."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: TMHMM is a computational tool that uses hidden Markov models to predict transmembrane helices in proteins, but it does not predict beta-barrels.\n2. FALSE [correction]: SMART is a web-based tool that allows the identification of domains and functional sites in proteins, but it does not predict beta-barrels or transmembrane helices.\n3. FALSE [correction]: PSIPRED is a tool that uses machine learning techniques to predict protein secondary structure, but it does not specifically predict beta-barrels and transmembrane helices.\n4. FALSE [correction]: IUPred is a tool designed to predict intrinsically unstructured regions of proteins, not secondary structures like beta-barrels and transmembrane helices.\n5. FALSE [correction]: While TMHMM and PSIPRED are widely used in bioinformatics research for their respective purposes (predicting transmembrane helices and secondary structure), the statement is incorrect in claiming that all four tools are noted for high accuracy in predicting beta-barrels and transmembrane helices, especially since SMART and IUPred do not predict these structures as stated.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1251,
    "user_query": "You MUST give a detailed answer to the following question: Galassi classification is used for which disorder?",
    "llama-7b_response": "Galassi classification is a system used to classify the severity of aortic stenosis, a condition in which the aortic valve narrows, making it difficult for blood to flow properly from the heart to the rest of the body. The classification system is based on the degree of narrowing of the aortic valve and is named after the Italian cardiologist who first described it, Giuseppe Galassi.\n\nGalassi classifies aortic stenosis into three categories:\n\n1. Galassi I: Mild aortic stenosis with a mean aortic valve area of 1.0 cm or more.\n2. Galassi II: Moderate aortic stenosis with a mean aortic valve area of 0.6-1.0 cm.\n3. Galassi III: Severe aortic stenosis with a mean aortic valve area of less than 0.6 cm.\n\nGalassi classification is used to determine the severity of aortic stenosis and guide treatment options. It is typically used in conjunction with other diagnostic tests, such as echocardiography, to assess the condition of the aortic valve and determine the best course of treatment.",
    "llama-7b_fact_raw": "1. Galassi classification is used to classify the severity of aortic stenosis.\n2. The classification system is named after Italian cardiologist Giuseppe Galassi.\n3. Galassi classification divides aortic stenosis into three categories based on the mean aortic valve area.\n4. Galassi I is defined as mild aortic stenosis with a mean aortic valve area of 1.0 cm or more.\n5. Galassi III is defined as severe aortic stenosis with a mean aortic valve area of less than 0.6 cm.",
    "llama-7b_fact": [
      "Galassi classification is used to classify the severity of aortic stenosis.",
      "The classification system is named after Italian cardiologist Giuseppe Galassi.",
      "Galassi classification divides aortic stenosis into three categories based on the mean aortic valve area.",
      "Galassi I is defined as mild aortic stenosis with a mean aortic valve area of 1.0 cm or more.",
      "Galassi III is defined as severe aortic stenosis with a mean aortic valve area of less than 0.6 cm."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Galassi classification is used to classify the access of the coronary artery in the context of percutaneous coronary intervention, not the severity of aortic stenosis.\n2. TRUE\n3. FALSE [correction]: The Galassi classification does not pertain to aortic stenosis but rather to coronary artery access.\n4. FALSE [correction]: Galassi classification does not define aortic stenosis categories; it is related to coronary artery access for cardiac procedures.\n5. FALSE [correction]: Galassi classification does not define aortic stenosis severity; it is a classification for coronary artery access.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1304,
    "user_query": "You MUST give a detailed answer to the following question: List common features of Shapiro syndrome",
    "llama-7b_response": "",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1320,
    "user_query": "You MUST give a detailed answer to the following question: Which disease is linked to mutations within BRAG1?",
    "llama-7b_response": "BRAG1 (BRCA1-associated glycoprotein 1) is a protein that plays a role in the repair of damaged DNA. Mutations in the BRAG1 gene have been linked to an increased risk of certain types of cancer, including breast, ovarian, and prostate cancer.\n\nSpecifically, mutations in the BRAG1 gene have been found to be associated with an increased risk of hereditary breast and ovarian cancer syndrome (HBOC), which is a genetic disorder that increases the risk of developing breast and ovarian cancer. Individuals with mutations in the BRAG1 gene may also have an increased risk of developing other types of cancer, such as prostate cancer.\n\nIn summary, mutations in the BRAG1 gene have been linked to an increased risk of cancer, particularly breast, ovarian, and prostate cancer. These mutations are associated with hereditary breast and ovarian cancer syndrome and may also increase the risk of developing other types of cancer.",
    "llama-7b_fact_raw": "1. Mutations in the BRAG1 gene have been linked to an increased risk of certain types of cancer.\n2. These cancers include breast, ovarian, and prostate cancer.\n3. Mutations in the BRAG1 gene are associated with hereditary breast and ovarian cancer syndrome (HBOC).\n4. HBOC is a genetic disorder that increases the risk of developing breast and ovarian cancer.\n5. Individuals with mutations in the BRAG1 gene may have an increased risk of developing other types of cancer as well.",
    "llama-7b_fact": [
      "Mutations in the BRAG1 gene have been linked to an increased risk of certain types of cancer.",
      "These cancers include breast, ovarian, and prostate cancer.",
      "Mutations in the BRAG1 gene are associated with hereditary breast and ovarian cancer syndrome (HBOC).",
      "HBOC is a genetic disorder that increases the risk of developing breast and ovarian cancer.",
      "Individuals with mutations in the BRAG1 gene may have an increased risk of developing other types of cancer as well."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mutations in the BRCA1 gene have been linked to an increased risk of certain types of cancer.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1362,
    "user_query": "You MUST give a detailed answer to the following question: Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-7b_response": "The main inhibitor of protein phosphatase 1 (PP1) is a protein called \"protein inhibitor of activated STAT1 (PIAS1)\". PIAS1 is a member of the protein inhibitor of activated STAT (PIAS) family of proteins, which are known to inhibit a variety of protein kinases and phosphatases, including PP1.\n\nPP1 is a serine/threonine protein phosphatase that plays a crucial role in regulating a variety of cellular processes, including cell growth, differentiation, and apoptosis. It is activated by the binding of its regulatory subunit, PP1gamma, to its substrate, protein kinase A (PKA). However, PP1 activity can also be inhibited by the binding of specific inhibitors, such as PIAS1.\n\nPIAS1 is a ubiquitously expressed protein that binds to and inhibits the activity of STAT1, a transcription factor that plays a key role in the immune response. PIAS1 also has been shown to inhibit a number of other protein kinases and phosphatases, including PP1.\n\nIn summary, PIAS1 is the main inhibitor of protein phosphatase 1 (PP1), and it plays an important role in regulating cellular processes by inhibiting the activity of a variety of protein kinases and phosphatases, including PP1.",
    "llama-7b_fact_raw": "1. Protein inhibitor of activated STAT1 (PIAS1) is the main inhibitor of protein phosphatase 1 (PP1).\n2. PIAS1 is a member of the protein inhibitor of activated STAT family of proteins.\n3. Protein phosphatase 1 (PP1) is a serine/threonine protein phosphatase involved in regulating cell growth, differentiation, and apoptosis.\n4. PP1 is activated by the binding of its regulatory subunit, PP1gamma, to its substrate, protein kinase A (PKA).\n5. PIAS1 binds to and inhibits the activity of STAT1, a transcription factor involved in the immune response.",
    "llama-7b_fact": [
      "Protein inhibitor of activated STAT1 (PIAS1) is the main inhibitor of protein phosphatase 1 (PP1).",
      "PIAS1 is a member of the protein inhibitor of activated STAT family of proteins.",
      "Protein phosphatase 1 (PP1) is a serine/threonine protein phosphatase involved in regulating cell growth, differentiation, and apoptosis.",
      "PP1 is activated by the binding of its regulatory subunit, PP1gamma, to its substrate, protein kinase A (PKA).",
      "PIAS1 binds to and inhibits the activity of STAT1, a transcription factor involved in the immune response."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Protein inhibitor of activated STAT1 (PIAS1) is not the main inhibitor of protein phosphatase 1 (PP1). PIAS1 is involved in the inhibition of STAT (Signal Transducer and Activator of Transcription) proteins, not PP1.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: PP1 is not activated by the binding of its regulatory subunit, PP1gamma, to protein kinase A (PKA). PP1 is regulated by various regulatory subunits that can target the phosphatase to specific locations and substrates, but the activation is not through binding to PKA as a substrate.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1374,
    "user_query": "You MUST give a detailed answer to the following question: Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-7b_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria, such as Bacillus subtilis, undergo a significant increase in mutation rates in response to stressful conditions, such as starvation or exposure to antibiotics. This increase in mutation rates allows the bacteria to adapt and survive in these stressful environments.\n\nThere are several mechanisms that underlie adaptive mutagenesis in B. subtilis:\n\n1. DNA Damage: One of the key mechanisms underlying adaptive mutagenesis is DNA damage. When bacteria are exposed to stressful conditions, such as starvation or exposure to antibiotics, they undergo a significant increase in DNA damage. This DNA damage can lead to mutations, which can help the bacteria adapt and survive in these environments.\n2. Mutator Mutations: Another mechanism that underlies adaptive mutagenesis is the presence of mutator mutations. Mutator mutations are mutations that increase the mutation rate in the bacteria. These mutations can occur spontaneously or be passed down from one generation to the next. When bacteria with mutator mutations are exposed to stressful conditions, they undergo a significant increase in mutation rates, allowing them to adapt and survive in these environments.\n3. RecA Protein: The RecA protein is a key player in the repair of DNA damage in bacteria. When bacteria are exposed to stressful conditions, such as starvation or exposure to antibiotics, the RecA protein is activated, leading to an increase in the mutation rate. This increase in mutation rate allows the bacteria to repair DNA damage and adapt to the stressful environment.\n4. Transcriptional Activation: Another mechanism that underlies adaptive mutagenesis is transcriptional activation. When bacteria are exposed to stressful conditions, such as starvation or exposure to antibiotics, certain genes are activated, leading to an increase in the mutation rate. This increase in mutation rate allows the bacteria to adapt and survive in these environments.\n\nOverall, adaptive mutagenesis is a complex process that involves multiple mechanisms, including DNA damage, mutator mutations, the RecA protein,",
    "llama-7b_fact_raw": "1. Bacillus subtilis undergoes an increase in mutation rates in response to stressful conditions such as starvation or exposure to antibiotics.\n2. DNA damage is a key mechanism that leads to mutations in Bacillus subtilis during adaptive mutagenesis.\n3. Mutator mutations in Bacillus subtilis can increase the mutation rate and occur spontaneously or be inherited.\n4. The RecA protein in Bacillus subtilis is involved in the repair of DNA damage and is activated under stressful conditions, leading to an increased mutation rate.\n5. Transcriptional activation in Bacillus subtilis can lead to an increased mutation rate when the bacteria are exposed to stressful conditions.",
    "llama-7b_fact": [
      "Bacillus subtilis undergoes an increase in mutation rates in response to stressful conditions such as starvation or exposure to antibiotics.",
      "DNA damage is a key mechanism that leads to mutations in Bacillus subtilis during adaptive mutagenesis.",
      "Mutator mutations in Bacillus subtilis can increase the mutation rate and occur spontaneously or be inherited.",
      "The RecA protein in Bacillus subtilis is involved in the repair of DNA damage and is activated under stressful conditions, leading to an increased mutation rate.",
      "Transcriptional activation in Bacillus subtilis can lead to an increased mutation rate when the bacteria are exposed to stressful conditions."
    ],
    "llama-7b_judge_raw": "1. TRUE: Bacillus subtilis is known to undergo an increase in mutation rates in response to stressful conditions, a phenomenon known as stress-induced mutagenesis or adaptive mutagenesis.\n2. TRUE: DNA damage is one of the mechanisms that can lead to mutations during adaptive mutagenesis in various organisms, including Bacillus subtilis.\n3. TRUE: Mutator mutations can increase the mutation rate in bacteria and can occur spontaneously or be inherited.\n4. TRUE: The RecA protein is involved in the SOS response to DNA damage in bacteria, including Bacillus subtilis, and can lead to an increased mutation rate under stressful conditions.\n5. UNKNOWN: While transcriptional activation can be a response to stress, the statement is vague and does not provide enough information to determine whether it directly leads to an increased mutation rate in Bacillus subtilis under stressful conditions.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1399,
    "user_query": "You MUST give a detailed answer to the following question: What causes erucism?",
    "llama-7b_response": "Erucic acid is a type of fatty acid that is found in rapeseed (also known as canola) and other oilseed crops. Erucism is a condition that is caused by the consumption of foods that contain high levels of erucic acid.\n\nErucism is a rare condition that can cause a variety of symptoms, including nerve damage, muscle weakness, and heart problems. The exact cause of erucism is not fully understood, but it is believed to be related to the accumulation of erucic acid in the body.\n\nWhen erucic acid is consumed in large amounts, it can build up in the body and cause damage to cells and tissues. This can lead to a range of symptoms, including nerve damage, muscle weakness, and heart problems. Erucic acid can also interfere with the body's ability to use other fats, which can further contribute to the development of erucism.\n\nIt is worth noting that erucism is a rare condition and is typically only seen in people who consume large amounts of rapeseed oil or other foods that contain high levels of erucic acid. In most cases, the consumption of small amounts of rapeseed oil or other foods that contain erucic acid is not likely to cause any harm.",
    "llama-7b_fact_raw": "1. Erucic acid is a type of fatty acid found in rapeseed (canola) and other oilseed crops.\n2. Erucism is caused by the consumption of foods that contain high levels of erucic acid.\n3. Symptoms of erucism can include nerve damage, muscle weakness, and heart problems.\n4. The accumulation of erucic acid in the body is believed to be related to the development of erucism.\n5. Erucism is a rare condition typically seen in people who consume large amounts of rapeseed oil or foods high in erucic acid.",
    "llama-7b_fact": [
      "Erucic acid is a type of fatty acid found in rapeseed (canola) and other oilseed crops.",
      "Erucism is caused by the consumption of foods that contain high levels of erucic acid.",
      "Symptoms of erucism can include nerve damage, muscle weakness, and heart problems.",
      "The accumulation of erucic acid in the body is believed to be related to the development of erucism.",
      "Erucism is a rare condition typically seen in people who consume large amounts of rapeseed oil or foods high in erucic acid."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "You MUST give a detailed answer to the following question: What are the indications for hydrochlorothiazide?",
    "llama-7b_response": "",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1447,
    "user_query": "You MUST give a detailed answer to the following question: Has silicon been used in treatment of  incontinence ?",
    "llama-7b_response": "Yes, silicone has been used in the treatment of urinary incontinence. Silicone is a synthetic material that is commonly used in medical devices and has been found to be effective in treating stress urinary incontinence (SUI), which is a type of incontinence that occurs due to pressure on the bladder during activities that put stress on the abdomen, such as coughing, sneezing, or lifting.\n\nSilicone is used to create a device called a urinary sling, which is a type of mesh implant that is placed around the urethra to support it and prevent urine from leaking out. The sling is typically made of silicone and is placed through a minimally invasive procedure that requires only small incisions in the abdomen.\n\nSilicone has several advantages as a material for urinary sling implants. It is biocompatible, meaning that it is not recognized as foreign by the body and is not likely to cause an immune response. It is also highly durable and can withstand the forces placed on the bladder during activities that cause SUI. Additionally, silicone is flexible and can conform to the shape of the body, which allows it to provide a stable support for the urethra while still allowing for normal movement and function.\n\nOverall, silicone has been found to be a safe and effective material for the treatment of urinary incontinence, particularly stress urinary incontinence. However, as with any medical treatment, there are potential risks and complications associated with the use of silicone implants, and patients should discuss the risks and benefits with their healthcare provider before deciding on a treatment option.",
    "llama-7b_fact_raw": "1. Silicone has been used in the treatment of urinary incontinence.\n2. Silicone is used to create a urinary sling, which is a mesh implant placed around the urethra.\n3. The urinary sling is used to treat stress urinary incontinence (SUI).\n4. Silicone is biocompatible and not likely to cause an immune response.\n5. Silicone urinary slings are placed through a minimally invasive procedure with small incisions in the abdomen.",
    "llama-7b_fact": [
      "Silicone has been used in the treatment of urinary incontinence.",
      "Silicone is used to create a urinary sling, which is a mesh implant placed around the urethra.",
      "The urinary sling is used to treat stress urinary incontinence (SUI).",
      "Silicone is biocompatible and not likely to cause an immune response.",
      "Silicone urinary slings are placed through a minimally invasive procedure with small incisions in the abdomen."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: While silicone has been used in various medical applications, urinary slings are typically made of synthetic mesh material, not silicone.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "You MUST give a detailed answer to the following question: What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-7b_response": "The association between the moon cycle and rupture risk of intracranial aneurysms is a topic of ongoing research and debate. Some studies have suggested that there may be a link between the phases of the moon and the rupture risk of intracranial aneurysms, while others have found no such association.\n\nIntracranial aneurysms are abnormal balloon-like bulges in the walls of blood vessels that supply the brain. These aneurysms can rupture and cause stroke, which is a leading cause of disability and death worldwide. Rupture of an intracranial aneurysm is a medical emergency that requires immediate treatment.\n\nSeveral studies have investigated the potential association between the moon cycle and the rupture risk of intracranial aneurysms. Some studies have found that the risk of rupture may be higher during certain phases of the moon, such as the full moon or the new moon. For example, one study found that the risk of rupture was highest during the full moon, while another study found that the risk was highest during the new moon.\n\nOther studies, however, have not found a consistent association between the moon cycle and the rupture risk of intracranial aneurysms. Some studies have suggested that the association may be due to confounding factors, such as changes in blood pressure or blood flow that occur during the different phases of the moon.\n\nOverall, the association between the moon cycle and the rupture risk of intracranial aneurysms is still not well understood, and more research is needed to clarify this relationship. It is important for patients with intracranial aneurysms to follow their doctor's recommendations for monitoring and management of their condition, regardless of the phase of the moon.",
    "llama-7b_fact_raw": "1. Intracranial aneurysms are abnormal balloon-like bulges in the walls of blood vessels that supply the brain.\n2. Rupture of an intracranial aneurysm can cause stroke, which is a leading cause of disability and death worldwide.\n3. Some studies have suggested a higher risk of rupture of intracranial aneurysms during certain phases of the moon, such as the full moon or the new moon.\n4. Other studies have not found a consistent association between the moon cycle and the rupture risk of intracranial aneurysms.\n5. More research is needed to clarify the relationship between the moon cycle and the rupture risk of intracranial aneurysms.",
    "llama-7b_fact": [
      "Intracranial aneurysms are abnormal balloon-like bulges in the walls of blood vessels that supply the brain.",
      "Rupture of an intracranial aneurysm can cause stroke, which is a leading cause of disability and death worldwide.",
      "Some studies have suggested a higher risk of rupture of intracranial aneurysms during certain phases of the moon, such as the full moon or the new moon.",
      "Other studies have not found a consistent association between the moon cycle and the rupture risk of intracranial aneurysms.",
      "More research is needed to clarify the relationship between the moon cycle and the rupture risk of intracranial aneurysms."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "You MUST give a detailed answer to the following question: Does HuR protein regulate the splicing process?",
    "llama-7b_response": "The HuR (ELAVL1) protein is a member of the ELAV (embryonic lethal, abnormal vision) family of RNA-binding proteins, which play a role in the regulation of RNA metabolism. While there is evidence to suggest that HuR may be involved in the regulation of the splicing process, the precise mechanisms by which it does so are not fully understood.\n\nHuR has been shown to interact with a variety of RNAs, including mRNAs, microRNAs, and long non-coding RNAs (lncRNAs), and to play a role in the transport and stabilization of these RNAs. In addition, HuR has been implicated in the regulation of alternative splicing, a process by which different splicing variants of a single gene can be produced from a single gene transcript.\n\nFor example, studies have shown that HuR can interact with pre-mRNA splicing factors and modulate their activity, leading to changes in alternative splicing patterns. HuR has also been shown to interact with lncRNAs, which have been implicated in the regulation of alternative splicing, and to play a role in the transport and stabilization of these RNAs.\n\nOverall, while the precise mechanisms by which HuR regulates the splicing process are not fully understood, there is evidence to suggest that it may play a role in the regulation of alternative splicing by interacting with splicing factors and lncRNAs and modulating their activity. Further research is needed to fully elucidate the role of HuR in the regulation of the splicing process.",
    "llama-7b_fact_raw": "1. The HuR (ELAVL1) protein is a member of the ELAV family of RNA-binding proteins.\n2. HuR is involved in the regulation of RNA metabolism.\n3. HuR has been shown to interact with various RNAs, including mRNAs, microRNAs, and long non-coding RNAs (lncRNAs).\n4. HuR has been implicated in the regulation of alternative splicing.\n5. Studies indicate that HuR can interact with pre-mRNA splicing factors and modulate their activity, affecting alternative splicing patterns.",
    "llama-7b_fact": [
      "The HuR (ELAVL1) protein is a member of the ELAV family of RNA-binding proteins.",
      "HuR is involved in the regulation of RNA metabolism.",
      "HuR has been shown to interact with various RNAs, including mRNAs, microRNAs, and long non-coding RNAs (lncRNAs).",
      "HuR has been implicated in the regulation of alternative splicing.",
      "Studies indicate that HuR can interact with pre-mRNA splicing factors and modulate their activity, affecting alternative splicing patterns."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the known functions of the HuR (ELAVL1) protein, which is indeed a member of the ELAV family of RNA-binding proteins and is involved in various aspects of RNA metabolism, including interactions with different types of RNAs and the regulation of alternative splicing.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "You MUST give a detailed answer to the following question: Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-7b_response": "Prothymosin alpha (PTMA) is a small protein that is expressed in a variety of tissues and plays a role in the regulation of cell growth and differentiation. The C-terminal peptide of PTMA, which is the portion of the protein that is located at the end of the polypeptide chain, has several known functions.\n\nOne known function of the PTMA C-terminal peptide is its ability to bind to and activate the JAK/STAT signaling pathway. The JAK/STAT pathway is a key signaling pathway that plays a role in the regulation of cell growth and differentiation, and it is activated in response to a variety of stimuli, such as growth factors and cytokines. The PTMA C-terminal peptide can bind to and activate the JAK/STAT pathway by interacting with the receptor for erythropoietin (EPO), which is a hormone that plays a role in the regulation of red blood cell production.\n\nAnother known function of the PTMA C-terminal peptide is its ability to regulate the activity of the androgen receptor (AR). The AR is a nuclear receptor that plays a role in the regulation of male sex characteristics, and it is activated in response to androgens, such as testosterone. The PTMA C-terminal peptide can bind to and activate the AR by interacting with the ligand-binding domain of the receptor.\n\nIn addition to its functions in the JAK/STAT and androgen receptor signaling pathways, the PTMA C-terminal peptide has also been shown to have other functions. For example, it has been shown to play a role in the regulation of cell survival and apoptosis, and it has also been shown to have anti-inflammatory effects.\n\nOverall, the PTMA C-terminal peptide has several known functions, including its ability to activate the JAK/STAT and androgen receptor signaling pathways, regulate cell survival and apoptosis, and have anti-inflammatory effects. These functions make the PTMA C-terminal peptide a promising target for the development of therapeutics for a",
    "llama-7b_fact_raw": "1. The C-terminal peptide of prothymosin alpha (PTMA) can bind to and activate the JAK/STAT signaling pathway.\n2. The PTMA C-terminal peptide interacts with the receptor for erythropoietin (EPO) to activate the JAK/STAT pathway.\n3. The PTMA C-terminal peptide can regulate the activity of the androgen receptor (AR).\n4. The PTMA C-terminal peptide interacts with the ligand-binding domain of the androgen receptor.\n5. The PTMA C-terminal peptide has been shown to play a role in the regulation of cell survival and apoptosis, as well as having anti-inflammatory effects.",
    "llama-7b_fact": [
      "The C-terminal peptide of prothymosin alpha (PTMA) can bind to and activate the JAK/STAT signaling pathway.",
      "The PTMA C-terminal peptide interacts with the receptor for erythropoietin (EPO) to activate the JAK/STAT pathway.",
      "The PTMA C-terminal peptide can regulate the activity of the androgen receptor (AR).",
      "The PTMA C-terminal peptide interacts with the ligand-binding domain of the androgen receptor.",
      "The PTMA C-terminal peptide has been shown to play a role in the regulation of cell survival and apoptosis, as well as having anti-inflammatory effects."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are highly specific and pertain to molecular biology and biochemistry. Without access to the specific scientific literature or studies that these statements are based on, it is not possible to accurately verify the truthfulness of these claims. These statements would require specialized knowledge in the field of molecular biology, specifically regarding the function of prothymosin alpha (PTMA) and its interactions with cellular signaling pathways and receptors.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "You MUST give a detailed answer to the following question: Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-7b_response": "The peptide that plays a pivotal role in human cystatin C fibrillization is the C-terminal domain (CTD) of cystatin C.\n\nCystatin C is a cysteine protease inhibitor that is widely expressed in various tissues and fluids, including plasma and urine. It plays an important role in regulating proteolytic activity and has been implicated in various physiological and pathological processes, including kidney function, inflammation, and neurodegeneration.\n\nCystatin C can exist in two forms: a soluble, monomeric form and a fibrillar, insoluble form. The fibrillar form of cystatin C is characterized by the formation of amyloid fibrils, which are insoluble, cross-linked aggregates of misfolded proteins. The fibrillization of cystatin C has been implicated in various diseases, including nephropathies, neurodegenerative disorders, and cardiovascular diseases.\n\nThe CTD of cystatin C has been shown to play a pivotal role in the fibrillization of cystatin C. The CTD is a highly conserved region of cystatin C that contains multiple disulfide bonds and is responsible for its enzymatic activity and interactions with other proteins. Studies have shown that mutations in the CTD of cystatin C can lead to the formation of amyloid fibrils and the development of cystatin C-related diseases.\n\nIn summary, the CTD of cystatin C plays a pivotal role in the fibrillization of cystatin C by promoting the formation of amyloid fibrils. Understanding the mechanisms underlying cystatin C fibrillization may provide insights into the pathogenesis of cystatin C-related diseases and may lead to the development of novel therapeutic strategies for their treatment.",
    "llama-7b_fact_raw": "1. The C-terminal domain (CTD) of cystatin C plays a pivotal role in human cystatin C fibrillization.\n2. Cystatin C is a cysteine protease inhibitor that is expressed in various tissues and fluids, including plasma and urine.\n3. Cystatin C can exist in a soluble, monomeric form and a fibrillar, insoluble form.\n4. The fibrillar form of cystatin C is characterized by the formation of amyloid fibrils.\n5. Mutations in the CTD of cystatin C can lead to the formation of amyloid fibrils and the development of cystatin C-related diseases.",
    "llama-7b_fact": [
      "The C-terminal domain (CTD) of cystatin C plays a pivotal role in human cystatin C fibrillization.",
      "Cystatin C is a cysteine protease inhibitor that is expressed in various tissues and fluids, including plasma and urine.",
      "Cystatin C can exist in a soluble, monomeric form and a fibrillar, insoluble form.",
      "The fibrillar form of cystatin C is characterized by the formation of amyloid fibrils.",
      "Mutations in the CTD of cystatin C can lead to the formation of amyloid fibrils and the development of cystatin C-related diseases."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the known properties and behavior of cystatin C. The C-terminal domain (CTD) of cystatin C is indeed important in the protein's fibrillization process. Cystatin C is a well-known cysteine protease inhibitor found in various tissues and body fluids. It can exist in both soluble and fibrillar forms, and the fibrillar form is associated with the formation of amyloid fibrils. Mutations in the CTD of cystatin C are known to lead to hereditary cerebral amyloid angiopathy, which is a cystatin C-related disease.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "You MUST give a detailed answer to the following question: Does the concentration of protein HIF-1 increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-7b_response": "The concentration of protein hypoxia-inducible factor 1 alpha (HIF-1) has not been extensively studied in relation to the administration of the cytoprotective prodrug amifostine (ethyol). However, there is some evidence to suggest that amifostine may protect against hypoxia-induced HIF-1 accumulation.\n\nHIF-1 is a transcription factor that plays a crucial role in the response to hypoxia. Under normoxic conditions, HIF-1 is rapidly degraded by the proteasome. However, under hypoxic conditions, HIF-1 accumulates and translocates to the nucleus, where it binds to DNA and activates the expression of genes involved in adaptive responses to hypoxia, such as angiogenesis, erythropoiesis, and glycolysis.\n\nAmifostine is a cytoprotective prodrug that has been shown to protect against the toxic effects of chemotherapy and radiation by reducing oxidative stress and inflammation. Amifostine has also been shown to protect against hypoxia-induced cell death in vitro and in vivo. However, the mechanisms by which amifostine exerts its cytoprotective effects are not fully understood.\n\nIt is possible that amifostine may protect against hypoxia-induced HIF-1 accumulation by reducing oxidative stress and inflammation. Oxidative stress and inflammation have been shown to play a role in the accumulation of HIF-1 under hypoxic conditions. Therefore, it is possible that amifostine may protect against hypoxia-induced HIF-1 accumulation by reducing oxidative stress and inflammation.\n\nIn summary, while there is some evidence to suggest that amifostine may protect against hypoxia-induced HIF-1 accumulation, the concentration of HIF-1 has not been extensively studied in relation to the administration of amifostine. Further research is needed to fully understand the mechanisms by which amifostine exerts its cytoprotective effects.",
    "llama-7b_fact_raw": "1. Amifostine is a cytoprotective prodrug that can protect against the toxic effects of chemotherapy and radiation.\n2. HIF-1 is a transcription factor that is rapidly degraded under normoxic conditions but accumulates under hypoxic conditions.\n3. Under hypoxic conditions, HIF-1 translocates to the nucleus and activates the expression of genes involved in adaptive responses to hypoxia.\n4. Amifostine has been shown to protect against hypoxia-induced cell death in vitro and in vivo.\n5. Oxidative stress and inflammation are factors that contribute to the accumulation of HIF-1 under hypoxic conditions.",
    "llama-7b_fact": [
      "Amifostine is a cytoprotective prodrug that can protect against the toxic effects of chemotherapy and radiation.",
      "HIF-1 is a transcription factor that is rapidly degraded under normoxic conditions but accumulates under hypoxic conditions.",
      "Under hypoxic conditions, HIF-1 translocates to the nucleus and activates the expression of genes involved in adaptive responses to hypoxia.",
      "Amifostine has been shown to protect against hypoxia-induced cell death in vitro and in vivo.",
      "Oxidative stress and inflammation are factors that contribute to the accumulation of HIF-1 under hypoxic conditions."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1588,
    "user_query": "You MUST give a detailed answer to the following question: Which histone marks are deposited by Set7?",
    "llama-7b_response": "Set7 is an enzyme that adds a methyl group to histone H3 lysine 9 (H3K9me2) and histone H3 lysine 27 (H3K27me3) to mark specific regions of the genome for transcriptional repression.\n\nH3K9me2 is a mark that is associated with transcriptionally active regions of the genome, such as promoters and enhancers. It is deposited by Set7 and other histone methyltransferases, including G9a and ESET. H3K9me2 is typically found in euchromatic regions of the genome and is thought to play a role in the regulation of gene expression during development and differentiation.\n\nH3K27me3 is a mark that is associated with transcriptionally repressed regions of the genome, such as heterochromatin. It is deposited by Set7 and other histone methyltransferases, including G9a and ESET. H3K27me3 is typically found in heterochromatic regions of the genome and is thought to play a role in the silencing of repetitive elements and transposable elements.\n\nIn summary, Set7 deposits both H3K9me2 and H3K27me3 histone marks, which are involved in the regulation of gene expression and the silencing of repetitive elements and transposable elements in the genome.",
    "llama-7b_fact_raw": "1. Set7 is an enzyme that adds a methyl group to histone H3 lysine 9 (H3K9me2).\n2. Set7 also adds a methyl group to histone H3 lysine 27 (H3K27me3).\n3. H3K9me2 is associated with transcriptionally active regions of the genome.\n4. H3K27me3 is associated with transcriptionally repressed regions of the genome.\n5. Both H3K9me2 and H3K27me3 are involved in the regulation of gene expression and the silencing of repetitive elements and transposable elements in the genome.",
    "llama-7b_fact": [
      "Set7 is an enzyme that adds a methyl group to histone H3 lysine 9 (H3K9me2).",
      "Set7 also adds a methyl group to histone H3 lysine 27 (H3K27me3).",
      "H3K9me2 is associated with transcriptionally active regions of the genome.",
      "H3K27me3 is associated with transcriptionally repressed regions of the genome.",
      "Both H3K9me2 and H3K27me3 are involved in the regulation of gene expression and the silencing of repetitive elements and transposable elements in the genome."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Set7 is an enzyme that adds a methyl group to histone H3 lysine 4 (H3K4me1), not lysine 9 (H3K9me2).\n2. FALSE [correction]: Set7 specifically methylates lysine 4 on histone H3 (H3K4me1) and does not typically add a methyl group to histone H3 lysine 27 (H3K27me3).\n3. FALSE [correction]: H3K9me2 is generally associated with transcriptionally repressed regions of the genome, not active ones.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "You MUST give a detailed answer to the following question: How many disulfide bridges has the protein hepcidin got?",
    "llama-7b_response": "Hepcidin is a protein that plays a crucial role in regulating iron metabolism in the body. It is produced primarily by hepatocytes in the liver and acts as a negative regulator of iron absorption from the gut. Hepcidin binds to the iron transporter divalent metal transporter 1 (DMT1) on the surface of enterocytes in the small intestine, leading to the internalization and degradation of DMT1. This in turn reduces the absorption of dietary iron.\n\nDisulfide bridges are covalent bonds between two cysteine residues that have been oxidized and then reduced, resulting in the formation of a disulfide bond. The number of disulfide bridges in a protein can provide information about its structure, stability, and function.\n\nTo answer the question of how many disulfide bridges hepcidin has, we need to determine the amino acid sequence of the protein. Disulfide bridges are formed between cysteine residues that are located within a certain distance of each other, typically no more than 60-80 amino acids apart. Therefore, the number of disulfide bridges in hepcidin will depend on the number of cysteine residues present in the protein and their proximity to each other.\n\nIt is not possible for me to accurately determine the number of disulfide bridges in hepcidin without access to the amino acid sequence of the protein. However, it is known that hepcidin contains several cysteine residues, which are likely to form disulfide bridges. The exact number of disulfide bridges in hepcidin will depend on the specific amino acid sequence of the protein.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1643,
    "user_query": "You MUST give a detailed answer to the following question: What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-7b_response": "DNAJC11 is a protein that is encoded by a gene located on chromosome 11q23.3. It is a member of the DNAJ (HSP40) family of proteins, which are involved in the transport and folding of proteins within the endoplasmic reticulum (ER) of eukaryotic cells.\n\nThe localization of DNAJC11 within the cell is important for its function in protein folding and transport. Studies have shown that DNAJC11 is primarily localized to the ER lumen, where it interacts with other ER-resident chaperones and proteins to facilitate the folding and assembly of newly synthesized proteins.\n\nIn addition to its role in protein folding, DNAJC11 has also been implicated in the regulation of autophagy, a cellular process involved in the degradation and recycling of damaged organelles and proteins. Studies have shown that DNAJC11 can interact with autophagy-related proteins and play a role in the formation of autophagosomes, the membrane-bound structures that engulf and degrade damaged organelles and proteins.\n\nOverall, the localization of DNAJC11 to the ER lumen and its involvement in autophagy make it an important protein for maintaining cellular homeostasis and preventing the accumulation of damaged proteins and organelles.",
    "llama-7b_fact_raw": "1. The gene encoding DNAJC11 is located on chromosome 11q23.3.\n2. DNAJC11 is a member of the DNAJ (HSP40) family of proteins.\n3. DNAJC11 is involved in the transport and folding of proteins within the endoplasmic reticulum (ER) of eukaryotic cells.\n4. DNAJC11 is primarily localized to the ER lumen.\n5. DNAJC11 has been implicated in the regulation of autophagy and can interact with autophagy-related proteins.",
    "llama-7b_fact": [
      "The gene encoding DNAJC11 is located on chromosome 11q23.3.",
      "DNAJC11 is a member of the DNAJ (HSP40) family of proteins.",
      "DNAJC11 is involved in the transport and folding of proteins within the endoplasmic reticulum (ER) of eukaryotic cells.",
      "DNAJC11 is primarily localized to the ER lumen.",
      "DNAJC11 has been implicated in the regulation of autophagy and can interact with autophagy-related proteins."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: DNAJC11 is primarily localized to the mitochondria, not the ER lumen.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "You MUST give a detailed answer to the following question: Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-7b_response": "Ultraconserved elements (UCEs) are non-coding regions of the human genome that are highly conserved across different individuals and populations. They are defined as regions of at least 200 nucleotides that are identical in at least 95% of the human population. UCEs are thought to be functionally important and have been implicated in a variety of biological processes, including embryonic development, gene regulation, and disease susceptibility.\n\nCopy number variants (CNVs) are variations in the number of copies of a particular genomic region in an individual's genome. CNVs can arise through a variety of mechanisms, including duplication, deletion, and translocation, and have been implicated in a number of human diseases, including autism, schizophrenia, and cancer.\n\nIt is not clear whether UCEs are depleted among CNVs. Some studies have reported that UCEs are overrepresented among CNVs, suggesting that CNVs may be more likely to disrupt UCEs than other regions of the genome. However, other studies have found that UCEs are underrepresented among CNVs, suggesting that CNVs may be less likely to disrupt UCEs than other regions of the genome.\n\nOverall, the relationship between UCEs and CNVs is complex and not well understood. Further research is needed to clarify the frequency and impact of UCEs among CNVs.",
    "llama-7b_fact_raw": "1. Ultraconserved elements (UCEs) are non-coding regions of the human genome that are highly conserved across different individuals and populations.\n2. UCEs are defined as regions of at least 200 nucleotides that are identical in at least 95% of the human population.\n3. Copy number variants (CNVs) are variations in the number of copies of a particular genomic region in an individual's genome.\n4. CNVs have been implicated in a number of human diseases, including autism, schizophrenia, and cancer.\n5. The relationship between UCEs and CNVs is not well understood and requires further research.",
    "llama-7b_fact": [
      "Ultraconserved elements (UCEs) are non-coding regions of the human genome that are highly conserved across different individuals and populations.",
      "UCEs are defined as regions of at least 200 nucleotides that are identical in at least 95% of the human population.",
      "Copy number variants (CNVs) are variations in the number of copies of a particular genomic region in an individual's genome.",
      "CNVs have been implicated in a number of human diseases, including autism, schizophrenia, and cancer.",
      "The relationship between UCEs and CNVs is not well understood and requires further research."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Ultraconserved elements (UCEs) are highly conserved regions of the genome that are not only conserved across different individuals and populations but also across different species, often including mammals, birds, and fish.\n2. FALSE [correction]: UCEs are defined as regions of at least 200 base pairs that are 100% identical across different species, not just within the human population.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "You MUST give a detailed answer to the following question: Which is the substrate of the haspin kinase during mitosis?",
    "llama-7b_response": "The Haspin kinase is a serine/threonine kinase that plays a role in regulating the mitotic spindle assembly checkpoint in eukaryotic cells. During mitosis, the Haspin kinase is activated in response to spindle damage or kinetochore misalignment, and it phosphorylates several proteins to prevent the progression of anaphase until all spindle checkpoint proteins are properly attached to kinetochores.\n\nThe substrate of the Haspin kinase during mitosis is not well understood, and there is ongoing research to identify the specific proteins that are phosphorylated by the Haspin kinase. However, some studies have suggested that the Haspin kinase may phosphorylate and activate the protein BubR1, which is a key regulator of the mitotic spindle assembly checkpoint. Other potential substrates of the Haspin kinase during mitosis include the protein Mad2, which is also involved in the spindle checkpoint, and the protein Aurora B, which is involved in the formation and maintenance of the mitotic spindle.\n\nOverall, the substrate of the Haspin kinase during mitosis is an area of active research, and further studies are needed to fully understand the specific proteins that are phosphorylated by the Haspin kinase and how these phosphorylation events contribute to the regulation of the mitotic spindle assembly checkpoint.",
    "llama-7b_fact_raw": "1. The Haspin kinase is a serine/threonine kinase involved in regulating the mitotic spindle assembly checkpoint in eukaryotic cells.\n2. The Haspin kinase is activated during mitosis in response to spindle damage or kinetochore misalignment.\n3. The Haspin kinase phosphorylates several proteins to prevent the progression of anaphase until spindle checkpoint proteins are properly attached to kinetochores.\n4. The protein BubR1, a key regulator of the mitotic spindle assembly checkpoint, may be phosphorylated and activated by the Haspin kinase.\n5. Other potential substrates of the Haspin kinase during mitosis include the proteins Mad2 and Aurora B.",
    "llama-7b_fact": [
      "The Haspin kinase is a serine/threonine kinase involved in regulating the mitotic spindle assembly checkpoint in eukaryotic cells.",
      "The Haspin kinase is activated during mitosis in response to spindle damage or kinetochore misalignment.",
      "The Haspin kinase phosphorylates several proteins to prevent the progression of anaphase until spindle checkpoint proteins are properly attached to kinetochores.",
      "The protein BubR1, a key regulator of the mitotic spindle assembly checkpoint, may be phosphorylated and activated by the Haspin kinase.",
      "Other potential substrates of the Haspin kinase during mitosis include the proteins Mad2 and Aurora B."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the known functions of Haspin kinase in the regulation of the mitotic spindle assembly checkpoint. Haspin kinase is indeed involved in phosphorylating proteins that are crucial for the proper attachment of spindle checkpoint proteins to kinetochores, and it is known to interact with various substrates, including those mentioned, during mitosis.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "You MUST give a detailed answer to the following question: What is the mechanism of viroid replication?",
    "llama-7b_response": "Viroid replication is a process that occurs in the cytoplasm of infected plant cells. Viroids are small, circular, single-stranded RNA molecules that lack a protein coat and are unable to replicate on their own. Instead, they rely on the host cell's machinery for replication.\n\nThe mechanism of viroid replication involves the following steps:\n\n1. Entry into the host cell: Viroids enter the host cell through various mechanisms, such as by penetration of the cell membrane or uptake via endocytosis.\n2. Uncoating of the viroid: Once inside the host cell, the viroid is released from its protein coat.\n3. RNA replication: The viroid uses the host cell's ribonucleic acid (RNA) polymerase to synthesize a complementary strand of RNA. This process is initiated at the 5' end of the viroid and proceeds in the 5' to 3' direction.\n4. Maturation of the viroid: Once the complementary strand of RNA has been synthesized, the viroid undergoes maturation to form a double-stranded RNA molecule. This process involves the formation of a stem-loop structure at the 3' end of the viroid.\n5. Release of the mature viroid: The mature viroid is released from the host cell and can infect other cells.\n\nOverall, the mechanism of viroid replication involves the use of the host cell's RNA polymerase to synthesize a complementary strand of RNA, followed by maturation of the viroid into a double-stranded RNA molecule. This process occurs in the cytoplasm of infected plant cells and is essential for the survival and spread of viroids.",
    "llama-7b_fact_raw": "1. Viroids are small, circular, single-stranded RNA molecules that lack a protein coat.\n2. Viroid replication occurs in the cytoplasm of infected plant cells.\n3. Viroids rely on the host cell's machinery, specifically RNA polymerase, to replicate.\n4. The replication process of viroids includes the synthesis of a complementary RNA strand initiated at the 5' end and proceeding in the 5' to 3' direction.\n5. The mature viroid forms a double-stranded RNA molecule with a stem-loop structure at the 3' end before being released to infect other cells.",
    "llama-7b_fact": [
      "Viroids are small, circular, single-stranded RNA molecules that lack a protein coat.",
      "Viroid replication occurs in the cytoplasm of infected plant cells.",
      "Viroids rely on the host cell's machinery, specifically RNA polymerase, to replicate.",
      "The replication process of viroids includes the synthesis of a complementary RNA strand initiated at the 5' end and proceeding in the 5' to 3' direction.",
      "The mature viroid forms a double-stranded RNA molecule with a stem-loop structure at the 3' end before being released to infect other cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroid replication typically occurs in the nucleus of infected plant cells, not the cytoplasm.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: The mature viroid does not form a double-stranded RNA molecule; it remains a single-stranded RNA with a highly base-paired rod-like or branched structure due to intramolecular pairing.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1723,
    "user_query": "You MUST give a detailed answer to the following question: Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-7b_response": "Fibronectin is a protein that plays a role in cell-matrix adhesion and is found in the extracellular matrix. It is not a serum biomarker for Duchenne muscular dystrophy.\n\nDuchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. The disease is caused by mutations in the dystrophin gene, which results in the absence of the protein dystrophin. Dystrophin is essential for maintaining the structure and function of muscle fibers.\n\nFibronectin is a protein that is found in the extracellular matrix and plays a role in cell-matrix adhesion. It is not directly related to the pathophysiology of DMD. While fibronectin has been studied in the context of muscular dystrophy, it has not been shown to be a serum biomarker for DMD.\n\nThere are several serum biomarkers that have been studied in the context of DMD, including creatine kinase, muscle-specific kinase, and myoglobin. These biomarkers can be used to diagnose and monitor the progression of the disease. However, they are not specific to DMD and can also be elevated in other muscle disorders.\n\nIn summary, while fibronectin is a protein that plays a role in muscle function, it is not a serum biomarker for Duchenne muscular dystrophy. There are other serum biomarkers that have been studied in the context of DMD, including creatine kinase, muscle-specific kinase, and myoglobin. These biomarkers can be used to diagnose and monitor the progression of the disease, but they are not specific to DMD and can also be elevated in other muscle disorders.",
    "llama-7b_fact_raw": "1. Fibronectin is a protein that plays a role in cell-matrix adhesion and is found in the extracellular matrix.\n2. Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness.\n3. DMD is caused by mutations in the dystrophin gene, which results in the absence of the protein dystrophin.\n4. Fibronectin has not been shown to be a serum biomarker for Duchenne muscular dystrophy.\n5. Serum biomarkers that have been studied in the context of DMD include creatine kinase, muscle-specific kinase, and myoglobin.",
    "llama-7b_fact": [
      "Fibronectin is a protein that plays a role in cell-matrix adhesion and is found in the extracellular matrix.",
      "Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness.",
      "DMD is caused by mutations in the dystrophin gene, which results in the absence of the protein dystrophin.",
      "Fibronectin has not been shown to be a serum biomarker for Duchenne muscular dystrophy.",
      "Serum biomarkers that have been studied in the context of DMD include creatine kinase, muscle-specific kinase, and myoglobin."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Fibronectin has been shown to be a potential serum biomarker for Duchenne muscular dystrophy.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "You MUST give a detailed answer to the following question: Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-7b_response": "The DeepBlue epigenomic data server contains data from several major epigenome projects, including:\n\n1. ENCODE (Encyclopedia of DNA Elements): This project aims to identify and characterize all functional elements in the human genome, including regulatory elements such as promoters, enhancers, and silencers. The ENCODE data in DeepBlue includes ChIP-seq (chromatin immunoprecipitation sequencing) data for histone modifications, transcription factors, and other regulatory elements.\n2. Roadmap Epigenomics Project: This project aims to create a comprehensive resource for epigenomic data across human cells and tissues. The Roadmap Epigenomics data in DeepBlue includes ChIP-seq data for histone modifications, transcription factors, and other regulatory elements, as well as bisulfite sequencing data for DNA methylation.\n3. Epigenomic Roadmap Project: This project aims to create a comprehensive resource for epigenomic data across mouse cells and tissues. The Epigenomic Roadmap data in DeepBlue includes ChIP-seq data for histone modifications, transcription factors, and other regulatory elements, as well as bisulfite sequencing data for DNA methylation.\n4. Human Epigenome Atlas: This project aims to create a comprehensive resource for epigenomic data across a variety of human tissues and cell types. The Human Epigenome Atlas data in DeepBlue includes ChIP-seq data for histone modifications, transcription factors, and other regulatory elements, as well as bisulfite sequencing data for DNA methylation.\n\nThese are just a few examples of the major epigenome projects that are represented in the DeepBlue epigenomic data server. The server also contains data from many other smaller projects and individual research groups, providing a comprehensive resource for epigenomic data across a wide range of organisms and tissues.",
    "llama-7b_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE (Encyclopedia of DNA Elements) project.\n2. The ENCODE project data in DeepBlue includes ChIP-seq data for histone modifications, transcription factors, and other regulatory elements.\n3. The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server and features ChIP-seq and bisulfite sequencing data for DNA methylation.\n4. The Epigenomic Roadmap Project, focusing on mouse cells and tissues, contributes data to the DeepBlue server, including ChIP-seq and bisulfite sequencing data.\n5. The Human Epigenome Atlas project data, which includes ChIP-seq and bisulfite sequencing data for various human tissues and cell types, is available on the DeepBlue epigenomic data server.",
    "llama-7b_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE (Encyclopedia of DNA Elements) project.",
      "The ENCODE project data in DeepBlue includes ChIP-seq data for histone modifications, transcription factors, and other regulatory elements.",
      "The Roadmap Epigenomics Project data is included in the DeepBlue epigenomic data server and features ChIP-seq and bisulfite sequencing data for DNA methylation.",
      "The Epigenomic Roadmap Project, focusing on mouse cells and tissues, contributes data to the DeepBlue server, including ChIP-seq and bisulfite sequencing data.",
      "The Human Epigenome Atlas project data, which includes ChIP-seq and bisulfite sequencing data for various human tissues and cell types, is available on the DeepBlue epigenomic data server."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Roadmap Epigenomics Project focuses on human cells and tissues, not mouse cells and tissues.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "You MUST give a detailed answer to the following question: Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-7b_response": "One tool that employs self-organizing maps (SOMs) for analyzing synonymous codon usage is the software package PAML (Phylogenetic Analysis by Maximum Likelihood).\n\nSOMs are a type of unsupervised machine learning algorithm that can be used to analyze and visualize high-dimensional data. In the context of codon usage analysis, SOMs can be used to identify clusters of synonymous codons that exhibit similar patterns of usage across different species.\n\nPAML is a widely used software package for conducting phylogenetic analysis of molecular sequences. It includes a module called \"ModelAver\" that can be used to analyze synonymous codon usage patterns across different species. ModelAver uses SOMs to identify clusters of synonymous codons that exhibit similar patterns of usage, and it can also perform statistical tests to compare the usage patterns of different codons within each cluster.\n\nOverall, PAML is a powerful tool for analyzing synonymous codon usage patterns across multiple species, and its use of SOMs provides a useful way to visualize and interpret the results of these analyses.",
    "llama-7b_fact_raw": "1. The software package PAML uses self-organizing maps (SOMs) for analyzing synonymous codon usage.\n2. Self-organizing maps are a type of unsupervised machine learning algorithm.\n3. PAML is used for conducting phylogenetic analysis of molecular sequences.\n4. PAML includes a module called \"ModelAver\" for analyzing synonymous codon usage patterns.\n5. ModelAver can perform statistical tests to compare the usage patterns of different codons.",
    "llama-7b_fact": [
      "The software package PAML uses self-organizing maps (SOMs) for analyzing synonymous codon usage.",
      "Self-organizing maps are a type of unsupervised machine learning algorithm.",
      "PAML is used for conducting phylogenetic analysis of molecular sequences.",
      "PAML includes a module called \"ModelAver\" for analyzing synonymous codon usage patterns.",
      "ModelAver can perform statistical tests to compare the usage patterns of different codons."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The software package PAML does not use self-organizing maps (SOMs) for analyzing synonymous codon usage. PAML stands for Phylogenetic Analysis by Maximum Likelihood and is used for phylogenetic analyses, not for analyzing codon usage with SOMs.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: PAML does not include a module called \"ModelAver.\" It includes various models for phylogenetic analysis, but \"ModelAver\" is not one of them.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "You MUST give a detailed answer to the following question: What is MINDY-1?",
    "llama-7b_response": "I'm sorry, but I am not familiar with the term \"MINDY-1.\" Can you provide more context or information about what you are referring to? This will help me better understand your question and provide a more accurate answer.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 1810,
    "user_query": "You MUST give a detailed answer to the following question: Which software package is available for the analysis of conserved genomic loci?",
    "llama-7b_response": "There are several software packages available for the analysis of conserved genomic loci, including:\n\n1. RepeatMasker: RepeatMasker is a software tool that can be used to identify repetitive elements in genomic DNA and to predict the location of conserved genomic regions. It can be used to identify repetitive elements such as microsatellites, minisatellites, and transposable elements, and to predict the location of conserved genomic regions such as genes, regulatory elements, and other functional elements.\n2. RepeatScout: RepeatScout is a software tool that can be used to identify repetitive elements in genomic DNA and to predict the location of conserved genomic regions. It can be used to identify repetitive elements such as microsatellites, minisatellites, and transposable elements, and to predict the location of conserved genomic regions such as genes, regulatory elements, and other functional elements.\n3. Genomic Repeats Finder: Genomic Repeats Finder is a software tool that can be used to identify repetitive elements in genomic DNA and to predict the location of conserved genomic regions. It can be used to identify repetitive elements such as microsatellites, minisatellites, and transposable elements, and to predict the location of conserved genomic regions such as genes, regulatory elements, and other functional elements.\n4. RepeatAnno: RepeatAnno is a software tool that can be used to identify repetitive elements in genomic DNA and to predict the location of conserved genomic regions. It can be used to identify repetitive elements such as microsatellites, minisatellites, and transposable elements, and to predict the location of conserved genomic regions such as genes, regulatory elements, and other functional elements.\n5. RepeatModeler: RepeatModeler is a software tool that can be used to identify repetitive elements in genomic DNA and to predict the location of conserved genomic regions. It can be used to identify repetitive elements such as microsatellites, minisatellites, and transposable elements, and to predict the location of conserved genomic regions such as genes, regulatory elements, and other functional elements.\n\nThese are just a few examples of the many software packages available",
    "llama-7b_fact_raw": "1. RepeatMasker is a software tool used to identify repetitive elements in genomic DNA.\n2. RepeatScout is a software tool used to identify repetitive elements in genomic DNA.\n3. Genomic Repeats Finder is a software tool used to identify repetitive elements in genomic DNA.\n4. RepeatAnno is a software tool used to identify repetitive elements in genomic DNA.\n5. RepeatModeler is a software tool used to identify repetitive elements in genomic DNA.",
    "llama-7b_fact": [
      "RepeatMasker is a software tool used to identify repetitive elements in genomic DNA.",
      "RepeatScout is a software tool used to identify repetitive elements in genomic DNA.",
      "Genomic Repeats Finder is a software tool used to identify repetitive elements in genomic DNA.",
      "RepeatAnno is a software tool used to identify repetitive elements in genomic DNA.",
      "RepeatModeler is a software tool used to identify repetitive elements in genomic DNA."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "You MUST give a detailed answer to the following question: Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-7b_response": "The PIEZO2 gene is associated with several diseases, including:\n\n1. Hereditary hemorrhagic telangiectasia (HHT): HHT is a genetic disorder that causes abnormal blood vessels to form in the skin, mucous membranes, and organs. The PIEZO2 gene plays a role in the development of blood vessels, and mutations in this gene can increase the risk of HHT.\n2. Ehlers-Danlos syndrome (EDS): EDS is a group of genetic disorders that affect the connective tissues in the body, including the skin, joints, and blood vessels. Mutations in the PIEZO2 gene have been associated with a specific subtype of EDS known as EDS type 3B.\n3. Autosomal dominant polycystic kidney disease (ADPKD): ADPKD is a genetic disorder that causes the kidneys to become enlarged and filled with cysts. The PIEZO2 gene plays a role in the development of the kidneys, and mutations in this gene can increase the risk of ADPKD.",
    "llama-7b_fact_raw": "1. Mutations in the PIEZO2 gene can increase the risk of Hereditary hemorrhagic telangiectasia (HHT).\n2. Ehlers-Danlos syndrome (EDS) type 3B has been associated with mutations in the PIEZO2 gene.\n3. Autosomal dominant polycystic kidney disease (ADPKD) risk can be increased by mutations in the PIEZO2 gene.",
    "llama-7b_fact": [
      "Mutations in the PIEZO2 gene can increase the risk of Hereditary hemorrhagic telangiectasia (HHT).",
      "Ehlers-Danlos syndrome (EDS) type 3B has been associated with mutations in the PIEZO2 gene.",
      "Autosomal dominant polycystic kidney disease (ADPKD) risk can be increased by mutations in the PIEZO2 gene."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Mutations in the ENG, ACVRL1, and SMAD4 genes are associated with an increased risk of Hereditary hemorrhagic telangiectasia (HHT), not the PIEZO2 gene.\n2. UNKNOWN\n3. FALSE [correction]: Autosomal dominant polycystic kidney disease (ADPKD) risk is increased by mutations in the PKD1 and PKD2 genes, not the PIEZO2 gene.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1867,
    "user_query": "You MUST give a detailed answer to the following question: What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-7b_response": "ERAP1 and ERAP2 are two proteins that are involved in the processing of antigenic peptides presented on the surface of antigen-presenting cells (APCs), such as dendritic cells and macrophages. These proteins belong to the ERAP (endoplasmic reticulum aminopeptidase) family and play a crucial role in the maturation and presentation of peptides derived from pathogens and self-antigens.\n\nERAP1 and ERAP2 are both expressed in the endoplasmic reticulum (ER) of APCs, where they process and trim peptides derived from pathogens and self-antigens. ERAP1 and ERAP2 then transport these peptides to the Golgi apparatus, where they are further processed and presented on the surface of APCs in the context of major histocompatibility complex (MHC) molecules.\n\nERAP1 and ERAP2 can exist as monomers or dimers in the ER and Golgi apparatus. The dimerization of ERAP1 and ERAP2 has been shown to play an important role in the processing and presentation of antigenic peptides. When ERAP1 and ERAP2 form a dimer, they can interact with each other and process peptides more efficiently, leading to the production of higher-quality peptides that are better suited for presentation on the surface of APCs.\n\nIn addition, ERAP1-ERAP2 dimerization has been shown to play a role in the regulation of the immune response. For example, ERAP1 and ERAP2 can interact with each other and with other immune signaling molecules, such as Toll-like receptors (TLRs) and interleukin-1 (IL-1), to regulate the production of pro-inflammatory cytokines and the activation of immune cells.\n\nOverall, ERAP1-ERAP2 dimerization plays an important role in the processing and presentation of antigenic peptides, as well as in the regulation of the immune response. Dimerization allows ERAP1 and ERAP2 to interact with each other and with other immune signaling molecules, leading to the production of higher-quality peptides and the regulation of",
    "llama-7b_fact_raw": "1. ERAP1 and ERAP2 are involved in the processing of antigenic peptides presented on the surface of antigen-presenting cells (APCs).\n2. ERAP1 and ERAP2 are expressed in the endoplasmic reticulum (ER) of APCs.\n3. The dimerization of ERAP1 and ERAP2 plays an important role in the processing and presentation of antigenic peptides.\n4. ERAP1-ERAP2 dimerization leads to the production of higher-quality peptides that are better suited for presentation on the surface of APCs.\n5. ERAP1-ERAP2 dimerization is involved in the regulation of the immune response, including the production of pro-inflammatory cytokines and the activation of immune cells.",
    "llama-7b_fact": [
      "ERAP1 and ERAP2 are involved in the processing of antigenic peptides presented on the surface of antigen-presenting cells (APCs).",
      "ERAP1 and ERAP2 are expressed in the endoplasmic reticulum (ER) of APCs.",
      "The dimerization of ERAP1 and ERAP2 plays an important role in the processing and presentation of antigenic peptides.",
      "ERAP1-ERAP2 dimerization leads to the production of higher-quality peptides that are better suited for presentation on the surface of APCs.",
      "ERAP1-ERAP2 dimerization is involved in the regulation of the immune response, including the production of pro-inflammatory cytokines and the activation of immune cells."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements are consistent with current scientific understanding of the roles of ERAP1 and ERAP2 in antigen processing. ERAP1 and ERAP2 are indeed involved in the trimming of peptides within the endoplasmic reticulum for presentation by MHC class I molecules on the surface of antigen-presenting cells. The dimerization of these enzymes can affect their activity and specificity, which is important for the immune system's ability to recognize and respond to pathogens.\n\nHowever, the fourth and fifth statements are more specific and would require additional context or specific research evidence to confirm their accuracy. The quality of peptides and their suitability for MHC class I presentation can be influenced by many factors, and the role of ERAP1-ERAP2 dimerization in this process is a specific detail that is not universally established. Similarly, the involvement of ERAP1-ERAP2 dimerization in the regulation of the immune response, including cytokine production and immune cell activation, is a complex topic that would require specific evidence to support the statements. Without additional context or references, the truth of these statements cannot be determined.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-7b_response": "R-spondin 1 and noggin are two proteins that play important roles in the regulation of gallbladder development and function.\n\nR-spondin 1 is a member of the R-spondin family of proteins, which are secreted by various tissues and have been implicated in the regulation of bone growth and development. In the gallbladder, R-spondin 1 has been shown to play a role in the regulation of cholesterol synthesis and secretion. Specifically, R-spondin 1 has been shown to stimulate the expression of genes involved in cholesterol synthesis and secretion in gallbladder cells.\n\nNoggin, on the other hand, is a protein that has been shown to inhibit the activity of bone morphogenetic proteins (BMPs), which are signaling molecules that play important roles in the regulation of cell growth and differentiation. In the gallbladder, noggin has been shown to play a role in the regulation of cholesterol synthesis and secretion. Specifically, noggin has been shown to inhibit the activity of BMPs, which in turn has been shown to inhibit the expression of genes involved in cholesterol synthesis and secretion in gallbladder cells.\n\nIn summary, R-spondin 1 and noggin play important roles in the regulation of cholesterol synthesis and secretion in the gallbladder. R-spondin 1 stimulates the expression of genes involved in cholesterol synthesis and secretion, while noggin inhibits the activity of BMPs, which in turn inhibits the expression of genes involved in cholesterol synthesis and secretion.",
    "llama-7b_fact_raw": "1. R-spondin 1 is involved in the regulation of cholesterol synthesis and secretion in gallbladder cells.\n2. R-spondin 1 stimulates the expression of genes involved in cholesterol synthesis and secretion in gallbladder cells.\n3. Noggin inhibits the activity of bone morphogenetic proteins (BMPs) in the gallbladder.\n4. The inhibition of BMPs by noggin leads to a decrease in the expression of genes involved in cholesterol synthesis and secretion in gallbladder cells.\n5. Both R-spondin 1 and noggin are proteins that play roles in the regulation of gallbladder development and function.",
    "llama-7b_fact": [
      "R-spondin 1 is involved in the regulation of cholesterol synthesis and secretion in gallbladder cells.",
      "R-spondin 1 stimulates the expression of genes involved in cholesterol synthesis and secretion in gallbladder cells.",
      "Noggin inhibits the activity of bone morphogenetic proteins (BMPs) in the gallbladder.",
      "The inhibition of BMPs by noggin leads to a decrease in the expression of genes involved in cholesterol synthesis and secretion in gallbladder cells.",
      "Both R-spondin 1 and noggin are proteins that play roles in the regulation of gallbladder development and function."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: R-spondin 1 is not involved in the regulation of cholesterol synthesis and secretion in gallbladder cells; it is involved in the regulation of Wnt signaling, which is important for cell proliferation and differentiation.\n2. FALSE [correction]: R-spondin 1 does not stimulate the expression of genes involved in cholesterol synthesis and secretion in gallbladder cells; it acts as an activator of the Wnt signaling pathway.\n3. TRUE: Noggin is known to inhibit the activity of bone morphogenetic proteins (BMPs), which are involved in various developmental processes.\n4. UNKNOWN: While noggin does inhibit BMPs, the specific effect of this inhibition on the expression of genes involved in cholesterol synthesis and secretion in gallbladder cells is not well-established and would require specific scientific evidence to confirm.\n5. TRUE: Both R-spondin 1 and noggin are proteins that play roles in developmental processes, which can include the regulation of gallbladder development and function, although their specific roles in the gallbladder may not be directly related to cholesterol synthesis and secretion.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1937,
    "user_query": "You MUST give a detailed answer to the following question: Does NADPH oxidase 5 require any subunit for function?",
    "llama-7b_response": "Yes, NADPH oxidase 5 (NOX5) requires multiple subunits for its function. NOX5 is a member of the NADPH oxidase family of enzymes, which generate reactive oxygen species (ROS) through the oxidation of NADPH.\n\nNOX5 is composed of two catalytic subunits, p22phox and p40phox, and two regulatory subunits, p67phox and p41phox. The p22phox and p40phox subunits are required for the enzymatic activity of NOX5, while the p67phox and p41phox subunits play a role in the targeting and localization of NOX5 to specific cellular compartments.\n\nIn the absence of one or more of the NOX5 subunits, the enzymatic activity of NOX5 is reduced or absent, leading to a decrease in ROS production and a corresponding impact on cellular function. For example, mice lacking the p22phox subunit have a reduced ability to mount an immune response to bacterial infections, while mice lacking the p41phox subunit have an increased susceptibility to inflammation and tissue damage.\n\nOverall, NOX5 requires all of its subunits for proper function, and the absence of any one of these subunits can result in altered ROS production and cellular responses.",
    "llama-7b_fact_raw": "1. NADPH oxidase 5 (NOX5) requires multiple subunits for its function.\n2. NOX5 is composed of two catalytic subunits, p22phox and p40phox.\n3. NOX5 also has two regulatory subunits, p67phox and p41phox.\n4. The absence of one or more of the NOX5 subunits leads to a decrease in reactive oxygen species (ROS) production.\n5. Mice lacking the p22phox subunit have a reduced ability to mount an immune response to bacterial infections.",
    "llama-7b_fact": [
      "NADPH oxidase 5 (NOX5) requires multiple subunits for its function.",
      "NOX5 is composed of two catalytic subunits, p22phox and p40phox.",
      "NOX5 also has two regulatory subunits, p67phox and p41phox.",
      "The absence of one or more of the NOX5 subunits leads to a decrease in reactive oxygen species (ROS) production.",
      "Mice lacking the p22phox subunit have a reduced ability to mount an immune response to bacterial infections."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is unique among NOX isoforms because it does not require the presence of multiple subunits for its function; it is calcium-dependent and functions independently of p22phox, p47phox, or p67phox.\n2. FALSE [correction]: NOX5 does not have p22phox and p40phox as catalytic subunits. NOX5 is a single catalytic subunit enzyme that is activated by calcium binding.\n3. FALSE [correction]: NOX5 does not have regulatory subunits such as p67phox and p41phox. It is regulated by calcium ions and does not require these subunits for its activation.\n4. TRUE: Generally, the absence of necessary subunits in NADPH oxidase complexes can lead to a decrease in reactive oxygen species (ROS) production. However, since NOX5 does not require additional subunits, this statement is true for other NOX isoforms that do require subunits for proper function.\n5. UNKNOWN: The statement is about a specific experimental outcome, and without additional context or research data, it is not possible to determine the truthfulness of the statement. However, it is worth noting that NOX5 is not present in mice as they lack the gene for this enzyme, so the statement may be incorrect or based on a hypothetical or genetically modified scenario.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "You MUST give a detailed answer to the following question: What is the connection between furin and hepcidin?",
    "llama-7b_response": "Furin and hepcidin are two distinct proteins that have different functions in the body. Furin is an enzyme that plays a role in the processing and activation of other proteins, while hepcidin is a hormone that regulates iron absorption and storage in the body.\n\nFurin is an asparaginyl endopeptidase enzyme that cleaves peptide bonds between asparagine residues in proteins. It is involved in the processing and activation of various proteins, including growth factors, cytokines, and hormones. Furin is expressed in many tissues, including the liver, kidney, and pancreas, and plays a role in the regulation of various physiological processes, including cell growth, differentiation, and inflammation.\n\nHepcidin, on the other hand, is a hormone that is produced by hepatocytes in the liver. It is the primary regulator of iron absorption and storage in the body. Hepcidin binds to and inhibits the expression of divalent metal transporter 1 (DMT1), a transmembrane protein that facilitates the uptake of iron from the diet into enterocytes in the small intestine. By inhibiting DMT1, hepcidin prevents the absorption of dietary iron and maintains iron homeostasis in the body.\n\nDespite their different functions, there is a connection between furin and hepcidin. Recent studies have shown that furin can play a role in the regulation of hepcidin expression and activity. For example, furin has been shown to cleave and activate hepcidin, which can enhance its biological activity and increase iron absorption. Conversely, inhibition of furin activity has been shown to decrease hepcidin expression and iron absorption.\n\nFurthermore, there is evidence to suggest that hepcidin can regulate the activity of furin. For example, hepcidin has been shown to inhibit the activity of furin, which can decrease the processing and activation of other proteins.\n\nIn summary, while furin and hepcidin are two distinct proteins with different functions, there is a connection between them. Furin can play a role in the",
    "llama-7b_fact_raw": "1. Furin is an enzyme that plays a role in the processing and activation of other proteins.\n2. Hepcidin is a hormone that regulates iron absorption and storage in the body.\n3. Furin is expressed in many tissues, including the liver, kidney, and pancreas.\n4. Hepcidin is produced by hepatocytes in the liver and inhibits the expression of divalent metal transporter 1 (DMT1).\n5. Furin has been shown to cleave and activate hepcidin, enhancing its biological activity and affecting iron absorption.",
    "llama-7b_fact": [
      "Furin is an enzyme that plays a role in the processing and activation of other proteins.",
      "Hepcidin is a hormone that regulates iron absorption and storage in the body.",
      "Furin is expressed in many tissues, including the liver, kidney, and pancreas.",
      "Hepcidin is produced by hepatocytes in the liver and inhibits the expression of divalent metal transporter 1 (DMT1).",
      "Furin has been shown to cleave and activate hepcidin, enhancing its biological activity and affecting iron absorption."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Furin does not cleave and activate hepcidin. Hepcidin is a regulatory hormone itself that controls iron homeostasis, and its activity is not enhanced by furin-mediated cleavage.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1956,
    "user_query": "You MUST give a detailed answer to the following question: Which is the largest metabolic gene cluster in yeast?",
    "llama-7b_response": "The largest metabolic gene cluster in yeast is the pyruvate dehydrogenase (PDH) complex, which is responsible for converting pyruvate into acetyl-CoA, an important intermediate in cellular metabolism. The PDH complex is composed of four subunits: E1 (pyruvate dehydrogenase), E2 (dihydrolipoyl succinyltransferase), E3 (dihydrolipoyl dehydrogenase), and E4 (dihydrolipoyl dehydrogenase).\n\nThe PDH complex is one of the largest metabolic gene clusters in yeast because it is composed of multiple genes that are co-transcribed and co-translated. The genes for the four subunits of the PDH complex are located on different chromosomes, but they are transcribed as a single unit and translated as a single polypeptide chain. This co-transcription and co-translation of multiple genes is a common feature of many metabolic gene clusters in yeast and other organisms.\n\nThe PDH complex is also one of the largest metabolic gene clusters in yeast because it plays a critical role in cellular metabolism. The conversion of pyruvate into acetyl-CoA is an important step in the citric acid cycle, which is the primary means by which cells generate energy in the form of ATP. Disruption of the PDH complex can lead to a variety of metabolic disorders, including lactic acidosis, diabetes, and liver disease.\n\nOverall, the PDH complex is the largest metabolic gene cluster in yeast because it is composed of multiple genes that are co-transcribed and co-translated, and it plays a critical role in cellular metabolism.",
    "llama-7b_fact_raw": "1. The pyruvate dehydrogenase (PDH) complex is the largest metabolic gene cluster in yeast.\n2. The PDH complex is responsible for converting pyruvate into acetyl-CoA.\n3. The PDH complex is composed of four subunits: E1, E2, E3, and E4.\n4. The genes for the four subunits of the PDH complex are located on different chromosomes but are transcribed as a single unit.\n5. Disruption of the PDH complex can lead to metabolic disorders such as lactic acidosis, diabetes, and liver disease.",
    "llama-7b_fact": [
      "The pyruvate dehydrogenase (PDH) complex is the largest metabolic gene cluster in yeast.",
      "The PDH complex is responsible for converting pyruvate into acetyl-CoA.",
      "The PDH complex is composed of four subunits: E1, E2, E3, and E4.",
      "The genes for the four subunits of the PDH complex are located on different chromosomes but are transcribed as a single unit.",
      "Disruption of the PDH complex can lead to metabolic disorders such as lactic acidosis, diabetes, and liver disease."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: The statement about the pyruvate dehydrogenase (PDH) complex being the largest metabolic gene cluster in yeast is specific and would require specialized knowledge or a specific source to verify. Without additional context, it's difficult to determine the truth of this statement.\n2. TRUE: The PDH complex is indeed responsible for converting pyruvate into acetyl-CoA, a critical step in cellular respiration.\n3. FALSE [correction]: The PDH complex is composed of three subunits: E1, E2, and E3. There is no E4 subunit.\n4. FALSE [correction]: While the genes for the subunits of the PDH complex are indeed located on different chromosomes, they are not transcribed as a single unit. Each subunit is encoded by a separate gene and transcribed independently.\n5. TRUE: Disruption of the PDH complex can lead to a variety of metabolic disorders, including lactic acidosis. It can also contribute to the pathology of diseases such as diabetes and neurological dysfunction, but the direct association with liver disease is less clear and may depend on the specific context or additional factors.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1967,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of LIMT lncRNA?",
    "llama-7b_response": "Long non-coding RNA (lncRNA) LIMT has been shown to play a crucial role in various biological processes, including cell proliferation, differentiation, and apoptosis. LIMT lncRNA has also been implicated in the regulation of gene expression at the transcriptional level.\n\nOne of the key functions of LIMT lncRNA is to act as a competing endogenous RNA (ceRNA) molecule. ceRNAs are non-coding RNAs that can bind to microRNAs (miRNAs) and prevent them from binding to their target mRNAs, thereby regulating gene expression. LIMT lncRNA has been shown to function as a miRNA sponge, binding to miRNAs and preventing them from targeting specific mRNAs.\n\nFor example, LIMT lncRNA has been shown to bind to let-7 family miRNAs and prevent them from targeting PTEN, a tumor suppressor gene. This leads to the deregulation of PTEN expression and contributes to the development of various cancers.\n\nIn addition to its ceRNA function, LIMT lncRNA has also been shown to regulate gene expression at the transcriptional level. LIMT lncRNA has been shown to bind to the promoter region of target genes and recruit transcriptional co-activators, leading to the activation of gene transcription.\n\nFurthermore, LIMT lncRNA has also been shown to play a role in the regulation of cellular signaling pathways. For example, LIMT lncRNA has been shown to bind to the androgen receptor (AR) and enhance its transcriptional activity, thereby promoting the growth of prostate cancer cells.\n\nIn summary, LIMT lncRNA plays a crucial role in regulating gene expression at the transcriptional and post-transcriptional levels, and contributes to various biological processes, including cell proliferation, differentiation, and apoptosis. Its deregulation has been implicated in the development of various diseases, including cancer.",
    "llama-7b_fact_raw": "1. LIMT lncRNA plays a role in cell proliferation, differentiation, and apoptosis.\n2. LIMT lncRNA functions as a competing endogenous RNA (ceRNA) molecule.\n3. LIMT lncRNA can bind to let-7 family miRNAs and prevent them from targeting the PTEN tumor suppressor gene.\n4. LIMT lncRNA can bind to the promoter region of target genes and recruit transcriptional co-activators.\n5. LIMT lncRNA has been shown to bind to the androgen receptor (AR) and enhance its transcriptional activity, promoting the growth of prostate cancer cells.",
    "llama-7b_fact": [
      "LIMT lncRNA plays a role in cell proliferation, differentiation, and apoptosis.",
      "LIMT lncRNA functions as a competing endogenous RNA (ceRNA) molecule.",
      "LIMT lncRNA can bind to let-7 family miRNAs and prevent them from targeting the PTEN tumor suppressor gene.",
      "LIMT lncRNA can bind to the promoter region of target genes and recruit transcriptional co-activators.",
      "LIMT lncRNA has been shown to bind to the androgen receptor (AR) and enhance its transcriptional activity, promoting the growth of prostate cancer cells."
    ],
    "llama-7b_judge_raw": "1. TRUE: LIMT lncRNA is known to be involved in various cellular processes including cell proliferation, differentiation, and apoptosis.\n2. TRUE: LIMT lncRNA can function as a competing endogenous RNA (ceRNA) molecule, which means it can sequester microRNAs and prevent them from binding to their target mRNAs.\n3. TRUE: LIMT lncRNA has been reported to bind to let-7 family miRNAs, which are known to target the PTEN tumor suppressor gene, thereby preventing the miRNAs from downregulating PTEN expression.\n4. FALSE [correction]: LIMT lncRNA is not known to bind directly to the promoter region of target genes to recruit transcriptional co-activators. This function is more commonly associated with other types of regulatory RNAs or DNA-binding proteins.\n5. UNKNOWN: Without specific evidence or a reference to a study that shows LIMT lncRNA binding to the androgen receptor (AR) and enhancing its transcriptional activity, the truth of this statement cannot be determined.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "You MUST give a detailed answer to the following question: Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-7b_response": "There are several R/Bioconductor packages that can be used for performing SNP (Single Nucleotide Polymorphism) enrichment analysis, including:\n\n1. snpEff: The snpEff package is a widely used R/Bioconductor package for predicting the functional consequences of SNPs. It uses a combination of machine learning algorithms and databases of known functional SNPs to predict the effect of a given SNP on gene expression, protein function, and other biological processes.\n2. Genome-Wide Association Studies (GWAS): The GWAS package is another R/Bioconductor package that can be used for performing SNP enrichment analysis. It provides tools for analyzing genome-wide association studies (GWAS), which involve analyzing large datasets of SNPs to identify associations between SNPs and certain traits or diseases.\n3. GenABEL: The GenABEL package is a general-purpose R/Bioconductor package for analyzing gene expression data. It can be used for performing SNP enrichment analysis by comparing the expression levels of SNP-associated genes to those of non-SNP-associated genes.\n4. DESeq2: The DESeq2 package is another R/Bioconductor package that can be used for analyzing gene expression data. It can be used for performing SNP enrichment analysis by comparing the expression levels of SNP-associated genes to those of non-SNP-associated genes.\n\nOverall, the choice of which R/Bioconductor package to use for performing SNP enrichment analysis will depend on the specific goals of the analysis and the type of data being analyzed.",
    "llama-7b_fact_raw": "1. The snpEff package is an R/Bioconductor package used for predicting the functional consequences of SNPs.\n2. The GWAS package is an R/Bioconductor package that provides tools for analyzing genome-wide association studies.\n3. The GenABEL package is an R/Bioconductor package for analyzing gene expression data and can be used for SNP enrichment analysis.\n4. The DESeq2 package is an R/Bioconductor package that can be used for analyzing gene expression data, including SNP enrichment analysis.",
    "llama-7b_fact": [
      "The snpEff package is an R/Bioconductor package used for predicting the functional consequences of SNPs.",
      "The GWAS package is an R/Bioconductor package that provides tools for analyzing genome-wide association studies.",
      "The GenABEL package is an R/Bioconductor package for analyzing gene expression data and can be used for SNP enrichment analysis.",
      "The DESeq2 package is an R/Bioconductor package that can be used for analyzing gene expression data, including SNP enrichment analysis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The snpEff package is not an R/Bioconductor package; it is a standalone Java tool used for predicting the functional consequences of genetic variants such as SNPs.\n2. UNKNOWN: While there are packages in R/Bioconductor for analyzing genome-wide association studies, \"GWAS\" is a general term for the study type, and without a specific package name, it's unclear whether a package named \"GWAS\" exists in R/Bioconductor.\n3. FALSE [correction]: The GenABEL package is an R package for genome-wide association analysis, not specifically for analyzing gene expression data or SNP enrichment analysis.\n4. TRUE: The DESeq2 package is an R/Bioconductor package used for analyzing count-based gene expression data, such as data from RNA-Seq experiments, but it is not typically used for SNP enrichment analysis.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2015,
    "user_query": "You MUST give a detailed answer to the following question: Which are the key players on radial glial specification to ependymal cells?",
    "llama-7b_response": "Radial glial cells are a type of glial cell that give rise to the ependymal cells that line the ventricular system of the brain and spinal cord. The process of radial glial specification to ependymal cells involves a series of molecular signals and cellular interactions that occur during embryonic development.\n\nOne of the key players in the specification of radial glial cells to ependymal cells is the transcription factor Sox2. Sox2 is expressed in radial glial cells and is necessary for the specification of these cells to ependymal cells. Sox2 works by activating the expression of genes that are specific to ependymal cells, such as the ependymin gene.\n\nAnother key player in the specification of radial glial cells to ependymal cells is the transcription factor Nkx2.1. Nkx2.1 is expressed in a subset of radial glial cells and is necessary for the specification of these cells to ependymal cells. Nkx2.1 works by activating the expression of genes that are specific to ependymal cells, such as the ependymin gene.\n\nIn addition to Sox2 and Nkx2.1, other transcription factors that have been implicated in the specification of radial glial cells to ependymal cells include Olig2, Ngn2, and Ascl1. These transcription factors work by activating the expression of genes that are specific to ependymal cells, or by inhibiting the expression of genes that are specific to other cell types.\n\nOverall, the specification of radial glial cells to ependymal cells involves a complex interplay of molecular signals and cellular interactions. The transcription factors Sox2, Nkx2.1, Olig2, Ngn2, and Ascl1 are all important players in this process, and further research is needed to fully understand how they work together to specify radial glial cells to ependymal cells.",
    "llama-7b_fact_raw": "1. Radial glial cells give rise to ependymal cells that line the ventricular system of the brain and spinal cord.\n2. The transcription factor Sox2 is necessary for the specification of radial glial cells to ependymal cells.\n3. Sox2 activates the expression of genes specific to ependymal cells, such as the ependymin gene.\n4. The transcription factor Nkx2.1 is expressed in a subset of radial glial cells and is necessary for their specification to ependymal cells.\n5. Other transcription factors implicated in the specification of radial glial cells to ependymal cells include Olig2, Ngn2, and Ascl1.",
    "llama-7b_fact": [
      "Radial glial cells give rise to ependymal cells that line the ventricular system of the brain and spinal cord.",
      "The transcription factor Sox2 is necessary for the specification of radial glial cells to ependymal cells.",
      "Sox2 activates the expression of genes specific to ependymal cells, such as the ependymin gene.",
      "The transcription factor Nkx2.1 is expressed in a subset of radial glial cells and is necessary for their specification to ependymal cells.",
      "Other transcription factors implicated in the specification of radial glial cells to ependymal cells include Olig2, Ngn2, and Ascl1."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The ependymin gene is not specific to ependymal cells; it is associated with the extracellular matrix of the brain and is involved in neuroplasticity. Sox2 does activate the expression of genes specific to ependymal cells, but ependymin is not one of them.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "You MUST give a detailed answer to the following question: How are triple negative gliomas characterized?",
    "llama-7b_response": "Triple negative breast cancers are characterized by the absence of three receptors for hormones and growth factors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These cancers do not overexpress HER2, which is a positive prognostic factor in other types of breast cancer. Triple negative breast cancers are more aggressive and tend to have a worse prognosis than other types of breast cancer. They are also more likely to recur and to metastasize to other parts of the body.\n\nTriple negative gliomas are a type of brain tumor that are characterized by the absence of three receptors for hormones and growth factors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These cancers do not overexpress HER2, which is a positive prognostic factor in other types of gliomas. Triple negative gliomas are more aggressive and tend to have a worse prognosis than other types of gliomas. They are also more likely to recur and to metastasize to other parts of the body.\n\nTriple negative breast cancers and triple negative gliomas are characterized by the absence of three receptors for hormones and growth factors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These cancers do not overexpress HER2, which is a positive prognostic factor in other types of cancer.\n\nTriple negative breast cancers and triple negative gliomas are characterized by the absence of three receptors for hormones and growth factors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). These cancers do not overexpress HER2, which is a positive prognostic factor in other types of cancer.\n\nTriple negative breast cancers and triple negative gliomas are characterized by the absence of three receptors for hormones and growth factors: estrogen receptor (ER), progesterone receptor (PR), and human epidermal",
    "llama-7b_fact_raw": "1. Triple negative breast cancers lack estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).\n2. HER2 overexpression is a positive prognostic factor in types of breast cancer other than triple negative.\n3. Triple negative breast cancers are more aggressive and have a worse prognosis compared to other breast cancer types.\n4. Triple negative breast cancers are more likely to recur and metastasize to other parts of the body.\n5. Triple negative gliomas, like triple negative breast cancers, are characterized by the absence of ER, PR, and HER2 receptors.",
    "llama-7b_fact": [
      "Triple negative breast cancers lack estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2).",
      "HER2 overexpression is a positive prognostic factor in types of breast cancer other than triple negative.",
      "Triple negative breast cancers are more aggressive and have a worse prognosis compared to other breast cancer types.",
      "Triple negative breast cancers are more likely to recur and metastasize to other parts of the body.",
      "Triple negative gliomas, like triple negative breast cancers, are characterized by the absence of ER, PR, and HER2 receptors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: HER2 overexpression is generally considered a negative prognostic factor in breast cancer, although targeted therapies have improved outcomes for patients with HER2-positive breast cancer.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Gliomas are a type of brain tumor and do not have ER, PR, and HER2 receptors as defining characteristics. The term \"triple negative\" is not typically used in the context of gliomas. Gliomas are classified based on different molecular and histological criteria.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2069,
    "user_query": "You MUST give a detailed answer to the following question: What is TOPAZ1?",
    "llama-7b_response": "TOPAZ1 is a cryptocurrency that was created in 2014 as a hard fork of the Litecoin blockchain. It is a peer-to-peer electronic cash system and a decentralized digital currency that operates on a proof-of-work consensus algorithm. TOPAZ1 is similar to Litecoin in many ways, but it has a few key differences, such as a different block time and a different proof-of-work algorithm. TOPAZ1 is not as widely used or well-known as some other cryptocurrencies, but it has a dedicated community of users and developers.",
    "llama-7b_fact_raw": "1. TOPAZ1 is a cryptocurrency that was created in 2014.\n2. TOPAZ1 was created as a hard fork of the Litecoin blockchain.\n3. It operates on a proof-of-work consensus algorithm.\n4. TOPAZ1 has a different block time and a different proof-of-work algorithm compared to Litecoin.\n5. TOPAZ1 has a dedicated community of users and developers.",
    "llama-7b_fact": [
      "TOPAZ1 is a cryptocurrency that was created in 2014.",
      "TOPAZ1 was created as a hard fork of the Litecoin blockchain.",
      "It operates on a proof-of-work consensus algorithm.",
      "TOPAZ1 has a different block time and a different proof-of-work algorithm compared to Litecoin.",
      "TOPAZ1 has a dedicated community of users and developers."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific and verifiable information about a cryptocurrency named TOPAZ1, it is not possible to determine the truthfulness of these statements. As of my knowledge cutoff date in early 2023, TOPAZ1 is not a widely recognized or established cryptocurrency, and there is no widely available information to confirm or refute these claims.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2075,
    "user_query": "You MUST give a detailed answer to the following question: Which gene controls the expression of GATA-1 isoforms?",
    "llama-7b_response": "GATA-1 is a transcription factor that plays an important role in the development and function of various tissues, including the heart, kidney, and immune system. GATA-1 isoforms are different forms of the protein that are produced by alternative splicing of the GATA-1 mRNA.\n\nThe gene that controls the expression of GATA-1 isoforms is the GATA-1 gene itself. Alternative splicing of the GATA-1 gene results in the production of multiple transcripts that can encode different isoforms of the GATA-1 protein. The choice of which exons to include in each transcript is determined by a complex network of regulatory elements in the GATA-1 gene, including promoter regions, enhancers, silencers, and other cis-acting elements.\n\nThe expression of GATA-1 isoforms can be regulated at different levels, including transcriptional, post-transcriptional, and post-translational modifications. For example, the transcriptional regulation of GATA-1 isoforms can be influenced by the binding of transcription factors to specific regulatory elements in the GATA-1 gene, as well as by the availability of cofactors and co-regulators that modulate the activity of the transcriptional machinery.\n\nOverall, the expression of GATA-1 isoforms is a complex process that involves the coordinated action of multiple genetic and epigenetic factors. The precise regulation of GATA-1 isoform expression is critical for the proper development and function of various tissues, and dysregulation of GATA-1 isoform expression has been implicated in a number of human diseases, including cardiovascular disease, immune disorders, and cancer.",
    "llama-7b_fact_raw": "1. GATA-1 is a transcription factor important for the development and function of the heart, kidney, and immune system.\n2. GATA-1 isoforms are produced by alternative splicing of the GATA-1 mRNA.\n3. The GATA-1 gene itself controls the expression of GATA-1 isoforms.\n4. Alternative splicing of the GATA-1 gene results in multiple transcripts that encode different isoforms of the GATA-1 protein.\n5. Dysregulation of GATA-1 isoform expression has been implicated in human diseases such as cardiovascular disease, immune disorders, and cancer.",
    "llama-7b_fact": [
      "GATA-1 is a transcription factor important for the development and function of the heart, kidney, and immune system.",
      "GATA-1 isoforms are produced by alternative splicing of the GATA-1 mRNA.",
      "The GATA-1 gene itself controls the expression of GATA-1 isoforms.",
      "Alternative splicing of the GATA-1 gene results in multiple transcripts that encode different isoforms of the GATA-1 protein.",
      "Dysregulation of GATA-1 isoform expression has been implicated in human diseases such as cardiovascular disease, immune disorders, and cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: GATA-1 is a transcription factor important for the development and function of erythroid and megakaryocytic lineages, not primarily the heart, kidney, and immune system.\n2. TRUE\n3. TRUE: The GATA-1 gene does control the expression of its own isoforms through the process of transcription and alternative splicing.\n4. TRUE\n5. TRUE: Dysregulation of GATA-1 isoform expression has been implicated in various hematological disorders, which can include certain types of cancer, and could potentially be linked to cardiovascular disease and immune disorders due to its role in erythroid and megakaryocytic cells.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "You MUST give a detailed answer to the following question: What is MIRA-seq?",
    "llama-7b_response": "MIRA-seq (Mutually Informative Regions by Association) is a method used in genomics to identify regions of the genome that are associated with multiple traits or diseases. The method is based on the idea that regions of the genome that are associated with multiple traits or diseases are likely to contain genes that are involved in common biological pathways or processes.\n\nMIRA-seq works by comparing the genetic information of individuals with a particular trait or disease to a reference population without the trait or disease. The method identifies regions of the genome that are overrepresented in the individuals with the trait or disease compared to the reference population. These regions are then prioritized for further investigation to determine if they contain genes that are involved in common biological pathways or processes.\n\nOne advantage of MIRA-seq is that it can identify regions of the genome that may be involved in multiple traits or diseases, which can be difficult to identify using other methods. Additionally, MIRA-seq can be used to identify genes that are involved in common biological pathways or processes, which can provide insights into the underlying biology of a particular trait or disease.\n\nOverall, MIRA-seq is a powerful method for identifying regions of the genome that are associated with multiple traits or diseases, and can provide valuable insights into the biology of complex traits and diseases.",
    "llama-7b_fact_raw": "1. MIRA-seq stands for Mutually Informative Regions by Association.\n2. MIRA-seq is used to identify regions of the genome associated with multiple traits or diseases.\n3. The method compares genetic information of individuals with a trait or disease to a reference population without it.\n4. MIRA-seq identifies regions of the genome that are overrepresented in individuals with the trait or disease.\n5. MIRA-seq can be used to identify genes involved in common biological pathways or processes.",
    "llama-7b_fact": [
      "MIRA-seq stands for Mutually Informative Regions by Association.",
      "MIRA-seq is used to identify regions of the genome associated with multiple traits or diseases.",
      "The method compares genetic information of individuals with a trait or disease to a reference population without it.",
      "MIRA-seq identifies regions of the genome that are overrepresented in individuals with the trait or disease.",
      "MIRA-seq can be used to identify genes involved in common biological pathways or processes."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: MIRA-seq stands for Methylation-based Inference of Regulatory Activity sequencing.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2108,
    "user_query": "You MUST give a detailed answer to the following question: What is the indication of ARCALYST?",
    "llama-7b_response": "The indication of ARCALYST (rilonacept) is the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children who are at least 12 years old. ARCALYST is also used to treat adults and children who are at least 12 years old with Familial Mediterranean Fever (FMF) who are intolerant of, or have failed, colchicine treatment.",
    "llama-7b_fact_raw": "1. ARCALYST (rilonacept) is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).\n2. ARCALYST is used to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).\n3. ARCALYST can be administered to adults and children who are at least 12 years old.\n4. ARCALYST is also indicated for the treatment of Familial Mediterranean Fever (FMF) in those who are intolerant of, or have failed, colchicine treatment.",
    "llama-7b_fact": [
      "ARCALYST (rilonacept) is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS).",
      "ARCALYST is used to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).",
      "ARCALYST can be administered to adults and children who are at least 12 years old.",
      "ARCALYST is also indicated for the treatment of Familial Mediterranean Fever (FMF) in those who are intolerant of, or have failed, colchicine treatment."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: ARCALYST can be administered to adults and children who are at least 12 years old for some indications, but for CAPS, it is approved for use in adults and children aged 4 and older.\n4. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "You MUST give a detailed answer to the following question: List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-7b_response": "Robertsonian translocation is a type of chromosomal rearrangement that results in the fusion of two acrocentric chromosomes. The human acrocentric chromosomes involved in Robertsonian translocation are:\n\n1. Chromosome 16 and Chromosome 17\n2. Chromosome 21 and Chromosome 22\n3. Chromosome 22 and Chromosome 23\n4. Chromosome 23 and Chromosome 24\n5. Chromosome 24 and Chromosome 25\n6. Chromosome 25 and Chromosome 26\n7. Chromosome 26 and Chromosome 27\n8. Chromosome 27 and Chromosome 28\n9. Chromosome 28 and Chromosome 29\n10. Chromosome 29 and Chromosome 30\n11. Chromosome 30 and Chromosome 31\n12. Chromosome 31 and Chromosome 32\n13. Chromosome 32 and Chromosome 33\n14. Chromosome 33 and Chromosome 34\n15. Chromosome 34 and Chromosome 35\n16. Chromosome 35 and Chromosome 36\n17. Chromosome 36 and Chromosome 37\n18. Chromosome 37 and Chromosome 38\n19. Chromosome 38 and Chromosome 39\n20. Chromosome 39 and Chromosome 40\n21. Chromosome 40 and Chromosome 41\n22. Chromosome 41 and Chromosome 42\n23. Chromosome 42 and Chromosome 43\n24. Chromosome 43 and Chromosome 44\n25. Chromosome 44",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2237,
    "user_query": "You MUST give a detailed answer to the following question: Which R package could be used for the identification of pediatric brain tumors?",
    "llama-7b_response": "There is no single R package that can be used for the identification of pediatric brain tumors. However, there are several R packages that can be used for analyzing and visualizing data related to brain tumors, including pediatric brain tumors. Some of these packages include:\n\n1. ggplot2: This package is used for data visualization and can be used to create plots and charts of brain tumor data, including pediatric brain tumors.\n2. RColorBrewer: This package is used for creating color palettes and can be used to create color-coded maps of brain tumor data, including pediatric brain tumors.\n3. reshape2: This package is used for reshaping and munging data and can be used to restructure brain tumor data, including pediatric brain tumors, for analysis.\n4. dplyr: This package is used for data manipulation and can be used to filter and aggregate brain tumor data, including pediatric brain tumors.\n5. tidyr: This package is used for data tidying and can be used to restructure brain tumor data, including pediatric brain tumors, for analysis.\n6. caret: This package is used for machine learning and can be used to build predictive models for the identification of pediatric brain tumors.\n7. survival: This package is used for survival analysis and can be used to analyze and interpret time-to-event data, such as survival data for pediatric brain tumor patients.\n\nOverall, the choice of R package(s) for analyzing and visualizing brain tumor data, including pediatric brain tumors, will depend on the specific research question and the type of data being analyzed.",
    "llama-7b_fact_raw": "1. The ggplot2 package in R is used for data visualization.\n2. The RColorBrewer package in R is used for creating color palettes.\n3. The reshape2 package in R is used for reshaping and munging data.\n4. The dplyr package in R is used for data manipulation.\n5. The caret package in R is used for machine learning and can be used to build predictive models.",
    "llama-7b_fact": [
      "The ggplot2 package in R is used for data visualization.",
      "The RColorBrewer package in R is used for creating color palettes.",
      "The reshape2 package in R is used for reshaping and munging data.",
      "The dplyr package in R is used for data manipulation.",
      "The caret package in R is used for machine learning and can be used to build predictive models."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "You MUST give a detailed answer to the following question: Is NEMO a zinc finger protein?",
    "llama-7b_response": "No, NEMO (NF-B essential modulator) is not a zinc finger protein.\n\nZinc finger proteins are a class of proteins that contain zinc ions bound to amino acid residues in their structure, which allows them to recognize and bind to specific DNA or RNA sequences. Zinc finger proteins are known for their ability to regulate gene expression by binding to specific DNA sequences and modulating the activity of other proteins.\n\nNEMO, on the other hand, is a protein that plays a crucial role in the regulation of the NF-B signaling pathway. NF-B is a transcription factor that regulates the expression of genes involved in immune and inflammatory responses. NEMO acts as a negative regulator of NF-B by inhibiting its activation and preventing it from binding to DNA.\n\nWhile NEMO does not contain zinc finger domains, it does contain several other domains that are important for its function in regulating the NF-B signaling pathway. These domains include an N-terminal death domain, a central ring finger domain, and a C-terminal coiled-coil domain that interacts with other proteins to regulate NF-B activity.\n\nIn summary, while NEMO is not a zinc finger protein, it is an important regulator of the NF-B signaling pathway and plays a crucial role in the regulation of immune and inflammatory responses.",
    "llama-7b_fact_raw": "1. NEMO (NF-B essential modulator) is not a zinc finger protein.\n2. Zinc finger proteins contain zinc ions bound to amino acid residues in their structure.\n3. Zinc finger proteins can regulate gene expression by binding to specific DNA sequences.\n4. NEMO plays a crucial role in the regulation of the NF-B signaling pathway.\n5. NF-B is a transcription factor that regulates the expression of genes involved in immune and inflammatory responses.",
    "llama-7b_fact": [
      "NEMO (NF-B essential modulator) is not a zinc finger protein.",
      "Zinc finger proteins contain zinc ions bound to amino acid residues in their structure.",
      "Zinc finger proteins can regulate gene expression by binding to specific DNA sequences.",
      "NEMO plays a crucial role in the regulation of the NF-B signaling pathway.",
      "NF-B is a transcription factor that regulates the expression of genes involved in immune and inflammatory responses."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "You MUST give a detailed answer to the following question: Does TFIIS affect nucleosome positioning?",
    "llama-7b_response": "Yes, TFIIS (Transcription Factor IIS) can affect nucleosome positioning. TFIIS is a general transcription factor that plays a crucial role in the initiation of RNA polymerase II-mediated transcription. It is involved in the formation of the pre-initiation complex, which is the first step in the transcription process.\n\nDuring the formation of the pre-initiation complex, TFIIS interacts with the RNA polymerase II holoenzyme and other transcription factors, such as TFIIE and TFIIB. This interaction helps to position the RNA polymerase II holoenzyme at the promoter region of the gene, where it can initiate transcription.\n\nIn addition to its role in positioning the RNA polymerase II holoenzyme, TFIIS can also affect nucleosome positioning. Nucleosomes are the basic units of chromatin, which consist of DNA wrapped around a core of histone proteins. The positioning of nucleosomes can affect the accessibility of the DNA to the RNA polymerase II holoenzyme and other transcription factors, which can in turn affect the rate and efficiency of transcription.\n\nTFIIS has been shown to interact with histone proteins, such as histone H1 and histone H3. These interactions can affect the positioning of nucleosomes and the accessibility of the DNA to the RNA polymerase II holoenzyme. For example, TFIIS has been shown to stimulate the dissociation of nucleosomes from the promoter region of the gene, which can increase the accessibility of the DNA to the RNA polymerase II holoenzyme and other transcription factors.\n\nIn summary, TFIIS can affect nucleosome positioning by interacting with histone proteins and stimulating the dissociation of nucleosomes from the promoter region of the gene, which can increase the accessibility of the DNA to the RNA polymerase II holoenzyme and other transcription factors. This, in turn, can affect the rate and efficiency of transcription.",
    "llama-7b_fact_raw": "1. TFIIS is a general transcription factor that plays a role in the initiation of RNA polymerase II-mediated transcription.\n2. TFIIS is involved in the formation of the pre-initiation complex, which is the first step in the transcription process.\n3. TFIIS interacts with the RNA polymerase II holoenzyme and other transcription factors, such as TFIIE and TFIIB.\n4. TFIIS can affect nucleosome positioning, which consists of DNA wrapped around a core of histone proteins.\n5. TFIIS has been shown to interact with histone proteins, such as histone H1 and histone H3, and can stimulate the dissociation of nucleosomes from the promoter region of a gene.",
    "llama-7b_fact": [
      "TFIIS is a general transcription factor that plays a role in the initiation of RNA polymerase II-mediated transcription.",
      "TFIIS is involved in the formation of the pre-initiation complex, which is the first step in the transcription process.",
      "TFIIS interacts with the RNA polymerase II holoenzyme and other transcription factors, such as TFIIE and TFIIB.",
      "TFIIS can affect nucleosome positioning, which consists of DNA wrapped around a core of histone proteins.",
      "TFIIS has been shown to interact with histone proteins, such as histone H1 and histone H3, and can stimulate the dissociation of nucleosomes from the promoter region of a gene."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: TFIIS is not a general transcription factor; it is a transcription elongation factor that plays a role in the process of RNA polymerase II-mediated transcription after initiation has occurred.\n2. FALSE [correction]: TFIIS is not involved in the formation of the pre-initiation complex; it functions during the elongation phase of transcription by RNA polymerase II.\n3. TRUE: TFIIS does interact with RNA polymerase II and can also interact with other transcription factors, although the specific mention of TFIIE and TFIIB in this context is not accurate as these are involved in the initiation phase.\n4. UNKNOWN: The statement about TFIIS affecting nucleosome positioning is not standard knowledge and would require specific scientific evidence to confirm or refute.\n5. UNKNOWN: The interaction of TFIIS with histone proteins and its role in nucleosome dissociation from the promoter region is a specific claim that would need to be supported by scientific research. Without specific evidence, the truth of this statement cannot be determined.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "You MUST give a detailed answer to the following question: Do origins of replication close to yeast centromeres fire early or late?",
    "llama-7b_response": "The question of whether origins of replication close to yeast centromeres fire early or late is an important one in the field of genetics and cell biology. The answer to this question has important implications for our understanding of how chromosomes are duplicated during the cell cycle, and how errors in this process can lead to genetic instability and the development of cancer.\n\nTo understand the answer to this question, it is first necessary to understand a bit about the process of DNA replication and the structure of chromosomes. During DNA replication, the double helix structure of DNA is unwound, and each strand of DNA is copied by an enzyme called DNA polymerase. The process of replication begins at specific points on the chromosome, known as origins of replication, and proceeds in the direction of the chromosome.\n\nIn yeast, as in many other organisms, the origins of replication are clustered near the centromere region of the chromosome. The centromere is a specialized region of the chromosome that plays a crucial role in the proper separation of chromosomes during cell division.\n\nThe question of whether origins of replication close to yeast centromeres fire early or late refers to the timing of the initiation of DNA replication at these origins. Do the origins of replication fire early, before the chromosomes reach the centromere, or do they fire late, after the chromosomes have reached the centromere?\n\nThe answer to this question is not straightforward, and has been the subject of much research in the field of genetics and cell biology. Some studies have suggested that origins of replication close to yeast centromeres fire early, before the chromosomes reach the centromere, while other studies have suggested that they fire late, after the chromosomes have reached the centromere.\n\nThe exact timing of replication initiation at origins of replication close to yeast centromeres is likely to depend on a variety of factors, including the structure of the chromosome, the activity of specific proteins that regulate replication, and the cellular environment in which replication is taking place.\n\nIn summary, the answer to the question of whether origins of replication close to yeast centromeres fire early",
    "llama-7b_fact_raw": "1. Origins of replication are specific points on the chromosome where DNA replication begins.\n2. DNA polymerase is the enzyme responsible for copying each strand of DNA during replication.\n3. In yeast, origins of replication are clustered near the centromere region of the chromosome.\n4. The centromere is a specialized region of the chromosome that is important for the proper separation of chromosomes during cell division.\n5. The timing of replication initiation at origins of replication close to yeast centromeres has been the subject of research in genetics and cell biology.",
    "llama-7b_fact": [
      "Origins of replication are specific points on the chromosome where DNA replication begins.",
      "DNA polymerase is the enzyme responsible for copying each strand of DNA during replication.",
      "In yeast, origins of replication are clustered near the centromere region of the chromosome.",
      "The centromere is a specialized region of the chromosome that is important for the proper separation of chromosomes during cell division.",
      "The timing of replication initiation at origins of replication close to yeast centromeres has been the subject of research in genetics and cell biology."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: In yeast, origins of replication are not necessarily clustered near the centromere region of the chromosome; they are typically dispersed throughout the genome.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "You MUST give a detailed answer to the following question: Which are the properties of mammalian GA-sequences?",
    "llama-7b_response": "Mammalian GA-sequences are a type of non-coding RNA that have been identified in a wide range of mammalian tissues, including the brain, heart, liver, kidney, and pancreas. They are typically found in the cytoplasm of cells and are thought to play a role in regulating gene expression.\n\nOne of the key properties of mammalian GA-sequences is their length, which is typically between 200 and 400 nucleotides in length. They are also characterized by the presence of two distinct regions: a 5' untranslated region (UTR) and a 3' UTR. The 5' UTR is typically longer than the 3' UTR and is thought to play a role in regulating the stability and translation of the GA-sequence.\n\nAnother important property of mammalian GA-sequences is their ability to form complexes with other non-coding RNAs, including microRNAs (miRNAs) and small interfering RNAs (siRNAs). These complexes have been shown to play a role in regulating gene expression by targeting specific mRNAs for degradation or translational inhibition.\n\nIn addition to their role in regulating gene expression, mammalian GA-sequences have also been implicated in a number of other cellular processes, including cell differentiation, cell proliferation, and cell death. They have also been shown to play a role in the development of certain diseases, including cancer.\n\nOverall, the properties of mammalian GA-sequences make them an important and intriguing area of research, with potential applications in the development of new therapeutics for a wide range of diseases.",
    "llama-7b_fact_raw": "1. Mammalian GA-sequences are a type of non-coding RNA found in various mammalian tissues such as the brain, heart, liver, kidney, and pancreas.\n2. The typical length of mammalian GA-sequences is between 200 and 400 nucleotides.\n3. Mammalian GA-sequences contain a 5' untranslated region (UTR) and a 3' UTR, with the 5' UTR usually being longer.\n4. Mammalian GA-sequences can form complexes with other non-coding RNAs, including microRNAs (miRNAs) and small interfering RNAs (siRNAs).\n5. Mammalian GA-sequences have been implicated in cellular processes like cell differentiation, cell proliferation, and cell death, as well as in the development of diseases such as cancer.",
    "llama-7b_fact": [
      "Mammalian GA-sequences are a type of non-coding RNA found in various mammalian tissues such as the brain, heart, liver, kidney, and pancreas.",
      "The typical length of mammalian GA-sequences is between 200 and 400 nucleotides.",
      "Mammalian GA-sequences contain a 5' untranslated region (UTR) and a 3' UTR, with the 5' UTR usually being longer.",
      "Mammalian GA-sequences can form complexes with other non-coding RNAs, including microRNAs (miRNAs) and small interfering RNAs (siRNAs).",
      "Mammalian GA-sequences have been implicated in cellular processes like cell differentiation, cell proliferation, and cell death, as well as in the development of diseases such as cancer."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe term \"GA-sequences\" is not a standard term in molecular biology, and without additional context, it is not possible to determine the accuracy of these statements. The statements could be referring to a specific type of non-coding RNA that is not widely recognized or is specific to a particular study or set of studies. Therefore, without further context or clarification, the truthfulness of these statements cannot be assessed.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "You MUST give a detailed answer to the following question: How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-7b_response": "The number of Groucho-related genes (GRG) contained in the mouse genome is not a fixed or well-defined quantity. The term \"Groucho-related genes\" can refer to a family of transcriptional repressors that share structural similarity with the Groucho protein, which is involved in regulating the expression of certain genes in the Drosophila melanogaster (fruit fly) and Caenorhabditis elegans (roundworm) genomes. However, the extent to which these genes are present and functional in the mouse genome is not well understood.\n\nThere are several genes in the mouse genome that have been identified as members of the Groucho family of transcriptional repressors, but the number of these genes can vary depending on the specific criteria used for identification. For example, some studies have identified as few as three Groucho-related genes in the mouse genome, while other studies have identified as many as nine Groucho-related genes.\n\nIn summary, the number of Groucho-related genes (GRG) contained in the mouse genome is not a fixed or well-defined quantity, and can vary depending on the specific criteria used for identification.",
    "llama-7b_fact_raw": "1. Groucho-related genes (GRG) refer to a family of transcriptional repressors.\n2. Groucho protein is involved in regulating the expression of certain genes in Drosophila melanogaster (fruit fly) and Caenorhabditis elegans (roundworm).\n3. The number of Groucho-related genes in the mouse genome is not fixed or well-defined.\n4. Some studies have identified as few as three Groucho-related genes in the mouse genome.\n5. Other studies have identified as many as nine Groucho-related genes in the mouse genome.",
    "llama-7b_fact": [
      "Groucho-related genes (GRG) refer to a family of transcriptional repressors.",
      "Groucho protein is involved in regulating the expression of certain genes in Drosophila melanogaster (fruit fly) and Caenorhabditis elegans (roundworm).",
      "The number of Groucho-related genes in the mouse genome is not fixed or well-defined.",
      "Some studies have identified as few as three Groucho-related genes in the mouse genome.",
      "Other studies have identified as many as nine Groucho-related genes in the mouse genome."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The number of Groucho-related genes in the mouse genome is fixed and well-defined, although the exact number may vary depending on the source and the criteria used for defining what constitutes a Groucho-related gene.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2304,
    "user_query": "You MUST give a detailed answer to the following question: Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-7b_response": "RNA polymerase II is the enzyme responsible for transcribing DNA into RNA in eukaryotic cells. It is composed of multiple subunits, and one of these subunits, the RNA cleavage subunit, carries the RNA cleavage activity.\n\nThe RNA cleavage subunit of RNA polymerase II is called PTC1. PTC1 is a component of the RNA polymerase II holoenzyme, which is the active form of the enzyme that is responsible for transcribing DNA into RNA. PTC1 is involved in the process of transcription elongation, which is the phase of transcription where the RNA polymerase II holoenzyme moves along the DNA template and transcribes the genetic information into RNA.\n\nDuring transcription elongation, PTC1 interacts with the DNA template and with other components of the RNA polymerase II holoenzyme. It also plays a role in the process of transcription termination, which is the phase of transcription where the RNA polymerase II holoenzyme stops transcribing the DNA template and disassembles.\n\nIn summary, PTC1 is the RNA cleavage subunit of RNA polymerase II, and it is involved in the process of transcription elongation and transcription termination. It carries the RNA cleavage activity and is a key component of the RNA polymerase II holoenzyme, which is responsible for transcribing DNA into RNA in eukaryotic cells.",
    "llama-7b_fact_raw": "1. RNA polymerase II is responsible for transcribing DNA into RNA in eukaryotic cells.\n2. RNA polymerase II is composed of multiple subunits.\n3. The RNA cleavage subunit of RNA polymerase II is called PTC1.\n4. PTC1 is involved in the process of transcription elongation.\n5. PTC1 plays a role in the process of transcription termination.",
    "llama-7b_fact": [
      "RNA polymerase II is responsible for transcribing DNA into RNA in eukaryotic cells.",
      "RNA polymerase II is composed of multiple subunits.",
      "The RNA cleavage subunit of RNA polymerase II is called PTC1.",
      "PTC1 is involved in the process of transcription elongation.",
      "PTC1 plays a role in the process of transcription termination."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The RNA cleavage subunit of RNA polymerase II is not called PTC1. The term \"PTC\" often refers to the \"Peptidyl Transferase Center\" in the context of the ribosome, not RNA polymerase II. RNA polymerase II has a structure called the RNA polymerase II C-terminal domain (CTD), which is involved in processing RNA during transcription.\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2321,
    "user_query": "You MUST give a detailed answer to the following question: What is the genetic basis of Ohdo syndrome?",
    "llama-7b_response": "Ohdo syndrome is a rare genetic disorder that is characterized by a range of physical and developmental abnormalities. The genetic basis of Ohdo syndrome is complex and involves mutations in multiple genes.\n\nThe disorder is caused by mutations in the genes that encode for proteins involved in the development and function of various tissues and organs. Some of the genes that have been associated with Ohdo syndrome include:\n\n1. FGFR3: Fibroblast growth factor receptor 3 (FGFR3) is a protein that plays a crucial role in the development of bones and other tissues. Mutations in the FGFR3 gene have been identified in a significant proportion of patients with Ohdo syndrome. These mutations can lead to the formation of extra digits (polydactyly) and other skeletal abnormalities.\n2. PHOX2B: PHOX2B is a gene that encodes for a protein involved in the development of the respiratory system. Mutations in the PHOX2B gene have been associated with Ohdo syndrome, as they can lead to abnormal development of the lungs and other respiratory structures.\n3. KCNQ3: KCNQ3 is a gene that encodes for a protein involved in the function of heart muscle cells (cardiomyocytes). Mutations in the KCNQ3 gene have been associated with Ohdo syndrome, as they can lead to abnormal heart rhythms and other cardiac abnormalities.\n4. TBX1: TBX1 is a gene that encodes for a transcription factor involved in the development of various tissues and organs, including the heart, kidneys, and limbs. Mutations in the TBX1 gene have been associated with Ohdo syndrome, as they can lead to abnormal development of these structures.\n\nIn summary, the genetic basis of Ohdo syndrome involves mutations in multiple genes, including FGFR3, PHOX2B, KCNQ3, and TBX1. These mutations can disrupt the normal development and function of various tissues and organs, leading to the range of physical and developmental abnormalities characteristic of the disorder.",
    "llama-7b_fact_raw": "1. Ohdo syndrome is a rare genetic disorder characterized by physical and developmental abnormalities.\n2. Mutations in the FGFR3 gene have been identified in patients with Ohdo syndrome and can lead to skeletal abnormalities such as polydactyly.\n3. Mutations in the PHOX2B gene associated with Ohdo syndrome can lead to abnormal development of the lungs and other respiratory structures.\n4. Mutations in the KCNQ3 gene have been linked to Ohdo syndrome and can result in abnormal heart rhythms and cardiac abnormalities.\n5. Mutations in the TBX1 gene are associated with Ohdo syndrome and can affect the development of the heart, kidneys, and limbs.",
    "llama-7b_fact": [
      "Ohdo syndrome is a rare genetic disorder characterized by physical and developmental abnormalities.",
      "Mutations in the FGFR3 gene have been identified in patients with Ohdo syndrome and can lead to skeletal abnormalities such as polydactyly.",
      "Mutations in the PHOX2B gene associated with Ohdo syndrome can lead to abnormal development of the lungs and other respiratory structures.",
      "Mutations in the KCNQ3 gene have been linked to Ohdo syndrome and can result in abnormal heart rhythms and cardiac abnormalities.",
      "Mutations in the TBX1 gene are associated with Ohdo syndrome and can affect the development of the heart, kidneys, and limbs."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in the FGFR3 gene are not associated with Ohdo syndrome. Instead, mutations in genes such as SALL1 and KAT6B have been identified in patients with Ohdo syndrome.\n3. FALSE [correction]: Mutations in the PHOX2B gene are not associated with Ohdo syndrome. PHOX2B mutations are typically associated with congenital central hypoventilation syndrome (CCHS), which affects the nervous system's control of breathing.\n4. FALSE [correction]: Mutations in the KCNQ3 gene have not been linked to Ohdo syndrome. KCNQ3 mutations are more commonly associated with benign familial neonatal epilepsy.\n5. FALSE [correction]: Mutations in the TBX1 gene are not associated with Ohdo syndrome. TBX1 gene mutations are associated with DiGeorge syndrome (22q11.2 deletion syndrome), which affects the development of several body systems.",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "You MUST give a detailed answer to the following question: Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-7b_response": "One R/Bioconductor package that has been developed for the analysis of psychiatric disease genes is the \"PsychiatricGWAS\" package. This package provides tools for the analysis of genome-wide association studies (GWAS) of psychiatric disorders, including schizophrenia, bipolar disorder, and major depressive disorder.\n\nThe package includes functions for genotype imputation, association testing, and gene set analysis, as well as tools for visualizing and interpreting the results of these analyses. It also provides access to a large database of psychiatric GWAS data, which can be used to perform these analyses on a large scale.\n\nIn addition to the \"PsychiatricGWAS\" package, there are several other R/Bioconductor packages that may be useful for the analysis of psychiatric disease genes, including the \"rnaseqtest\" package for RNA sequencing data analysis, the \"edgeR\" package for gene expression analysis, and the \"limma\" package for microarray data analysis. These packages can be used in combination with the \"PsychiatricGWAS\" package to perform more comprehensive analyses of psychiatric disease genes.",
    "llama-7b_fact_raw": "1. The \"PsychiatricGWAS\" package is an R/Bioconductor package developed for the analysis of psychiatric disease genes.\n2. The \"PsychiatricGWAS\" package includes tools for genotype imputation, association testing, and gene set analysis.\n3. The package provides tools for visualizing and interpreting the results of genome-wide association studies (GWAS) of psychiatric disorders.\n4. The \"PsychiatricGWAS\" package gives access to a large database of psychiatric GWAS data.\n5. Other R/Bioconductor packages useful for the analysis of psychiatric disease genes include \"rnaseqtest,\" \"edgeR,\" and \"limma.\"",
    "llama-7b_fact": [
      "The \"PsychiatricGWAS\" package is an R/Bioconductor package developed for the analysis of psychiatric disease genes.",
      "The \"PsychiatricGWAS\" package includes tools for genotype imputation, association testing, and gene set analysis.",
      "The package provides tools for visualizing and interpreting the results of genome-wide association studies (GWAS) of psychiatric disorders.",
      "The \"PsychiatricGWAS\" package gives access to a large database of psychiatric GWAS data.",
      "Other R/Bioconductor packages useful for the analysis of psychiatric disease genes include \"rnaseqtest,\" \"edgeR,\" and \"limma.\""
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE (assuming these packages are indeed part of R/Bioconductor and are used for the analysis of psychiatric disease genes, which is plausible given their general functionality in bioinformatics; \"edgeR\" and \"limma\" are commonly used for differential expression analysis, which can be related to disease gene analysis, and \"rnaseqtest\" could plausibly be related to RNA-seq data analysis in the context of psychiatric diseases.)",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2360,
    "user_query": "You MUST give a detailed answer to the following question: Describe swirl sign in intracerebral hemorrhage.",
    "llama-7b_response": "A swirl sign in intracerebral hemorrhage (ICH) is a radiologic finding that is seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans of the brain. It is characterized by a swirling pattern of blood within the hemisphere of the brain that is affected by the hemorrhage.\n\nThe swirl sign is caused by the movement of blood within the hemisphere as it spreads out from the site of the hemorrhage. This movement can cause the blood to appear as a swirling pattern on the CT or MRI scan. The swirl sign is typically seen in the early stages of ICH, before the hemorrhage has had a chance to expand significantly.\n\nThe swirl sign is an important radiologic finding because it can help diagnose ICH and guide treatment decisions. It is often used in conjunction with other radiologic findings, such as the location and size of the hemorrhage, to assess the severity of the injury and determine the best course of treatment.\n\nIn some cases, the swirl sign may be accompanied by other radiologic findings, such as midline shift or hematoma expansion. These findings can indicate a more severe injury and may require more aggressive treatment, such as surgical intervention.\n\nOverall, the swirl sign in ICH is an important radiologic finding that can help diagnose and assess the severity of this type of brain injury.",
    "llama-7b_fact_raw": "1. A swirl sign in intracerebral hemorrhage is a radiologic finding seen on CT or MRI scans of the brain.\n2. The swirl sign is characterized by a swirling pattern of blood within the affected hemisphere of the brain.\n3. The swirl sign is typically observed in the early stages of intracerebral hemorrhage.\n4. The presence of the swirl sign can help diagnose intracerebral hemorrhage and guide treatment decisions.\n5. Accompanying radiologic findings such as midline shift or hematoma expansion may indicate a more severe injury.",
    "llama-7b_fact": [
      "A swirl sign in intracerebral hemorrhage is a radiologic finding seen on CT or MRI scans of the brain.",
      "The swirl sign is characterized by a swirling pattern of blood within the affected hemisphere of the brain.",
      "The swirl sign is typically observed in the early stages of intracerebral hemorrhage.",
      "The presence of the swirl sign can help diagnose intracerebral hemorrhage and guide treatment decisions.",
      "Accompanying radiologic findings such as midline shift or hematoma expansion may indicate a more severe injury."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The swirl sign is characterized by a heterogeneous appearance of blood densities within a hematoma, which may look like a swirling pattern of mixed density, but it is not specifically limited to one hemisphere of the brain.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "You MUST give a detailed answer to the following question: What induces Arabidopsis ROF1 expression?",
    "llama-7b_response": "ROF1 (Regulator of Flowering 1) is a transcription factor that plays a crucial role in the regulation of flowering time in Arabidopsis thaliana. ROF1 expression is regulated by various environmental and developmental cues, including light, temperature, and hormones such as auxin and cytokinin.\n\nOne of the key inducers of ROF1 expression is light. ROF1 is a photoreceptor that responds to both red and far-red light. Exposure to these wavelengths of light leads to an increase in ROF1 expression, which in turn regulates the expression of downstream genes involved in flowering time control.\n\nAnother inducer of ROF1 expression is temperature. ROF1 expression is induced by both high and low temperatures, with higher temperatures leading to a more rapid increase in ROF1 expression. This suggests that ROF1 may play a role in the acclimation of plants to changing environmental temperatures.\n\nIn addition to light and temperature, ROF1 expression can also be regulated by hormones such as auxin and cytokinin. For example, auxin has been shown to inhibit ROF1 expression, while cytokinin has been shown to induce ROF1 expression.\n\nOverall, the regulation of ROF1 expression is complex and involves the integration of multiple environmental and developmental cues. A better understanding of the regulatory mechanisms controlling ROF1 expression may provide insights into the control of flowering time and the regulation of plant growth and development.",
    "llama-7b_fact_raw": "1. ROF1 (Regulator of Flowering 1) is a transcription factor that regulates flowering time in Arabidopsis thaliana.\n2. Light is a key inducer of ROF1 expression, with both red and far-red light increasing its expression.\n3. ROF1 expression is induced by both high and low temperatures.\n4. Auxin inhibits ROF1 expression, while cytokinin induces it.\n5. ROF1 expression is regulated by various environmental and developmental cues.",
    "llama-7b_fact": [
      "ROF1 (Regulator of Flowering 1) is a transcription factor that regulates flowering time in Arabidopsis thaliana.",
      "Light is a key inducer of ROF1 expression, with both red and far-red light increasing its expression.",
      "ROF1 expression is induced by both high and low temperatures.",
      "Auxin inhibits ROF1 expression, while cytokinin induces it.",
      "ROF1 expression is regulated by various environmental and developmental cues."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe statements about ROF1 (Regulator of Flowering 1) in Arabidopsis thaliana are specific to plant biology and molecular genetics. While the first and last statements are generally true, as ROF1 is indeed a transcription factor that regulates flowering time and is regulated by various environmental and developmental cues, the specifics of how light, temperature, and plant hormones like auxin and cytokinin affect its expression require detailed scientific knowledge or research that is not provided in the context. Therefore, without additional information, the truthfulness of statements 2, 3, and 4 cannot be determined with certainty.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "You MUST give a detailed answer to the following question: What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-7b_response": "The most common cause of hereditary renal amyloidosis is transthyretin (TTR). Amyloidosis is a group of diseases characterized by the deposit of an abnormal protein called amyloid in various tissues and organs of the body. Hereditary renal amyloidosis is a type of amyloidosis that affects the kidneys and is passed down through families. TTR is a protein that is normally found in the blood and is involved in transporting thyroid hormone and retinol (vitamin A) throughout the body. In hereditary renal amyloidosis, mutations in the TTR gene cause the production of abnormal TTR protein that accumulates in the kidneys, leading to damage and eventually loss of kidney function. Treatment for hereditary renal amyloidosis typically involves managing symptoms and slowing the progression of the disease, as there is currently no cure for the condition.",
    "llama-7b_fact_raw": "1. Transthyretin (TTR) is the most common cause of hereditary renal amyloidosis.\n2. Amyloidosis is characterized by the deposit of an abnormal protein called amyloid in tissues and organs.\n3. Hereditary renal amyloidosis affects the kidneys and is inherited.\n4. TTR is involved in transporting thyroid hormone and retinol (vitamin A) in the body.\n5. Mutations in the TTR gene can lead to the production of abnormal TTR protein that accumulates in the kidneys.",
    "llama-7b_fact": [
      "Transthyretin (TTR) is the most common cause of hereditary renal amyloidosis.",
      "Amyloidosis is characterized by the deposit of an abnormal protein called amyloid in tissues and organs.",
      "Hereditary renal amyloidosis affects the kidneys and is inherited.",
      "TTR is involved in transporting thyroid hormone and retinol (vitamin A) in the body.",
      "Mutations in the TTR gene can lead to the production of abnormal TTR protein that accumulates in the kidneys."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Transthyretin (TTR) is not the most common cause of hereditary renal amyloidosis; it is more commonly associated with hereditary ATTR amyloidosis, which affects the nervous system and the heart. The most common cause of hereditary renal amyloidosis is related to mutations in the genes encoding fibrinogen A alpha-chain, apolipoprotein A-I, apolipoprotein A-II, and lysozyme.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Mutations in the TTR gene can lead to the production of abnormal TTR protein that accumulates in various tissues, including the nervous system and the heart, rather than specifically in the kidneys. Hereditary ATTR amyloidosis with kidney involvement is possible, but it is not the primary organ affected.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "You MUST give a detailed answer to the following question: Has the proteome of mice hippocampus been analysed?",
    "llama-7b_response": "Yes, the proteome of mice hippocampus has been analyzed. The hippocampus is a region of the brain that is critical for learning and memory, and studies have used a variety of techniques to identify and characterize the proteins present in this region of the mouse brain.\n\nOne approach to studying the proteome of the mouse hippocampus is to use mass spectrometry, which can be used to identify and quantify proteins present in a sample. This approach has been used in a number of studies to identify and characterize the proteins present in the mouse hippocampus.\n\nFor example, one study used mass spectrometry to identify over 3,000 proteins present in the mouse hippocampus, including both known and novel proteins. The study also used bioinformatics tools to analyze the data and identify potential functions for many of the proteins identified.\n\nAnother study used a similar approach to identify over 2,000 proteins present in the mouse hippocampus, and also used bioinformatics tools to analyze the data and identify potential roles for many of the proteins identified.\n\nOverall, these studies have provided a wealth of information about the proteins present in the mouse hippocampus, and have helped to advance our understanding of the molecular mechanisms underlying learning and memory.",
    "llama-7b_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed.\n2. The hippocampus is a region of the brain important for learning and memory.\n3. Mass spectrometry has been used to identify and quantify proteins in the mouse hippocampus.\n4. One study identified over 3,000 proteins in the mouse hippocampus using mass spectrometry.\n5. Another study identified over 2,000 proteins in the mouse hippocampus and used bioinformatics tools for analysis.",
    "llama-7b_fact": [
      "The proteome of the mouse hippocampus has been analyzed.",
      "The hippocampus is a region of the brain important for learning and memory.",
      "Mass spectrometry has been used to identify and quantify proteins in the mouse hippocampus.",
      "One study identified over 3,000 proteins in the mouse hippocampus using mass spectrometry.",
      "Another study identified over 2,000 proteins in the mouse hippocampus and used bioinformatics tools for analysis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nGiven the context of the statements, they all seem plausible. The proteome of the mouse hippocampus is a common subject of study in neuroscience and mass spectrometry is a standard technique used to analyze proteomes. The numbers of proteins identified in studies can vary, but identifying over 2,000 or 3,000 proteins is within the expected range for such analyses. Without specific references to the studies mentioned, the exact numbers cannot be verified, but the statements are consistent with common scientific findings in the field.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "You MUST give a detailed answer to the following question: Are mouse chromosomes acrocentric?",
    "llama-7b_response": "No, mouse chromosomes are not acrocentric.\n\nAcrocentric chromosomes are a type of chromosome that have their centromeres located towards the ends of the chromosome rather than in the middle. This is in contrast to metacentric chromosomes, which have their centromeres located in the middle of the chromosome.\n\nIn the mouse genome, there are 20 autosomal chromosomes and two sex chromosomes (X and Y). The centromeres of the mouse autosomal chromosomes are located in the middle of each chromosome, which is consistent with the definition of metacentric chromosomes. Therefore, mouse chromosomes are not acrocentric.",
    "llama-7b_fact_raw": "1. Acrocentric chromosomes have their centromeres located towards the ends of the chromosome.\n2. Metacentric chromosomes have their centromeres located in the middle of the chromosome.\n3. The mouse genome consists of 20 autosomal chromosomes and two sex chromosomes (X and Y).\n4. The centromeres of mouse autosomal chromosomes are located in the middle of each chromosome.\n5. Mouse chromosomes are not acrocentric.",
    "llama-7b_fact": [
      "Acrocentric chromosomes have their centromeres located towards the ends of the chromosome.",
      "Metacentric chromosomes have their centromeres located in the middle of the chromosome.",
      "The mouse genome consists of 20 autosomal chromosomes and two sex chromosomes (X and Y).",
      "The centromeres of mouse autosomal chromosomes are located in the middle of each chromosome.",
      "Mouse chromosomes are not acrocentric."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The mouse genome consists of 19 autosomal chromosomes and two sex chromosomes (X and Y).\n4. FALSE [correction]: The centromeres of mouse autosomal chromosomes are not located in the middle; most mouse chromosomes are acrocentric, meaning their centromeres are located towards the ends of the chromosome.\n5. FALSE [correction]: Mouse chromosomes are indeed acrocentric.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 2417,
    "user_query": "You MUST give a detailed answer to the following question: Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-7b_response": "One siRNA-based drug that is currently in clinical trials for the treatment of pancreatic cancer is GSK2879552.\n\nGSK2879552 is an RNA interference (RNAi) therapeutic candidate that is being developed by GlaxoSmithKline (GSK) for the treatment of various types of cancer, including pancreatic cancer. The drug works by using small interfering RNA (siRNA) molecules to silence specific genes that are involved in the growth and survival of cancer cells.\n\nGSK2879552 has shown promising results in preclinical studies, and it is currently being tested in phase 1 and phase 2 clinical trials for the treatment of various types of solid tumors, including pancreatic cancer. In these trials, the drug is being administered intravenously to patients with advanced or metastatic cancer.\n\nSo far, the results of the clinical trials have been encouraging, with some patients experiencing partial or complete responses to the treatment. However, more research is needed to fully understand the safety and efficacy of GSK2879552 for the treatment of pancreatic cancer, and the drug is not yet approved for use in patients.",
    "llama-7b_fact_raw": "1. GSK2879552 is an siRNA-based drug currently in clinical trials for the treatment of pancreatic cancer.\n2. GlaxoSmithKline (GSK) is developing GSK2879552.\n3. GSK2879552 uses small interfering RNA (siRNA) molecules to target genes involved in cancer cell growth and survival.\n4. GSK2879552 is being tested in phase 1 and phase 2 clinical trials for various types of solid tumors, including pancreatic cancer.\n5. The drug GSK2879552 is administered intravenously to patients with advanced or metastatic cancer.",
    "llama-7b_fact": [
      "GSK2879552 is an siRNA-based drug currently in clinical trials for the treatment of pancreatic cancer.",
      "GlaxoSmithKline (GSK) is developing GSK2879552.",
      "GSK2879552 uses small interfering RNA (siRNA) molecules to target genes involved in cancer cell growth and survival.",
      "GSK2879552 is being tested in phase 1 and phase 2 clinical trials for various types of solid tumors, including pancreatic cancer.",
      "The drug GSK2879552 is administered intravenously to patients with advanced or metastatic cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: GSK2879552 is not an siRNA-based drug; it is a small molecule inhibitor that targets lysine-specific demethylase 1 (LSD1), which is involved in epigenetic regulation.\n2. TRUE\n3. FALSE [correction]: GSK2879552 does not use siRNA molecules; it is a small molecule that inhibits LSD1, a histone demethylase enzyme implicated in the progression of certain cancers.\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "You MUST give a detailed answer to the following question: What is the HPG pore?",
    "llama-7b_response": "The HPG (hypothalamus-pituitary-gonadal) axis is a system of hormonal communication between the hypothalamus, pituitary gland, and gonads (ovaries or testes) that regulates reproductive processes and other physiological functions. The HPG pore is a hypothetical structure that is thought to exist in the hypothalamus and regulate the release of hormones into the bloodstream.\n\nThe hypothalamus is a region of the brain that plays a key role in the regulation of many bodily functions, including reproductive processes. The hypothalamus produces hormones that regulate the release of gonadotropin-releasing hormone (GnRH) from the pituitary gland. GnRH is a peptide hormone that stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland, which in turn stimulate the ovaries or testes to produce sex hormones.\n\nThe HPG pore is a hypothetical structure that is thought to exist in the hypothalamus and regulate the release of hormones into the bloodstream. It is believed that the HPG pore opens and closes in response to various stimuli, allowing hormones to be released into the bloodstream and regulate reproductive processes and other physiological functions. However, there is currently no scientific evidence to support the existence of the HPG pore.",
    "llama-7b_fact_raw": "1. The HPG axis is a system of hormonal communication between the hypothalamus, pituitary gland, and gonads.\n2. The HPG axis regulates reproductive processes and other physiological functions.\n3. The hypothalamus produces hormones that regulate the release of gonadotropin-releasing hormone (GnRH) from the pituitary gland.\n4. Gonadotropin-releasing hormone (GnRH) stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.\n5. There is currently no scientific evidence to support the existence of the HPG pore.",
    "llama-7b_fact": [
      "The HPG axis is a system of hormonal communication between the hypothalamus, pituitary gland, and gonads.",
      "The HPG axis regulates reproductive processes and other physiological functions.",
      "The hypothalamus produces hormones that regulate the release of gonadotropin-releasing hormone (GnRH) from the pituitary gland.",
      "Gonadotropin-releasing hormone (GnRH) stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland.",
      "There is currently no scientific evidence to support the existence of the HPG pore."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The hypothalamus itself produces gonadotropin-releasing hormone (GnRH) which regulates the release of other hormones from the pituitary gland.\n4. TRUE\n5. TRUE [clarification]: The statement is a bit vague because \"HPG pore\" is not a standard term in endocrinology. Assuming it refers to a hypothetical or non-existent feature related to the HPG axis, it is true that there is no scientific evidence for an \"HPG pore\" as the HPG axis refers to a hormonal communication system, not a physical pore.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "You MUST give a detailed answer to the following question: What is the 959 Nematode Genomes initiative?",
    "llama-7b_response": "The 959 Nematode Genomes initiative is a large-scale project aimed at sequencing and analyzing the genomes of 959 species of roundworms, also known as nematodes. Nematodes are a diverse group of microscopic worms that are found in a wide range of environments, including soil, water, and the guts of animals. They are one of the most species-rich phyla of animals, with over 100,000 known species.\n\nThe 959 Nematode Genomes initiative is a collaborative effort between researchers from around the world, with the goal of creating a comprehensive resource for the study of nematode biology and evolution. The project involves sequencing the genomes of a representative sample of nematode species, using a combination of next-generation sequencing technologies and traditional Sanger sequencing. The sequenced genomes are then analyzed using a variety of computational methods, including comparative genomics, transcriptomics, and functional annotation.\n\nThe 959 Nematode Genomes initiative is expected to have a significant impact on our understanding of nematode biology and evolution. By analyzing the genomes of a diverse set of nematode species, researchers hope to identify conserved genes and functional modules that are shared across different species, as well as genes that are specific to individual species or groups of species. This information will be used to gain insights into the evolutionary history of nematodes, as well as to identify potential targets for the development of new drugs and other applications.\n\nOverall, the 959 Nematode Genomes initiative is a landmark project that will provide a valuable resource for the study of nematode biology and evolution, with implications for a wide range of fields, including medicine, agriculture, and ecology.",
    "llama-7b_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of roundworms.\n2. Nematodes are found in various environments such as soil, water, and the guts of animals.\n3. The initiative is a collaborative effort involving researchers from around the world.\n4. The project uses next-generation sequencing technologies and traditional Sanger sequencing for genome sequencing.\n5. The initiative's goal is to create a comprehensive resource for studying nematode biology and evolution.",
    "llama-7b_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of roundworms.",
      "Nematodes are found in various environments such as soil, water, and the guts of animals.",
      "The initiative is a collaborative effort involving researchers from around the world.",
      "The project uses next-generation sequencing technologies and traditional Sanger sequencing for genome sequencing.",
      "The initiative's goal is to create a comprehensive resource for studying nematode biology and evolution."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "You MUST give a detailed answer to the following question: Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-7b_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Some of the most popular ones include:\n\n1. \"NIPT\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n2. \"NIPT-R\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n3. \"NIPTdata\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n4. \"NIPT-R\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n5. \"NIPTdata\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n6. \"NIPT-R\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n7. \"NIPTdata\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n8. \"NIPT-R\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using R. It includes functions for imputation of missing data, quality control, and statistical analysis of the data.\n9. \"NIPTdata\" package: This package provides functions for analyzing and visualizing data from non-invasive prenatal testing using",
    "llama-7b_fact_raw": "1. The \"NIPT\" package is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n2. The \"NIPT-R\" package is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n3. The \"NIPTdata\" package is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.\n4. These R packages include functions for imputation of missing data, quality control, and statistical analysis of NIPT data.\n5. The R packages mentioned are used for visualizing NIPT data.",
    "llama-7b_fact": [
      "The \"NIPT\" package is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "The \"NIPT-R\" package is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "The \"NIPTdata\" package is an R package developed for analyzing Non-invasive prenatal testing (NIPT) data.",
      "These R packages include functions for imputation of missing data, quality control, and statistical analysis of NIPT data.",
      "The R packages mentioned are used for visualizing NIPT data."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE (assuming that at least one of the mentioned R packages is designed for NIPT data analysis, it is reasonable to assume they would include such functions)\n5. TRUE (similarly, if the R packages are for NIPT data analysis, they likely include visualization functions)",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2560,
    "user_query": "You MUST give a detailed answer to the following question: Describe Achenbachs syndrome.",
    "llama-7b_response": "Achenbach's syndrome, also known as Achenbach's triad, is a rare neurological disorder characterized by a triad of symptoms, including hemiparesis (weakness on one side of the body), ataxia (lack of coordination and balance), and cerebellar signs such as dysarthria (speech difficulties) and nystagmus (rapid, involuntary eye movements).\n\nThe syndrome is named after German neurologist August Achenbach, who first described it in 1881. It is believed to be caused by a lesion or injury to the cerebellum, which is a part of the brain responsible for coordination and balance.\n\nThe symptoms of Achenbach's syndrome can vary in severity and may be accompanied by other neurological symptoms such as dizziness, headache, and difficulty with speech and swallowing. The syndrome can occur at any age, but it is more common in older adults.\n\nDiagnosis of Achenbach's syndrome typically involves a thorough neurological examination, including tests to assess coordination, balance, and speech. Imaging tests such as MRI or CT scans may also be used to identify any lesions or other abnormalities in the brain.\n\nTreatment for Achenbach's syndrome typically focuses on managing symptoms and improving function. Physical therapy and rehabilitation may be helpful in improving coordination and balance, while medications may be used to manage symptoms such as dizziness and headache. In some cases, surgery may be necessary to treat a specific underlying cause of the syndrome.",
    "llama-7b_fact_raw": "1. Achenbach's syndrome is characterized by a triad of symptoms: hemiparesis, ataxia, and cerebellar signs.\n2. The syndrome was first described by German neurologist August Achenbach in 1881.\n3. Achenbach's syndrome is believed to be caused by a lesion or injury to the cerebellum.\n4. Diagnosis of Achenbach's syndrome involves a neurological examination and may include imaging tests such as MRI or CT scans.\n5. Treatment for Achenbach's syndrome may include physical therapy, medications, and possibly surgery.",
    "llama-7b_fact": [
      "Achenbach's syndrome is characterized by a triad of symptoms: hemiparesis, ataxia, and cerebellar signs.",
      "The syndrome was first described by German neurologist August Achenbach in 1881.",
      "Achenbach's syndrome is believed to be caused by a lesion or injury to the cerebellum.",
      "Diagnosis of Achenbach's syndrome involves a neurological examination and may include imaging tests such as MRI or CT scans.",
      "Treatment for Achenbach's syndrome may include physical therapy, medications, and possibly surgery."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Achenbach's syndrome is characterized by sudden, unexplained bruising in the hand or fingers, not by hemiparesis, ataxia, and cerebellar signs.\n2. FALSE [correction]: Achenbach's syndrome was described by German physician Dr. Walter Achenbach in the 1950s, not by August Achenbach in 1881.\n3. FALSE [correction]: Achenbach's syndrome is not believed to be caused by a lesion or injury to the cerebellum. The exact cause is unknown, but it is thought to be related to minor traumas or spontaneous bleeding.\n4. UNKNOWN: While a neurological examination may be performed to rule out other conditions, the statement does not accurately describe the diagnosis process for Achenbach's syndrome specifically. Imaging tests are not typically used for diagnosing Achenbach's syndrome.\n5. UNKNOWN: Since Achenbach's syndrome involves bruising, the primary treatment is often reassurance as the condition is benign and self-limiting. The statement may apply to other neurological conditions but is not specific to Achenbach's syndrome.",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2581,
    "user_query": "You MUST give a detailed answer to the following question: Which algorithm is used for detection of long repeat expansions?",
    "llama-7b_response": "There are several algorithms that can be used for the detection of long repeat expansions. One such algorithm is the \"sliding window\" approach.\n\nIn this approach, a window of DNA sequence is scanned for the presence of the repeat sequence. The window is moved along the DNA sequence one nucleotide at a time, and for each nucleotide, the repeat sequence is compared to the DNA sequence in the window. If the repeat sequence matches the DNA sequence in the window, the window is incremented by one nucleotide and the process is repeated. If the repeat sequence does not match the DNA sequence in the window, the window is not incremented and the process is repeated for the next nucleotide.\n\nOnce the entire DNA sequence has been scanned, the size of the repeat expansion can be determined by counting the number of nucleotides in the window that match the repeat sequence. If the repeat expansion is shorter than a certain threshold, it is considered to be normal. If the repeat expansion is longer than the threshold, it is considered to be pathological and may indicate a genetic disorder.\n\nAnother algorithm that can be used for the detection of long repeat expansions is the \"markov model\".\n\nIn this approach, a Markov model is constructed using the repeat sequence and the surrounding DNA sequence. The Markov model represents the probability of each nucleotide at each position in the repeat sequence and the surrounding DNA sequence. The Markov model is then used to scan the DNA sequence for the presence of the repeat sequence.\n\nFor each nucleotide in the DNA sequence, the probability of that nucleotide being present in the repeat sequence is calculated using the Markov model. If the probability of the nucleotide being present in the repeat sequence is greater than a certain threshold, it is considered to be part of the repeat expansion and the process is repeated for the next nucleotide. If the probability of the nucleotide being present in the repeat sequence is less than the threshold, it is considered to be part of the surrounding DNA sequence and the process is repeated for the next nucleotide.\n\nOnce the entire DNA sequence has been scanned, the size of the repeat expansion can be determined by counting the number of nucleotides in the DNA sequence that match the repeat sequence. If the repeat expansion is shorter than a certain threshold, it is considered to be normal. If the repeat expansion is longer than the threshold, it is considered",
    "llama-7b_fact_raw": "1. The \"sliding window\" approach is an algorithm used for the detection of long repeat expansions in DNA sequences.\n2. In the \"sliding window\" approach, a window of DNA sequence is moved along the DNA one nucleotide at a time to scan for repeat sequences.\n3. The size of the repeat expansion can be determined by counting the number of nucleotides in the window that match the repeat sequence.\n4. A \"markov model\" is another algorithm that can be used for the detection of long repeat expansions.\n5. The \"markov model\" represents the probability of each nucleotide at each position in the repeat sequence and the surrounding DNA sequence.",
    "llama-7b_fact": [
      "The \"sliding window\" approach is an algorithm used for the detection of long repeat expansions in DNA sequences.",
      "In the \"sliding window\" approach, a window of DNA sequence is moved along the DNA one nucleotide at a time to scan for repeat sequences.",
      "The size of the repeat expansion can be determined by counting the number of nucleotides in the window that match the repeat sequence.",
      "A \"markov model\" is another algorithm that can be used for the detection of long repeat expansions.",
      "The \"markov model\" represents the probability of each nucleotide at each position in the repeat sequence and the surrounding DNA sequence."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The size of the repeat expansion is determined by the number of consecutive windows that contain the repeat sequence, not by counting the number of nucleotides in a single window.\n4. UNKNOWN\n5. FALSE [correction]: A \"Markov model\" represents the probability of each nucleotide occurring, given the previous nucleotide(s), rather than the probability of each nucleotide at each position in the repeat sequence and the surrounding DNA sequence.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "You MUST give a detailed answer to the following question: Which brain tumors does neuroligin-3 promote?",
    "llama-7b_response": "Neuroligin-3 is a protein that has been implicated in the development and progression of various types of brain tumors, including gliomas. Gliomas are a type of brain tumor that arise from glial cells, which are supportive cells in the brain that help to maintain its structure and function.\n\nNeuroligin-3 has been found to be overexpressed in a number of different types of gliomas, including astrocytomas, oligodendrogliomas, and ependymomas. These tumors are characterized by the abnormal proliferation of glial cells, and the overexpression of neuroligin-3 has been shown to promote the growth and survival of these cells.\n\nIn addition to promoting the growth of gliomas, neuroligin-3 has also been implicated in the development of other types of brain tumors, such as meningiomas and schwannomas. However, the role of neuroligin-3 in the development and progression of these tumors is not as well understood as it is in gliomas.\n\nOverall, the overexpression of neuroligin-3 has been implicated in the development and progression of a number of different types of brain tumors, including gliomas, meningiomas, and schwannomas. Further research is needed to fully understand the role of neuroligin-3 in the development and progression of these tumors, and to identify potential therapeutic targets for the treatment of brain tumors.",
    "llama-7b_fact_raw": "1. Neuroligin-3 is a protein implicated in the development and progression of various types of brain tumors.\n2. Gliomas, a type of brain tumor that arises from glial cells, are associated with the overexpression of neuroligin-3.\n3. Neuroligin-3 is overexpressed in different types of gliomas, including astrocytomas, oligodendrogliomas, and ependymomas.\n4. The overexpression of neuroligin-3 promotes the growth and survival of glial cells in gliomas.\n5. Neuroligin-3 has also been implicated in the development of other brain tumors such as meningiomas and schwannomas.",
    "llama-7b_fact": [
      "Neuroligin-3 is a protein implicated in the development and progression of various types of brain tumors.",
      "Gliomas, a type of brain tumor that arises from glial cells, are associated with the overexpression of neuroligin-3.",
      "Neuroligin-3 is overexpressed in different types of gliomas, including astrocytomas, oligodendrogliomas, and ependymomas.",
      "The overexpression of neuroligin-3 promotes the growth and survival of glial cells in gliomas.",
      "Neuroligin-3 has also been implicated in the development of other brain tumors such as meningiomas and schwannomas."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Neuroligin-3 has been primarily implicated in the development of gliomas. While it may play a role in other brain tumors, the statement specifically mentioning meningiomas and schwannomas is not widely supported in the scientific literature as of my last update. These tumors arise from different types of cells (meningiomas from the meninges and schwannomas from Schwann cells), and the involvement of neuroligin-3 in their development is less clear.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2586,
    "user_query": "You MUST give a detailed answer to the following question: What is the approximate size of gas vesicles?",
    "llama-7b_response": "Gas vacuoles, also known as gas vesicles, are small, gas-filled organelles found in some bacteria and archaea. Their size can vary depending on the species of bacteria or archaea and can range from a few nanometers to several micrometers in diameter. In general, gas vacuoles are relatively small compared to the size of the bacterial cell, but they can still have a significant impact on the overall size and shape of the cell.",
    "llama-7b_fact_raw": "1. Gas vesicles are found in some bacteria and archaea.\n2. The size of gas vesicles can range from a few nanometers to several micrometers in diameter.\n3. Gas vesicles are relatively small compared to the size of the bacterial cell.",
    "llama-7b_fact": [
      "Gas vesicles are found in some bacteria and archaea.",
      "The size of gas vesicles can range from a few nanometers to several micrometers in diameter.",
      "Gas vesicles are relatively small compared to the size of the bacterial cell."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The size of gas vesicles can range from a few tens of nanometers to several micrometers in length, not diameter.\n3. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2589,
    "user_query": "You MUST give a detailed answer to the following question: List BET proteins.",
    "llama-7b_response": "BET (Bromodomain and Extra-terminal domain) proteins are a family of epigenetic regulators that play a crucial role in the regulation of gene expression. They are characterized by the presence of two distinct domains: the bromodomain, which recognizes acetylated lysine residues on histone tails, and the extra-terminal (ET) domain, which is involved in protein-protein interactions and transcriptional regulation.\n\nThe BET protein family includes:\n\n1. BRD2 (Bromodomain and Extra-terminal domain 2)\n2. BRD3 (Bromodomain and Extra-terminal domain 3)\n3. BRD4 (Bromodomain and Extra-terminal domain 4)\n4. BAP1 (Bromodomain and Extra-terminal domain containing protein 1)\n5. BAP3 (Bromodomain and Extra-terminal domain containing protein 3)\n6. BAP2 (Bromodomain and Extra-terminal domain containing protein 2)\n7. BAP4 (Bromodomain and Extra-terminal domain containing protein 4)\n8. BAP5 (Bromodomain and Extra-terminal domain containing protein 5)\n9. BAP6 (Bromodomain and Extra-terminal domain containing protein 6)\n10. BAP7 (Bromodomain and Extra-terminal domain containing protein 7)\n11. BAP8 (Bromodomain and Extra-terminal domain containing protein 8)\n12. BAP9 (Bromodomain and Extra-terminal domain containing protein 9)\n13. BAP10 (Bromodomain and Extra-terminal domain containing protein 10)\n14. BAP11 (Bromodomain and Extra-terminal domain containing protein 11)\n15. BAP12 (Bromodomain and Extra-terminal domain containing protein 12)\n16. BAP13 (Bromodomain and Extra-terminal domain containing protein 13)\n17",
    "llama-7b_fact_raw": "1. BET proteins are a family of epigenetic regulators.\n2. BET proteins have a bromodomain that recognizes acetylated lysine residues on histone tails.\n3. BET proteins have an extra-terminal (ET) domain involved in protein-protein interactions and transcriptional regulation.\n4. BRD2, BRD3, and BRD4 are members of the BET protein family.\n5. The BET protein family includes proteins named BAP1 through BAP13.",
    "llama-7b_fact": [
      "BET proteins are a family of epigenetic regulators.",
      "BET proteins have a bromodomain that recognizes acetylated lysine residues on histone tails.",
      "BET proteins have an extra-terminal (ET) domain involved in protein-protein interactions and transcriptional regulation.",
      "BRD2, BRD3, and BRD4 are members of the BET protein family.",
      "The BET protein family includes proteins named BAP1 through BAP13."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The BET protein family includes BRD2, BRD3, BRD4, and BRDT, not proteins named BAP1 through BAP13. BAP1 (BRCA1-associated protein 1) is a different protein involved in chromatin dynamics and DNA repair.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2610,
    "user_query": "You MUST give a detailed answer to the following question: Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-7b_response": "There are several algorithms that have been developed for the prediction of protein subcellular localization using deep learning. Some of the most popular ones include:\n\n1. DeepSubella: This is a deep learning-based algorithm that uses a convolutional neural network (CNN) to predict the subcellular localization of proteins. The algorithm was developed by Li et al. in 2017 and has been shown to be highly accurate in predicting the subcellular localization of proteins.\n2. DeepLocal: This is another deep learning-based algorithm that uses a CNN to predict the subcellular localization of proteins. The algorithm was developed by Li et al. in 2016 and has been shown to be highly accurate in predicting the subcellular localization of proteins.\n3. SMALLE: This is a deep learning-based algorithm that uses a recurrent neural network (RNN) to predict the subcellular localization of proteins. The algorithm was developed by Wang et al. in 2018 and has been shown to be highly accurate in predicting the subcellular localization of proteins.\n4. DeepSub: This is a deep learning-based algorithm that uses a CNN to predict the subcellular localization of proteins. The algorithm was developed by Li et al. in 2015 and has been shown to be highly accurate in predicting the subcellular localization of proteins.\n\nOverall, these algorithms have been shown to be highly accurate in predicting the subcellular localization of proteins and have the potential to revolutionize the field of protein subcellular localization prediction.",
    "llama-7b_fact_raw": "1. DeepSubella is a deep learning-based algorithm that uses a convolutional neural network to predict protein subcellular localization, developed by Li et al. in 2017.\n2. DeepLocal is a deep learning-based algorithm that uses a convolutional neural network to predict protein subcellular localization, developed by Li et al. in 2016.\n3. SMALLE is a deep learning-based algorithm that uses a recurrent neural network to predict protein subcellular localization, developed by Wang et al. in 2018.\n4. DeepSub is a deep learning-based algorithm that uses a convolutional neural network to predict protein subcellular localization, developed by Li et al. in 2015.",
    "llama-7b_fact": [
      "DeepSubella is a deep learning-based algorithm that uses a convolutional neural network to predict protein subcellular localization, developed by Li et al. in 2017.",
      "DeepLocal is a deep learning-based algorithm that uses a convolutional neural network to predict protein subcellular localization, developed by Li et al. in 2016.",
      "SMALLE is a deep learning-based algorithm that uses a recurrent neural network to predict protein subcellular localization, developed by Wang et al. in 2018.",
      "DeepSub is a deep learning-based algorithm that uses a convolutional neural network to predict protein subcellular localization, developed by Li et al. in 2015."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nThe provided statements refer to specific algorithms and their developers, along with the years they were purportedly developed. Without access to the relevant scientific literature or databases that confirm the existence and details of these algorithms, it is not possible to verify the accuracy of these statements. Therefore, the truthfulness of the statements regarding DeepSubella, DeepLocal, SMALLE, and DeepSub, including their developers and the years they were developed, remains unknown.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2634,
    "user_query": "You MUST give a detailed answer to the following question: What is MULTOVL?",
    "llama-7b_response": "I'm sorry, but I am not familiar with the term \"MULTOVL.\" Can you provide more context or information about what you are asking?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2660,
    "user_query": "You MUST give a detailed answer to the following question: Can GDF15 be a biomarker for metformin treatment?",
    "llama-7b_response": "GDF15, also known as growth differentiation factor 15, is a protein that has been studied as a potential biomarker for various conditions, including diabetes. Metformin is a commonly used medication for treating type 2 diabetes, and it has been suggested that GDF15 may be a biomarker for the effectiveness of metformin treatment. However, the relationship between GDF15 and metformin treatment is complex and not yet fully understood.\n\nStudies have shown that metformin can reduce levels of GDF15 in the blood of people with type 2 diabetes. This suggests that metformin may be able to lower GDF15 levels by improving insulin sensitivity and glucose control. Lower levels of GDF15 have also been associated with improved insulin sensitivity and glucose control in people with type 2 diabetes, which further supports the idea that GDF15 may be a biomarker for the effectiveness of metformin treatment.\n\nHowever, the relationship between GDF15 and metformin treatment is not always consistent. Some studies have found no association between GDF15 levels and the effectiveness of metformin treatment, while others have found conflicting results. Additionally, the relationship between GDF15 and metformin treatment may vary depending on the individual and the stage of diabetes.\n\nOverall, while GDF15 has been studied as a potential biomarker for the effectiveness of metformin treatment, the relationship between the two is complex and not yet fully understood. Further research is needed to clarify the role of GDF15 as a biomarker for metformin treatment.",
    "llama-7b_fact_raw": "1. GDF15, also known as growth differentiation factor 15, is a protein that has been studied as a potential biomarker for various conditions, including diabetes.\n2. Metformin is a commonly used medication for treating type 2 diabetes.\n3. Studies have shown that metformin can reduce levels of GDF15 in the blood of people with type 2 diabetes.\n4. Lower levels of GDF15 have been associated with improved insulin sensitivity and glucose control in people with type 2 diabetes.\n5. The relationship between GDF15 levels and the effectiveness of metformin treatment has shown inconsistent results across different studies.",
    "llama-7b_fact": [
      "GDF15, also known as growth differentiation factor 15, is a protein that has been studied as a potential biomarker for various conditions, including diabetes.",
      "Metformin is a commonly used medication for treating type 2 diabetes.",
      "Studies have shown that metformin can reduce levels of GDF15 in the blood of people with type 2 diabetes.",
      "Lower levels of GDF15 have been associated with improved insulin sensitivity and glucose control in people with type 2 diabetes.",
      "The relationship between GDF15 levels and the effectiveness of metformin treatment has shown inconsistent results across different studies."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Studies have shown that metformin can increase levels of GDF15 in the blood of people with type 2 diabetes.\n4. FALSE [correction]: Higher levels of GDF15 have been associated with improved insulin sensitivity and glucose control in people with type 2 diabetes.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2664,
    "user_query": "You MUST give a detailed answer to the following question: Is recursive splicing more common in short introns?",
    "llama-7b_response": "Recursive splicing is a process in which an intron is spliced out of an mRNA molecule and then spliced back into the same mRNA molecule, resulting in the creation of a new mRNA molecule with the intron removed. Recursive splicing can occur in both short and long introns, and the frequency of recursive splicing is not necessarily higher in short introns compared to long introns.\n\nThe frequency of recursive splicing is influenced by several factors, including the length of the intron, the presence of regulatory elements within the intron, and the presence of other splicing events in the vicinity of the intron. Short introns may be more prone to recursive splicing if they contain regulatory elements that promote splicing, or if they are located in close proximity to other splicing events that require the removal and reinsertion of the intron.\n\nHowever, the frequency of recursive splicing is also influenced by the overall splicing efficiency of the mRNA molecule, which can vary depending on factors such as the abundance of splicing machinery, the stability of the mRNA molecule, and the presence of alternative splicing events. In general, recursive splicing is more likely to occur in mRNA molecules with high splicing efficiency, regardless of the length of the intron.\n\nIn summary, while recursive splicing can occur in both short and long introns, the frequency of recursive splicing is not necessarily higher in short introns compared to long introns. The frequency of recursive splicing is influenced by several factors, including the length of the intron, the presence of regulatory elements, and the overall splicing efficiency of the mRNA molecule.",
    "llama-7b_fact_raw": "1. Recursive splicing is a process where an intron is spliced out of an mRNA molecule and then spliced back into the same mRNA molecule.\n2. The frequency of recursive splicing is not necessarily higher in short introns compared to long introns.\n3. Factors influencing the frequency of recursive splicing include the length of the intron, the presence of regulatory elements within the intron, and the presence of other splicing events nearby.\n4. Short introns may be more prone to recursive splicing if they contain regulatory elements that promote splicing or are located near other splicing events.\n5. The overall splicing efficiency of the mRNA molecule, which can vary due to factors like the abundance of splicing machinery and the stability of the mRNA, also influences the frequency of recursive splicing.",
    "llama-7b_fact": [
      "Recursive splicing is a process where an intron is spliced out of an mRNA molecule and then spliced back into the same mRNA molecule.",
      "The frequency of recursive splicing is not necessarily higher in short introns compared to long introns.",
      "Factors influencing the frequency of recursive splicing include the length of the intron, the presence of regulatory elements within the intron, and the presence of other splicing events nearby.",
      "Short introns may be more prone to recursive splicing if they contain regulatory elements that promote splicing or are located near other splicing events.",
      "The overall splicing efficiency of the mRNA molecule, which can vary due to factors like the abundance of splicing machinery and the stability of the mRNA, also influences the frequency of recursive splicing."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Recursive splicing is a process where an intron is spliced out of a pre-mRNA molecule, and a part of the intron (the \"recursive splice site\") is used in a subsequent splicing event to join exons that are initially distant in the primary transcript.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "You MUST give a detailed answer to the following question: What is the TALE-iD method used for?",
    "llama-7b_response": "The TALE-iD (Transcription Activator-Like Effector (TALE) proteins for the Identification of Disease-associated Variants) method is used for the identification of disease-associated variants in the human genome.\n\nTALE proteins are engineered DNA-binding proteins that can recognize specific DNA sequences with high specificity and affinity. The TALE-iD method uses TALE proteins to selectively bind to regions of the genome that contain disease-associated variants, such as single nucleotide polymorphisms (SNPs) or copy number variations (CNVs).\n\nThe TALE-iD method involves the following steps:\n\n1. Design of TALE proteins: TALE proteins are designed to recognize specific DNA sequences, such as those found in disease-associated variants.\n2. Target enrichment: The genome is targeted for enrichment using the TALE-protein-bound probes. This allows for the selective capture of regions of the genome that contain disease-associated variants.\n3. Sequencing: The captured regions of the genome are then sequenced to identify the disease-associated variants.\n4. Variant calling: The sequencing data is analyzed to identify the disease-associated variants.\n\nThe TALE-iD method has several advantages over other methods for the identification of disease-associated variants. It allows for the targeted enrichment of specific regions of the genome, which reduces the amount of sequencing required and increases the sensitivity of the analysis. It also allows for the identification of rare variants, which can be difficult to detect using other methods.\n\nOverall, the TALE-iD method is a powerful tool for the identification of disease-associated variants in the human genome, and has the potential to improve our understanding of the genetic basis of complex diseases and enable the development of personalized medicine.",
    "llama-7b_fact_raw": "1. The TALE-iD method is used for the identification of disease-associated variants in the human genome.\n2. TALE proteins are engineered DNA-binding proteins that can recognize specific DNA sequences.\n3. The TALE-iD method uses TALE proteins to selectively bind to regions of the genome that contain disease-associated variants, such as SNPs or CNVs.\n4. The TALE-iD method includes steps such as design of TALE proteins, target enrichment, sequencing, and variant calling.\n5. The TALE-iD method allows for targeted enrichment of specific regions of the genome, which reduces the amount of sequencing required and increases the sensitivity of the analysis.",
    "llama-7b_fact": [
      "The TALE-iD method is used for the identification of disease-associated variants in the human genome.",
      "TALE proteins are engineered DNA-binding proteins that can recognize specific DNA sequences.",
      "The TALE-iD method uses TALE proteins to selectively bind to regions of the genome that contain disease-associated variants, such as SNPs or CNVs.",
      "The TALE-iD method includes steps such as design of TALE proteins, target enrichment, sequencing, and variant calling.",
      "The TALE-iD method allows for targeted enrichment of specific regions of the genome, which reduces the amount of sequencing required and increases the sensitivity of the analysis."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe statements provided are consistent with the general principles of TALE (Transcription Activator-Like Effector) technology and its application in genomic research, such as the TALE-iD method for identifying disease-associated variants. TALE proteins are indeed engineered to bind specific DNA sequences, and the TALE-iD method would involve steps like designing these proteins, enriching the target regions, sequencing, and calling variants. This method would allow for targeted enrichment, which can reduce the sequencing workload and increase sensitivity for detecting variants in specific genomic regions.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2747,
    "user_query": "You MUST give a detailed answer to the following question: Which Lisp framework has been developed for image processing?",
    "llama-7b_response": "There are several Lisp frameworks that have been developed for image processing, including:\n\n1. Common Lisp Image Processing (CL-IP): CL-IP is a Common Lisp library for image processing and analysis. It provides a wide range of functions for tasks such as image manipulation, filtering, segmentation, and feature extraction.\n2. QuickDraw CL: QuickDraw CL is a Common Lisp library for image processing and computer vision. It provides a range of functions for tasks such as image manipulation, feature extraction, and object recognition.\n3. LispWorks Image Processing Library (LIP): LIP is a LispWorks library for image processing and analysis. It provides a range of functions for tasks such as image manipulation, filtering, segmentation, and feature extraction.\n4. SBCL Image Processing Library (SBCL-IP): SBCL-IP is a SBCL library for image processing and analysis. It provides a range of functions for tasks such as image manipulation, filtering, segmentation, and feature extraction.\n\nOverall, there are several Lisp frameworks available for image processing, and the choice of which one to use will depend on the specific requirements of the project.",
    "llama-7b_fact_raw": "1. Common Lisp Image Processing (CL-IP) is a Common Lisp library for image processing and analysis.\n2. QuickDraw CL is a Common Lisp library for image processing and computer vision.\n3. LispWorks Image Processing Library (LIP) is a LispWorks library for image processing and analysis.\n4. SBCL Image Processing Library (SBCL-IP) is a SBCL library for image processing and analysis.",
    "llama-7b_fact": [
      "Common Lisp Image Processing (CL-IP) is a Common Lisp library for image processing and analysis.",
      "QuickDraw CL is a Common Lisp library for image processing and computer vision.",
      "LispWorks Image Processing Library (LIP) is a LispWorks library for image processing and analysis.",
      "SBCL Image Processing Library (SBCL-IP) is a SBCL library for image processing and analysis."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: There is no specific SBCL Image Processing Library (SBCL-IP) known as a standard library for image processing and analysis in SBCL (Steel Bank Common Lisp). SBCL is an implementation of the Common Lisp language, and while it can use Common Lisp libraries for image processing, there isn't a library named SBCL-IP that is specifically part of SBCL.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "true",
      "false"
    ]
  },
  {
    "id": 2759,
    "user_query": "You MUST give a detailed answer to the following question: How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-7b_response": "The question of how many genes in Saccharomyces cerevisiae (baker's yeast) are the result of an ancient whole genome duplication event is a complex one that has been the subject of much research.\n\nS. cerevisiae is a eukaryotic, single-celled fungus that is widely used as a model organism in genetics and molecular biology. The genome of S. cerevisiae consists of 12 megabases (Mb) of DNA and contains approximately 6,000 protein-coding genes.\n\nAncient whole genome duplications (WGDs) are a common feature of the evolution of eukaryotic genomes. WGDs result in the duplication of large portions of the genome, leading to the formation of duplicate genes and the evolution of new gene functions.\n\nThere have been several studies that have attempted to identify the number of genes in S. cerevisiae that are the result of an ancient WGD. These studies have used a variety of approaches, including comparative genomics, gene family analysis, and phylogenetic reconstruction.\n\nOne of the earliest studies to address this question was published in 2001 by Li and Durbin, who used a comparative genomics approach to identify duplicated blocks of genes in the S. cerevisiae genome. They identified several large blocks of duplicated genes that were likely the result of an ancient WGD, and estimated that approximately 25% of the S. cerevisiae genes were the result of this event.\n\nMore recent studies have used a variety of approaches to estimate the number of genes in S. cerevisiae that are the result of an ancient WGD. For example, a study published in 2014 used a combination of gene family analysis and phylogenetic reconstruction to estimate that approximately 30% of the S. cerevisiae genes were the result of an ancient WGD.\n\nOverall, the number of genes in S. cerevisiae that are the result of an ancient WGD is estimated to be between 1500 and 3000. However, the exact number is difficult to determine with certainty, and further research is likely to refine",
    "llama-7b_fact_raw": "1. Saccharomyces cerevisiae (baker's yeast) is a eukaryotic, single-celled fungus.\n2. The genome of S. cerevisiae consists of 12 megabases (Mb) of DNA.\n3. S. cerevisiae contains approximately 6,000 protein-coding genes.\n4. A study by Li and Durbin in 2001 estimated that approximately 25% of the S. cerevisiae genes were the result of an ancient whole genome duplication.\n5. A study published in 2014 estimated that approximately 30% of the S. cerevisiae genes were the result of an ancient whole genome duplication.",
    "llama-7b_fact": [
      "Saccharomyces cerevisiae (baker's yeast) is a eukaryotic, single-celled fungus.",
      "The genome of S. cerevisiae consists of 12 megabases (Mb) of DNA.",
      "S. cerevisiae contains approximately 6,000 protein-coding genes.",
      "A study by Li and Durbin in 2001 estimated that approximately 25% of the S. cerevisiae genes were the result of an ancient whole genome duplication.",
      "A study published in 2014 estimated that approximately 30% of the S. cerevisiae genes were the result of an ancient whole genome duplication."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The percentage of genes resulting from an ancient whole genome duplication in S. cerevisiae is generally estimated to be around 8% to 20%, not 30%. The exact percentage can vary based on different studies and methodologies, but 30% is higher than the commonly accepted range.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2763,
    "user_query": "You MUST give a detailed answer to the following question: Which complex is bound by estrogen-related receptor  (Esrrb)?",
    "llama-7b_response": "Estrogen-related receptor  (Esrrb) is a member of the nuclear receptor superfamily of transcription factors. It is a ligand-activated transcription factor that binds to DNA and regulates the expression of target genes involved in a variety of biological processes, including development, differentiation, and homeostasis.\n\nEsrrb is primarily expressed in the brain, where it plays a role in the regulation of neurotransmitter release, synaptic plasticity, and neuroprotection. It has also been shown to play a role in the regulation of bone metabolism, lipid metabolism, and immune function.\n\nEsrrb is known to be bound by a variety of ligands, including estrogens, androgens, and other steroid hormones. It has also been shown to be bound by non-steroidal ligands, such as thyroid hormones and retinoic acid.\n\nThere is limited information available on the specific complex that is bound by Esrrb. However, it is known that Esrrb can form heterodimers with other nuclear receptors, such as estrogen receptor  (Esr1) and glucocorticoid receptor (GR). These heterodimers can bind to DNA and regulate the expression of target genes involved in a variety of biological processes.\n\nIn summary, while there is limited information available on the specific complex that is bound by Esrrb, it is known to form heterodimers with other nuclear receptors and regulate the expression of target genes involved in a variety of biological processes.",
    "llama-7b_fact_raw": "1. Estrogen-related receptor  (Esrrb) is a member of the nuclear receptor superfamily of transcription factors.\n2. Esrrb is a ligand-activated transcription factor that binds to DNA and regulates the expression of target genes.\n3. Esrrb is primarily expressed in the brain and is involved in the regulation of neurotransmitter release, synaptic plasticity, and neuroprotection.\n4. Esrrb can be bound by various ligands, including estrogens, androgens, thyroid hormones, and retinoic acid.\n5. Esrrb is known to form heterodimers with other nuclear receptors such as estrogen receptor  (Esr1) and glucocorticoid receptor (GR).",
    "llama-7b_fact": [
      "Estrogen-related receptor  (Esrrb) is a member of the nuclear receptor superfamily of transcription factors.",
      "Esrrb is a ligand-activated transcription factor that binds to DNA and regulates the expression of target genes.",
      "Esrrb is primarily expressed in the brain and is involved in the regulation of neurotransmitter release, synaptic plasticity, and neuroprotection.",
      "Esrrb can be bound by various ligands, including estrogens, androgens, thyroid hormones, and retinoic acid.",
      "Esrrb is known to form heterodimers with other nuclear receptors such as estrogen receptor  (Esr1) and glucocorticoid receptor (GR)."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: Estrogen-related receptor  (Esrrb) is an orphan nuclear receptor, which means it is not known to be activated by any endogenous ligands.\n3. UNKNOWN\n4. FALSE [correction]: As an orphan receptor, Esrrb is not known to be bound and activated by conventional ligands such as estrogens, androgens, thyroid hormones, and retinoic acid.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2842,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of ZCCHC17?",
    "llama-7b_response": "ZCCHC17 is a gene that encodes for a protein called zinc finger CCCH-type containing 17. This protein is a member of the CCCH-type zinc finger family, which is a class of transcription factors that bind to DNA and regulate gene expression.\n\nThe exact function of ZCCHC17 is not fully understood, but it is believed to play a role in regulating the expression of genes involved in a variety of biological processes, including cell growth, differentiation, and immune response.\n\nStudies have shown that ZCCHC17 is expressed in a variety of tissues and cells, including immune cells such as T cells and B cells. It has been suggested that ZCCHC17 may play a role in regulating the activation and proliferation of these immune cells.\n\nIn addition, ZCCHC17 has been implicated in the development of certain types of cancer, including leukemia and lymphoma. It has been shown that overexpression of ZCCHC17 can promote the growth and survival of cancer cells, suggesting that it may be a potential target for cancer therapy.\n\nOverall, while more research is needed to fully understand the role of ZCCHC17, it is clear that this protein plays an important role in regulating gene expression and may have implications for a variety of biological processes, including immune response and cancer development.",
    "llama-7b_fact_raw": "1. ZCCHC17 is a gene that encodes for a protein called zinc finger CCCH-type containing 17.\n2. The protein ZCCHC17 is a member of the CCCH-type zinc finger family of transcription factors.\n3. ZCCHC17 is believed to play a role in regulating gene expression involved in cell growth, differentiation, and immune response.\n4. ZCCHC17 is expressed in various tissues and cells, including immune cells like T cells and B cells.\n5. Overexpression of ZCCHC17 has been implicated in the development of certain types of cancer, such as leukemia and lymphoma.",
    "llama-7b_fact": [
      "ZCCHC17 is a gene that encodes for a protein called zinc finger CCCH-type containing 17.",
      "The protein ZCCHC17 is a member of the CCCH-type zinc finger family of transcription factors.",
      "ZCCHC17 is believed to play a role in regulating gene expression involved in cell growth, differentiation, and immune response.",
      "ZCCHC17 is expressed in various tissues and cells, including immune cells like T cells and B cells.",
      "Overexpression of ZCCHC17 has been implicated in the development of certain types of cancer, such as leukemia and lymphoma."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: ZCCHC17 is not a transcription factor but a protein that is thought to be involved in pre-mRNA splicing.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2861,
    "user_query": "You MUST give a detailed answer to the following question: Which proteins form the nuclear pore basket in human cells?",
    "llama-7b_response": "The nuclear pore complex (NPC) is a large protein complex that forms a selective barrier between the nucleus and the cytoplasm of eukaryotic cells. The NPC consists of an outer ring of approximately 30 nucleoporins (Nups) and an inner ring of approximately 80 nucleoporins.\n\nThe proteins that form the nuclear pore basket are a group of nucleoporins that are involved in the formation of the inner ring of the NPC. These proteins include:\n\n1. Nup107-160\n2. Nup153\n3. Nup214\n4. Nup215\n5. Nup231\n6. Nup232\n7. Nup233\n8. Nup234\n9. Nup235\n10. Nup236\n11. Nup237\n12. Nup238\n13. Nup239\n14. Nup240\n15. Nup241\n16. Nup242\n17. Nup243\n18. Nup244\n19. Nup245\n20. Nup246\n21. Nup247\n22. Nup248\n23. Nup249\n24. Nup250\n25. Nup251\n26. Nup252\n27. Nup253\n28. Nup254\n29. Nup255\n30. Nup256\n31. Nup257\n32. Nup258\n33. Nup259\n34. Nup260\n35. Nup261\n36. Nup262\n37. Nup263\n38. Nup264\n39. Nup265\n40. Nup266\n41. Nup267\n42. Nup268\n43. Nup269\n44. Nup270\n45. Nup",
    "llama-7b_fact_raw": "1. The nuclear pore complex (NPC) forms a selective barrier between the nucleus and the cytoplasm of eukaryotic cells.\n2. The NPC consists of an outer ring of approximately 30 nucleoporins (Nups).\n3. The inner ring of the NPC consists of approximately 80 nucleoporins.\n4. Nup107-160 is one of the proteins that form the nuclear pore basket.\n5. Nup153 is also a protein that contributes to the formation of the nuclear pore basket.",
    "llama-7b_fact": [
      "The nuclear pore complex (NPC) forms a selective barrier between the nucleus and the cytoplasm of eukaryotic cells.",
      "The NPC consists of an outer ring of approximately 30 nucleoporins (Nups).",
      "The inner ring of the NPC consists of approximately 80 nucleoporins.",
      "Nup107-160 is one of the proteins that form the nuclear pore basket.",
      "Nup153 is also a protein that contributes to the formation of the nuclear pore basket."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: The NPC does not consist of an outer ring of approximately 30 nucleoporins. The NPC is composed of multiple proteins called nucleoporins, but the number is not limited to 30 for any specific ring structure. The entire NPC is made up of around 30 different types of nucleoporins, with a total number of nucleoporins in the hundreds.\n3. FALSE [correction]: The inner ring of the NPC does not consist of approximately 80 nucleoporins. The NPC is a complex structure composed of multiple copies of around 30 different types of nucleoporins, and the inner ring structure is formed by a subset of these nucleoporins, but not specifically 80.\n4. FALSE [correction]: Nup107-160 is not one of the proteins that form the nuclear pore basket. It is part of a subcomplex that is involved in the formation of the outer rings of the NPC.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "You MUST give a detailed answer to the following question: What type of topoisomerase inhibitor is gepotidacin?",
    "llama-7b_response": "Gepotidacin is a topoisomerase I inhibitor.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2943,
    "user_query": "You MUST give a detailed answer to the following question: Describe Canvas SPW",
    "llama-7b_response": "I'm sorry, but I'm not sure what you mean by \"Canvas SPW.\" Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2960,
    "user_query": "You MUST give a detailed answer to the following question: List STING agonists.",
    "llama-7b_response": "",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 2964,
    "user_query": "You MUST give a detailed answer to the following question: Describe SLIC-CAGE",
    "llama-7b_response": "SLIC-CAGE is a method used to classify and organize software systems based on their architecture. It stands for Software Layered Infrastructure Classification and Genetic Algorithm for Evolution.\n\nThe SLIC-CAGE method uses a genetic algorithm to evolve a classification of software systems based on their architecture. The classification is based on a layered infrastructure model, which divides software systems into layers based on their functionality and the interactions between them.\n\nThe genetic algorithm used in SLIC-CAGE starts with a set of initial classifications of software systems, which are then evolved over time through a process of mutation and selection. The goal of the algorithm is to find a set of classifications that accurately reflect the architecture of the software systems and are consistent with each other.\n\nThe SLIC-CAGE method can be used to classify a wide range of software systems, including operating systems, web applications, and embedded systems. It can also be used to compare the architecture of different software systems and to identify patterns and trends in their design.\n\nOverall, SLIC-CAGE is a powerful tool for classifying and organizing software systems based on their architecture, and it has a wide range of potential applications in software engineering and research.",
    "llama-7b_fact_raw": "1. SLIC-CAGE stands for Software Layered Infrastructure Classification and Genetic Algorithm for Evolution.\n2. SLIC-CAGE uses a genetic algorithm to evolve a classification of software systems based on their architecture.\n3. The classification in SLIC-CAGE is based on a layered infrastructure model.\n4. The genetic algorithm in SLIC-CAGE involves a process of mutation and selection to evolve initial classifications.\n5. SLIC-CAGE can be used to classify various software systems, including operating systems, web applications, and embedded systems.",
    "llama-7b_fact": [
      "SLIC-CAGE stands for Software Layered Infrastructure Classification and Genetic Algorithm for Evolution.",
      "SLIC-CAGE uses a genetic algorithm to evolve a classification of software systems based on their architecture.",
      "The classification in SLIC-CAGE is based on a layered infrastructure model.",
      "The genetic algorithm in SLIC-CAGE involves a process of mutation and selection to evolve initial classifications.",
      "SLIC-CAGE can be used to classify various software systems, including operating systems, web applications, and embedded systems."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: SLIC-CAGE stands for Software Layered Infrastructure Classification with the aid of Genetic Algorithms for Evolution.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "You MUST give a detailed answer to the following question: What are the roles of LEM-3?",
    "llama-7b_response": "LEM-3, also known as Lymphoid Enhancer-Binding Factor 3, is a transcription factor that plays a crucial role in the development and function of the immune system. It is primarily expressed in lymphoid tissues, such as the thymus and bone marrow, and regulates the expression of genes involved in T cell development, B cell differentiation, and antibody production.\n\nOne of the key functions of LEM-3 is to regulate the differentiation of T cells, which are a type of white blood cell that play a central role in the immune response. LEM-3 regulates the expression of genes involved in the activation and proliferation of T cells, as well as the production of cytokines and chemokines that attract other immune cells to the site of an infection or inflammation.\n\nIn addition to its role in T cell development, LEM-3 is also involved in the differentiation of B cells, which are a type of white blood cell that produce antibodies to protect the body against infections. LEM-3 regulates the expression of genes involved in the activation and maturation of B cells, as well as the production of antibodies.\n\nOverall, LEM-3 plays a critical role in the development and function of the immune system, and its dysregulation has been implicated in a number of immune disorders, including autoimmune diseases and cancer.",
    "llama-7b_fact_raw": "1. LEM-3 is a transcription factor involved in the development and function of the immune system.\n2. It is primarily expressed in lymphoid tissues such as the thymus and bone marrow.\n3. LEM-3 regulates the expression of genes involved in T cell development and B cell differentiation.\n4. LEM-3 plays a role in the regulation of cytokines and chemokines production.\n5. Dysregulation of LEM-3 has been implicated in immune disorders, including autoimmune diseases and cancer.",
    "llama-7b_fact": [
      "LEM-3 is a transcription factor involved in the development and function of the immune system.",
      "It is primarily expressed in lymphoid tissues such as the thymus and bone marrow.",
      "LEM-3 regulates the expression of genes involved in T cell development and B cell differentiation.",
      "LEM-3 plays a role in the regulation of cytokines and chemokines production.",
      "Dysregulation of LEM-3 has been implicated in immune disorders, including autoimmune diseases and cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: LEM-3 is not a transcription factor; it is a nuclease involved in DNA repair processes.\n2. FALSE [correction]: Since LEM-3 is not a transcription factor but a nuclease, it is not primarily expressed in lymphoid tissues such as the thymus and bone marrow with the function described.\n3. FALSE [correction]: LEM-3 does not regulate the expression of genes involved in T cell development and B cell differentiation as it is not a transcription factor.\n4. FALSE [correction]: LEM-3 is not known to play a role in the regulation of cytokines and chemokines production as it is involved in DNA repair.\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "You MUST give a detailed answer to the following question: List the releases of tmVar",
    "llama-7b_response": "I'm sorry, but I'm not sure what you mean by \"tmVar.\" Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3018,
    "user_query": "You MUST give a detailed answer to the following question: Which is the database of somatic mutations in normal cells?",
    "llama-7b_response": "The database of somatic mutations in normal cells is called the Cancer Genome Atlas (TCGA). TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) to characterize the genetic changes that occur in cancer cells.\n\nTCGA collects and analyzes DNA and RNA sequencing data from tumors and normal tissue samples from patients with a wide range of cancer types. The data is used to identify somatic mutations, which are changes in the DNA or RNA that occur in cancer cells but not in normal cells.\n\nTCGA has generated a vast amount of data on somatic mutations in normal cells, which is publicly available and can be accessed through the TCGA Data Portal. Researchers can use this data to study the genetic changes that occur in normal cells and how they may contribute to the development of cancer.\n\nOverall, TCGA is an important resource for the study of somatic mutations in normal cells and their role in cancer development.",
    "llama-7b_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a database of somatic mutations in normal cells.\n2. TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n3. TCGA collects and analyzes DNA and RNA sequencing data from tumors and normal tissue samples.\n4. The data from TCGA is publicly available and can be accessed through the TCGA Data Portal.\n5. TCGA's data is used to identify somatic mutations in cancer cells and to study their role in cancer development.",
    "llama-7b_fact": [
      "The Cancer Genome Atlas (TCGA) is a database of somatic mutations in normal cells.",
      "TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "TCGA collects and analyzes DNA and RNA sequencing data from tumors and normal tissue samples.",
      "The data from TCGA is publicly available and can be accessed through the TCGA Data Portal.",
      "TCGA's data is used to identify somatic mutations in cancer cells and to study their role in cancer development."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Cancer Genome Atlas (TCGA) is a database of somatic mutations in cancer cells, not normal cells.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3037,
    "user_query": "You MUST give a detailed answer to the following question: Are there graph kernel libraries available implemented in JAVA?",
    "llama-7b_response": "",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3045,
    "user_query": "You MUST give a detailed answer to the following question: List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-7b_response": "The SHERLOCKv2 platform integrates four key advances:\n\n1. Real-time analytics: SHERLOCKv2 uses real-time analytics to process and analyze large amounts of data in real-time, allowing for faster and more accurate decision-making.\n2. Artificial intelligence and machine learning: SHERLOCKv2 incorporates artificial intelligence and machine learning algorithms to improve the accuracy and speed of threat detection and response.\n3. Automation and orchestration: SHERLOCKv2 includes automation and orchestration capabilities, allowing for more efficient and effective incident response and remediation.\n4. Open architecture and extensibility: SHERLOCKv2 has an open architecture and is extensible, allowing for easy integration with other systems and tools, as well as the ability to add new capabilities as needed.",
    "llama-7b_fact_raw": "1. SHERLOCKv2 uses real-time analytics to process and analyze data.\n2. SHERLOCKv2 incorporates artificial intelligence and machine learning algorithms.\n3. SHERLOCKv2 includes automation and orchestration capabilities for incident response.\n4. SHERLOCKv2 has an open architecture and is extensible for integration with other systems.",
    "llama-7b_fact": [
      "SHERLOCKv2 uses real-time analytics to process and analyze data.",
      "SHERLOCKv2 incorporates artificial intelligence and machine learning algorithms.",
      "SHERLOCKv2 includes automation and orchestration capabilities for incident response.",
      "SHERLOCKv2 has an open architecture and is extensible for integration with other systems."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nWithout specific context or a known reference to a system named SHERLOCKv2, it is not possible to determine the accuracy of these statements. SHERLOCKv2 could be a hypothetical or proprietary system not publicly documented as of my knowledge cutoff date.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3078,
    "user_query": "You MUST give a detailed answer to the following question: Describe the bartender algorithm",
    "llama-7b_response": "The bartender algorithm, also known as the bartender problem, is a classic problem in computer science that involves scheduling a set of tasks to be executed on a set of processors. The problem is named after the bartender problem, which is a classic problem in artificial intelligence that involves a bartender trying to serve drinks to a group of customers as efficiently as possible.\n\nThe bartender algorithm is a scheduling algorithm that is used to determine the order in which tasks should be executed on a set of processors. The algorithm works by dividing the set of tasks into groups of tasks that can be executed concurrently, and then assigning each group of tasks to a separate processor. The algorithm then assigns the next task to be executed to the processor that has the least amount of work to do.\n\nThe bartender algorithm is a simple and efficient algorithm that can be used to schedule a large number of tasks on a set of processors. The algorithm works by dividing the set of tasks into groups of tasks that can be executed concurrently, and then assigning each group of tasks to a separate processor. The algorithm then assigns the next task to be executed to the processor that has the least amount of work to do.\n\nOne of the key advantages of the bartender algorithm is that it is simple to implement and does not require any complex data structures or algorithms. The algorithm is also highly efficient and can be used to schedule a large number of tasks on a set of processors.\n\nIn conclusion, the bartender algorithm is a classic problem in computer science that involves scheduling a set of tasks to be executed on a set of processors. The algorithm works by dividing the set of tasks into groups of tasks that can be executed concurrently, and then assigning each group of tasks to a separate processor. The algorithm then assigns the next task to be executed to the processor that has the least amount of work to do. The bartender algorithm is a simple and efficient algorithm that can be used to schedule a large number of tasks on a set of processors.",
    "llama-7b_fact_raw": "1. The bartender algorithm is a scheduling algorithm used to determine the order in which tasks should be executed on a set of processors.\n2. It involves dividing the set of tasks into groups that can be executed concurrently.\n3. Each group of tasks is assigned to a separate processor.\n4. The next task is assigned to the processor with the least amount of work.\n5. The bartender algorithm is known for being simple to implement and highly efficient.",
    "llama-7b_fact": [
      "The bartender algorithm is a scheduling algorithm used to determine the order in which tasks should be executed on a set of processors.",
      "It involves dividing the set of tasks into groups that can be executed concurrently.",
      "Each group of tasks is assigned to a separate processor.",
      "The next task is assigned to the processor with the least amount of work.",
      "The bartender algorithm is known for being simple to implement and highly efficient."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: There is no widely recognized scheduling algorithm known as the \"bartender algorithm.\" It is possible that this is a fictional or less-known algorithm not established in computer science literature.\n2. UNKNOWN: Since the \"bartender algorithm\" is not established, the details of how it would divide tasks are unknown.\n3. UNKNOWN: The assignment of task groups to processors cannot be confirmed for the \"bartender algorithm.\"\n4. UNKNOWN: Without confirmation of the algorithm's existence and its methods, the process of task assignment to processors cannot be determined.\n5. FALSE [correction]: Since the \"bartender algorithm\" is not a recognized scheduling algorithm, its simplicity and efficiency cannot be confirmed.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3100,
    "user_query": "You MUST give a detailed answer to the following question: Which web-based pedigree editors are available?",
    "llama-7b_response": "There are several web-based pedigree editors available that can be used to create and edit family trees online. Some of the most popular options include:\n\n1. Geni: Geni is a free online genealogy and family history platform that allows users to create and manage their family trees. It offers a range of features, including the ability to collaborate with other users, add photos and documents, and track ancestors.\n2. WeRelate: WeRelate is a free, open-source genealogy website that allows users to create and edit family trees. It offers a range of features, including the ability to search for ancestors, add photos and documents, and collaborate with other users.\n3. FamilySearch: FamilySearch is a free online genealogy platform that allows users to create and manage their family trees. It offers a range of features, including the ability to collaborate with other users, add photos and documents, and search for ancestors.\n4. MyHeritage: MyHeritage is a paid genealogy platform that allows users to create and manage their family trees. It offers a range of features, including the ability to collaborate with other users, add photos and documents, and search for ancestors.\n5. Ancestry: Ancestry is a paid genealogy platform that allows users to create and manage their family trees. It offers a range of features, including the ability to collaborate with other users, add photos and documents, and search for ancestors.\n\nThese are just a few examples of the many web-based pedigree editors available. Each platform has its own unique features and benefits, so it's worth exploring a few options to find the one that best suits your needs.",
    "llama-7b_fact_raw": "1. Geni is a free online genealogy and family history platform that allows users to create and manage their family trees.\n2. WeRelate is a free, open-source genealogy website that enables users to create and edit family trees.\n3. FamilySearch is a free online genealogy platform that provides tools for users to create and manage their family trees.\n4. MyHeritage is a paid genealogy platform that offers services for creating and managing family trees.\n5. Ancestry is a paid genealogy platform that allows users to create and manage their family trees and offers collaborative features.",
    "llama-7b_fact": [
      "Geni is a free online genealogy and family history platform that allows users to create and manage their family trees.",
      "WeRelate is a free, open-source genealogy website that enables users to create and edit family trees.",
      "FamilySearch is a free online genealogy platform that provides tools for users to create and manage their family trees.",
      "MyHeritage is a paid genealogy platform that offers services for creating and managing family trees.",
      "Ancestry is a paid genealogy platform that allows users to create and manage their family trees and offers collaborative features."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Geni is an online genealogy platform that allows users to create and manage their family trees, but it offers both free and paid subscription options.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: MyHeritage offers both free and paid subscription options for creating and managing family trees.\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "You MUST give a detailed answer to the following question: Which curated databases exist for spider-venom toxins?",
    "llama-7b_response": "There are several curated databases that exist for spider venom toxins. Here are some of the most notable ones:\n\n1. SpiderTox: SpiderTox is a database of spider venom toxins that was developed by researchers at the University of Melbourne in Australia. It contains information on the biochemical and biological properties of spider venom toxins, as well as their potential therapeutic applications. The database includes information on toxins from a wide range of spider species, including both venomous and non-venomous spiders.\n2. Arachnovibes: Arachnovibes is a database of spider venom toxins that was developed by researchers at the University of California, Riverside. It contains information on the biochemical and biological properties of spider venom toxins, as well as their potential therapeutic applications. The database includes information on toxins from a wide range of spider species, including both venomous and non-venomous spiders.\n3. SpiderGen: SpiderGen is a database of spider venom toxins that was developed by researchers at the University of California, Los Angeles. It contains information on the biochemical and biological properties of spider venom toxins, as well as their potential therapeutic applications. The database includes information on toxins from a wide range of spider species, including both venomous and non-venomous spiders.\n4. SpiderTech: SpiderTech is a database of spider venom toxins that was developed by researchers at the University of California, Irvine. It contains information on the biochemical and biological properties of spider venom toxins, as well as their potential therapeutic applications. The database includes information on toxins from a wide range of spider species, including both venomous and non-venomous spiders.\n\nThese databases are valuable resources for researchers studying spider venom toxins, as they provide a wealth of information on the biochemical and biological properties of these toxins, as well as their potential therapeutic applications.",
    "llama-7b_fact_raw": "1. SpiderTox is a database of spider venom toxins developed by researchers at the University of Melbourne in Australia.\n2. Arachnovibes is a database of spider venom toxins developed by researchers at the University of California, Riverside.\n3. SpiderGen is a database of spider venom toxins developed by researchers at the University of California, Los Angeles.\n4. SpiderTech is a database of spider venom toxins developed by researchers at the University of California, Irvine.\n5. The databases mentioned include information on toxins from a wide range of spider species, both venomous and non-venomous.",
    "llama-7b_fact": [
      "SpiderTox is a database of spider venom toxins developed by researchers at the University of Melbourne in Australia.",
      "Arachnovibes is a database of spider venom toxins developed by researchers at the University of California, Riverside.",
      "SpiderGen is a database of spider venom toxins developed by researchers at the University of California, Los Angeles.",
      "SpiderTech is a database of spider venom toxins developed by researchers at the University of California, Irvine.",
      "The databases mentioned include information on toxins from a wide range of spider species, both venomous and non-venomous."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: ArachnoServer is a database of spider venom toxins developed by researchers at the University of Queensland in Australia.\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: The databases mentioned would likely include information on toxins from venomous spider species, as non-venomous spiders do not produce toxins that would be of interest in such databases.",
    "llama-7b_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3111,
    "user_query": "You MUST give a detailed answer to the following question: Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-7b_response": "Axitinib is a medication that is used to treat certain types of cancer, including pancreatic cancer. While there is some evidence to suggest that axitinib may be effective at prolonging survival in some patients with pancreatic cancer, the evidence is not definitive and more research is needed to fully understand its effects on survival in this population.\n\nOne study published in the journal Cancer Research in 2015 found that axitinib may be effective at prolonging survival in patients with advanced pancreatic cancer. In this study, patients who received axitinib had a median survival time of 6.1 months, compared to 4.7 months in patients who did not receive the medication. However, it is worth noting that this study was small and further research is needed to confirm these findings.\n\nAnother study published in the journal Clinical Cancer Research in 2018 found that axitinib may be effective at prolonging survival in patients with advanced pancreatic cancer who have already received chemotherapy. In this study, patients who received axitinib had a median survival time of 6.9 months, compared to 4.4 months in patients who did not receive the medication.\n\nOverall, while there is some evidence to suggest that axitinib may be effective at prolonging survival in patients with pancreatic cancer, more research is needed to fully understand its effects on survival in this population. It is important for patients to discuss the potential benefits and risks of axitinib with their healthcare provider, and to consider all available treatment options before making a decision about their care.",
    "llama-7b_fact_raw": "1. Axitinib is used to treat certain types of cancer, including pancreatic cancer.\n2. A study published in Cancer Research in 2015 suggested that axitinib might prolong survival in patients with advanced pancreatic cancer, with a median survival time of 6.1 months versus 4.7 months for those who did not receive it.\n3. The study mentioned from Cancer Research in 2015 was small, indicating a need for further research to confirm the findings.\n4. A study published in Clinical Cancer Research in 2018 also suggested that axitinib might prolong survival in patients with advanced pancreatic cancer who have received chemotherapy, with a median survival time of 6.9 months compared to 4.4 months for those who did not receive it.\n5. More research is needed to fully understand the effects of axitinib on survival in patients with pancreatic cancer.",
    "llama-7b_fact": [
      "Axitinib is used to treat certain types of cancer, including pancreatic cancer.",
      "A study published in Cancer Research in 2015 suggested that axitinib might prolong survival in patients with advanced pancreatic cancer, with a median survival time of 6.1 months versus 4.7 months for those who did not receive it.",
      "The study mentioned from Cancer Research in 2015 was small, indicating a need for further research to confirm the findings.",
      "A study published in Clinical Cancer Research in 2018 also suggested that axitinib might prolong survival in patients with advanced pancreatic cancer who have received chemotherapy, with a median survival time of 6.9 months compared to 4.4 months for those who did not receive it.",
      "More research is needed to fully understand the effects of axitinib on survival in patients with pancreatic cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Axitinib is used to treat advanced renal cell carcinoma (kidney cancer) and not specifically indicated for pancreatic cancer.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3113,
    "user_query": "You MUST give a detailed answer to the following question: Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-7b_response": "MLP (Microtubule-associated protein-like) is a protein that has been shown to play a role in regulating F-actin dynamics, which are the dynamics of the actin cytoskeleton. The actin cytoskeleton is a network of actin filaments that provides structural support to cells and plays a role in a variety of cellular processes, including cell division, cell motility, and cell shape.\n\nThere are several ways in which MLP can regulate F-actin dynamics. One way is through its interaction with the Arp2/3 complex, which is a protein complex that is involved in the formation of branched actin filaments. MLP has been shown to interact with the Arp2/3 complex and to play a role in regulating its activity, which in turn can affect the dynamics of the actin cytoskeleton.\n\nAnother way in which MLP can regulate F-actin dynamics is through its interaction with the Wiskott-Aldrich syndrome protein (WASP). WASP is a protein that is involved in the regulation of actin filament dynamics and is known to interact with the Arp2/3 complex. MLP has been shown to interact with WASP and to play a role in regulating its activity, which in turn can affect the dynamics of the actin cytoskeleton.\n\nOverall, MLP appears to regulate F-actin dynamics through its interactions with the Arp2/3 complex and WASP, which are both important players in the regulation of actin filament dynamics.",
    "llama-7b_fact_raw": "1. MLP (Microtubule-associated protein-like) plays a role in regulating F-actin dynamics.\n2. The actin cytoskeleton is a network of actin filaments that provides structural support to cells.\n3. MLP interacts with the Arp2/3 complex, which is involved in the formation of branched actin filaments.\n4. MLP's interaction with the Arp2/3 complex affects the activity of the complex and the dynamics of the actin cytoskeleton.\n5. MLP also interacts with the Wiskott-Aldrich syndrome protein (WASP), which is involved in the regulation of actin filament dynamics.",
    "llama-7b_fact": [
      "MLP (Microtubule-associated protein-like) plays a role in regulating F-actin dynamics.",
      "The actin cytoskeleton is a network of actin filaments that provides structural support to cells.",
      "MLP interacts with the Arp2/3 complex, which is involved in the formation of branched actin filaments.",
      "MLP's interaction with the Arp2/3 complex affects the activity of the complex and the dynamics of the actin cytoskeleton.",
      "MLP also interacts with the Wiskott-Aldrich syndrome protein (WASP), which is involved in the regulation of actin filament dynamics."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: MLP (Muscle LIM protein) is known for its role in the cytoarchitecture of muscle cells and does not directly regulate F-actin dynamics. It is more associated with mechanical stress response in muscle tissues. However, there are other proteins, such as MAPs (Microtubule-associated proteins), that play a role in regulating microtubules and can interact with actin filaments.\n2. TRUE\n3. UNKNOWN: Without specific information on which MLP is being referred to, it is difficult to confirm its interaction with the Arp2/3 complex. The statement may be confusing MLP with other proteins that are known to interact with the Arp2/3 complex.\n4. UNKNOWN: As the interaction of MLP with the Arp2/3 complex is not established, the effect of such an interaction on the activity of the complex and the dynamics of the actin cytoskeleton is also unknown.\n5. UNKNOWN: Similar to the previous statements, without specific information on which MLP is being referred to, it is difficult to confirm its interaction with WASP. The statement may be confusing MLP with other proteins that are known to interact with WASP and regulate actin filament dynamics.",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "You MUST give a detailed answer to the following question: How many pseudokinases are there in the human kinome?",
    "llama-7b_response": "The number of pseudokinases in the human kinome is not a fixed or well-defined quantity, as the definition of a pseudokinase can be somewhat subjective. However, it is generally accepted that pseudokinases are proteins that share structural and functional similarities with kinases, but lack the ability to phosphorylate proteins in the same way as true kinases.\n\nThere are several reasons why a protein may be classified as a pseudokinase:\n\n1. Lack of enzymatic activity: Some pseudokinases may lack the ability to phosphorylate proteins, either due to mutations that disrupt their catalytic activity or because they have evolved to perform other functions.\n2. Divergent evolution: Pseudokinases may have evolved from true kinases through a process of divergent evolution, in which they have acquired new functions or lost their enzymatic activity.\n3. Functional redundancy: In some cases, multiple proteins may share similar functions and be classified as pseudokinases, even though they have some residual enzymatic activity.\n\nThe number of pseudokinases in the human kinome is difficult to estimate with certainty, as the definition of a pseudokinase can be somewhat subjective and the boundaries between true kinases and pseudokinases can be fuzzy. However, recent studies have suggested that pseudokinases may make up a significant proportion of the human kinome, with estimates ranging from several hundred to several thousand.\n\nIt is worth noting that pseudokinases can play important roles in regulating cellular processes, even if they lack true kinase activity. For example, some pseudokinases may participate in signaling pathways by interacting with other proteins or modulating their activity, without directly phosphorylating proteins. As such, pseudokinases are an important and diverse component of the human kinome, and further research is needed to fully understand their functions and roles in cellular processes.",
    "llama-7b_fact_raw": "1. Pseudokinases are proteins that share structural and functional similarities with kinases but typically lack the ability to phosphorylate proteins.\n2. Some pseudokinases may lack enzymatic activity due to mutations or because they have evolved to perform other functions.\n3. Pseudokinases may have evolved from true kinases through a process of divergent evolution.\n4. Pseudokinases can play important roles in regulating cellular processes, even without true kinase activity.\n5. Estimates of the number of pseudokinases in the human kinome range from several hundred to several thousand.",
    "llama-7b_fact": [
      "Pseudokinases are proteins that share structural and functional similarities with kinases but typically lack the ability to phosphorylate proteins.",
      "Some pseudokinases may lack enzymatic activity due to mutations or because they have evolved to perform other functions.",
      "Pseudokinases may have evolved from true kinases through a process of divergent evolution.",
      "Pseudokinases can play important roles in regulating cellular processes, even without true kinase activity.",
      "Estimates of the number of pseudokinases in the human kinome range from several hundred to several thousand."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Estimates of the number of pseudokinases in the human kinome are generally around 10% of the approximately 500-600 human kinases, which would be around 50-60 pseudokinases, not several hundred to several thousand.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3139,
    "user_query": "You MUST give a detailed answer to the following question: List 3 apoE mimetics.",
    "llama-7b_response": "ApoE (apolipoprotein E) is a protein that plays a crucial role in the transport and metabolism of lipids in the blood. It is a major protein component of low-density lipoprotein (LDL) particles and is involved in the transport of cholesterol and other lipids throughout the body. ApoE is also involved in the regulation of immune function and has been implicated in the development of Alzheimer's disease.\n\nThere are three major isoforms of apoE: apoE2, apoE3, and apoE4. ApoE3 is the most common isoform and is associated with a lower risk of cardiovascular disease, while apoE4 is associated with an increased risk of Alzheimer's disease.\n\nMimetics are compounds or substances that mimic the function of a specific protein or hormone. Here are three examples of apoE mimetics:\n\n1. Resveratrol: Resveratrol is a polyphenol compound found in red wine, grapes, and peanuts. It has been shown to have anti-inflammatory and antioxidant properties and has been suggested as a potential therapeutic agent for the treatment of Alzheimer's disease. Resveratrol has been shown to increase the expression of apoE in the brain and has been suggested as a potential mimetic of apoE.\n2. Curcumin: Curcumin is a polyphenol compound found in the spice turmeric. It has been shown to have anti-inflammatory and antioxidant properties and has been suggested as a potential therapeutic agent for the treatment of Alzheimer's disease. Curcumin has been shown to increase the expression of apoE in the brain and has been suggested as a potential mimetic of apoE.\n3. Omega-3 fatty acids: Omega-3 fatty acids are essential fatty acids that are found in fatty fish, flaxseed, and chia seeds. They have been shown to have anti-inflammatory and neuroprotective properties and have been suggested as a potential therapeutic agent for the treatment of Alzheimer's disease. Omega-3 fatty",
    "llama-7b_fact_raw": "1. ApoE (apolipoprotein E) is involved in the transport and metabolism of lipids in the blood.\n2. There are three major isoforms of apoE: apoE2, apoE3, and apoE4.\n3. ApoE3 is associated with a lower risk of cardiovascular disease.\n4. ApoE4 is associated with an increased risk of Alzheimer's disease.\n5. Resveratrol, found in red wine, grapes, and peanuts, has been suggested as a potential apoE mimetic.",
    "llama-7b_fact": [
      "ApoE (apolipoprotein E) is involved in the transport and metabolism of lipids in the blood.",
      "There are three major isoforms of apoE: apoE2, apoE3, and apoE4.",
      "ApoE3 is associated with a lower risk of cardiovascular disease.",
      "ApoE4 is associated with an increased risk of Alzheimer's disease.",
      "Resveratrol, found in red wine, grapes, and peanuts, has been suggested as a potential apoE mimetic."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3140,
    "user_query": "You MUST give a detailed answer to the following question: What are there sex differences in SAMHD1 activity?",
    "llama-7b_response": "Sex differences in SAMHD1 activity have not been extensively studied, but there is some evidence to suggest that there may be differences in SAMHD1 activity between males and females.\n\nSAMHD1 is an RNA-dependent DNA helicase that plays a critical role in regulating the replication of HIV-1 in CD4+ T cells. It has been shown that SAMHD1 activity is high in immune cells, such as CD4+ T cells and dendritic cells, and is low in non-immune cells, such as fibroblasts and epithelial cells.\n\nStudies have shown that SAMHD1 activity is lower in the female reproductive tract compared to the male reproductive tract. This may be due to the fact that the female reproductive tract has a higher concentration of immune cells, such as CD4+ T cells and dendritic cells, which require high levels of SAMHD1 activity to prevent HIV-1 replication.\n\nIt is also worth noting that there are sex differences in the prevalence of HIV-1 infection, with HIV-1 being more prevalent in men than in women. This may be due to differences in sexual behavior, such as the number of sexual partners and the likelihood of being exposed to HIV-1.\n\nOverall, while there is some evidence to suggest that there may be sex differences in SAMHD1 activity, more research is needed to fully understand the role of SAMHD1 in regulating HIV-1 replication in males and females.",
    "llama-7b_fact_raw": "1. SAMHD1 is an RNA-dependent DNA helicase that plays a critical role in regulating the replication of HIV-1 in CD4+ T cells.\n2. SAMHD1 activity is high in immune cells, such as CD4+ T cells and dendritic cells.\n3. SAMHD1 activity is low in non-immune cells, such as fibroblasts and epithelial cells.\n4. Studies have indicated that SAMHD1 activity is lower in the female reproductive tract compared to the male reproductive tract.\n5. There are sex differences in the prevalence of HIV-1 infection, with HIV-1 being more prevalent in men than in women.",
    "llama-7b_fact": [
      "SAMHD1 is an RNA-dependent DNA helicase that plays a critical role in regulating the replication of HIV-1 in CD4+ T cells.",
      "SAMHD1 activity is high in immune cells, such as CD4+ T cells and dendritic cells.",
      "SAMHD1 activity is low in non-immune cells, such as fibroblasts and epithelial cells.",
      "Studies have indicated that SAMHD1 activity is lower in the female reproductive tract compared to the male reproductive tract.",
      "There are sex differences in the prevalence of HIV-1 infection, with HIV-1 being more prevalent in men than in women."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: SAMHD1 is a dNTP triphosphohydrolase, not an RNA-dependent DNA helicase, that plays a critical role in regulating the replication of HIV-1 in CD4+ T cells by depleting the pool of deoxynucleoside triphosphates (dNTPs) needed for viral DNA synthesis.\n2. TRUE\n3. TRUE\n4. UNKNOWN: The statement about SAMHD1 activity being lower in the female reproductive tract compared to the male reproductive tract is specific and would require direct evidence from scientific studies. Without the specific studies or data, it is not possible to determine the truth of this statement.\n5. FALSE [correction]: There are sex differences in the prevalence of HIV-1 infection, but it is generally more prevalent in women than in men, particularly in sub-Saharan Africa where the majority of people living with HIV are women. The prevalence can vary by region and is influenced by a variety of social, economic, and biological factors.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3205,
    "user_query": "You MUST give a detailed answer to the following question: Does RUNX2 inhibit astrocyte differentiation?",
    "llama-7b_response": "Yes, RUNX2 has been shown to inhibit astrocyte differentiation.\n\nRUNX2 is a transcription factor that plays a crucial role in the regulation of gene expression during embryonic development. It has been extensively studied in the context of hematopoiesis and osteogenesis, but its role in the differentiation of other cell types, including astrocytes, has also been investigated.\n\nSeveral studies have shown that RUNX2 can inhibit astrocyte differentiation. For example, in vitro experiments have demonstrated that overexpression of RUNX2 in neural progenitor cells leads to a decrease in the number of cells that differentiate into astrocytes and an increase in the number of cells that differentiate into oligodendrocytes. Similarly, knockdown of RUNX2 in astrocyte cultures has been shown to promote astrocyte differentiation.\n\nThese findings suggest that RUNX2 may play a role in regulating the balance between astrocyte and oligodendrocyte differentiation in the developing nervous system. However, the precise mechanisms by which RUNX2 regulates astrocyte differentiation are not fully understood and require further investigation.",
    "llama-7b_fact_raw": "1. RUNX2 has been shown to inhibit astrocyte differentiation.\n2. RUNX2 is a transcription factor involved in the regulation of gene expression during embryonic development.\n3. Overexpression of RUNX2 in neural progenitor cells leads to a decrease in the number of cells that differentiate into astrocytes.\n4. Overexpression of RUNX2 in neural progenitor cells leads to an increase in the number of cells that differentiate into oligodendrocytes.\n5. Knockdown of RUNX2 in astrocyte cultures promotes astrocyte differentiation.",
    "llama-7b_fact": [
      "RUNX2 has been shown to inhibit astrocyte differentiation.",
      "RUNX2 is a transcription factor involved in the regulation of gene expression during embryonic development.",
      "Overexpression of RUNX2 in neural progenitor cells leads to a decrease in the number of cells that differentiate into astrocytes.",
      "Overexpression of RUNX2 in neural progenitor cells leads to an increase in the number of cells that differentiate into oligodendrocytes.",
      "Knockdown of RUNX2 in astrocyte cultures promotes astrocyte differentiation."
    ],
    "llama-7b_judge_raw": "1. TRUE: RUNX2 has been shown to inhibit astrocyte differentiation, as it is primarily associated with osteoblast differentiation and bone formation.\n2. TRUE: RUNX2 is indeed a transcription factor that plays a critical role in the regulation of gene expression during embryonic development, particularly in the development of bone.\n3. TRUE: Given that RUNX2 inhibits astrocyte differentiation, overexpression of RUNX2 in neural progenitor cells would logically lead to a decrease in the number of cells that differentiate into astrocytes.\n4. UNKNOWN: The effect of RUNX2 overexpression on the differentiation of neural progenitor cells into oligodendrocytes is not specified in the provided statements and would require specific scientific evidence to confirm.\n5. TRUE: If RUNX2 inhibits astrocyte differentiation, then knockdown (reduction) of RUNX2 expression in astrocyte cultures would be expected to promote astrocyte differentiation, as it would remove the inhibitory effect.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "You MUST give a detailed answer to the following question: Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-7b_response": "The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the knee joint. It involves the removal of a wedge-shaped portion of the articular cartilage and underlying subchondral bone from the medial or lateral compartment of the knee joint. The procedure is typically performed on an outpatient basis under regional or general anesthesia.\n\nThe Cobb-Stainsby excision arthroplasty is typically performed on the medial or lateral compartment of the knee joint, depending on the location of the osteoarthritis. The medial compartment of the knee joint is located on the inside of the knee, and the lateral compartment is located on the outside of the knee.\n\nDuring the surgical procedure, the surgeon will make an incision over the affected knee joint and expose the joint surface. The Cobb-Stainsby excision arthroplasty involves the removal of a wedge-shaped portion of the articular cartilage and underlying subchondral bone from the medial or lateral compartment of the knee joint. The underlying bone is then resurfaced with a bone graft or a metal or plastic implant, depending on the surgeon's preference.\n\nThe Cobb-Stainsby excision arthroplasty is a surgical option for patients with osteoarthritis of the knee joint who have not responded to non-surgical treatments such as physical therapy and medications. The procedure can help reduce pain and improve knee function, but it may not be suitable for all patients and may have potential risks and complications. It is important for patients to discuss the risks and benefits of the Cobb-Stainsby excision arthroplasty with their surgeon to determine if the procedure is right for them.",
    "llama-7b_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the knee joint.\n2. The procedure involves the removal of a wedge-shaped portion of the articular cartilage and underlying subchondral bone from the knee joint.\n3. The Cobb-Stainsby excision arthroplasty can be performed on either the medial or lateral compartment of the knee joint.\n4. The procedure is typically performed on an outpatient basis under regional or general anesthesia.\n5. The Cobb-Stainsby excision arthroplasty is an option for patients with osteoarthritis of the knee joint who have not responded to non-surgical treatments.",
    "llama-7b_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the knee joint.",
      "The procedure involves the removal of a wedge-shaped portion of the articular cartilage and underlying subchondral bone from the knee joint.",
      "The Cobb-Stainsby excision arthroplasty can be performed on either the medial or lateral compartment of the knee joint.",
      "The procedure is typically performed on an outpatient basis under regional or general anesthesia.",
      "The Cobb-Stainsby excision arthroplasty is an option for patients with osteoarthritis of the knee joint who have not responded to non-surgical treatments."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure used to treat osteoarthritis of the hip joint, not the knee joint.\n2. FALSE [correction]: The procedure involves the removal of the femoral head and neck, not a wedge-shaped portion of the articular cartilage and underlying subchondral bone from the knee joint.\n3. FALSE [correction]: Since the Cobb-Stainsby excision arthroplasty is performed on the hip joint, it does not apply to the medial or lateral compartment of the knee joint.\n4. UNKNOWN: The statement about whether the procedure is typically performed on an outpatient basis under regional or general anesthesia is vague without specific medical guidelines or standards for this procedure.\n5. FALSE [correction]: The Cobb-Stainsby excision arthroplasty would be an option for patients with osteoarthritis of the hip joint who have not responded to non-surgical treatments, not the knee joint.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3243,
    "user_query": "You MUST give a detailed answer to the following question: Does GRHL2 over-expression lead to EMT?",
    "llama-7b_response": "Yes, GRHL2 over-expression can lead to epithelial-to-mesenchymal transition (EMT).\n\nGRHL2, also known as E-cadherin repressor 2, is a transcriptional repressor that plays a crucial role in the regulation of E-cadherin expression. E-cadherin is a cell-cell adhesion protein that is essential for maintaining epithelial cell structure and function. During EMT, cells lose their cell-cell adhesion and acquire a mesenchymal phenotype, which is characterized by the loss of cell-cell adhesion, the upregulation of mesenchymal markers, and the ability to migrate and invade.\n\nGRHL2 has been shown to play a crucial role in the regulation of E-cadherin expression during EMT. Over-expression of GRHL2 has been shown to lead to the down-regulation of E-cadherin expression, resulting in the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype. Furthermore, GRHL2 has also been shown to interact with and repress the transcription of the E-cadherin gene.\n\nIn summary, GRHL2 over-expression can lead to EMT by down-regulating E-cadherin expression and promoting the acquisition of a mesenchymal phenotype.",
    "llama-7b_fact_raw": "1. GRHL2 over-expression can lead to epithelial-to-mesenchymal transition (EMT).\n2. GRHL2 is also known as E-cadherin repressor 2.\n3. E-cadherin is a cell-cell adhesion protein important for maintaining epithelial cell structure and function.\n4. Over-expression of GRHL2 leads to the down-regulation of E-cadherin expression.\n5. The down-regulation of E-cadherin expression by GRHL2 results in the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype.",
    "llama-7b_fact": [
      "GRHL2 over-expression can lead to epithelial-to-mesenchymal transition (EMT).",
      "GRHL2 is also known as E-cadherin repressor 2.",
      "E-cadherin is a cell-cell adhesion protein important for maintaining epithelial cell structure and function.",
      "Over-expression of GRHL2 leads to the down-regulation of E-cadherin expression.",
      "The down-regulation of E-cadherin expression by GRHL2 results in the loss of cell-cell adhesion and the acquisition of a mesenchymal phenotype."
    ],
    "llama-7b_judge_raw": "1. TRUE: GRHL2 (Grainyhead-like transcription factor 2) over-expression has been associated with the induction of epithelial-to-mesenchymal transition (EMT), a process where epithelial cells lose their characteristics and gain mesenchymal properties.\n2. FALSE [correction]: GRHL2 is not commonly known as E-cadherin repressor 2. It is a transcription factor that can regulate various genes, including those involved in EMT. The term \"E-cadherin repressor\" is not a standard alias for GRHL2.\n3. TRUE: E-cadherin is indeed a cell-cell adhesion protein that is crucial for maintaining the structure and function of epithelial cells.\n4. TRUE: Over-expression of GRHL2 has been shown to lead to the down-regulation of E-cadherin expression, which is a hallmark event in the process of EMT.\n5. TRUE: The down-regulation of E-cadherin expression by GRHL2 or other factors results in the loss of cell-cell adhesion, which is a key step in the acquisition of a mesenchymal phenotype during EMT.",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "You MUST give a detailed answer to the following question: Which T-UCRs have been implicated in lung cancer?",
    "llama-7b_response": "T-cell receptors (TCRs) are a type of immune cell that play a crucial role in the immune system's ability to recognize and attack foreign invaders, such as viruses and bacteria. T-cell receptors are expressed on the surface of T-cells, a type of immune cell that plays a crucial role in the immune system's ability to recognize and attack foreign invaders.\n\nT-cell receptors (TCRs) are a type of immune cell that play a crucial role in the immune system's ability to recognize and attack foreign invaders, such as viruses and bacteria. T-cell receptors are expressed on the surface of T-cells, a type of immune cell that plays a crucial role in the immune system's ability to recognize and attack foreign invaders.\n\nT-cell receptors (TCRs) are a type of immune cell that play a crucial role in the immune system's ability to recognize and attack foreign invaders, such as viruses and bacteria. T-cell receptors are expressed on the surface of T-cells, a type of immune cell that plays a crucial role in the immune system's ability to recognize and attack foreign invaders.\n\nT-cell receptors (TCRs) are a type of immune cell that play a crucial role in the immune system's ability to recognize and attack foreign invaders, such as viruses and bacteria. T-cell receptors are expressed on the surface of T-cells, a type of immune cell that plays a crucial role in the immune system's ability to recognize and attack foreign invaders.\n\nT-cell receptors (TCRs) are a type of immune cell that play a crucial role in the immune system's ability to recognize and attack foreign invaders, such as viruses and bacteria. T-cell receptors are expressed on the surface of T-cells, a type of immune cell that plays a crucial role in the immune system's ability to recognize and attack foreign invaders.\n\nT-cell receptors (TCRs) are a type of immune cell that play a crucial role in the immune system'",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3268,
    "user_query": "You MUST give a detailed answer to the following question: What is known about the orphan receptor GPR151?",
    "llama-7b_response": "GPR151, also known as G protein-coupled receptor 151, is an orphan receptor that belongs to the G protein-coupled receptor (GPCR) family. GPCRs are a large family of transmembrane proteins that are activated by a variety of extracellular signals, including hormones, neurotransmitters, and other molecules. GPR151 is primarily expressed in the brain, particularly in the hippocampus and cerebral cortex, and has been implicated in a number of neurological processes, including learning and memory, anxiety, and depression. However, little is known about the function of GPR151, and further research is needed to fully understand its role in the brain.",
    "llama-7b_fact_raw": "1. GPR151 is known as G protein-coupled receptor 151.\n2. GPR151 is a member of the G protein-coupled receptor (GPCR) family.\n3. G protein-coupled receptors are activated by various extracellular signals such as hormones and neurotransmitters.\n4. GPR151 is primarily expressed in the brain, especially in the hippocampus and cerebral cortex.\n5. GPR151 has been implicated in neurological processes including learning and memory, anxiety, and depression.",
    "llama-7b_fact": [
      "GPR151 is known as G protein-coupled receptor 151.",
      "GPR151 is a member of the G protein-coupled receptor (GPCR) family.",
      "G protein-coupled receptors are activated by various extracellular signals such as hormones and neurotransmitters.",
      "GPR151 is primarily expressed in the brain, especially in the hippocampus and cerebral cortex.",
      "GPR151 has been implicated in neurological processes including learning and memory, anxiety, and depression."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3285,
    "user_query": "You MUST give a detailed answer to the following question: List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-7b_response": "The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses of four influenza strains: influenza virus type A/California/7/2009 (H1N1), influenza virus type A/Victoria/361/2011 (H1N1), influenza virus type A/Perth/16/2009 (H3N2), and influenza virus type B/Brisbane/60/2008.",
    "llama-7b_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses.\n2. The vaccine includes the influenza virus type A/California/7/2009 (H1N1) strain.\n3. The vaccine includes the influenza virus type A/Victoria/361/2011 (H1N1) strain.\n4. The vaccine includes the influenza virus type A/Perth/16/2009 (H3N2) strain.\n5. The vaccine includes the influenza virus type B/Brisbane/60/2008 strain.",
    "llama-7b_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains attenuated live viruses.",
      "The vaccine includes the influenza virus type A/California/7/2009 (H1N1) strain.",
      "The vaccine includes the influenza virus type A/Victoria/361/2011 (H1N1) strain.",
      "The vaccine includes the influenza virus type A/Perth/16/2009 (H3N2) strain.",
      "The vaccine includes the influenza virus type B/Brisbane/60/2008 strain."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains inactivated (killed) viruses, not attenuated live viruses.\n2. TRUE\n3. FALSE [correction]: The influenza virus type A/Victoria/361/2011 is an H3N2 strain, not an H1N1 strain.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3345,
    "user_query": "You MUST give a detailed answer to the following question: Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-7b_response": "The TNFR2 gene, also known as the tumor necrosis factor receptor 2 gene, is associated with systemic lupus erythematosus (SLE) through several genetic variants. SLE is an autoimmune disorder in which the immune system attacks healthy cells and tissues in the body, leading to inflammation and damage to various organs and tissues.\n\nOne of the genetic variants associated with SLE is a single nucleotide polymorphism (SNP) located in the promoter region of the TNFR2 gene. This SNP, known as -138G/A, has been found to be associated with an increased risk of developing SLE. The -138G/A SNP alters the binding of transcription factors to the promoter region of the TNFR2 gene, leading to altered expression of the TNFR2 gene and potentially increased susceptibility to SLE.\n\nAnother genetic variant associated with SLE is a copy number variation (CNV) in the TNFR2 gene. This CNV involves duplication of a region of the TNFR2 gene, leading to increased expression of the TNFR2 gene and potentially increased susceptibility to SLE.\n\nOverall, the TNFR2 gene is genetically associated with SLE through both SNPs and CNVs, with the -138G/A SNP and the TNFR2 CNV being the most well-studied genetic variants associated with SLE.",
    "llama-7b_fact_raw": "1. The TNFR2 gene is associated with systemic lupus erythematosus (SLE).\n2. A single nucleotide polymorphism (SNP) in the promoter region of the TNFR2 gene, known as -138G/A, is associated with an increased risk of developing SLE.\n3. The -138G/A SNP affects the binding of transcription factors to the promoter region of the TNFR2 gene.\n4. A copy number variation (CNV) in the TNFR2 gene, involving duplication, is associated with increased expression of the TNFR2 gene and potentially increased susceptibility to SLE.\n5. Both SNPs and CNVs in the TNFR2 gene contribute to the genetic association with SLE.",
    "llama-7b_fact": [
      "The TNFR2 gene is associated with systemic lupus erythematosus (SLE).",
      "A single nucleotide polymorphism (SNP) in the promoter region of the TNFR2 gene, known as -138G/A, is associated with an increased risk of developing SLE.",
      "The -138G/A SNP affects the binding of transcription factors to the promoter region of the TNFR2 gene.",
      "A copy number variation (CNV) in the TNFR2 gene, involving duplication, is associated with increased expression of the TNFR2 gene and potentially increased susceptibility to SLE.",
      "Both SNPs and CNVs in the TNFR2 gene contribute to the genetic association with SLE."
    ],
    "llama-7b_judge_raw": "1. TRUE: The TNFR2 gene has been associated with systemic lupus erythematosus (SLE) in various studies, suggesting a link between the gene and the disease.\n2. UNKNOWN: Without specific scientific literature or studies to confirm the association of the -138G/A SNP in the promoter region of the TNFR2 gene with SLE, the truth of this statement cannot be determined.\n3. UNKNOWN: The effect of the -138G/A SNP on the binding of transcription factors to the promoter region of the TNFR2 gene would require specific experimental evidence to confirm, which is not provided here.\n4. UNKNOWN: The association of a copy number variation (CNV) in the TNFR2 gene with increased expression and susceptibility to SLE would need to be supported by scientific research, which is not referenced in the statement.\n5. UNKNOWN: While both SNPs and CNVs can contribute to genetic associations with diseases, the specific contribution of these genetic variations in the TNFR2 gene to SLE would need to be substantiated by scientific evidence.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "You MUST give a detailed answer to the following question: Is there a vaccine for peanut allergy?",
    "llama-7b_response": "No, there is currently no vaccine for peanut allergy. Peanut allergy is an immune system disorder that affects the way the body responds to proteins found in peanuts and other nuts. It is caused by an overreaction of the immune system to these proteins, which can lead to a range of symptoms including itching, hives, difficulty breathing, and anaphylaxis.\n\nWhile there are treatments available for peanut allergy, such as epinephrine and antihistamines, there is currently no cure or vaccine for the condition. Researchers are working on developing a vaccine, but it is still in the early stages of development and has not yet been approved for use.",
    "llama-7b_fact_raw": "1. There is currently no vaccine for peanut allergy.\n2. Peanut allergy is an immune system disorder.\n3. Symptoms of peanut allergy can include itching, hives, difficulty breathing, and anaphylaxis.\n4. Treatments available for peanut allergy include epinephrine and antihistamines.\n5. Researchers are working on developing a vaccine for peanut allergy, but it has not yet been approved for use.",
    "llama-7b_fact": [
      "There is currently no vaccine for peanut allergy.",
      "Peanut allergy is an immune system disorder.",
      "Symptoms of peanut allergy can include itching, hives, difficulty breathing, and anaphylaxis.",
      "Treatments available for peanut allergy include epinephrine and antihistamines.",
      "Researchers are working on developing a vaccine for peanut allergy, but it has not yet been approved for use."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "You MUST give a detailed answer to the following question: What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-7b_response": "The mouse Fxy gene is located on the X chromosome, which is one of the two sex chromosomes in mice. Female mice have two X chromosomes, while male mice have one X chromosome and one Y chromosome.\n\nThe position of the Fxy gene on the X chromosome is particular because it is located in a region that is known to be prone to rearrangements and deletions, which can lead to genetic abnormalities. This region of the X chromosome is known as the \"X-inactivation center\" and is responsible for the process of X-chromosome inactivation, which occurs during embryonic development in female mice.\n\nDuring inactivation, one of the two X chromosomes in female mice is randomly chosen to be silenced, while the other X chromosome is maintained in an active state. This process helps to prevent the expression of X-linked genes from interfering with the expression of genes on the active X chromosome.\n\nThe Fxy gene is located near the center of the X-inactivation center, which means that it is at a higher risk of being inactivated than other genes on the X chromosome. This is because the X-inactivation center is a hotspot for genetic rearrangements and deletions, which can lead to the inactivation of genes in this region.\n\nOverall, the position of the Fxy gene on the X chromosome is particular because it is located in a region that is prone to genetic rearrangements and deletions, which can lead to genetic abnormalities and increase the risk of the gene being inactivated during embryonic development.",
    "llama-7b_fact_raw": "1. The mouse Fxy gene is located on the X chromosome.\n2. Female mice have two X chromosomes, while male mice have one X chromosome and one Y chromosome.\n3. The region of the X chromosome where the Fxy gene is located is known as the \"X-inactivation center.\"\n4. The X-inactivation center is responsible for the process of X-chromosome inactivation during embryonic development in female mice.\n5. The Fxy gene is at a higher risk of being inactivated due to its proximity to the center of the X-inactivation center, which is a hotspot for genetic rearrangements and deletions.",
    "llama-7b_fact": [
      "The mouse Fxy gene is located on the X chromosome.",
      "Female mice have two X chromosomes, while male mice have one X chromosome and one Y chromosome.",
      "The region of the X chromosome where the Fxy gene is located is known as the \"X-inactivation center.\"",
      "The X-inactivation center is responsible for the process of X-chromosome inactivation during embryonic development in female mice.",
      "The Fxy gene is at a higher risk of being inactivated due to its proximity to the center of the X-inactivation center, which is a hotspot for genetic rearrangements and deletions."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: The region of the X chromosome where the Fxy gene is located is not known as the \"X-inactivation center.\" The correct term for the region responsible for X-chromosome inactivation is the \"X-inactivation center\" or \"XIC,\" but without specific knowledge about the Fxy gene's location, it cannot be confirmed to be in the XIC.\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "You MUST give a detailed answer to the following question: What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-7b_response": "Methylation propyl-EDTA sequencing (MPE-seq) is a method used to study DNA methylation, which is the addition of a methyl group to cytosine residues in the DNA molecule. The method involves the use of a compound called methyl-propyl-EDTA, which is a derivative of EDTA (ethylenediaminetetraacetic acid).\n\nThe basis of the MPE-seq method is the ability of methyl-propyl-EDTA to recognize and bind to methylated cytosine residues in the DNA molecule. Methyl-propyl-EDTA has a negatively charged nitrogen atom that can interact with the positively charged methyl group on the cytosine residue. This interaction results in the formation of a stable complex between the methyl-propyl-EDTA and the methylated cytosine residue.\n\nTo perform MPE-seq, DNA samples are first treated with methyl-propyl-EDTA to form complexes between the methyl-propyl-EDTA and the methylated cytosine residues. The complexes are then isolated and purified, and the DNA is released from the complexes. The purified complexes are then subjected to mass spectrometry analysis to determine the sequence of the DNA molecule.\n\nThe mass spectrometry analysis involves the use of a mass spectrometer to measure the mass-to-charge ratio of the complexes. The mass-to-charge ratio of the complexes is determined by the mass of the methyl-propyl-EDTA molecule and the number of methylated cytosine residues in the DNA molecule. By comparing the mass-to-charge ratios of the complexes from different DNA samples, it is possible to determine the sequence of the DNA molecule.\n\nOverall, the basis of the MPE-seq method is the ability of methyl-propyl-EDTA to recognize and bind to methylated cytosine residues in the DNA molecule, allowing for the sequencing of DNA molecules using mass spectrometry analysis.",
    "llama-7b_fact_raw": "1. Methylation propyl-EDTA sequencing (MPE-seq) is used to study DNA methylation, specifically the addition of a methyl group to cytosine residues in DNA.\n2. Methyl-propyl-EDTA, a derivative of EDTA, is used in MPE-seq to recognize and bind to methylated cytosine residues.\n3. In MPE-seq, DNA samples are treated with methyl-propyl-EDTA to form complexes with methylated cytosine residues.\n4. The complexes formed in MPE-seq are isolated, purified, and then subjected to mass spectrometry analysis to determine the DNA sequence.\n5. The mass spectrometry analysis in MPE-seq measures the mass-to-charge ratio of the complexes to determine the sequence of the DNA molecule.",
    "llama-7b_fact": [
      "Methylation propyl-EDTA sequencing (MPE-seq) is used to study DNA methylation, specifically the addition of a methyl group to cytosine residues in DNA.",
      "Methyl-propyl-EDTA, a derivative of EDTA, is used in MPE-seq to recognize and bind to methylated cytosine residues.",
      "In MPE-seq, DNA samples are treated with methyl-propyl-EDTA to form complexes with methylated cytosine residues.",
      "The complexes formed in MPE-seq are isolated, purified, and then subjected to mass spectrometry analysis to determine the DNA sequence.",
      "The mass spectrometry analysis in MPE-seq measures the mass-to-charge ratio of the complexes to determine the sequence of the DNA molecule."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The correct term is \"Methylated DNA immunoprecipitation sequencing (MeDIP-seq)\" which is used to study DNA methylation, specifically the addition of a methyl group to cytosine residues in DNA.\n2. FALSE [correction]: There is no known derivative of EDTA called methyl-propyl-EDTA used in DNA methylation studies. In MeDIP-seq, an antibody specific to methylated cytosine is used to immunoprecipitate the methylated DNA fragments.\n3. FALSE [correction]: In MeDIP-seq, DNA samples are treated with an antibody that specifically binds to methylated cytosine residues, not with a compound called methyl-propyl-EDTA.\n4. TRUE: In MeDIP-seq, the methylated DNA fragments bound by the antibody are indeed isolated, purified, and then subjected to sequencing analysis to determine the DNA sequence.\n5. FALSE [correction]: In MeDIP-seq, the sequencing analysis is typically performed using next-generation sequencing (NGS) technologies, not mass spectrometry. The NGS reads the sequence of the DNA molecule, not by measuring the mass-to-charge ratio of complexes.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3400,
    "user_query": "You MUST give a detailed answer to the following question: Which programming language has been used for implementing GWAR?",
    "llama-7b_response": "I'm sorry, but I'm not sure what you mean by \"GWAR.\" Could you please provide more context or clarify your question?",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3406,
    "user_query": "You MUST give a detailed answer to the following question: Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-7b_response": "Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, leading to muscle weakness and eventual paralysis. There is currently no cure for ALS, and the prognosis is typically poor, with a median survival time of 2-5 years from the onset of symptoms.\n\nXaliproden is a drug that has been investigated for its potential to slow the progression of ALS. It is a selective agonist of the melanocortin-4 receptor (MC-4R), which is a G-protein-coupled receptor that is expressed in several tissues, including the brain. Activation of the MC-4R has been shown to have neuroprotective effects in animal models of ALS, by reducing inflammation and promoting the survival of motor neurons.\n\nSeveral studies have investigated the use of xaliproden in patients with ALS, with mixed results. Some studies have reported that xaliproden may slow the progression of ALS, as measured by the rate of decline in muscle strength and function, as well as the duration of survival after the onset of symptoms. However, other studies have not found any beneficial effects of xaliproden on the prognosis of ALS.\n\nIn summary, while some studies have suggested that xaliproden may improve the prognosis of ALS, the evidence is not conclusive. Further research is needed to determine the efficacy and safety of xaliproden in patients with ALS.",
    "llama-7b_fact_raw": "1. Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.\n2. The median survival time of ALS from the onset of symptoms is 2-5 years.\n3. Xaliproden is a selective agonist of the melanocortin-4 receptor (MC-4R).\n4. Activation of the MC-4R has been shown to have neuroprotective effects in animal models of ALS.\n5. Studies on xaliproden have shown mixed results regarding its ability to slow the progression of ALS.",
    "llama-7b_fact": [
      "Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord.",
      "The median survival time of ALS from the onset of symptoms is 2-5 years.",
      "Xaliproden is a selective agonist of the melanocortin-4 receptor (MC-4R).",
      "Activation of the MC-4R has been shown to have neuroprotective effects in animal models of ALS.",
      "Studies on xaliproden have shown mixed results regarding its ability to slow the progression of ALS."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Xaliproden is not a selective agonist of the melanocortin-4 receptor (MC-4R). It is a compound that was investigated for its potential neuroprotective and neurotrophic effects in various neurological conditions, including ALS.\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "You MUST give a detailed answer to the following question: In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-7b_response": "In the case of the LiPS-A3S line, the transgenes are inserted into the X chromosome.",
    "llama-7b_fact_raw": "1. In the LiPS-A3S line, transgenes are inserted into the X chromosome.",
    "llama-7b_fact": [
      "In the LiPS-A3S line, transgenes are inserted into the X chromosome."
    ],
    "llama-7b_judge_raw": "UNKNOWN\n\nWithout additional context or information about the \"LiPS-A3S line\" and the specifics of the transgenes insertion, it is not possible to determine the accuracy of this statement.",
    "llama-7b_judge": [
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "You MUST give a detailed answer to the following question: Which tool exist for predicting drug synergy with deep learning?",
    "llama-7b_response": "There are several tools that exist for predicting drug synergy with deep learning, including:\n\n1. DeepDrug: This is a deep learning-based approach for predicting drug-target interactions. It uses a neural network to predict the binding affinity of small molecules to a given protein target.\n2. DrugPredict: This is a machine learning-based approach for predicting drug-target interactions. It uses a random forest classifier to predict the binding affinity of small molecules to a given protein target.\n3. SynergyNet: This is a deep learning-based approach for predicting drug synergy. It uses a neural network to predict the effect of combining two drugs on the growth of cancer cells.\n4. DrugSynth: This is a machine learning-based approach for predicting drug synergy. It uses a random forest classifier to predict the effect of combining two drugs on the growth of cancer cells.\n\nOverall, there are several tools available for predicting drug synergy with deep learning, each with its own strengths and weaknesses. The choice of tool will depend on the specific application and the available data.",
    "llama-7b_fact_raw": "1. DeepDrug is a deep learning-based tool for predicting drug-target interactions.\n2. DrugPredict uses a random forest classifier to predict drug-target interactions.\n3. SynergyNet is a deep learning-based tool for predicting the effect of drug combinations on cancer cell growth.\n4. DrugSynth uses a random forest classifier to predict the effect of drug combinations on cancer cell growth.",
    "llama-7b_fact": [
      "DeepDrug is a deep learning-based tool for predicting drug-target interactions.",
      "DrugPredict uses a random forest classifier to predict drug-target interactions.",
      "SynergyNet is a deep learning-based tool for predicting the effect of drug combinations on cancer cell growth.",
      "DrugSynth uses a random forest classifier to predict the effect of drug combinations on cancer cell growth."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "You MUST give a detailed answer to the following question: Which cloud-based platform has been developed for comparing GWAS?",
    "llama-7b_response": "There are several cloud-based platforms that have been developed for comparing genome-wide association studies (GWAS), including:\n\n1. The National Center for Biotechnology Information's (NCBI) dbGaP (Database of Genotypes and Phenotypes): dbGaP is a public database that provides access to genotype and phenotype data from large-scale genetic studies, including GWAS. Researchers can use dbGaP to compare GWAS data from different studies and identify potential genetic associations.\n2. The National Institutes of Health's (NIH) National Center for Biotechnology Information's (NCBI) Gene Expression Omnibus (GEO): GEO is a public database that provides access to gene expression data from a variety of studies, including GWAS. Researchers can use GEO to compare gene expression data from different studies and identify potential genetic associations.\n3. The European Bioinformatics Institute's (EBI) ArrayExpress: ArrayExpress is a public database that provides access to array-based gene expression data from a variety of studies, including GWAS. Researchers can use ArrayExpress to compare gene expression data from different studies and identify potential genetic associations.\n\nOverall, these cloud-based platforms provide researchers with the tools they need to compare GWAS data and identify potential genetic associations.",
    "llama-7b_fact_raw": "1. The National Center for Biotechnology Information's dbGaP is a public database for accessing genotype and phenotype data from genetic studies.\n2. dbGaP allows researchers to compare GWAS data from different studies.\n3. The National Institutes of Health's Gene Expression Omnibus is a public database for accessing gene expression data.\n4. Researchers can use the Gene Expression Omnibus to compare gene expression data from different GWAS.\n5. The European Bioinformatics Institute's ArrayExpress is a public database that provides access to array-based gene expression data from studies including GWAS.",
    "llama-7b_fact": [
      "The National Center for Biotechnology Information's dbGaP is a public database for accessing genotype and phenotype data from genetic studies.",
      "dbGaP allows researchers to compare GWAS data from different studies.",
      "The National Institutes of Health's Gene Expression Omnibus is a public database for accessing gene expression data.",
      "Researchers can use the Gene Expression Omnibus to compare gene expression data from different GWAS.",
      "The European Bioinformatics Institute's ArrayExpress is a public database that provides access to array-based gene expression data from studies including GWAS."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Researchers can use the Gene Expression Omnibus to compare gene expression data from different studies, but not specifically from GWAS, as GWAS refers to genome-wide association studies which focus on genetic variants across the genome and their association with traits, rather than gene expression.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3434,
    "user_query": "You MUST give a detailed answer to the following question: Can CMB305 be used against sarcomas?",
    "llama-7b_response": "CMB305 is a monoclonal antibody that is currently being studied for its potential use in the treatment of various types of cancer, including sarcomas. Sarcomas are a type of cancer that develops in the soft tissues of the body, such as muscles, tendons, and fat, as well as in the bones and cartilage.\n\nCMB305 is an antibody that is designed to target a protein called CD47, which is a \"don't eat me\" signal that is often expressed on the surface of cancer cells, including sarcoma cells. When CMB305 binds to CD47 on the surface of sarcoma cells, it tags the cells for destruction by the body's immune system. This can help to stimulate an immune response against the cancer cells and potentially lead to their destruction.\n\nWhile CMB305 has shown promise in preclinical studies as a potential treatment for sarcomas, it has not yet been tested in clinical trials in patients with this type of cancer. Therefore, it is not yet clear whether CMB305 will be effective in the treatment of sarcomas or whether it will have any side effects.\n\nIt is important for anyone considering the use of CMB305 or any other treatment for sarcomas to discuss their options with their healthcare provider and to carefully consider the potential benefits and risks of the treatment.",
    "llama-7b_fact_raw": "1. CMB305 is a monoclonal antibody being studied for the treatment of various types of cancer, including sarcomas.\n2. Sarcomas are a type of cancer that develops in soft tissues like muscles, tendons, and fat, as well as bones and cartilage.\n3. CMB305 targets a protein called CD47, which is expressed on the surface of cancer cells, including sarcoma cells.\n4. CMB305 has shown promise in preclinical studies as a potential treatment for sarcomas.\n5. CMB305 has not yet been tested in clinical trials for patients with sarcomas.",
    "llama-7b_fact": [
      "CMB305 is a monoclonal antibody being studied for the treatment of various types of cancer, including sarcomas.",
      "Sarcomas are a type of cancer that develops in soft tissues like muscles, tendons, and fat, as well as bones and cartilage.",
      "CMB305 targets a protein called CD47, which is expressed on the surface of cancer cells, including sarcoma cells.",
      "CMB305 has shown promise in preclinical studies as a potential treatment for sarcomas.",
      "CMB305 has not yet been tested in clinical trials for patients with sarcomas."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific and current information on the development of CMB305, it is not possible to verify the accuracy of statements 1, 3, 4, and 5. These details would require access to the latest scientific research or clinical trial data.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "You MUST give a detailed answer to the following question: What are manifestations of the Saint's Triad?",
    "llama-7b_response": "The manifestations of the Saint's Triad refer to the various ways in which the three aspects of the divine - the Father, the Son, and the Holy Spirit - can be experienced and expressed in the world. These manifestations can take many different forms, and can vary depending on the cultural and religious context in which they are encountered.\n\nOne common manifestation of the Saint's Triad is through prayer and worship. In many religious traditions, prayer and worship are seen as ways of experiencing and expressing the presence of the divine. Prayer can take many different forms, such as silent meditation, spoken words, or sung hymns, and can be directed towards the Father, the Son, or the Holy Spirit, or all three. Worship can also take many different forms, such as singing, dancing, or offering gifts, and can be seen as a way of honoring and glorifying the divine.\n\nAnother manifestation of the Saint's Triad is through acts of service and compassion. In many religious traditions, acts of service and compassion are seen as ways of expressing the love and grace of the divine. These acts can take many different forms, such as feeding the hungry, clothing the naked, or visiting the sick and imprisoned. They can also include more abstract forms of service, such as advocating for social justice or working to protect the environment.\n\nA third manifestation of the Saint's Triad is through the experience of spiritual gifts. In many religious traditions, spiritual gifts are seen as ways in which the divine can be experienced and expressed in the world. These gifts can take many different forms, such as prophecy, healing, or speaking in tongues, and can be seen as evidence of the presence and power of the divine.\n\nOverall, the manifestations of the Saint's Triad can be seen as different ways in which the divine can be experienced and expressed in the world. They can take many different forms, and can vary depending on the cultural and religious context in which they are encountered.",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3470,
    "user_query": "You MUST give a detailed answer to the following question: Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-7b_response": "Overexpression of LY6K has not been consistently associated with better prognosis for non-small cell lung cancer (NSCLC) patients. While some studies have suggested that high levels of LY6K may be associated with improved survival in NSCLC, other studies have found no such association or have even suggested that high levels of LY6K may be associated with worse outcomes.\n\nOne study published in the journal Cancer Research in 2016 found that high levels of LY6K were associated with improved overall survival in patients with NSCLC. The study included 186 patients with NSCLC and found that those with high levels of LY6K had a significantly better overall survival compared to those with low levels of LY6K.\n\nHowever, another study published in the journal Clinical Cancer Research in 2018 found no association between LY6K expression and overall survival in patients with NSCLC. The study included 422 patients with NSCLC and found that high levels of LY6K were not associated with improved overall survival.\n\nAdditionally, a study published in the journal Oncotarget in 2019 found that high levels of LY6K were associated with worse overall survival in patients with NSCLC. The study included 402 patients with NSCLC and found that high levels of LY6K were associated with worse overall survival, even after adjusting for other factors that may affect survival.\n\nOverall, the available evidence is not consistent in terms of whether overexpression of LY6K is associated with better or worse prognosis for NSCLC patients. Further research is needed to better understand the role of LY6K in NSCLC and its potential as a prognostic factor.",
    "llama-7b_fact_raw": "1. Some studies have suggested that high levels of LY6K may be associated with improved survival in non-small cell lung cancer (NSCLC) patients.\n2. A study published in the journal Cancer Research in 2016 found that patients with NSCLC who had high levels of LY6K had a significantly better overall survival compared to those with low levels of LY6K.\n3. Another study published in the journal Clinical Cancer Research in 2018 found no association between LY6K expression and overall survival in patients with NSCLC.\n4. A study published in the journal Oncotarget in 2019 found that high levels of LY6K were associated with worse overall survival in patients with NSCLC.\n5. The evidence regarding the association of LY6K overexpression with the prognosis for NSCLC patients is inconsistent, and further research is needed.",
    "llama-7b_fact": [
      "Some studies have suggested that high levels of LY6K may be associated with improved survival in non-small cell lung cancer (NSCLC) patients.",
      "A study published in the journal Cancer Research in 2016 found that patients with NSCLC who had high levels of LY6K had a significantly better overall survival compared to those with low levels of LY6K.",
      "Another study published in the journal Clinical Cancer Research in 2018 found no association between LY6K expression and overall survival in patients with NSCLC.",
      "A study published in the journal Oncotarget in 2019 found that high levels of LY6K were associated with worse overall survival in patients with NSCLC.",
      "The evidence regarding the association of LY6K overexpression with the prognosis for NSCLC patients is inconsistent, and further research is needed."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: High levels of LY6K are generally associated with poor prognosis in non-small cell lung cancer (NSCLC) patients, not improved survival.\n2. FALSE [correction]: A study published in the journal Cancer Research in 2016 would likely have found that high levels of LY6K are associated with worse overall survival, not better, as LY6K overexpression is often linked to poor outcomes in cancer.\n3. UNKNOWN: Without access to the specific study from Clinical Cancer Research in 2018, it is not possible to confirm the findings regarding LY6K expression and overall survival in NSCLC patients.\n4. TRUE: This statement is consistent with the general scientific consensus that high levels of LY6K are associated with worse outcomes in NSCLC.\n5. TRUE: Given the conflicting statements provided, it is reasonable to conclude that the evidence regarding LY6K overexpression and prognosis in NSCLC patients is inconsistent, and further research would be needed to clarify the association.",
    "llama-7b_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "You MUST give a detailed answer to the following question: List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-7b_response": "Cdk targets that are dephosphorylated during cytokinesis include:\n\n1. Cyclin B1: Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis, leading to its degradation by the ubiquitin-proteasome pathway.\n2. Plk1: Plk1 is dephosphorylated by Cdk1 during cytokinesis, leading to its inactivation and the completion of mitotic spindle assembly.\n3. Aurora B: Aurora B is dephosphorylated by Cdk1 during cytokinesis, leading to its activation and the completion of chromosome segregation.\n4. Cdc20: Cdc20 is dephosphorylated by Cdk1 during cytokinesis, leading to its release from securin and its activation of the anaphase-promoting complex/cyclosome (APC/C) for the degradation of securin and other inhibitors of mitosis.\n5. Cdc25C: Cdc25C is dephosphorylated by Cdk1 during cytokinesis, leading to its activation and the completion of mitotic exit.\n\nThese Cdk targets are dephosphorylated by Cdk1 during cytokinesis, allowing for the completion of cell division and the formation of two daughter cells.",
    "llama-7b_fact_raw": "1. Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis.\n2. Plk1 is dephosphorylated by Cdk1 during cytokinesis.\n3. Aurora B is dephosphorylated by Cdk1 during cytokinesis.\n4. Cdc20 is dephosphorylated by Cdk1 during cytokinesis.\n5. Cdc25C is dephosphorylated by Cdk1 during cytokinesis.",
    "llama-7b_fact": [
      "Cyclin B1 is dephosphorylated by Cdk1 during cytokinesis.",
      "Plk1 is dephosphorylated by Cdk1 during cytokinesis.",
      "Aurora B is dephosphorylated by Cdk1 during cytokinesis.",
      "Cdc20 is dephosphorylated by Cdk1 during cytokinesis.",
      "Cdc25C is dephosphorylated by Cdk1 during cytokinesis."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Cyclin B1 is not dephosphorylated by Cdk1 during cytokinesis; rather, it is targeted for degradation by the anaphase-promoting complex/cyclosome (APC/C) in conjunction with Cdc20 to allow exit from mitosis.\n2. UNKNOWN: The phosphorylation status of Plk1 (Polo-like kinase 1) during cytokinesis and its relationship with Cdk1 (Cyclin-dependent kinase 1) is complex and context-dependent, and without specific context, it is difficult to determine the accuracy of this statement.\n3. FALSE [correction]: Aurora B is not dephosphorylated by Cdk1 during cytokinesis. Aurora B is a kinase itself and is part of the chromosomal passenger complex that is involved in regulating various processes during mitosis and cytokinesis.\n4. FALSE [correction]: Cdc20 is not dephosphorylated by Cdk1 during cytokinesis. Cdc20 is an activator of the anaphase-promoting complex/cyclosome (APC/C), which is responsible for the ubiquitination and subsequent degradation of specific proteins to regulate the cell cycle.\n5. FALSE [correction]: Cdc25C is a phosphatase that activates Cdk1 by dephosphorylating it, not the other way around. Cdc25C itself is regulated by phosphorylation, but not directly by Cdk1 during cytokinesis.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3508,
    "user_query": "You MUST give a detailed answer to the following question: What is Xanamem?",
    "llama-7b_response": "Xanamem is a medication that is used to treat the symptoms of mild to moderate Alzheimer's disease. It is a type of drug called a cholinesterase inhibitor, which works by increasing the levels of a chemical called acetylcholine in the brain. Acetylcholine is a neurotransmitter that is important for memory and cognitive function.\n\nXanamem is different from other cholinesterase inhibitors, such as donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), in that it also inhibits the enzyme butyrylcholinesterase. Butyrylcholinesterase is an enzyme that breaks down acetylcholine, so by inhibiting it, Xanamem can increase the levels of acetylcholine in the brain for a longer period of time.\n\nXanamem was approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of Alzheimer's disease. It is available in tablet form and is usually taken twice a day, with meals. Like other cholinesterase inhibitors, Xanamem may cause side effects such as nausea, diarrhea, and vomiting. It is important for patients to discuss any side effects they experience with their healthcare provider.",
    "llama-7b_fact_raw": "1. Xanamem is used to treat the symptoms of mild to moderate Alzheimer's disease.\n2. Xanamem is a cholinesterase inhibitor that increases levels of acetylcholine in the brain.\n3. Xanamem also inhibits the enzyme butyrylcholinesterase.\n4. The U.S. Food and Drug Administration (FDA) approved Xanamem for the treatment of Alzheimer's disease in 2018.\n5. Xanamem is available in tablet form and is typically taken twice a day with meals.",
    "llama-7b_fact": [
      "Xanamem is used to treat the symptoms of mild to moderate Alzheimer's disease.",
      "Xanamem is a cholinesterase inhibitor that increases levels of acetylcholine in the brain.",
      "Xanamem also inhibits the enzyme butyrylcholinesterase.",
      "The U.S. Food and Drug Administration (FDA) approved Xanamem for the treatment of Alzheimer's disease in 2018.",
      "Xanamem is available in tablet form and is typically taken twice a day with meals."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: Xanamem is not a cholinesterase inhibitor; it is designed to block the production of excess cortisol by inhibiting the activity of the enzyme 11-HSD1.\n3. UNKNOWN\n4. FALSE [correction]: As of my knowledge cutoff in 2023, Xanamem has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.\n5. UNKNOWN",
    "llama-7b_judge": [
      "unknown",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-7b_response": "The Hof1-Cyk3 interaction plays a crucial role in regulating the cellular response to oxidative stress in yeast. Hof1 is a ubiquitin-conjugating enzyme that adds ubiquitin molecules to other proteins, marking them for degradation by the proteasome. Cyk3 is a member of the cytochrome c oxidase complex, which is responsible for generating ATP through the oxidation of molecular oxygen.\n\nWhen cells are exposed to oxidative stress, such as when they are subjected to high levels of reactive oxygen species (ROS), the Hof1-Cyk3 interaction is activated. This interaction causes Hof1 to transfer ubiquitin molecules to Cyk3, marking it for degradation by the proteasome. The degradation of Cyk3 leads to a decrease in the production of ATP through the cytochrome c oxidase complex, which in turn reduces the cell's ability to generate energy and respond to oxidative stress.\n\nThe activation of the Hof1-Cyk3 interaction in response to oxidative stress is thought to play a role in protecting the cell from damage caused by ROS. By reducing the activity of the cytochrome c oxidase complex, the cell is able to reduce the production of reactive oxygen species and limit the damage caused by oxidative stress.\n\nOverall, the Hof1-Cyk3 interaction plays an important role in regulating the cellular response to oxidative stress in yeast, helping to protect the cell from damage caused by reactive oxygen species.",
    "llama-7b_fact_raw": "1. The Hof1-Cyk3 interaction regulates the cellular response to oxidative stress in yeast.\n2. Hof1 is a ubiquitin-conjugating enzyme that tags proteins for degradation by the proteasome.\n3. Cyk3 is part of the cytochrome c oxidase complex involved in ATP generation through the oxidation of molecular oxygen.\n4. The Hof1-Cyk3 interaction leads to the ubiquitination and subsequent degradation of Cyk3 when cells are exposed to high levels of reactive oxygen species (ROS).\n5. The degradation of Cyk3 results in a decrease in ATP production and a reduced ability of the cell to generate energy in response to oxidative stress.",
    "llama-7b_fact": [
      "The Hof1-Cyk3 interaction regulates the cellular response to oxidative stress in yeast.",
      "Hof1 is a ubiquitin-conjugating enzyme that tags proteins for degradation by the proteasome.",
      "Cyk3 is part of the cytochrome c oxidase complex involved in ATP generation through the oxidation of molecular oxygen.",
      "The Hof1-Cyk3 interaction leads to the ubiquitination and subsequent degradation of Cyk3 when cells are exposed to high levels of reactive oxygen species (ROS).",
      "The degradation of Cyk3 results in a decrease in ATP production and a reduced ability of the cell to generate energy in response to oxidative stress."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN: Without specific scientific literature or context, it's not possible to confirm the role of the Hof1-Cyk3 interaction in the cellular response to oxidative stress in yeast.\n2. FALSE [correction]: Hof1 is not a ubiquitin-conjugating enzyme; it is a protein involved in cytokinesis in yeast. Ubiquitin-conjugating enzymes are a separate class of proteins.\n3. FALSE [correction]: Cyk3 is not part of the cytochrome c oxidase complex. Cyk3 is a protein involved in cell wall remodeling during cytokinesis in yeast. The cytochrome c oxidase complex is a component of the mitochondrial electron transport chain involved in ATP generation.\n4. UNKNOWN: Without specific information, it is not possible to confirm whether the Hof1-Cyk3 interaction leads to the ubiquitination and subsequent degradation of Cyk3 under conditions of oxidative stress.\n5. UNKNOWN: Given that Cyk3 is not part of the cytochrome c oxidase complex, the statement about its degradation leading to a decrease in ATP production is questionable. However, without specific details, the effect of Cyk3 degradation on ATP production in response to oxidative stress cannot be confirmed.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "You MUST give a detailed answer to the following question: Which T-UCRs have been implicated in gastric cancer?",
    "llama-7b_response": "T-UCRs (tumor-infiltrating urokinase-type plasminogen activator receptors) have been implicated in various types of cancer, including gastric cancer. Gastric cancer is a type of cancer that starts in the lining of the stomach and can spread to other parts of the body.\n\nStudies have shown that high levels of T-UCRs are associated with poor prognosis in patients with gastric cancer. T-UCRs can promote cancer cell growth, invasion, and metastasis by activating the proteolytic enzyme urokinase-type plasminogen activator (u-PA), which degrades the extracellular matrix and promotes cancer cell migration and invasion.\n\nSeveral studies have identified specific T-UCRs that are implicated in gastric cancer. For example, a study published in the journal Cancer Research in 2012 found that T-UCR-1, a specific type of T-UCR, is highly expressed in gastric cancer tissues and correlates with poor prognosis in patients with gastric cancer. Another study published in the journal Oncology Reports in 2015 found that T-UCR-2, another type of T-UCR, is highly expressed in gastric cancer tissues and promotes cancer cell growth and invasion.\n\nIn summary, T-UCRs, particularly T-UCR-1 and T-UCR-2, have been implicated in gastric cancer and are thought to play a role in promoting cancer cell growth, invasion, and metastasis. Further research is needed to better understand the role of T-UCRs in gastric cancer and to identify potential therapeutic targets for this type of cancer.",
    "llama-7b_fact_raw": "1. T-UCRs have been implicated in various types of cancer, including gastric cancer.\n2. High levels of T-UCRs are associated with poor prognosis in patients with gastric cancer.\n3. T-UCRs can activate the proteolytic enzyme urokinase-type plasminogen activator (u-PA), which degrades the extracellular matrix and promotes cancer cell migration and invasion.\n4. A study published in Cancer Research in 2012 found that T-UCR-1 is highly expressed in gastric cancer tissues and correlates with poor prognosis.\n5. Research published in Oncology Reports in 2015 indicated that T-UCR-2 is highly expressed in gastric cancer tissues and promotes cancer cell growth and invasion.",
    "llama-7b_fact": [
      "T-UCRs have been implicated in various types of cancer, including gastric cancer.",
      "High levels of T-UCRs are associated with poor prognosis in patients with gastric cancer.",
      "T-UCRs can activate the proteolytic enzyme urokinase-type plasminogen activator (u-PA), which degrades the extracellular matrix and promotes cancer cell migration and invasion.",
      "A study published in Cancer Research in 2012 found that T-UCR-1 is highly expressed in gastric cancer tissues and correlates with poor prognosis.",
      "Research published in Oncology Reports in 2015 indicated that T-UCR-2 is highly expressed in gastric cancer tissues and promotes cancer cell growth and invasion."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first two statements are consistent with general scientific findings that certain non-coding RNAs, such as T-UCRs (Transcribed Ultraconserved Regions), have been implicated in various types of cancer, including gastric cancer, and that high levels are often associated with poor prognosis. However, without specific references to the studies or more detailed information, it is not possible to verify the exact roles of T-UCRs like u-PA activation, or the specific findings of studies published in Cancer Research in 2012 or Oncology Reports in 2015. Therefore, the last three statements are marked as UNKNOWN.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3607,
    "user_query": "You MUST give a detailed answer to the following question: What is the Lupus Severity Index (LSI)?",
    "llama-7b_response": "The Lupus Severity Index (LSI) is a tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that can affect various organs and systems in the body. The LSI was developed in 1982 by the National Lupus Assessment Team, which was composed of rheumatologists, dermatologists, and other healthcare professionals.\n\nThe LSI is based on a comprehensive review of the patient's medical history, physical examination findings, and laboratory results. The index assigns a score to each of these factors, which are then combined to produce a total LSI score. The score ranges from 0 to 100, with higher scores indicating more severe disease activity.\n\nThe LSI takes into account several key factors, including:\n\n1. Malar rash: The presence or absence of a butterfly-shaped rash on the cheeks (malar rash) is assessed on a scale of 0 to 3.\n2. Discoid rash: The presence or absence of a scaly, red rash on the skin is assessed on a scale of 0 to 3.\n3. Oral ulcers: The presence or absence of oral ulcers is assessed on a scale of 0 to 3.\n4. Photosensitivity: The degree of sensitivity to sunlight is assessed on a scale of 0 to 3.\n5. Renal involvement: The presence or absence of kidney involvement is assessed on a scale of 0 to 3.\n6. Hematologic abnormalities: The presence or absence of hematologic abnormalities, such as anemia or thrombocytopenia, is assessed on a scale of 0 to 3.\n7. Fever: The presence or absence of fever is assessed on a scale of 0 to 3.\n8. Mental status: The patient's mental status is assessed on a scale of 0 to 3.\n\nEach factor is assigned a score based on the degree of severity, with higher scores indicating more severe disease activity. The scores for each factor are then added together to produce the total LSI score.\n\nThe LSI ha",
    "llama-7b_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI was developed in 1982 by the National Lupus Assessment Team.\n3. The LSI score ranges from 0 to 100, with higher scores indicating more severe disease activity.\n4. The LSI includes assessments of malar rash, discoid rash, oral ulcers, photosensitivity, renal involvement, hematologic abnormalities, fever, and mental status, each on a scale of 0 to 3.\n5. The total LSI score is the sum of the scores assigned to each factor based on the degree of severity.",
    "llama-7b_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI was developed in 1982 by the National Lupus Assessment Team.",
      "The LSI score ranges from 0 to 100, with higher scores indicating more severe disease activity.",
      "The LSI includes assessments of malar rash, discoid rash, oral ulcers, photosensitivity, renal involvement, hematologic abnormalities, fever, and mental status, each on a scale of 0 to 3.",
      "The total LSI score is the sum of the scores assigned to each factor based on the degree of severity."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: There is no widely recognized index known as the Lupus Severity Index (LSI) developed by the National Lupus Assessment Team in 1982. The SLE Disease Activity Index (SLEDAI) is a commonly used tool to assess the severity of systemic lupus erythematosus, and it was developed in 1985.\n3. FALSE [correction]: Since the LSI as described does not exist, this statement about the score range is incorrect. However, for the SLEDAI, the score can range from 0 to 105, with higher scores indicating more severe disease activity.\n4. FALSE [correction]: This statement seems to mix elements of the SLEDAI and the British Isles Lupus Assessment Group (BILAG) index. The SLEDAI includes various clinical and laboratory criteria, but they are not all scored on a scale of 0 to 3. The BILAG index uses a grading system from A to E for different systems.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "You MUST give a detailed answer to the following question: Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-7b_response": "De novo mutations are genetic changes that occur in a person's DNA and are not inherited from their parents. These mutations can occur at any point during the formation of reproductive cells (eggs or sperm) and can result in genetic disorders.\n\nZSWIM6 is a gene that has been associated with several genetic disorders caused by de novo mutations. ZSWIM6 encodes a protein that plays a role in the endoplasmic reticulum (ER) stress response, which is a mechanism that the cell uses to deal with stress and maintain cellular homeostasis.\n\nHere are some disorders caused by de novo mutations in ZSWIM6:\n\n1. Danon disease: Danon disease is a rare genetic disorder that affects the heart and other organs. It is caused by mutations in genes involved in the ER stress response, including ZSWIM6. People with Danon disease often have enlarged hearts, abnormal heart rhythms, and other cardiovascular problems.\n2. Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS): ARSACS is a neurological disorder that affects coordination and balance. It is caused by mutations in genes involved in the ER stress response, including ZSWIM6. People with ARSACS often have spasticity, ataxia (lack of coordination), and other neurological symptoms.\n3. Congenital disorders of glycosylation (CDG): Congenital disorders of glycosylation are a group of genetic disorders that affect the way the body produces glycoproteins, which are proteins that have sugar molecules attached to them. Mutations in genes involved in the ER stress response, including ZSWIM6, can cause congenital disorders of glycosylation.\n\nIn summary, ZSWIM6 is a gene that has been associated with several genetic disorders caused by de novo mutations, including Danon disease, autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS), and congenital disorders of glycosylation. These disorders can affect the heart,",
    "llama-7b_fact_raw": "1. De novo mutations in ZSWIM6 can cause Danon disease, which affects the heart and other organs.\n2. Danon disease patients often experience enlarged hearts, abnormal heart rhythms, and cardiovascular problems.\n3. Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurological disorder caused by mutations in ZSWIM6.\n4. Individuals with ARSACS typically exhibit symptoms such as spasticity and ataxia.\n5. Congenital disorders of glycosylation (CDG) can be caused by mutations in ZSWIM6 and affect the production of glycoproteins.",
    "llama-7b_fact": [
      "De novo mutations in ZSWIM6 can cause Danon disease, which affects the heart and other organs.",
      "Danon disease patients often experience enlarged hearts, abnormal heart rhythms, and cardiovascular problems.",
      "Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neurological disorder caused by mutations in ZSWIM6.",
      "Individuals with ARSACS typically exhibit symptoms such as spasticity and ataxia.",
      "Congenital disorders of glycosylation (CDG) can be caused by mutations in ZSWIM6 and affect the production of glycoproteins."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: De novo mutations in ZSWIM6 can cause developmental disorders with intellectual disability and other issues, but Danon disease is caused by mutations in the LAMP2 gene.\n2. TRUE\n3. FALSE [correction]: Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is caused by mutations in the SACS gene, not ZSWIM6.\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3626,
    "user_query": "You MUST give a detailed answer to the following question: Which disease can be classified using the Koos Classification?",
    "llama-7b_response": "The Koos Classification is a system used to classify congenital talipes equinovarus (CTEV), also known as clubfoot. CTEV is a condition in which a baby is born with one or both feet turned inward and downward, making it difficult for the child to walk properly. The Koos Classification is a way to categorize the severity of CTEV based on the position and shape of the foot and ankle.\n\nThere are four main categories in the Koos Classification:\n\n1. Type I: This is the mildest form of CTEV, characterized by a normal-looking foot and ankle.\n2. Type II: In this category, the foot is turned inward and downward, but the ankle is also turned outward.\n3. Type III: In this more severe form of CTEV, the foot is turned inward and downward, and the ankle is also turned inward.\n4. Type IV: This is the most severe form of CTEV, in which the foot is turned inward and downward, and the ankle is also turned inward and downward.\n\nThe Koos Classification is important because it helps doctors to determine the best treatment plan for each individual case of CTEV. Treatment options may include physical therapy, casting, and surgery, depending on the severity of the condition.",
    "llama-7b_fact_raw": "1. The Koos Classification is used to classify congenital talipes equinovarus (CTEV), also known as clubfoot.\n2. CTEV is a condition where a baby is born with one or both feet turned inward and downward.\n3. The Koos Classification categorizes CTEV severity based on the position and shape of the foot and ankle.\n4. Type I CTEV is characterized by a normal-looking foot and ankle.\n5. Treatment options for CTEV may include physical therapy, casting, and surgery, depending on the severity of the condition.",
    "llama-7b_fact": [
      "The Koos Classification is used to classify congenital talipes equinovarus (CTEV), also known as clubfoot.",
      "CTEV is a condition where a baby is born with one or both feet turned inward and downward.",
      "The Koos Classification categorizes CTEV severity based on the position and shape of the foot and ankle.",
      "Type I CTEV is characterized by a normal-looking foot and ankle.",
      "Treatment options for CTEV may include physical therapy, casting, and surgery, depending on the severity of the condition."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Type I CTEV is characterized by a foot that is correctable (mild deformity) with passive manipulation, not a normal-looking foot and ankle.\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "You MUST give a detailed answer to the following question: What are the in vivo effects of AZD8601?",
    "llama-7b_response": "AZD8601 is a small molecule inhibitor of the PI3K/mTOR pathway, which is a key signaling pathway involved in cell growth, proliferation, and survival. In vivo, AZD8601 has been shown to have anti-tumor effects in various preclinical studies.\n\nOne study published in the journal Cancer Research in 2012 investigated the effects of AZD8601 in a mouse model of pancreatic ductal adenocarcinoma (PDAC), a type of pancreatic cancer. The study found that treatment with AZD8601 resulted in a significant reduction in tumor growth and increased survival of the mice compared to controls. The researchers concluded that AZD8601 may be a promising therapeutic agent for the treatment of PDAC.\n\nAnother study published in the journal Clinical Cancer Research in 2014 investigated the effects of AZD8601 in combination with chemotherapy in a mouse model of breast cancer. The study found that treatment with AZD8601 in combination with chemotherapy resulted in a significant reduction in tumor growth and increased survival of the mice compared to chemotherapy alone. The researchers concluded that AZD8601 may have potential as an adjuvant therapy for breast cancer.\n\nOverall, the in vivo data suggests that AZD8601 has anti-tumor effects in preclinical studies and may be a promising therapeutic agent for the treatment of various types of cancer. However, further clinical trials are needed to confirm these findings and determine the safety and efficacy of AZD8601 in humans.",
    "llama-7b_fact_raw": "1. AZD8601 is a small molecule inhibitor of the PI3K/mTOR pathway.\n2. In vivo preclinical studies have shown that AZD8601 has anti-tumor effects.\n3. A study published in Cancer Research in 2012 found that AZD8601 significantly reduced tumor growth and increased survival in a mouse model of pancreatic ductal adenocarcinoma.\n4. A study published in Clinical Cancer Research in 2014 found that AZD8601 in combination with chemotherapy significantly reduced tumor growth and increased survival in a mouse model of breast cancer.\n5. The studies suggest that AZD8601 may be a promising therapeutic agent for the treatment of various types of cancer.",
    "llama-7b_fact": [
      "AZD8601 is a small molecule inhibitor of the PI3K/mTOR pathway.",
      "In vivo preclinical studies have shown that AZD8601 has anti-tumor effects.",
      "A study published in Cancer Research in 2012 found that AZD8601 significantly reduced tumor growth and increased survival in a mouse model of pancreatic ductal adenocarcinoma.",
      "A study published in Clinical Cancer Research in 2014 found that AZD8601 in combination with chemotherapy significantly reduced tumor growth and increased survival in a mouse model of breast cancer.",
      "The studies suggest that AZD8601 may be a promising therapeutic agent for the treatment of various types of cancer."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: AZD8601 is not a small molecule inhibitor of the PI3K/mTOR pathway; it is an mRNA-based therapy that encodes for vascular endothelial growth factor A (VEGF-A).\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3640,
    "user_query": "You MUST give a detailed answer to the following question: How are SAHFS created?",
    "llama-7b_response": "SAHFS, or Secure Attention Handshakes, are created through a multi-step process that involves several parties working together to establish a secure and trusted connection. Here's a detailed explanation of how SAHFS are created:\n\n1. Authentication: The first step in creating a SAHFS is authentication. This involves verifying the identity of the parties involved in the handshake, ensuring that they are who they claim to be. This is typically done through the use of digital certificates or public key infrastructure (PKI) systems.\n2. Key Agreement: Once the parties have been authenticated, they can proceed to the key agreement phase. In this step, they exchange cryptographic keys that will be used to encrypt and decrypt data transmitted between them. The keys are exchanged using a secure protocol, such as the Secure Shell (SSH) protocol, to prevent eavesdropping and tampering.\n3. Confidentiality: Once the keys have been agreed upon, the parties can establish confidentiality. This means that any data transmitted between them will be encrypted, ensuring that it cannot be intercepted or read by unauthorized parties.\n4. Integrity: The next step is to establish integrity. This means that the data transmitted between the parties will be verified to ensure that it has not been tampered with. This is typically done through the use of digital signatures, which are created using the same cryptographic keys used for encryption.\n5. Authenticity: Finally, the parties can establish authenticity. This means that the identity of the parties involved in the handshake can be verified, ensuring that they are who they claim to be. This is typically done through the use of digital certificates or public key infrastructure (PKI) systems.\n\nOnce all of these steps have been completed, a secure and trusted connection has been established between the parties involved in the SAHFS. This connection can be used to transmit data securely and confidentially, ensuring that sensitive information is protected from unauthorized access.",
    "llama-7b_fact_raw": "1. SAHFS creation begins with authentication, which verifies the identity of the parties involved using digital certificates or public key infrastructure (PKI) systems.\n2. The key agreement phase of SAHFS creation involves the exchange of cryptographic keys using a secure protocol like the Secure Shell (SSH) protocol.\n3. Confidentiality in SAHFS is established by encrypting data transmitted between the parties to prevent unauthorized interception or reading.\n4. Integrity in SAHFS is ensured by verifying that the transmitted data has not been tampered with, often using digital signatures.\n5. Authenticity in SAHFS is confirmed by verifying the identity of the parties involved, typically through digital certificates or PKI systems.",
    "llama-7b_fact": [
      "SAHFS creation begins with authentication, which verifies the identity of the parties involved using digital certificates or public key infrastructure (PKI) systems.",
      "The key agreement phase of SAHFS creation involves the exchange of cryptographic keys using a secure protocol like the Secure Shell (SSH) protocol.",
      "Confidentiality in SAHFS is established by encrypting data transmitted between the parties to prevent unauthorized interception or reading.",
      "Integrity in SAHFS is ensured by verifying that the transmitted data has not been tampered with, often using digital signatures.",
      "Authenticity in SAHFS is confirmed by verifying the identity of the parties involved, typically through digital certificates or PKI systems."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE\n\nNote: The second statement is marked as UNKNOWN because, while the Secure Shell (SSH) protocol is indeed a secure protocol that can be used for key exchange, without specific context about SAHFS (which is not a widely recognized acronym in the field of cybersecurity or IT), it's unclear whether SSH is the protocol used for key agreement in this particular system. If SAHFS refers to a specific system or protocol not widely recognized or defined in available literature, more context would be needed to verify the accuracy of the statement.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "You MUST give a detailed answer to the following question: What is the function of the PDZ domain in SATB1?",
    "llama-7b_response": "The PDZ domain is a protein interaction domain found in many proteins, including the transcription factor SATB1 (Special AT-rich binding protein 1). The function of the PDZ domain in SATB1 is to mediate protein-protein interactions with other proteins.\n\nThe PDZ domain in SATB1 specifically binds to other proteins that contain PDZ domains, forming a stable complex. One of the proteins that SATB1 interacts with through its PDZ domain is the postsynaptic density protein 93 (PSD93). This interaction is important for the localization and function of SATB1 in the postsynaptic density of neurons, where it plays a role in the regulation of gene expression and synaptic plasticity.\n\nIn addition to its interaction with PSD93, the PDZ domain in SATB1 also interacts with other proteins that are involved in various cellular processes, such as cell adhesion, signal transduction, and protein degradation. These interactions help to regulate the activity of SATB1 and ensure its proper localization and function in the cell.\n\nOverall, the PDZ domain in SATB1 plays a crucial role in its function as a transcription factor by mediating protein-protein interactions with other proteins that are involved in various cellular processes. These interactions help to regulate the activity of SATB1 and ensure its proper localization and function in the cell.",
    "llama-7b_fact_raw": "1. The PDZ domain in SATB1 mediates protein-protein interactions with other proteins.\n2. SATB1 interacts with the postsynaptic density protein 93 (PSD93) through its PDZ domain.\n3. The interaction between SATB1 and PSD93 is important for the localization and function of SATB1 in the postsynaptic density of neurons.\n4. SATB1 plays a role in the regulation of gene expression and synaptic plasticity.\n5. The PDZ domain in SATB1 is involved in interactions with proteins related to cell adhesion, signal transduction, and protein degradation.",
    "llama-7b_fact": [
      "The PDZ domain in SATB1 mediates protein-protein interactions with other proteins.",
      "SATB1 interacts with the postsynaptic density protein 93 (PSD93) through its PDZ domain.",
      "The interaction between SATB1 and PSD93 is important for the localization and function of SATB1 in the postsynaptic density of neurons.",
      "SATB1 plays a role in the regulation of gene expression and synaptic plasticity.",
      "The PDZ domain in SATB1 is involved in interactions with proteins related to cell adhesion, signal transduction, and protein degradation."
    ],
    "llama-7b_judge_raw": "1. TRUE: The PDZ domain is known for mediating protein-protein interactions, and it is reasonable to assume that the PDZ domain in SATB1 would have this function.\n2. UNKNOWN: Without specific information on the interaction between SATB1 and PSD93, it is not possible to confirm the accuracy of this statement.\n3. UNKNOWN: Similarly, the importance of the interaction between SATB1 and PSD93 for the localization and function of SATB1 in the postsynaptic density of neurons cannot be determined without additional context or evidence.\n4. TRUE: SATB1 is known to play a role in the regulation of gene expression and has been implicated in synaptic plasticity, which is consistent with the functions of a matrix attachment region-binding protein.\n5. TRUE: PDZ domains typically interact with a variety of proteins involved in different cellular functions, including cell adhesion, signal transduction, and protein degradation. It is plausible that the PDZ domain in SATB1 would be involved in such interactions.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3678,
    "user_query": "You MUST give a detailed answer to the following question: What is the basis of the BLISS technique?",
    "llama-7b_response": "The BLISS technique is based on the principles of mindfulness and acceptance. Mindfulness involves being present in the current moment and observing one's thoughts and feelings without judgment. Acceptance involves acknowledging and embracing difficult emotions and experiences, rather than trying to avoid or control them.\n\nThe BLISS technique encourages individuals to focus on the positive aspects of their lives, such as their strengths, accomplishments, and gratitude. This helps to shift the focus away from negative thoughts and emotions, and promotes a more positive outlook.\n\nIn addition to mindfulness and acceptance, the BLISS technique also incorporates elements of self-compassion. This involves treating oneself with kindness, understanding, and patience, even in the face of difficult emotions or experiences.\n\nOverall, the BLISS technique is based on the idea that by focusing on the positive aspects of our lives, we can cultivate a more positive mindset and improve our overall well-being.",
    "llama-7b_fact_raw": "1. The BLISS technique is based on the principles of mindfulness and acceptance.\n2. Mindfulness, as part of the BLISS technique, involves being present in the current moment and observing thoughts and feelings without judgment.\n3. Acceptance in the BLISS technique means acknowledging and embracing difficult emotions and experiences.\n4. The BLISS technique encourages focusing on positive aspects of life, such as strengths, accomplishments, and gratitude.\n5. Self-compassion, which includes treating oneself with kindness, understanding, and patience, is an element of the BLISS technique.",
    "llama-7b_fact": [
      "The BLISS technique is based on the principles of mindfulness and acceptance.",
      "Mindfulness, as part of the BLISS technique, involves being present in the current moment and observing thoughts and feelings without judgment.",
      "Acceptance in the BLISS technique means acknowledging and embracing difficult emotions and experiences.",
      "The BLISS technique encourages focusing on positive aspects of life, such as strengths, accomplishments, and gratitude.",
      "Self-compassion, which includes treating oneself with kindness, understanding, and patience, is an element of the BLISS technique."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided pertain to the BLISS technique, which seems to be a psychological or therapeutic method. However, without specific context or a recognized framework for the BLISS technique, it is not possible to verify the accuracy of these statements. The principles mentioned (mindfulness, acceptance, focusing on positive aspects, and self-compassion) are common in various therapeutic and self-help approaches, but without more information, it is not possible to confirm their association with the BLISS technique specifically.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3679,
    "user_query": "You MUST give a detailed answer to the following question: List 3 NK3R antagonists.",
    "llama-7b_response": "NK3 receptors are a subtype of the neurokinin-1 (NK1) receptor, which are G-protein-coupled receptors that bind to the neurokinin peptide substance P. NK3 receptors are primarily found in the central nervous system and play a role in the regulation of pain, inflammation, and emotion.\n\nHere are three NK3R antagonists:\n\n1. AP33584: AP33584 is a selective NK3 receptor antagonist that has been studied for the treatment of chronic pain. It has been shown to reduce pain-related behaviors in animal models and has a good safety profile in clinical trials.\n2. AMG9810: AMG9810 is another selective NK3 receptor antagonist that has been developed for the treatment of chronic pain. It has been shown to reduce pain-related behaviors in animal models and has also been studied for the treatment of pruritus (itching) in patients with chronic kidney disease.\n3. LY341495: LY341495 is a non-selective NK1/NK3 receptor antagonist that has been studied for the treatment of chronic pain. It has been shown to reduce pain-related behaviors in animal models and has also been studied for the treatment of pruritus in patients with chronic kidney disease.",
    "llama-7b_fact_raw": "1. AP33584 is a selective NK3 receptor antagonist studied for the treatment of chronic pain.\n2. AMG9810 is a selective NK3 receptor antagonist developed for the treatment of chronic pain and pruritus in patients with chronic kidney disease.\n3. LY341495 is a non-selective NK1/NK3 receptor antagonist studied for the treatment of chronic pain and pruritus in patients with chronic kidney disease.",
    "llama-7b_fact": [
      "AP33584 is a selective NK3 receptor antagonist studied for the treatment of chronic pain.",
      "AMG9810 is a selective NK3 receptor antagonist developed for the treatment of chronic pain and pruritus in patients with chronic kidney disease.",
      "LY341495 is a non-selective NK1/NK3 receptor antagonist studied for the treatment of chronic pain and pruritus in patients with chronic kidney disease."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: AMG9810 is a selective TRPV1 receptor antagonist, not an NK3 receptor antagonist, and it has been studied for conditions such as pain and pruritus.\n3. FALSE [correction]: LY341495 is a selective antagonist of the metabotropic glutamate receptors 2/3 (mGlu2/3), not a non-selective NK1/NK3 receptor antagonist. It has been studied for various CNS disorders but not specifically for chronic pain and pruritus in patients with chronic kidney disease as stated.",
    "llama-7b_judge": [
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 3691,
    "user_query": "You MUST give a detailed answer to the following question: Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-7b_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is known as dronabinol. It is a synthetic form of delta-9-tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. Dronabinol was developed as a medication to treat nausea and vomiting associated with cancer chemotherapy, as well as to improve appetite and weight gain in patients with AIDS.\n\nDronabinol acts as an inverse agonist of the ghrelin receptor, which means that it binds to the receptor but does not stimulate it to produce the typical effects of ghrelin, such as increasing hunger and stimulating appetite. Instead, dronabinol has been shown to reduce hunger and food intake in both healthy volunteers and patients with anorexia associated with cancer or AIDS.\n\nWhile dronabinol has been used as a medication for several decades, its role as an oral ghrelin receptor inverse agonist was not well understood until recently. However, studies have shown that dronabinol's inverse agonist activity at the ghrelin receptor may contribute to its appetite-stimulating effects in patients with anorexia.",
    "llama-7b_fact_raw": "1. Dronabinol is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC).\n3. Dronabinol was developed to treat nausea and vomiting associated with cancer chemotherapy.\n4. Dronabinol is used to improve appetite and weight gain in patients with AIDS.\n5. Dronabinol has been shown to reduce hunger and food intake in both healthy volunteers and patients with anorexia associated with cancer or AIDS.",
    "llama-7b_fact": [
      "Dronabinol is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC).",
      "Dronabinol was developed to treat nausea and vomiting associated with cancer chemotherapy.",
      "Dronabinol is used to improve appetite and weight gain in patients with AIDS.",
      "Dronabinol has been shown to reduce hunger and food intake in both healthy volunteers and patients with anorexia associated with cancer or AIDS."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Dronabinol is not a ghrelin receptor inverse agonist; it is a synthetic form of delta-9-tetrahydrocannabinol (THC).\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Dronabinol is used to stimulate appetite and increase weight gain in patients with AIDS, but it has not been shown to reduce hunger and food intake; it is intended to have the opposite effect.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3693,
    "user_query": "You MUST give a detailed answer to the following question: What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-7b_response": "Vaxchora is a vaccine that is approved for the prevention of cholera caused by the serogroup O1 strain of the bacterium Vibrio cholerae. The protective efficacy of Vaxchora against moderate to severe cholera has been evaluated in several clinical trials.\n\nOne clinical trial, known as the CHOICE (Cholera Immunization for Oral Vaccine Efficacy in Children) trial, enrolled over 17,000 children aged 1-15 years in Bangladesh, India, and Nepal. The children were randomly assigned to receive either Vaxchora or a placebo. The trial found that Vaxchora was highly effective in preventing cholera in children, with a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group.\n\nAnother clinical trial, known as the CHOICE-II (Cholera Immunization for Oral Vaccine Efficacy in Children II) trial, enrolled over 20,000 children aged 1-15 years in Bangladesh, India, and Nepal. The children were randomly assigned to receive either Vaxchora or a placebo. The trial found that Vaxchora was highly effective in preventing cholera in children, with a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group.\n\nIn addition to these clinical trials, Vaxchora has also been shown to be highly effective in preventing cholera in adults. A clinical trial conducted in Haiti found that Vaxchora was highly effective in preventing cholera in adults, with a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group.\n\nOverall, the protective efficacy of Vaxchora against moderate to severe cholera has been demonstrated in multiple clinical trials in children and adults. The vaccine has been shown to be highly effective in preventing cholera, with a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group.",
    "llama-7b_fact_raw": "1. Vaxchora is approved for the prevention of cholera caused by the serogroup O1 strain of Vibrio cholerae.\n2. The CHOICE trial enrolled over 17,000 children aged 1-15 years in Bangladesh, India, and Nepal to evaluate the efficacy of Vaxchora.\n3. In the CHOICE trial, Vaxchora showed a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group.\n4. The CHOICE-II trial enrolled over 20,000 children aged 1-15 years in Bangladesh, India, and Nepal to assess the efficacy of Vaxchora.\n5. A clinical trial conducted in Haiti demonstrated that Vaxchora was highly effective in preventing cholera in adults, with a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group.",
    "llama-7b_fact": [
      "Vaxchora is approved for the prevention of cholera caused by the serogroup O1 strain of Vibrio cholerae.",
      "The CHOICE trial enrolled over 17,000 children aged 1-15 years in Bangladesh, India, and Nepal to evaluate the efficacy of Vaxchora.",
      "In the CHOICE trial, Vaxchora showed a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group.",
      "The CHOICE-II trial enrolled over 20,000 children aged 1-15 years in Bangladesh, India, and Nepal to assess the efficacy of Vaxchora.",
      "A clinical trial conducted in Haiti demonstrated that Vaxchora was highly effective in preventing cholera in adults, with a statistically significant reduction in the incidence of cholera in the vaccinated group compared to the placebo group."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe first statement is true as Vaxchora is indeed approved for the prevention of cholera caused by the serogroup O1 strain of Vibrio cholerae. However, without specific details about the CHOICE and CHOICE-II trials or the clinical trial conducted in Haiti, it is not possible to verify the accuracy of statements 2 through 5. These details would need to be cross-referenced with the actual trial data or publications to determine their truthfulness.",
    "llama-7b_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "You MUST give a detailed answer to the following question: Which was the first cholera vaccine approved in the US?",
    "llama-7b_response": "The first cholera vaccine approved in the US was the killed whole-cell cholera vaccine, also known as Dukoral. It was approved by the US Food and Drug Administration (FDA) in 2000. The vaccine is made from a killed form of the bacteria that causes cholera and is administered orally in a single dose. It provides protection against cholera for up to two years.",
    "llama-7b_fact_raw": "1. The first cholera vaccine approved in the US was known as Dukoral.\n2. The US Food and Drug Administration (FDA) approved the Dukoral cholera vaccine in 2000.\n3. Dukoral is a killed whole-cell cholera vaccine.\n4. The vaccine is administered orally.\n5. Dukoral provides protection against cholera for up to two years.",
    "llama-7b_fact": [
      "The first cholera vaccine approved in the US was known as Dukoral.",
      "The US Food and Drug Administration (FDA) approved the Dukoral cholera vaccine in 2000.",
      "Dukoral is a killed whole-cell cholera vaccine.",
      "The vaccine is administered orally.",
      "Dukoral provides protection against cholera for up to two years."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The first cholera vaccine approved in the US was known as Vaxchora, not Dukoral.\n2. FALSE [correction]: The US Food and Drug Administration (FDA) approved the Vaxchora cholera vaccine in 2016, not Dukoral in 2000.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Dukoral provides protection against cholera for about six months to two years in adults and about six months in children, with the duration of protection varying by age group.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3737,
    "user_query": "You MUST give a detailed answer to the following question: Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-7b_response": "The most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is X-linked agammaglobulinemia (XLA). XLA is caused by mutations in the BTK gene, which is located on the X chromosome. The BTK gene provides instructions for making a protein called Bruton's tyrosine kinase, which is essential for the development and function of B cells, a type of immune cell that produces antibodies.\n\nIndividuals with XLA have a severe deficiency of B cells and antibodies, which leaves them vulnerable to infections. XLA is an autosomal recessive disorder, meaning that an individual must inherit two copies of the mutated BTK gene (one from each parent) to develop the condition. However, because the BTK gene is located on the X chromosome, X-linked recessive disorders like XLA are more common in males, who have only one X chromosome, than in females, who have two X chromosomes.\n\nOther monogenic causes of CVID in Europeans include autosomal recessive mutations in the FCGR3A and FCGR3B genes, which encode the low-affinity immunoglobulin G (IgG) Fc receptors on the surface of B cells. These mutations can lead to reduced expression or function of the Fc receptors, resulting in impaired antibody production and immunodeficiency.\n\nIn summary, X-linked agammaglobulinemia (XLA) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans, caused by mutations in the BTK gene on the X chromosome. Other monogenic causes of CVID in Europeans include mutations in the FCGR3A and FCGR3B genes.",
    "llama-7b_fact_raw": "1. X-linked agammaglobulinemia (XLA) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.\n2. XLA is caused by mutations in the BTK gene, which is located on the X chromosome.\n3. The BTK gene is responsible for making Bruton's tyrosine kinase, a protein essential for B cell development and function.\n4. XLA is characterized by a severe deficiency of B cells and antibodies, making individuals more susceptible to infections.\n5. XLA is an X-linked recessive disorder, which means it is more common in males than in females.",
    "llama-7b_fact": [
      "X-linked agammaglobulinemia (XLA) is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans.",
      "XLA is caused by mutations in the BTK gene, which is located on the X chromosome.",
      "The BTK gene is responsible for making Bruton's tyrosine kinase, a protein essential for B cell development and function.",
      "XLA is characterized by a severe deficiency of B cells and antibodies, making individuals more susceptible to infections.",
      "XLA is an X-linked recessive disorder, which means it is more common in males than in females."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: X-linked agammaglobulinemia (XLA) and common variable immunodeficiency (CVID) are distinct conditions. XLA is not a cause of CVID; rather, CVID is a different type of primary immunodeficiency.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "You MUST give a detailed answer to the following question: Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-7b_response": "The IFIT1 gene, also known as Interferon, alpha-inducible protein 1, plays a role in the regulation of the interferon signaling pathway. Interferons are a group of proteins that are produced by cells in response to the presence of viruses or other pathogens. They play a crucial role in the immune system by activating immune cells and inducing the production of antiviral proteins.\n\nIn the context of Systemic Lupus Erythematosus (SLE), the IFIT1 gene has been implicated in the development and progression of the disease. Studies have shown that individuals with SLE have lower levels of IFIT1 compared to healthy individuals. Additionally, genetic variations in the IFIT1 gene have been associated with an increased risk of developing SLE.\n\nFurthermore, IFIT1 has been shown to play a role in the regulation of the interferon signaling pathway, which is known to be dysregulated in SLE. The interferon signaling pathway plays a crucial role in the immune system by activating immune cells and inducing the production of antiviral proteins. Dysregulation of this pathway has been linked to the development of autoimmune diseases such as SLE.\n\nIn summary, the role of the IFIT1 gene in SLE is to play a role in the regulation of the interferon signaling pathway, which is known to be dysregulated in the disease. Additionally, lower levels of IFIT1 and genetic variations in the IFIT1 gene have been associated with an increased risk of developing SLE.",
    "llama-7b_fact_raw": "1. The IFIT1 gene is involved in the regulation of the interferon signaling pathway.\n2. Interferons are proteins produced in response to pathogens and are important for immune system activation.\n3. Individuals with Systemic Lupus Erythematosus (SLE) have been found to have lower levels of IFIT1 compared to healthy individuals.\n4. Genetic variations in the IFIT1 gene have been associated with an increased risk of developing SLE.\n5. The interferon signaling pathway, regulated in part by IFIT1, is dysregulated in SLE and contributes to the disease's development.",
    "llama-7b_fact": [
      "The IFIT1 gene is involved in the regulation of the interferon signaling pathway.",
      "Interferons are proteins produced in response to pathogens and are important for immune system activation.",
      "Individuals with Systemic Lupus Erythematosus (SLE) have been found to have lower levels of IFIT1 compared to healthy individuals.",
      "Genetic variations in the IFIT1 gene have been associated with an increased risk of developing SLE.",
      "The interferon signaling pathway, regulated in part by IFIT1, is dysregulated in SLE and contributes to the disease's development."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe statements about the IFIT1 gene, interferons, and their role in the immune system are generally accurate based on current scientific understanding. However, the specific findings regarding IFIT1 levels in individuals with SLE and the association of genetic variations in the IFIT1 gene with an increased risk of developing SLE would require specific studies to confirm, and without the context of those studies, the truth of those statements cannot be determined.",
    "llama-7b_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "You MUST give a detailed answer to the following question: What is the use of the Liverpool Elbow Score?",
    "llama-7b_response": "",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 3763,
    "user_query": "You MUST give a detailed answer to the following question: Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-7b_response": "The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from NHS patients with cancer or rare diseases. As part of this project, efforts have been made to sequence genomes of patients with sarcoma, a type of cancer that affects the soft tissues and bones.\n\nSarcoma is a rare type of cancer, and it can be difficult to diagnose and treat. The 100,000 Genomes Project has sequenced the genomes of several patients with sarcoma in order to identify genetic mutations that may be driving the cancer. This information can be used to develop more personalized treatments for patients with sarcoma.\n\nIn addition to sequencing the genomes of patients with sarcoma, the 100,000 Genomes Project has also sequenced the genomes of healthy individuals with a family history of sarcoma. This information can be used to identify inherited genetic mutations that may increase the risk of developing sarcoma.\n\nOverall, the 100,000 Genomes Project has made significant efforts to sequence the genomes of patients with sarcoma in order to improve diagnosis and treatment of this rare and complex type of cancer.",
    "llama-7b_fact_raw": "1. The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from NHS patients with cancer or rare diseases.\n2. The project has included efforts to sequence the genomes of patients with sarcoma.\n3. Sarcoma is a type of cancer that affects the soft tissues and bones.\n4. The goal of sequencing sarcoma patients' genomes is to identify genetic mutations that may be driving the cancer.\n5. The project has also sequenced the genomes of healthy individuals with a family history of sarcoma to identify inherited genetic mutations.",
    "llama-7b_fact": [
      "The 100,000 Genomes Project is a UK-based initiative that aims to sequence 100,000 whole genomes from NHS patients with cancer or rare diseases.",
      "The project has included efforts to sequence the genomes of patients with sarcoma.",
      "Sarcoma is a type of cancer that affects the soft tissues and bones.",
      "The goal of sequencing sarcoma patients' genomes is to identify genetic mutations that may be driving the cancer.",
      "The project has also sequenced the genomes of healthy individuals with a family history of sarcoma to identify inherited genetic mutations."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "You MUST give a detailed answer to the following question: Does protein ALEX1 contain armadillo repeats?",
    "llama-7b_response": "Yes, protein ALEX1 contains armadillo repeats. Armadillo repeats are a type of protein domain that is named after the protein structure known as the \"armadillo\" repeat, which is found in proteins such as p53 and beta-catenin. Armadillo repeats are composed of a series of tandem repeats of a particular amino acid sequence, and they are often involved in protein-protein interactions.\n\nALEX1 is a protein that has been implicated in a variety of cellular processes, including cell proliferation, differentiation, and apoptosis. It is thought to play a role in the regulation of the cell cycle, and it has been shown to interact with a number of other proteins, including p53 and beta-catenin. It is likely that the armadillo repeats in ALEX1 are involved in these protein-protein interactions.\n\nOverall, the presence of armadillo repeats in ALEX1 suggests that this protein may have a role in regulating cellular processes through its interactions with other proteins. Further research is needed to fully understand the function of ALEX1 and its role in cellular signaling.",
    "llama-7b_fact_raw": "1. Protein ALEX1 contains armadillo repeats.\n2. Armadillo repeats are a type of protein domain.\n3. Armadillo repeats are composed of a series of tandem repeats of a particular amino acid sequence.\n4. ALEX1 has been implicated in cellular processes such as cell proliferation, differentiation, and apoptosis.\n5. ALEX1 is known to interact with other proteins, including p53 and beta-catenin.",
    "llama-7b_fact": [
      "Protein ALEX1 contains armadillo repeats.",
      "Armadillo repeats are a type of protein domain.",
      "Armadillo repeats are composed of a series of tandem repeats of a particular amino acid sequence.",
      "ALEX1 has been implicated in cellular processes such as cell proliferation, differentiation, and apoptosis.",
      "ALEX1 is known to interact with other proteins, including p53 and beta-catenin."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements regarding ALEX1 are specific to molecular biology and without the specific context or scientific literature to verify the claims about ALEX1, its functions, and interactions, it is not possible to determine the truthfulness of those statements. Therefore, the responses to statements 1, 4, and 5 are \"UNKNOWN\". Statements 2 and 3 are general knowledge about protein domains and are correct.",
    "llama-7b_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "You MUST give a detailed answer to the following question: List enzymes that removes histone modifications.",
    "llama-7b_response": "There are several enzymes that remove histone modifications. Here are some examples:\n\n1. Histone deacetylases (HDACs): HDACs remove acetyl groups from histone tails, leading to a more compact chromatin structure and the repression of gene expression. Examples of HDACs include HDAC1, HDAC2, HDAC3, HDAC8, and HDAC10.\n2. Histone demethylases: Histone demethylases remove methyl groups from lysine residues on histone tails, leading to the release of repressive histone modifications and the activation of gene expression. Examples of histone demethylases include JMJD3, KDM6A, KDM6B, and KDM6C.\n3. Lysine-specific demethylase 1 (LSD1): LSD1 removes methyl groups from lysine residues on histone tails, leading to the release of repressive histone modifications and the activation of gene expression.\n4. Jumonji domain-containing histone demethylases: These enzymes remove methyl groups from lysine residues on histone tails, leading to the release of repressive histone modifications and the activation of gene expression. Examples of jumonji domain-containing histone demethylases include JMJD3, KDM6A, and KDM6B.\n5. Lysine-specific demethylase 5A (LSD5): LSD5 removes methyl groups from lysine residues on histone tails, leading to the release of repressive histone modifications and the activation of gene expression.",
    "llama-7b_fact_raw": "1. Histone deacetylases (HDACs) remove acetyl groups from histone tails.\n2. HDAC1, HDAC2, HDAC3, HDAC8, and HDAC10 are examples of histone deacetylases.\n3. Histone demethylases remove methyl groups from lysine residues on histone tails.\n4. JMJD3, KDM6A, KDM6B, and KDM6C are examples of histone demethylases.\n5. Lysine-specific demethylase 1 (LSD1) removes methyl groups from lysine residues on histone tails.",
    "llama-7b_fact": [
      "Histone deacetylases (HDACs) remove acetyl groups from histone tails.",
      "HDAC1, HDAC2, HDAC3, HDAC8, and HDAC10 are examples of histone deacetylases.",
      "Histone demethylases remove methyl groups from lysine residues on histone tails.",
      "JMJD3, KDM6A, KDM6B, and KDM6C are examples of histone demethylases.",
      "Lysine-specific demethylase 1 (LSD1) removes methyl groups from lysine residues on histone tails."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "You MUST give a detailed answer to the following question: Does head ct increase brain tumor risk?",
    "llama-7b_response": "The relationship between head CT scans and the risk of brain tumors is complex and has been the subject of much research and debate.\n\nOn one hand, CT scans use X-rays to produce detailed images of the body's internal structures, including the brain. This can be useful for diagnosing a wide range of conditions, including brain tumors. However, CT scans also expose the body to ionizing radiation, which can increase the risk of cancer, including brain tumors.\n\nStudies have suggested that the risk of brain tumors may increase with the number of CT scans a person has undergone. This is because each CT scan exposes the body to a small amount of ionizing radiation, which can accumulate over time and increase the risk of cancer.\n\nHowever, it's worth noting that the risk of brain tumors from CT scans is generally considered to be low. Most people who undergo CT scans do not develop brain tumors as a result. In addition, the benefits of CT scans in diagnosing and treating certain medical conditions often outweigh the potential risks.\n\nIn summary, while CT scans do expose the body to ionizing radiation, which can increase the risk of cancer, the risk of brain tumors from CT scans is generally considered to be low. The decision to undergo a CT scan should be made on a case-by-case basis, taking into account the potential benefits and risks.",
    "llama-7b_fact_raw": "1. CT scans use X-rays to produce detailed images of the body's internal structures, including the brain.\n2. CT scans expose the body to ionizing radiation, which can increase the risk of cancer, including brain tumors.\n3. The risk of brain tumors may increase with the number of CT scans a person has undergone due to the accumulation of ionizing radiation exposure.\n4. The risk of developing brain tumors from CT scans is generally considered to be low.\n5. The benefits of CT scans in diagnosing and treating certain medical conditions often outweigh the potential risks.",
    "llama-7b_fact": [
      "CT scans use X-rays to produce detailed images of the body's internal structures, including the brain.",
      "CT scans expose the body to ionizing radiation, which can increase the risk of cancer, including brain tumors.",
      "The risk of brain tumors may increase with the number of CT scans a person has undergone due to the accumulation of ionizing radiation exposure.",
      "The risk of developing brain tumors from CT scans is generally considered to be low.",
      "The benefits of CT scans in diagnosing and treating certain medical conditions often outweigh the potential risks."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "You MUST give a detailed answer to the following question: Which type of pluripotency is Otx2 associated with?",
    "llama-7b_response": "Otx2 is a transcription factor that is primarily associated with the maintenance and regulation of pluripotency in embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).\n\nPluripotency refers to the ability of stem cells to differentiate into any cell type in the body. There are three main types of pluripotency:\n\n1. Embryonic stem cell pluripotency: Embryonic stem cells are derived from the inner cell mass of the blastocyst and have the ability to differentiate into all cell types in the body. Otx2 is required for the maintenance of embryonic stem cell pluripotency.\n2. Induced pluripotent stem cell pluripotency: Induced pluripotent stem cells (iPSCs) are derived from adult cells that have been reprogrammed to have the ability to differentiate into any cell type in the body. Otx2 is also required for the maintenance of iPSC pluripotency.\n3. Mesenchymal stem cell pluripotency: Mesenchymal stem cells (MSCs) are found in various tissues and have the ability to differentiate into cells of the mesenchymal lineage, including bone, cartilage, fat, and muscle. Otx2 is not required for the maintenance of MSC pluripotency.\n\nIn summary, Otx2 is primarily associated with the maintenance and regulation of pluripotency in embryonic stem cells and induced pluripotent stem cells, and is not required for the maintenance of mesenchymal stem cell pluripotency.",
    "llama-7b_fact_raw": "1. Otx2 is a transcription factor associated with the maintenance and regulation of pluripotency in embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).\n2. Embryonic stem cells are derived from the inner cell mass of the blastocyst and can differentiate into all cell types in the body.\n3. Otx2 is required for the maintenance of embryonic stem cell pluripotency.\n4. Induced pluripotent stem cells (iPSCs) are adult cells reprogrammed to differentiate into any cell type in the body.\n5. Otx2 is also required for the maintenance of iPSC pluripotency.",
    "llama-7b_fact": [
      "Otx2 is a transcription factor associated with the maintenance and regulation of pluripotency in embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs).",
      "Embryonic stem cells are derived from the inner cell mass of the blastocyst and can differentiate into all cell types in the body.",
      "Otx2 is required for the maintenance of embryonic stem cell pluripotency.",
      "Induced pluripotent stem cells (iPSCs) are adult cells reprogrammed to differentiate into any cell type in the body.",
      "Otx2 is also required for the maintenance of iPSC pluripotency."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Otx2 is a transcription factor, but it is not primarily associated with the maintenance and regulation of pluripotency in embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). It is more commonly associated with brain and eye development.\n2. TRUE\n3. FALSE [correction]: Otx2 is not required for the maintenance of embryonic stem cell pluripotency. Key transcription factors for maintaining ESC pluripotency include Oct4, Sox2, and Nanog.\n4. TRUE\n5. FALSE [correction]: Otx2 is not primarily known for maintaining iPSC pluripotency. The maintenance of iPSC pluripotency typically involves factors such as Oct4, Sox2, Klf4, and c-Myc, which are used in the reprogramming process.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3815,
    "user_query": "You MUST give a detailed answer to the following question: How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-7b_response": "The number of DNaseI hypersensitive sites (DHS) that mark the murine beta globin locus region is not a fixed or easily quantifiable number. DHS are regions of the genome that are more accessible to DNaseI, an enzyme that cuts DNA at specific sites, and are therefore more likely to be transcriptionally active. The number of DHS at a particular locus can vary depending on a variety of factors, including the stage of differentiation of the cells in which the locus is expressed, the level of transcriptional activity at the locus, and the presence of regulatory elements that influence DNaseI sensitivity.\n\nIn general, the beta globin locus is a region of chromosome 16 that contains genes responsible for producing the beta chains of hemoglobin. The locus includes several genes, including the beta globin genes themselves, as well as regulatory elements such as enhancers and silencers that control the expression of the genes. The number of DHS at the beta globin locus can vary depending on the tissue or cell type in which the locus is expressed, as well as the stage of differentiation of those cells.\n\nFor example, in erythroid cells, which are responsible for producing red blood cells, the beta globin locus is highly active and may contain many DHS. In contrast, in non-erythroid cells, such as fibroblasts, the beta globin locus may be less active and contain fewer DHS. The number of DHS at the beta globin locus can also vary depending on the stage of differentiation of erythroid cells, with more DHS appearing as the cells mature.\n\nOverall, while the number of DHS at the beta globin locus is not a fixed or easily quantifiable number, it can vary depending on a variety of factors, including the tissue or cell type in which the locus is expressed, the stage of differentiation of those cells, and the level of transcriptional activity at the locus.",
    "llama-7b_fact_raw": "1. DNaseI hypersensitive sites (DHS) are regions of the genome that are more accessible to DNaseI, an enzyme that cuts DNA at specific sites.\n2. The number of DHS at the murine beta globin locus region can vary depending on factors such as the stage of differentiation of the cells and the level of transcriptional activity at the locus.\n3. The beta globin locus is located on chromosome 16 and contains genes responsible for producing the beta chains of hemoglobin.\n4. The beta globin locus includes regulatory elements such as enhancers and silencers that control gene expression.\n5. In erythroid cells, which produce red blood cells, the beta globin locus may contain many DHS, while in non-erythroid cells, such as fibroblasts, there may be fewer DHS.",
    "llama-7b_fact": [
      "DNaseI hypersensitive sites (DHS) are regions of the genome that are more accessible to DNaseI, an enzyme that cuts DNA at specific sites.",
      "The number of DHS at the murine beta globin locus region can vary depending on factors such as the stage of differentiation of the cells and the level of transcriptional activity at the locus.",
      "The beta globin locus is located on chromosome 16 and contains genes responsible for producing the beta chains of hemoglobin.",
      "The beta globin locus includes regulatory elements such as enhancers and silencers that control gene expression.",
      "In erythroid cells, which produce red blood cells, the beta globin locus may contain many DHS, while in non-erythroid cells, such as fibroblasts, there may be fewer DHS."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The beta globin locus is located on chromosome 11, not chromosome 16.\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3822,
    "user_query": "You MUST give a detailed answer to the following question: List as many European influenza vaccines as possible.",
    "llama-7b_response": "There are several European influenza vaccines available, including:\n\n1. Fluarix: This is an inactivated influenza vaccine that is manufactured by GlaxoSmithKline (GSK). It is approved for use in adults and children aged 3 years and older.\n2. FluLaval: This is another inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children aged 6 months and older.\n3. Fluzone: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children aged 6 months and older.\n4. Fluad: This is an inactivated influenza vaccine that is manufactured by Seqirus. It is approved for use in adults aged 65 years and older.\n5. FluMist: This is a live attenuated influenza vaccine (LAIV) that is manufactured by MedImmune. It is approved for use in healthy children and adults aged 2-49 years old who are not pregnant.\n6. Fluarix Quadrivalent: This is an inactivated influenza vaccine that is manufactured by GSK. It is approved for use in adults and children aged 3 years and older.\n7. Fluarix Tetravalent: This is an inactivated influenza vaccine that is manufactured by GSK. It is approved for use in adults and children aged 3 years and older.\n8. Fluzone High-Dose: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults aged 65 years and older.\n9. Fluzone Quadrivalent: This is an inactivated influenza vaccine that is manufactured by Sanofi Pasteur. It is approved for use in adults and children aged 6 months and older.\n10. Fluad Quadrivalent: This is an inactivated influenza vaccine that is manufactured by Seqirus. It is approved for use in adults aged 65 years and older.",
    "llama-7b_fact_raw": "1. Fluarix is an inactivated influenza vaccine manufactured by GlaxoSmithKline (GSK) approved for use in adults and children aged 3 years and older.\n2. FluLaval is an inactivated influenza vaccine manufactured by Sanofi Pasteur approved for use in adults and children aged 6 months and older.\n3. Fluzone is an inactivated influenza vaccine manufactured by Sanofi Pasteur approved for use in adults and children aged 6 months and older.\n4. Fluad is an inactivated influenza vaccine manufactured by Seqirus approved for use in adults aged 65 years and older.\n5. FluMist is a live attenuated influenza vaccine (LAIV) manufactured by MedImmune approved for use in healthy children and adults aged 2-49 years old who are not pregnant.",
    "llama-7b_fact": [
      "Fluarix is an inactivated influenza vaccine manufactured by GlaxoSmithKline (GSK) approved for use in adults and children aged 3 years and older.",
      "FluLaval is an inactivated influenza vaccine manufactured by Sanofi Pasteur approved for use in adults and children aged 6 months and older.",
      "Fluzone is an inactivated influenza vaccine manufactured by Sanofi Pasteur approved for use in adults and children aged 6 months and older.",
      "Fluad is an inactivated influenza vaccine manufactured by Seqirus approved for use in adults aged 65 years and older.",
      "FluMist is a live attenuated influenza vaccine (LAIV) manufactured by MedImmune approved for use in healthy children and adults aged 2-49 years old who are not pregnant."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. FALSE [correction]: FluLaval is an inactivated influenza vaccine manufactured by GlaxoSmithKline (GSK) approved for use in adults and children aged 6 months and older.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3832,
    "user_query": "You MUST give a detailed answer to the following question: Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-7b_response": "Yes, the Paramyxovirus geneome is segmented and negative-sense RNA.\n\nParamyxoviruses are a family of viruses that include several important human pathogens, such as measles, mumps, and respiratory syncytial virus. These viruses have a single-stranded, negative-sense RNA genome, which means that the viral RNA is complementary to the antisense (positive-sense) RNA of the host cell.\n\nParamyxoviruses also have a segmented genome, which means that the RNA genome is divided into segments that are separated by non-coding regions. Each segment encodes a specific protein or group of proteins, and the segments are assembled during the replication process to form a complete, infectious virus particle. The segmented nature of the Paramyxovirus genome allows the virus to evolve and adapt more quickly than single-stranded RNA viruses that do not have segmented genomes.",
    "llama-7b_fact_raw": "1. Paramyxoviruses have a single-stranded, negative-sense RNA genome.\n2. The Paramyxovirus family includes human pathogens such as measles, mumps, and respiratory syncytial virus.\n3. The viral RNA of Paramyxoviruses is complementary to the antisense (positive-sense) RNA of the host cell.\n4. The Paramyxovirus genome is segmented, with the RNA genome divided into segments separated by non-coding regions.\n5. Each segment of the Paramyxovirus genome encodes a specific protein or group of proteins.",
    "llama-7b_fact": [
      "Paramyxoviruses have a single-stranded, negative-sense RNA genome.",
      "The Paramyxovirus family includes human pathogens such as measles, mumps, and respiratory syncytial virus.",
      "The viral RNA of Paramyxoviruses is complementary to the antisense (positive-sense) RNA of the host cell.",
      "The Paramyxovirus genome is segmented, with the RNA genome divided into segments separated by non-coding regions.",
      "Each segment of the Paramyxovirus genome encodes a specific protein or group of proteins."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Paramyxovirus genome is non-segmented, meaning the RNA genome is not divided into segments; it is a single continuous molecule.\n5. FALSE [correction]: Since the Paramyxovirus genome is non-segmented, this statement is incorrect as it implies segmentation. Each gene within the continuous RNA genome encodes a specific protein or group of proteins, but they are not divided into segments.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3869,
    "user_query": "You MUST give a detailed answer to the following question: Roflumilast Cream is effective for which disease?",
    "llama-7b_response": "Roflumilast cream is a medication that is used to treat a condition called chronic obstructive pulmonary disease (COPD). COPD is a group of lung diseases that includes chronic bronchitis and emphysema. It is characterized by the blockage of airflow in the lungs and can cause symptoms such as shortness of breath, coughing, and wheezing.\n\nRoflumilast cream works by reducing inflammation in the lungs, which can help to improve airflow and reduce symptoms of COPD. It is typically used in combination with other medications, such as bronchodilators and corticosteroids, to treat COPD.\n\nIt is worth noting that Roflumilast cream is not a cure for COPD, but it can help to manage the symptoms of the disease and improve quality of life. It is important for individuals with COPD to work closely with their healthcare provider to determine the best treatment plan for their individual needs.",
    "llama-7b_fact_raw": "1. Roflumilast cream is used to treat chronic obstructive pulmonary disease (COPD).\n2. COPD is a group of lung diseases that includes chronic bronchitis and emphysema.\n3. COPD is characterized by the blockage of airflow in the lungs.\n4. Roflumilast cream works by reducing inflammation in the lungs.\n5. Roflumilast cream is typically used in combination with other medications to treat COPD.",
    "llama-7b_fact": [
      "Roflumilast cream is used to treat chronic obstructive pulmonary disease (COPD).",
      "COPD is a group of lung diseases that includes chronic bronchitis and emphysema.",
      "COPD is characterized by the blockage of airflow in the lungs.",
      "Roflumilast cream works by reducing inflammation in the lungs.",
      "Roflumilast cream is typically used in combination with other medications to treat COPD."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Roflumilast is available as a pill or tablet for oral administration to treat chronic obstructive pulmonary disease (COPD); it is not a cream.\n2. TRUE\n3. TRUE\n4. TRUE, but the statement is slightly misleading as it implies the existence of a cream formulation. Roflumilast in its oral form works by reducing inflammation in the lungs.\n5. TRUE, but with the clarification that roflumilast is an oral medication, not a cream, and it is indeed often used in combination with other medications to manage COPD.",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "You MUST give a detailed answer to the following question: Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-7b_response": "There are several tools that have been developed for identifying and visualizing ncRNA promoters. Here are some of the most commonly used tools:\n\n1. RNAhybrid: RNAhybrid is a bioinformatics tool that uses a hybridization-based approach to identify promoter regions in ncRNAs. The tool uses a combination of sequence and structural information to identify potential promoter regions, and it has been shown to be highly sensitive and specific.\n2. MatInspector: MatInspector is a bioinformatics tool that uses a machine learning approach to identify potential promoter regions in ncRNAs. The tool uses a combination of sequence and structural information to identify potential promoter regions, and it has been shown to be highly accurate.\n3. RNAprom: RNAprom is a bioinformatics tool that uses a machine learning approach to identify potential promoter regions in ncRNAs. The tool uses a combination of sequence and structural information to identify potential promoter regions, and it has been shown to be highly accurate.\n4. RNAPIII-BP: RNAPIII-BP is a bioinformatics tool that uses a machine learning approach to identify potential RNA polymerase III promoter regions in ncRNAs. The tool uses a combination of sequence and structural information to identify potential promoter regions, and it has been shown to be highly accurate.\n5. RNAz: RNAz is a bioinformatics tool that uses a machine learning approach to identify potential promoter regions in ncRNAs. The tool uses a combination of sequence and structural information to identify potential promoter regions, and it has been shown to be highly accurate.\n\nOverall, these tools have been shown to be highly accurate in identifying and visualizing ncRNA promoters, and they are widely used in the field of ncRNA research.",
    "llama-7b_fact_raw": "1. RNAhybrid is a bioinformatics tool designed to identify promoter regions in ncRNAs using a hybridization-based approach.\n2. MatInspector is a bioinformatics tool that identifies potential promoter regions in ncRNAs through a machine learning approach.\n3. RNAprom is a bioinformatics tool that uses machine learning to identify potential promoter regions in ncRNAs.\n4. RNAPIII-BP is a bioinformatics tool aimed at identifying RNA polymerase III promoter regions in ncRNAs using machine learning.\n5. RNAz is a bioinformatics tool that employs machine learning to identify potential promoter regions in ncRNAs.",
    "llama-7b_fact": [
      "RNAhybrid is a bioinformatics tool designed to identify promoter regions in ncRNAs using a hybridization-based approach.",
      "MatInspector is a bioinformatics tool that identifies potential promoter regions in ncRNAs through a machine learning approach.",
      "RNAprom is a bioinformatics tool that uses machine learning to identify potential promoter regions in ncRNAs.",
      "RNAPIII-BP is a bioinformatics tool aimed at identifying RNA polymerase III promoter regions in ncRNAs using machine learning.",
      "RNAz is a bioinformatics tool that employs machine learning to identify potential promoter regions in ncRNAs."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: RNAhybrid is a bioinformatics tool designed to find the minimum free energy hybridization of a long and a short RNA. It is not specifically designed to identify promoter regions in ncRNAs.\n2. FALSE [correction]: MatInspector is a bioinformatics tool that identifies transcription factor binding sites using a library of matrix descriptions, not specifically for identifying promoter regions in ncRNAs through a machine learning approach.\n3. TRUE\n4. UNKNOWN: Without more context, it is difficult to determine the accuracy of this statement as RNAPIII-BP is not a well-known tool, and its description could be hypothetical or specific to a particular study.\n5. FALSE [correction]: RNAz is a bioinformatics tool that predicts structurally conserved and thermodynamically stable RNA secondary structures in multiple sequence alignments, not specifically for identifying potential promoter regions in ncRNAs using machine learning.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3918,
    "user_query": "You MUST give a detailed answer to the following question: List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-7b_response": "Sure, here are some examples of genes that the SWIM tool has identified as being down-regulated in glioblastoma:\n\n1. TP53: This gene, also known as p53, is a tumor suppressor gene that is frequently mutated in glioblastoma. The SWIM tool has identified TP53 as being down-regulated in glioblastoma.\n2. CDKN2A: This gene, also known as p16, is another tumor suppressor gene that is frequently mutated in glioblastoma. The SWIM tool has identified CDKN2A as being down-regulated in glioblastoma.\n3. PTEN: This gene encodes a phosphatase that negatively regulates the PI3K/AKT signaling pathway. The SWIM tool has identified PTEN as being down-regulated in glioblastoma.\n4. CDKN2B: This gene, also known as p14, is another tumor suppressor gene that is frequently mutated in glioblastoma. The SWIM tool has identified CDKN2B as being down-regulated in glioblastoma.\n5. SMAD4: This gene encodes a transcription factor that plays a role in the TGF-beta signaling pathway. The SWIM tool has identified SMAD4 as being down-regulated in glioblastoma.\n6. PTCH1: This gene encodes a receptor that plays a role in the Hedgehog signaling pathway. The SWIM tool has identified PTCH1 as being down-regulated in glioblastoma.\n7. CDKN1B: This gene, also known as p21, is a tumor suppressor gene that is frequently down-regulated in glioblastoma. The SWIM tool has identified CDKN1B as being down-regulated in glioblastoma.\n\nThese are just a few examples of the many genes that the SWIM tool has identified as being down-regulated in glioblastoma.",
    "llama-7b_fact_raw": "1. The SWIM tool has identified the TP53 gene as being down-regulated in glioblastoma.\n2. The SWIM tool has identified the CDKN2A gene as being down-regulated in glioblastoma.\n3. The SWIM tool has identified the PTEN gene as being down-regulated in glioblastoma.\n4. The SWIM tool has identified the CDKN2B gene as being down-regulated in glioblastoma.\n5. The SWIM tool has identified the SMAD4 gene as being down-regulated in glioblastoma.",
    "llama-7b_fact": [
      "The SWIM tool has identified the TP53 gene as being down-regulated in glioblastoma.",
      "The SWIM tool has identified the CDKN2A gene as being down-regulated in glioblastoma.",
      "The SWIM tool has identified the PTEN gene as being down-regulated in glioblastoma.",
      "The SWIM tool has identified the CDKN2B gene as being down-regulated in glioblastoma.",
      "The SWIM tool has identified the SMAD4 gene as being down-regulated in glioblastoma."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information on the results from the SWIM (Subnetworks of Within-Interconnected Modules) tool regarding its analysis of gene regulation in glioblastoma, it is not possible to determine the truthfulness of these statements. The SWIM tool is used for analyzing gene expression data to identify key regulatory networks, but without the actual data or results, the status of the genes mentioned (TP53, CDKN2A, PTEN, CDKN2B, SMAD4) in glioblastoma cannot be confirmed.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3926,
    "user_query": "You MUST give a detailed answer to the following question: Which R packages have been developed for studying TADs?",
    "llama-7b_response": "There are several R packages that have been developed for studying TADs (Three-dimensional architecture of the genome). Some of these packages include:\n\n1. TADMatrix: This package provides tools for analyzing and visualizing TADs in a genome. It can be used to identify TAD boundaries, calculate TAD properties, and visualize TADs in 3D.\n2. TADtools: This package provides tools for analyzing and visualizing TADs in a genome. It can be used to identify TAD boundaries, calculate TAD properties, and visualize TADs in 2D and 3D.\n3. GenomePlotR: This package provides tools for visualizing and analyzing genomic data. It can be used to visualize TADs in 2D and 3D, as well as to visualize other genomic features such as chromosomes, genes, and regulatory regions.\n4. Hi-C: This package provides tools for analyzing Hi-C data, which is used to study the 3D architecture of the genome. It can be used to analyze Hi-C data, identify TAD boundaries, and calculate TAD properties.\n5. GROMACS: This package provides tools for simulating and analyzing molecular systems. It can be used to study the 3D organization of chromosomes and other genomic features.\n\nThese are just a few examples of R packages that have been developed for studying TADs. There are many other packages available that may be useful for this purpose, depending on the specific research question and analysis methods being used.",
    "llama-7b_fact_raw": "1. TADMatrix is an R package designed for analyzing and visualizing TADs in a genome.\n2. TADtools is an R package that can be used to identify TAD boundaries and visualize TADs in both 2D and 3D.\n3. GenomePlotR is an R package that allows for the visualization of TADs and other genomic features such as chromosomes, genes, and regulatory regions.\n4. The Hi-C R package is used for analyzing Hi-C data to study the 3D architecture of the genome and identify TAD boundaries.\n5. GROMACS is an R package that can simulate and analyze molecular systems, including the 3D organization of chromosomes.",
    "llama-7b_fact": [
      "TADMatrix is an R package designed for analyzing and visualizing TADs in a genome.",
      "TADtools is an R package that can be used to identify TAD boundaries and visualize TADs in both 2D and 3D.",
      "GenomePlotR is an R package that allows for the visualization of TADs and other genomic features such as chromosomes, genes, and regulatory regions.",
      "The Hi-C R package is used for analyzing Hi-C data to study the 3D architecture of the genome and identify TAD boundaries.",
      "GROMACS is an R package that can simulate and analyze molecular systems, including the 3D organization of chromosomes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The correct name of the R package is GenomicRanges, which allows for the representation and manipulation of genomic intervals and variables defined along a genome.\n4. TRUE\n5. FALSE [correction]: GROMACS is not an R package; it is a versatile package to perform molecular dynamics, i.e., simulate the Newtonian equations of motion for systems with hundreds to millions of particles. It is not specifically designed for the 3D organization of chromosomes or genomic analysis.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "You MUST give a detailed answer to the following question: Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-7b_response": "One bioconductor tool that has been developed for accessing bacterial regulatory networks is the \"Biclustering of Regulatory Networks\" (BiclustR) package.\n\nBiclustR is a bioconductor package that allows for the identification of biclusters in regulatory networks, which are groups of genes that are co-expressed and co-regulated. Biclustering is a powerful tool for identifying patterns and relationships within large datasets, and can be used to identify key regulatory modules within bacterial populations.\n\nThe BiclustR package provides a set of functions for biclustering regulatory networks, as well as tools for visualizing and analyzing the results. The package can be used to identify biclusters of genes that are involved in specific biological processes, or that are regulated by specific transcription factors.\n\nOverall, the BiclustR package is a valuable tool for accessing bacterial regulatory networks, and can be used to identify key regulatory modules and patterns within these networks.",
    "llama-7b_fact_raw": "1. The \"Biclustering of Regulatory Networks\" (BiclustR) package is a bioconductor tool developed for accessing bacterial regulatory networks.\n2. BiclustR allows for the identification of biclusters in regulatory networks.\n3. Biclusters are groups of genes that are co-expressed and co-regulated.\n4. The BiclustR package includes functions for biclustering regulatory networks and tools for visualizing and analyzing the results.\n5. The package can be used to identify biclusters of genes involved in specific biological processes or regulated by specific transcription factors.",
    "llama-7b_fact": [
      "The \"Biclustering of Regulatory Networks\" (BiclustR) package is a bioconductor tool developed for accessing bacterial regulatory networks.",
      "BiclustR allows for the identification of biclusters in regulatory networks.",
      "Biclusters are groups of genes that are co-expressed and co-regulated.",
      "The BiclustR package includes functions for biclustering regulatory networks and tools for visualizing and analyzing the results.",
      "The package can be used to identify biclusters of genes involved in specific biological processes or regulated by specific transcription factors."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The \"Biclustering of Regulatory Networks\" (BiclustR) package is not specifically developed for accessing bacterial regulatory networks; it is a more general tool for biclustering, which can be applied to various types of data, including gene expression data.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3933,
    "user_query": "You MUST give a detailed answer to the following question: What are the end products of the shikimate pathway?",
    "llama-7b_response": "The shikimate pathway is a biosynthetic pathway that produces aromatic amino acids, which are the building blocks of many important biomolecules, including hormones, neurotransmitters, and antibiotics. The end products of the shikimate pathway are the aromatic amino acids that are synthesized through this pathway.\n\nThe aromatic amino acids that are produced through the shikimate pathway include:\n\n1. Phenylalanine: This amino acid is a precursor to the neurotransmitters dopamine and norepinephrine, as well as the hormone epinephrine.\n2. Tyrosine: This amino acid is a precursor to the skin pigment melanin, as well as the neurotransmitters dopamine and norepinephrine.\n3. Tryptophan: This amino acid is a precursor to the neurotransmitter serotonin, as well as the hormone melatonin.\n4. Valine: This amino acid is an essential amino acid that is not synthesized by the body and must be obtained through the diet.\n5. Leucine: This amino acid is an essential amino acid that is not synthesized by the body and must be obtained through the diet.\n6. Isoleucine: This amino acid is an essential amino acid that is not synthesized by the body and must be obtained through the diet.\n\nIn summary, the end products of the shikimate pathway are the aromatic amino acids phenylalanine, tyrosine, tryptophan, valine, leucine, and isoleucine, which are essential building blocks for many important biomolecules in the body.",
    "llama-7b_fact_raw": "1. The shikimate pathway produces aromatic amino acids.\n2. Phenylalanine is a precursor to the neurotransmitters dopamine and norepinephrine, as well as the hormone epinephrine.\n3. Tyrosine is a precursor to the skin pigment melanin, as well as the neurotransmitters dopamine and norepinephrine.\n4. Tryptophan is a precursor to the neurotransmitter serotonin, as well as the hormone melatonin.\n5. Valine, leucine, and isoleucine are essential amino acids that must be obtained through the diet.",
    "llama-7b_fact": [
      "The shikimate pathway produces aromatic amino acids.",
      "Phenylalanine is a precursor to the neurotransmitters dopamine and norepinephrine, as well as the hormone epinephrine.",
      "Tyrosine is a precursor to the skin pigment melanin, as well as the neurotransmitters dopamine and norepinephrine.",
      "Tryptophan is a precursor to the neurotransmitter serotonin, as well as the hormone melatonin.",
      "Valine, leucine, and isoleucine are essential amino acids that must be obtained through the diet."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "You MUST give a detailed answer to the following question: Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-7b_response": "Yes, cabergoline is used for the treatment of Nelson's syndrome.\n\nNelson's syndrome is a rare condition that occurs in patients with prostate cancer who have undergone surgery or radiation therapy to treat benign prostatic hyperplasia (BPH) or prostate cancer. It is characterized by the growth of excessive smooth muscle tissue in the prostate gland, leading to compression of the base of the skull and symptoms such as headaches, visual disturbances, and dizziness.\n\nCabergoline is a dopamine agonist that is used to treat hyperprolactinemia, a condition in which the body produces too much prolactin, a hormone that stimulates breast milk production. However, cabergoline has also been shown to be effective in the treatment of Nelson's syndrome.\n\nStudies have shown that cabergoline can reduce the size of the prostate gland and alleviate symptoms such as headaches, visual disturbances, and dizziness in patients with Nelson's syndrome. It works by decreasing the production of prolactin, which helps to shrink the excessive smooth muscle tissue in the prostate gland and relieve compression of the base of the skull.\n\nIn summary, cabergoline is an effective treatment option for patients with Nelson's syndrome, a rare condition that occurs in patients with prostate cancer and is characterized by the growth of excessive smooth muscle tissue in the prostate gland. Cabergoline works by reducing the production of prolactin, which helps to shrink the excessive smooth muscle tissue and alleviate symptoms such as headaches, visual disturbances, and dizziness.",
    "llama-7b_fact_raw": "1. Nelson's syndrome is a rare condition that occurs in patients with prostate cancer who have undergone surgery or radiation therapy.\n2. Nelson's syndrome is characterized by the growth of excessive smooth muscle tissue in the prostate gland.\n3. Cabergoline is a dopamine agonist used to treat hyperprolactinemia.\n4. Cabergoline has been shown to be effective in the treatment of Nelson's syndrome.\n5. Cabergoline can reduce the size of the prostate gland and alleviate symptoms such as headaches, visual disturbances, and dizziness in patients with Nelson's syndrome.",
    "llama-7b_fact": [
      "Nelson's syndrome is a rare condition that occurs in patients with prostate cancer who have undergone surgery or radiation therapy.",
      "Nelson's syndrome is characterized by the growth of excessive smooth muscle tissue in the prostate gland.",
      "Cabergoline is a dopamine agonist used to treat hyperprolactinemia.",
      "Cabergoline has been shown to be effective in the treatment of Nelson's syndrome.",
      "Cabergoline can reduce the size of the prostate gland and alleviate symptoms such as headaches, visual disturbances, and dizziness in patients with Nelson's syndrome."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Nelson's syndrome is a rare condition that occurs in patients with Cushing's disease who have undergone surgery to remove the adrenal glands.\n2. FALSE [correction]: Nelson's syndrome is characterized by the growth of a pituitary tumor and increased production of the hormone ACTH, not by the growth of smooth muscle tissue in the prostate gland.\n3. TRUE\n4. UNKNOWN: While cabergoline is used to treat various conditions related to hormone production, its effectiveness in the treatment of Nelson's syndrome specifically is not well-established and would require more context or medical literature to confirm.\n5. FALSE [correction]: Cabergoline is not used to reduce the size of the prostate gland. Nelson's syndrome involves the pituitary gland, not the prostate gland, and cabergoline's effects on symptoms such as headaches, visual disturbances, and dizziness would be related to its ability to reduce hormone levels, not prostate size.",
    "llama-7b_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3939,
    "user_query": "You MUST give a detailed answer to the following question: What is the main manifestation of Liebenberg syndrome?",
    "llama-7b_response": "Liebenberg syndrome is a rare genetic disorder that is characterized by a range of physical and developmental abnormalities. The main manifestation of Liebenberg syndrome is intellectual disability, which can range from mild to severe and may affect a person's ability to learn, communicate, and take care of themselves.\n\nIn addition to intellectual disability, people with Liebenberg syndrome may also have other physical abnormalities, such as:\n\n* Delayed development: Children with Liebenberg syndrome may take longer to reach developmental milestones, such as walking and talking, than typical children.\n* Small stature: People with Liebenberg syndrome may be shorter than average and may have a thin build.\n* Heart defects: Some people with Liebenberg syndrome may have abnormalities of the heart and blood vessels, such as a hole in the heart or narrowing of the blood vessels.\n* Eye abnormalities: People with Liebenberg syndrome may have abnormalities of the eyes, such as cataracts or glaucoma.\n* Hearing loss: Some individuals with Liebenberg syndrome may have hearing loss.\n* Dental abnormalities: Children with Liebenberg syndrome may have abnormalities of the teeth and gums.\n\nThese physical abnormalities can vary in severity among individuals with Liebenberg syndrome, and some people may have only a few of these symptoms while others may have many.",
    "llama-7b_fact_raw": "1. Liebenberg syndrome is a rare genetic disorder.\n2. The main manifestation of Liebenberg syndrome is intellectual disability.\n3. Children with Liebenberg syndrome may experience delayed development.\n4. Some people with Liebenberg syndrome may have heart defects.\n5. Individuals with Liebenberg syndrome can have eye abnormalities such as cataracts or glaucoma.",
    "llama-7b_fact": [
      "Liebenberg syndrome is a rare genetic disorder.",
      "The main manifestation of Liebenberg syndrome is intellectual disability.",
      "Children with Liebenberg syndrome may experience delayed development.",
      "Some people with Liebenberg syndrome may have heart defects.",
      "Individuals with Liebenberg syndrome can have eye abnormalities such as cataracts or glaucoma."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The main manifestation of Liebenberg syndrome is the development of limb malformations, particularly the upper limbs developing characteristics of the lower limbs.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Liebenberg syndrome is not a widely recognized or well-known genetic disorder in medical literature, and the provided statements do not correspond to a specific known condition. Therefore, the responses to statements 1, 3, 4, and 5 are marked as UNKNOWN due to the lack of available information to confirm or refute the claims.]",
    "llama-7b_judge": [
      "unknown",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "You MUST give a detailed answer to the following question: List orally bioavailable MPS1 kinase inhibitors",
    "llama-7b_response": "There are several orally bioavailable MPS1 kinase inhibitors that have been developed for the treatment of various cancers. Here are some examples:\n\n1. Midostaurin (Rydapt): This is an FDA-approved oral MPS1 kinase inhibitor that is used for the treatment of acute myeloid leukemia (AML) and systemic mastocytosis. Midostaurin targets the FMS-like tyrosine kinase 3 (FLT3) and MPS1 kinase pathways.\n2. ENMD-2076: This is an investigational oral MPS1 kinase inhibitor that is being developed for the treatment of various solid tumors. ENMD-2076 targets the MPS1 kinase and has shown promising results in preclinical studies.\n3. PF-04217900: This is an investigational oral MPS1 kinase inhibitor that is being developed for the treatment of various solid tumors. PF-04217900 targets the MPS1 kinase and has shown promising results in preclinical studies.\n4. GSK2879552: This is an investigational oral MPS1 kinase inhibitor that is being developed for the treatment of various solid tumors. GSK2879552 targets the MPS1 kinase and has shown promising results in preclinical studies.\n\nThese are just a few examples of orally bioavailable MPS1 kinase inhibitors that are currently being developed for the treatment of various cancers. However, it's worth noting that the development of these drugs is ongoing, and more research is needed to fully understand their potential benefits and risks.",
    "llama-7b_fact_raw": "1. Midostaurin (Rydapt) is an FDA-approved oral MPS1 kinase inhibitor used for the treatment of acute myeloid leukemia (AML) and systemic mastocytosis.\n2. Midostaurin targets the FMS-like tyrosine kinase 3 (FLT3) and MPS1 kinase pathways.\n3. ENMD-2076 is an investigational oral MPS1 kinase inhibitor being developed for the treatment of various solid tumors.\n4. PF-04217900 is an investigational oral MPS1 kinase inhibitor being developed for the treatment of various solid tumors.\n5. GSK2879552 is an investigational oral MPS1 kinase inhibitor being developed for the treatment of various solid tumors.",
    "llama-7b_fact": [
      "Midostaurin (Rydapt) is an FDA-approved oral MPS1 kinase inhibitor used for the treatment of acute myeloid leukemia (AML) and systemic mastocytosis.",
      "Midostaurin targets the FMS-like tyrosine kinase 3 (FLT3) and MPS1 kinase pathways.",
      "ENMD-2076 is an investigational oral MPS1 kinase inhibitor being developed for the treatment of various solid tumors.",
      "PF-04217900 is an investigational oral MPS1 kinase inhibitor being developed for the treatment of various solid tumors.",
      "GSK2879552 is an investigational oral MPS1 kinase inhibitor being developed for the treatment of various solid tumors."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: ENMD-2076 is an investigational oral kinase inhibitor, but it primarily targets Aurora A and angiogenic pathways, not specifically MPS1 kinase.\n4. FALSE [correction]: PF-04217903 (not PF-04217900) is an investigational oral MET kinase inhibitor, not specifically an MPS1 kinase inhibitor.\n5. FALSE [correction]: GSK2879552 is an investigational oral LSD1 inhibitor being developed for the treatment of acute myeloid leukemia (AML) and small cell lung carcinoma (SCLC), not an MPS1 kinase inhibitor.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4031,
    "user_query": "You MUST give a detailed answer to the following question: Was golimumab tested for diabetes?",
    "llama-7b_response": "Golimumab, also known by the trade name Simponi, is a medication that is used to treat several inflammatory conditions, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is a biologic drug that is administered as an injection and works by targeting a specific protein called tumor necrosis factor (TNF).\n\nAs of my knowledge cutoff in September 2021, there was no information available indicating that golimumab has been specifically tested or approved for the treatment of diabetes. The medication is primarily used to treat inflammatory conditions, and its effects on glucose metabolism have not been extensively studied.\n\nHowever, it is worth noting that some studies have suggested that TNF may play a role in the development of insulin resistance and type 2 diabetes. Therefore, it is possible that golimumab, or similar medications that target TNF, could potentially be used to treat diabetes in the future. However, more research would be needed to determine the safety and effectiveness of using golimumab or other TNF inhibitors for this purpose.\n\nIn summary, while golimumab has been tested and approved for the treatment of inflammatory conditions, there is no information available indicating that it has been specifically tested or approved for the treatment of diabetes. However, TNF may play a role in the development of insulin resistance and type 2 diabetes, and further research is needed to determine the potential of using TNF inhibitors like golimumab for diabetes treatment.",
    "llama-7b_fact_raw": "1. Golimumab is used to treat several inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.\n2. Golimumab is a biologic drug that is administered as an injection.\n3. Golimumab works by targeting a specific protein called tumor necrosis factor (TNF).\n4. As of September 2021, there was no information available indicating that golimumab has been specifically tested or approved for the treatment of diabetes.\n5. TNF may play a role in the development of insulin resistance and type 2 diabetes.",
    "llama-7b_fact": [
      "Golimumab is used to treat several inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.",
      "Golimumab is a biologic drug that is administered as an injection.",
      "Golimumab works by targeting a specific protein called tumor necrosis factor (TNF).",
      "As of September 2021, there was no information available indicating that golimumab has been specifically tested or approved for the treatment of diabetes.",
      "TNF may play a role in the development of insulin resistance and type 2 diabetes."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "You MUST give a detailed answer to the following question: Is progeria caused by an autosomal recessive gene?",
    "llama-7b_response": "Yes, progeria is caused by an autosomal recessive gene.\n\nProgeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder that causes rapid aging in children. It is caused by a mutation in the LMNA gene, which is located on chromosome 1",
    "llama-7b_fact_raw": "1. Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).\n2. Progeria is a rare genetic disorder that causes rapid aging in children.\n3. The mutation that causes progeria is in the LMNA gene.\n4. The LMNA gene is located on chromosome 1.",
    "llama-7b_fact": [
      "Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).",
      "Progeria is a rare genetic disorder that causes rapid aging in children.",
      "The mutation that causes progeria is in the LMNA gene.",
      "The LMNA gene is located on chromosome 1."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The LMNA gene is located on chromosome 20.",
    "llama-7b_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 4082,
    "user_query": "You MUST give a detailed answer to the following question: What are common variants at 12q14 and 12q24 associated with?",
    "llama-7b_response": "Common variants at 12q14 and 12q24 have been associated with various traits and diseases.\n\nAt 12q14, a common variant near the CDKN2A gene has been associated with an increased risk of melanoma, a type of skin cancer. The CDKN2A gene encodes proteins that regulate cell growth and division, and mutations in this gene have been linked to several types of cancer, including melanoma.\n\nAt 12q24, a common variant near the CDKN2B gene has been associated with an increased risk of prostate cancer. The CDKN2B gene encodes proteins that regulate cell growth and division, and mutations in this gene have been linked to several types of cancer, including prostate cancer.\n\nIn addition to these associations, common variants at 12q14 and 12q24 have also been associated with other traits and diseases. For example, a common variant near the CDKN2A gene has been associated with an increased risk of Alzheimer's disease, while a common variant near the CDKN2B gene has been associated with an increased risk of Parkinson's disease.\n\nOverall, common variants at 12q14 and 12q24 are associated with a variety of traits and diseases, including cancer and neurodegenerative disorders. Further research is needed to fully understand the role of these variants in human health and disease.",
    "llama-7b_fact_raw": "1. A common variant near the CDKN2A gene at 12q14 has been associated with an increased risk of melanoma.\n2. The CDKN2A gene is involved in encoding proteins that regulate cell growth and division.\n3. A common variant near the CDKN2B gene at 12q24 has been associated with an increased risk of prostate cancer.\n4. The CDKN2B gene is involved in encoding proteins that regulate cell growth and division.\n5. Common variants near the CDKN2A and CDKN2B genes have been associated with an increased risk of Alzheimer's disease and Parkinson's disease, respectively.",
    "llama-7b_fact": [
      "A common variant near the CDKN2A gene at 12q14 has been associated with an increased risk of melanoma.",
      "The CDKN2A gene is involved in encoding proteins that regulate cell growth and division.",
      "A common variant near the CDKN2B gene at 12q24 has been associated with an increased risk of prostate cancer.",
      "The CDKN2B gene is involved in encoding proteins that regulate cell growth and division.",
      "Common variants near the CDKN2A and CDKN2B genes have been associated with an increased risk of Alzheimer's disease and Parkinson's disease, respectively."
    ],
    "llama-7b_judge_raw": "1. TRUE: A common variant near the CDKN2A gene at 12q14 has indeed been associated with an increased risk of melanoma.\n2. TRUE: The CDKN2A gene is known for encoding proteins such as p16INK4a that regulate cell growth and division, and mutations in this gene can lead to cancer.\n3. FALSE [correction]: The CDKN2B gene at 9p21 has been associated with an increased risk of various diseases, including certain cancers, but the specific association with prostate cancer and the location at 12q24 is not accurate. The CDKN2B gene is indeed located at 9p21, and while it has been associated with various health issues, the direct association with prostate cancer risk is not well-established.\n4. TRUE: The CDKN2B gene, similar to CDKN2A, is involved in encoding proteins that regulate cell cycle progression, and alterations in this gene can contribute to disease processes.\n5. FALSE [correction]: While common variants near the CDKN2A and CDKN2B genes have been associated with various diseases, the specific claim that they have been associated with an increased risk of Alzheimer's disease and Parkinson's disease, respectively, is not well-supported in the literature. These genes are primarily known for their roles in cancer, and any associations with Alzheimer's or Parkinson's would require specific citations to support the claim.",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 4096,
    "user_query": "You MUST give a detailed answer to the following question: Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-7b_response": "The Roundabout (Robo) receptors are G protein-coupled receptors that play important roles in various cellular processes, including cell-cell adhesion, migration, and axon guidance. The ligands of the Roundabout receptors are proteins or peptides that bind to the extracellular domain of the receptor and activate its intracellular signaling pathway.\n\nThere are several known ligands of the Roundabout receptors, including:\n\n1. Robo4: Robo4 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and endothelial cells. It binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion, thereby maintaining tissue integrity.\n2. Robo1: Robo1 is another transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and endothelial cells. It also binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion.\n3. Robo3: Robo3 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and endothelial cells. It also binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion.\n4. Robo2: Robo2 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and endothelial cells. It also binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion.\n5. Robo5: Robo5 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and endothelial cells. It also binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion.\n6. Robo6: Robo6 is a transmembrane protein that is expressed on the surface of various cell types, including neurons, glia, and endothelial cells. It also binds to the Roundabout receptors on neighboring cells and promotes cell-cell adhesion.",
    "llama-7b_fact_raw": "1. The Roundabout (Robo) receptors are G protein-coupled receptors.\n2. Ligands of the Roundabout receptors include proteins or peptides that bind to the extracellular domain of the receptor.\n3. Robo4 is a transmembrane protein that binds to Roundabout receptors and promotes cell-cell adhesion.\n4. Robo1 is a transmembrane protein that binds to Roundabout receptors and promotes cell-cell adhesion.\n5. Robo2, Robo3, Robo5, and Robo6 are mentioned as transmembrane proteins that bind to Roundabout receptors and promote cell-cell adhesion.",
    "llama-7b_fact": [
      "The Roundabout (Robo) receptors are G protein-coupled receptors.",
      "Ligands of the Roundabout receptors include proteins or peptides that bind to the extracellular domain of the receptor.",
      "Robo4 is a transmembrane protein that binds to Roundabout receptors and promotes cell-cell adhesion.",
      "Robo1 is a transmembrane protein that binds to Roundabout receptors and promotes cell-cell adhesion.",
      "Robo2, Robo3, Robo5, and Robo6 are mentioned as transmembrane proteins that bind to Roundabout receptors and promote cell-cell adhesion."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: The Roundabout (Robo) receptors are not G protein-coupled receptors; they are single-pass transmembrane receptors.\n2. TRUE\n3. FALSE [correction]: Robo4 is a member of the Roundabout receptor family itself, not a protein that binds to other Roundabout receptors. It is involved in angiogenesis and vascular stability.\n4. FALSE [correction]: Robo1 is a member of the Roundabout receptor family itself, not a protein that binds to other Roundabout receptors. It is involved in processes like axon guidance and neuronal migration.\n5. FALSE [correction]: Robo2 and Robo3 are members of the Roundabout receptor family, similar to Robo1 and Robo4. There are no Robo5 and Robo6 receptors mentioned in the known Robo family; the family typically includes Robo1, Robo2, Robo3, and Robo4.",
    "llama-7b_judge": [
      "false",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "You MUST give a detailed answer to the following question: Is there a role for TFII-I in megakaryopoiesis?",
    "llama-7b_response": "Yes, there is a role for TFII-I in megakaryopoiesis. TFII-I is a transcription factor that plays an important role in the regulation of gene expression during the process of megakaryopoiesis.\n\nMegakaryopoiesis is the process by which megakaryocytes, which are specialized bone marrow cells that produce platelets, are formed. This process is regulated by a complex network of signaling molecules and transcription factors, including TFII-I.\n\nTFII-I is a component of the basal transcription complex, which is responsible for initiating transcription of genes in the absence of other transcription factors. In megakaryopoiesis, TFII-I is recruited to the promoter region of genes that are specifically expressed in megakaryocytes, where it plays a role in activating the transcription of these genes.\n\nOne of the genes that is specifically expressed in megakaryocytes and whose transcription is regulated by TFII-I is the platelet-derived growth factor receptor alpha (PDGFR) gene. PDGFR is a receptor tyrosine kinase that plays an important role in the development and maturation of megakaryocytes. Activation of PDGFR by its ligand, platelet-derived growth factor (PDGF), is required for the proliferation and differentiation of megakaryocytes. TFII-I is required for the transcription of the PDGFR gene and for the activation of PDGFR signaling during megakaryopoiesis.\n\nIn summary, TFII-I plays an important role in the regulation of gene expression during megakaryopoiesis by activating the transcription of genes that are specifically expressed in megakaryocytes, including the PDGFR gene. The activation of PDGFR signaling by TFII-I is required for the proliferation and differentiation of megakaryocytes, making TFII-I an important regulator of megakaryopoiesis.",
    "llama-7b_fact_raw": "1. TFII-I is a transcription factor that plays a role in the regulation of gene expression during megakaryopoiesis.\n2. Megakaryopoiesis is the process by which megakaryocytes, bone marrow cells that produce platelets, are formed.\n3. TFII-I is part of the basal transcription complex responsible for initiating transcription of genes in the absence of other transcription factors.\n4. The platelet-derived growth factor receptor alpha (PDGFR) gene, which is regulated by TFII-I, is specifically expressed in megakaryocytes.\n5. Activation of PDGFR signaling, which is necessary for the proliferation and differentiation of megakaryocytes, requires TFII-I for the transcription of the PDGFR gene.",
    "llama-7b_fact": [
      "TFII-I is a transcription factor that plays a role in the regulation of gene expression during megakaryopoiesis.",
      "Megakaryopoiesis is the process by which megakaryocytes, bone marrow cells that produce platelets, are formed.",
      "TFII-I is part of the basal transcription complex responsible for initiating transcription of genes in the absence of other transcription factors.",
      "The platelet-derived growth factor receptor alpha (PDGFR) gene, which is regulated by TFII-I, is specifically expressed in megakaryocytes.",
      "Activation of PDGFR signaling, which is necessary for the proliferation and differentiation of megakaryocytes, requires TFII-I for the transcription of the PDGFR gene."
    ],
    "llama-7b_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: TFII-I is not part of the basal transcription complex; it is a multifunctional transcription factor that can regulate gene expression but is not responsible for initiating transcription in the absence of other transcription factors.\n4. FALSE [correction]: The platelet-derived growth factor receptor alpha (PDGFR) gene is not specifically expressed in megakaryocytes; it is expressed in various cell types, although it may play a role in megakaryocyte development.\n5. UNKNOWN",
    "llama-7b_judge": [
      "true",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4145,
    "user_query": "You MUST give a detailed answer to the following question: Is atenolol metabolized by CYP2D6?",
    "llama-7b_response": "",
    "llama-7b_fact_raw": "NO FACTS",
    "llama-7b_fact": [],
    "llama-7b_judge": []
  },
  {
    "id": 4158,
    "user_query": "You MUST give a detailed answer to the following question: List versions of ExpansionHunter",
    "llama-7b_response": "As of my knowledge cutoff date in September 2021, there were several versions of ExpansionHunter, including:\n\n1. ExpansionHunter Classic: This was the original version of ExpansionHunter, which was released in 2016. It was a browser-based game that allowed players to explore a procedurally generated galaxy, discover new planets, and fight against hostile alien creatures to expand their empire.\n2. ExpansionHunter Reborn: This version of ExpansionHunter was released in 2018 and was a major update to the original game. It introduced new features such as improved graphics, a new user interface, and more advanced gameplay mechanics.\n3. ExpansionHunter Mobile: This version of ExpansionHunter was released in 2019 and was a mobile version of the game. It was designed to be played on smartphones and tablets, and allowed players to continue their adventures on the go.\n4. ExpansionHunter Universe: This version of ExpansionHunter was released in 2020 and was a spin-off of the original game. It was a multiplayer online battle arena (MOBA) game that allowed players to form teams and battle against other players in real-time.\n\nIt's possible that there may be additional versions of ExpansionHunter that have been released since my knowledge cutoff date in September 2021, but these are the versions that were available at that time.",
    "llama-7b_fact_raw": "1. ExpansionHunter Classic was released in 2016.\n2. ExpansionHunter Reborn was released in 2018.\n3. ExpansionHunter Mobile was released in 2019.\n4. ExpansionHunter Universe was released in 2020.\n5. ExpansionHunter Classic was a browser-based game.",
    "llama-7b_fact": [
      "ExpansionHunter Classic was released in 2016.",
      "ExpansionHunter Reborn was released in 2018.",
      "ExpansionHunter Mobile was released in 2019.",
      "ExpansionHunter Universe was released in 2020.",
      "ExpansionHunter Classic was a browser-based game."
    ],
    "llama-7b_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: ExpansionHunter Classic is not a game; it is a software tool designed to analyze genetic variants, specifically for detecting repeat expansions in genomic data.",
    "llama-7b_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4164,
    "user_query": "You MUST give a detailed answer to the following question: What is the role of Adamts18 in hormone receptor signaling?",
    "llama-7b_response": "Adamts18, also known as aggrecanase-1, is an enzyme that degrades the proteoglycan aggrecan, which is a major component of cartilage. Adamts18 has been shown to be involved in the regulation of hormone receptor signaling in several ways.\n\nFirst, Adamts18 has been shown to play a role in the regulation of estrogen receptor signaling in breast cancer cells. Estrogen receptor signaling is important for the development and progression of breast cancer, and Adamts18 has been shown to regulate this signaling pathway by degrading aggrecan, which in turn affects the expression of genes involved in estrogen receptor signaling.\n\nSecond, Adamts18 has been shown to play a role in the regulation of androgen receptor signaling in prostate cancer cells. Androgen receptor signaling is important for the development and progression of prostate cancer, and Adamts18 has been shown to regulate this signaling pathway by degrading aggrecan, which in turn affects the expression of genes involved in androgen receptor signaling.\n\nThird, Adamts18 has been shown to play a role in the regulation of thyroid hormone receptor signaling in thyroid cancer cells. Thyroid hormone receptor signaling is important for the development and progression of thyroid cancer, and Adamts18 has been shown to regulate this signaling pathway by degrading aggrecan, which in turn affects the expression of genes involved in thyroid hormone receptor signaling.\n\nOverall, these studies suggest that Adamts18 plays a role in the regulation of hormone receptor signaling by degrading aggrecan, which in turn affects the expression of genes involved in hormone receptor signaling. Further studies are needed to fully understand the role of Adamts18 in hormone receptor signaling and its potential as a therapeutic target for the treatment of hormone-dependent cancers.",
    "llama-7b_fact_raw": "1. Adamts18, also known as aggrecanase-1, is an enzyme that degrades the proteoglycan aggrecan.\n2. Adamts18 is involved in the regulation of estrogen receptor signaling in breast cancer cells.\n3. The enzyme regulates androgen receptor signaling in prostate cancer cells by degrading aggrecan.\n4. Adamts18 plays a role in the regulation of thyroid hormone receptor signaling in thyroid cancer cells.\n5. The degradation of aggrecan by Adamts18 affects the expression of genes involved in hormone receptor signaling.",
    "llama-7b_fact": [
      "Adamts18, also known as aggrecanase-1, is an enzyme that degrades the proteoglycan aggrecan.",
      "Adamts18 is involved in the regulation of estrogen receptor signaling in breast cancer cells.",
      "The enzyme regulates androgen receptor signaling in prostate cancer cells by degrading aggrecan.",
      "Adamts18 plays a role in the regulation of thyroid hormone receptor signaling in thyroid cancer cells.",
      "The degradation of aggrecan by Adamts18 affects the expression of genes involved in hormone receptor signaling."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: ADAMTS5, not ADAMTS18, is also known as aggrecanase-1 and is an enzyme that degrades the proteoglycan aggrecan.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe correction for statement 1 is based on the fact that ADAMTS5 is the enzyme commonly referred to as aggrecanase-1, which is involved in the degradation of aggrecan. The other statements regarding ADAMTS18's specific roles in hormone receptor signaling in various cancer cells and the effect of aggrecan degradation on gene expression in hormone receptor signaling are not well-established facts and would require specific scientific references to confirm their accuracy. Therefore, without additional context or references, the truthfulness of statements 2 through 5 cannot be determined.",
    "llama-7b_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "You MUST give a detailed answer to the following question: What is the mode of action of Thiazovivin?",
    "llama-7b_response": "Thiazovivin is a chemotherapy drug that belongs to the group of alkylating agents. It works by interfering with the process of DNA replication, which is necessary for the growth and division of cells.\n\nDuring DNA replication, the two strands of DNA that make up the double helix separate, and each strand serves as a template for the synthesis of a new complementary strand. Thiazovivin interferes with this process by binding to the sugar-phosphate backbone of DNA, which prevents the separation of the strands and the synthesis of the new complementary strands.\n\nAs a result, the cell is unable to divide and reproduce, leading to cell death. Thiazovivin is particularly effective against rapidly dividing cells, such as those found in cancer cells. However, it can also cause damage to normal cells that divide frequently, such as those in the bone marrow, leading to side effects such as hair loss, nausea, and anemia.",
    "llama-7b_fact_raw": "1. Thiazovivin is a chemotherapy drug that is categorized as an alkylating agent.\n2. Thiazovivin works by interfering with the process of DNA replication.\n3. The drug binds to the sugar-phosphate backbone of DNA, preventing the separation of the DNA strands.\n4. Thiazovivin's action results in the inability of cells to divide and reproduce, leading to cell death.\n5. Thiazovivin is particularly effective against rapidly dividing cancer cells but can also damage normal cells that divide frequently.",
    "llama-7b_fact": [
      "Thiazovivin is a chemotherapy drug that is categorized as an alkylating agent.",
      "Thiazovivin works by interfering with the process of DNA replication.",
      "The drug binds to the sugar-phosphate backbone of DNA, preventing the separation of the DNA strands.",
      "Thiazovivin's action results in the inability of cells to divide and reproduce, leading to cell death.",
      "Thiazovivin is particularly effective against rapidly dividing cancer cells but can also damage normal cells that divide frequently."
    ],
    "llama-7b_judge_raw": "1. FALSE [correction]: Thiazovivin is not a chemotherapy drug; it is a small molecule inhibitor used to enhance the survival of human pluripotent stem cells.\n2. FALSE [correction]: Since Thiazovivin is not a chemotherapy drug, it does not work by interfering with the process of DNA replication. It acts by inhibiting the Rho-associated protein kinase (ROCK) pathway.\n3. FALSE [correction]: Thiazovivin does not bind to the sugar-phosphate backbone of DNA as it is not an alkylating agent; it is a ROCK inhibitor.\n4. FALSE [correction]: Thiazovivin's action does not result in the inability of cells to divide and reproduce leading to cell death due to interference with DNA. It enhances cell survival and is used in stem cell culture.\n5. FALSE [correction]: Thiazovivin's effectiveness is not related to its action against rapidly dividing cancer cells, as it is not a chemotherapy drug. It is used to improve the survival and maintenance of stem cells in culture.",
    "llama-7b_judge": [
      "false",
      "false",
      "false",
      "false",
      "false"
    ]
  }
]